<SEC-DOCUMENT>0001125345-20-000152.txt : 20201104
<SEC-HEADER>0001125345-20-000152.hdr.sgml : 20201104
<ACCEPTANCE-DATETIME>20201104160450
ACCESSION NUMBER:		0001125345-20-000152
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201104
DATE AS OF CHANGE:		20201104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		201286625

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgnx-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe,d:837d975c068f41aa997c97c40d8bbcd5--><html xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:mgnx="http://macrogenics.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mgnx-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV8yLTEtMS0xLTA_b2d39294-305e-428a-9204-19dbb1d5a870">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV80LTEtMS0xLTA_caff1e4a-08c3-41b4-83a0-89c0b2a20f4c">2020</ix:nonNumeric><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV81LTEtMS0xLTA_44797ab3-ceba-4fb2-8340-637d8f674f7d">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGV4dHJlZ2lvbjozY2I2OGE4MWE2ZWQ0ZDI5OWRiN2MwYWQ1MDU4MzBiY18xMzA_5945b044-0026-4ca0-8b01-6bc008d37ad5">0001125345</ix:nonNumeric><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGV4dHJlZ2lvbjozY2I2OGE4MWE2ZWQ0ZDI5OWRiN2MwYWQ1MDU4MzBiY18xMzI_a480d401-29b5-4fdd-9b2f-4c5089dfd7e5">--12-31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mgnx-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i28ca4dfdd9aa48788b912cff0cd21aeb_I20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-10-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i656b1702d3e14be0be6085d06cdf2c30_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id03af012974e455383bba3223db02d75_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i11ab2ecbefa743f0831253b0bab43a2e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cbc36cf427b4048bb3cd430116a3d18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9aacc62ecec4769aef75e7e93eee7cb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f323311ba0f477e8a5eed6444e2f116_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0f0f42a48f649fb9adde86d8c8f3144_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice0dc1c1e98841ed97a1903b7430e16a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f191c2ca22041aba70b10b4dc29f16c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef210ab30594a5c96c8265ceede1a54_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93bb0acbca4c41b1918f1063893322c3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251ea0d889734a40a60b2db0510e4d30_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c7c0500c96d4870a7cda546e1d57804_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fbc608a7ebc4a189668ce0d769f101d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fcac574cbe44ff598b04d63a009d245_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide541262618d4b8ca172e4936bda305e_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecd98e62333946d2bde73cd3927ee687_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678618f17ae24eca9cb47796aaaaadc4_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5643da10e9664d89a666a86f3de255bf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44b26809617d43939a5329f6885680fd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b6082892bd94f66800a06bc094d50ff_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8d7e7284994e3a8718cbc86dddc39c_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2918b1588e24443b4687bb092493234_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i118dbb19ee294bef9dff06aee00e80a6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c17d69a6f44a56a03595fa8f30ca05_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i248e16c8b2404924963b17b9a022deea_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4a65ca63de24c97ba1095455858cfb6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id28db8212ed74e888a6a05d24557a148_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a04baa748a409cac40497b1ac71047_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0034cf911ef4d0987f18fbcf9c12c54_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89a9947c99a4486786e7e887b223f9bb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5da47fec875b45ca8dc4ef858f3b3373_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfbdee7a4f194e1f886e309d5f57e49c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2fcd1d3d2f4c02a9ca03c84aba1084_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168d44892dc64bcfa877caa22d4d2f47_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99d089ec986c490e9d7a9fe9003fab25_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i772e75c235df4ee2ba9c5db15a74d268_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99c4563ef8346599f6f5d683f3ab131_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28c7c5e832994f4984a2b72a7c12a323_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85172e0b52c945fcb48567a2d8cd5d66_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a099bff17804023b9870c32927d44b0_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i083e553805e84a4ab30278ee0b21eea1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86bc84252e164a12a5ef77a9c53239ab_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a85c5a33a1940e686e68c93aa8752a8_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad99730485234a69afe678ff8b091949_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dde4cd27157467b873b883bcb26a3e4_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc1dbdce58a458eb5f7eb8d375ea1df_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242d9a69e198416fb1411637de6c71d0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc1b1f56ad824f4d9f74ac2f6154dc3b_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic22ad87081f44452b54967d211ab676d_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5862997f33c54ac6981fb6685d18aa17_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idabb0d4b38a24297a10a88b8c412b614_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabea7eedc8ed4974a97afbe70ef669e3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52d6b5ad2eb1439ca7b9d6e530b4acd3_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89997c7fe90c43be8e6eac61d5f7f7ce_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i508ac6b80ba5482fb20c800a957c919f_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a5362c6893440ed81f5656a8c74e7d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d97bb4ee6084712b486bea7a21d603e_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11cb9793489f45eeb9391db0da058532_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fdf9d4e0da94e1194a5a8b2baceb2c0_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia192c40bd1d344abbf5835f4a19906fd_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f1781eeabb7431089fcd817959eee47_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f3d327578eb4a8fad5a02f88b706a81_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61390568815449f1b203b09838077cfd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifef9401807084084b4cfcd1497fbd03b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bc51ed445347d490417a0086d4ec6c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1f44ee2b6604e6faceef147adab156b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib02652ca68b840fdb8345db6c3943506_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95c791bd80414458bf798e3a5c8371ca_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53df1531613345a4a20cd107a152c452_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50a90c0416934ef191dae9248e6bd343_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3cd3e5b6f3bb423cb9c8241c4629352a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853b145d4b5d4ff887fe3c813723757a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia965ddea0c0d4929bcaaf10ab3dce00d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i429a8d866ab94f0887344d549058d4a7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i367e0e3322684eb693f6e0db308b49be_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd66a09550047b488eecee849d1ab89_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i351eacc89eba4a779a3a805096b50266_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e1427f09d0a4d849022fa592d4e2510_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd24cb204af040a1896e0e2e134b823c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eee048bc9214fcebfa85d929a62359a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5637258cb9f467daa8468f96fe90010_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76651544b7ed4a3aaf1e1ad08d30d686_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96cf5c6e27734accb1a3e05be19371c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i631c1559593f4350a22a93d85ffed1de_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i661301857c8140fcace77bc9000a2645_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4617b92aae94471a82ddc03195cb0603_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifff3a59bcb8f40719209839b68d4b087_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14cdb49cd71144059cc61727bd2504b3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07e730e5685e4559a024b11728b95988_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ac12fb37dda4afa812ff75ecbb55b47_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i930b7f72b4454a8986e9888ac10ffc56_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dc5e6a1bc8c48528ef4028801eaf60f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92b7234ef3f94f8f922de6a29f863ef0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac0308dd5c1146fd864acc4473bd9d02_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id98a1eb125924f9ebae87f7340768587_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4064a77523204a5c97651a32d316bd67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57bf751d79c94691b038938d560d3571_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7c8218ffeb4024b44e5ecc01780199_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec648d78c60f46bdb12dc3ce89f30a15_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97dd199628d2445cb4a47064a0b74d6a_D20190201-20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-02-01</xbrli:startDate><xbrli:endDate>2019-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e22609aae84c4ba9ad609e47840e0d_I20190228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6514c468c9e740d6b1d05c92467a1618_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2d7928761a04561a98b1772b844011e_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f6e1c1422a241b7865adbaac8d439a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a91773145ff4dc6bed1e4e7d3de5929_D20171001-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d800a4cc7cd4980bee11f68119d53b4_I20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic13ad679ef8a4def92ebbc15dce2b871_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i9e29c2c5bc4b44648d0a8b577e42de39_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if59acebf30ba44029fdad1f534a68269_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia791781a92464af29c8f02db3c401ab8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88964468ab69431eaebd92a52277944f_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e228120dad34e57a7e7cdf18d7fa48d_D20171001-20171031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea44bd2966be41888177853b425961ff_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc7d94081d340628b9b2a71457956e1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aff2b8c451a486ca958bc76fd5a67bb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a340d54cb3d485989696d575daa8669_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie54ccd6d1f4249b7b4f1ac381f526911_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e7d81a9da347bb85af6348231a2bab_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3132c81f87a4d99ba4f564ef87782a6_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b16f811de98474199d531dece74437d_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4f369c54f94171ad9af39bc0da5bbe_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2a7aa88cb654aa884f7e855835ec390_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f6d41510162452d9a466e6c347714d1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ca4c82e803497f86944bb5582a02f0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e461a0cdef74333a6a3069cedba5031_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107f7d71e8f24667bb86b994ab1d73a1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i314a584979b14a389f3c5d964af2863f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d284e79f3044a3ac9625ecf4e891e2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ac8ba9b2e14e9493c732eb3111af36_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea3b158fb7c41879720382aa02de77b_I20190709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f9cc003f349478ca3ed4fe7c6abc14e_D20190701-20190731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i695b50b168414938849dea296be40228_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie164583eab6942249da5bef115ef55e3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ecfdcfeec84c4ea913ab203c146751_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8369f5a9bc24605bd6959601bb26575_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8fb7e409d6b245e5b347e1f893c44d97_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i339805cc81504f138bc5f596b75adf4a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib280116fa7124f13b35c12a7dd273e86_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57e35a0253554ab4b773d0e5048648bb_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i398326bccf184051bda69d4a3c8a1a33_D20180531-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i280712410840475fadcbe6d4b410e8e6_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="performance_obligation"><xbrli:measure>mgnx:performance_obligation</xbrli:measure></xbrli:unit><xbrli:context id="i456c33b61451427ebca4b6600c9eeb6f_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i709d5a4375bc46bfa8eb06e60b804476_D20180701-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="molecule"><xbrli:measure>mgnx:Molecule</xbrli:measure></xbrli:unit><xbrli:context id="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-15</xbrli:startDate><xbrli:endDate>2015-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e4e3bc99de4302af0c36215cc08f6f_D20170101-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i084bc672cb2542ee93482822566c90cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ec7e2284b474d4997d8410cdd14f1b7_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied5a5d5f59e0443393b8732129f9e130_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e1a76d57ce94e01be30cf3cfa42cd5e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5332870f4e4706a838787952f9124b_D20101001-20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="numberofproductcandidates"><xbrli:measure>mgnx:numberOfProductCandidates</xbrli:measure></xbrli:unit><xbrli:context id="ib37d01f8e8ec44a3b82be406e14e4895_I20151031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be796f261a24d47bb6a08dee44be3f7_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8506fff30e343c0a108eac7ddb6eb91_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i682bc99e203a470fadd9467ce13ac26a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651dacb02b694c7cab3fc1042896bf4d_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4659cc916dd3432aa5e78628aca3effd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i301496abba464d8a8e453d6ff8bba901_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35072c1e740040a296f33ad007daa74c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d3cb74cabac4267807f2a0c571ab8f3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3c10bc20e144f36b196b86ec9fb610e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba2e860df1846c29d00f140ae5dfa0e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i267ca7ed35444cc1a4d6d12768b9c471_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3041645d5148e2885536c8ef463ce0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie09d12dbaa6c4616ae1d1ef7740fb483_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b36cc5e5fa4780a5d86d9a4a7471c5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328732a3cf7940cca770d218ab8234b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied85acb778bf4e98a18112866d8afde5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3f7b7f171b04570abfa521633907fa0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i837d975c068f41aa997c97c40d8bbcd5_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl84Mg_5d0292ff-89ab-4f5a-9c91-57ce12494a74">10-Q</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6NmNhZGQ4MjcxNzRkNGU4MjhlNjNiYTQ3NTViOTJlMDUvdGFibGVyYW5nZTo2Y2FkZDgyNzE3NGQ0ZTgyOGU2M2JhNDc1NWI5MmUwNV8wLTAtMS0xLTA_cf750e88-2af4-4dc9-89f1-6b400762f8f5">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xMTg_c88415c4-a363-405c-a649-525ff2b8d18b">September 30, 2020</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.463%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.337%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6M2I1ZTdiZGVmMDI4NDY4ZmIxYTc2YTlmNGQ2ZDVjYmMvdGFibGVyYW5nZTozYjVlN2JkZWYwMjg0NjhmYjFhNzZhOWY0ZDZkNWNiY18wLTAtMS0xLTA_ffe1124a-0d32-46e7-96ba-bea629b81af8">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yMTA_7dd83aa5-aee0-41f2-aae1-1b946565b3ec">001-36112</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yMTM_1c5e5626-d4af-4c45-aa4a-047e76c4fd12">MACROGENICS, INC.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:50.583%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.217%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18wLTAtMS0xLTA_c2a17b06-257e-4400-94ed-6cc7a2c1b4b0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18wLTEtMS0xLTA_d4f4528e-63bb-41d7-824a-fa433a0225d7">06-1591613</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl81_7783a045-bfed-48d2-87a9-53652f06177d">9704 Medical Center Drive</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl84_9e52f0a5-74c9-43a1-b1ab-f960f011fa79">Rockville</ix:nonNumeric>, <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl8xMg_eccc5d40-fecc-495a-81e6-14b6b3d8fa0d">Maryland</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTEtMS0xLTA_812c5d7a-5926-4c17-8b95-b0e74440a711">20850</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Zip code)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yNzM_6c158ede-0962-4c45-9210-fec3762bc9b8">301</ix:nonNumeric>-<ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yNzY_542e7ab2-126b-426b-8498-589b3b154378">251-5172</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant's telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:36.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTAtMS0xLTA_78fd29cf-ec67-417a-a09f-85913d038c5f">Common Stock, par value $0.01 per share</ix:nonNumeric></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTEtMS0xLTA_798b71b3-83bd-4feb-b905-1bf7720425cc">MGNX</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTItMS0xLTA_991b9b47-fa8f-4d54-af08-b434ce0aa5dd">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQw_169f964a-22a2-4abe-a955-e2403dab4573">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQx_116c1737-a9c6-4937-89d8-c71a8f431a20">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of "accelerated filer," "large accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:23.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM18wLTAtMS0xLTA_a1ba471d-2b32-4b34-bcca-8e4f86a1ad19">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM18yLTMtMS0xLTA_a021688e-1ef0-484e-a6c3-52b0eacc665c">&#9744;</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM180LTEtMS0xLTA_f6180d6b-1b0c-4f84-9100-f6629a8c11fb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160; &#9744;</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQy_9e19c908-aafb-448d-afeb-50e77a3d8666">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of October&#160;30, 2020, the number of outstanding shares of the registrant's common stock, par value $0.01 per share, was <ix:nonFraction unitRef="shares" contextRef="i28ca4dfdd9aa48788b912cff0cd21aeb_I20201030" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTMx_01a6bc81-9d13-4400-8d15-ae68ee1f5cde">56,204,015</ix:nonFraction> shares.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_16">Financial Statements</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_19">Consolidated Balance Sheets at </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_19"> (unaudited) and </a>December&#160;31, 2019</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_22">Consolidated Statements of Operations and Comprehensive Loss for the three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_22">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_22"> months ended </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_22"> and </a>September&#160;30, 2019<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_22"> (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Consolidated Statements of Stockholders' Equity for the three and nine months ended September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_25"> and </a>September&#160;30, 2019 (unaudited)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_28">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_28">nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_28"> months ended </a>September&#160;30, 2020<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_28"> and </a>September&#160;30, 2019 (unaudited)</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_31">Notes to Consolidated Financial Statements (unaudited)</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_58">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_79">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_82">Controls and Procedures</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_85">OTHER INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_88">Legal Proceedings</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_91">Risk Factors</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_94">Exhibits</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i837d975c068f41aa997c97c40d8bbcd5_97">Signatures</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in this Quarterly Report on Form 10-Q. Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the severity and duration of the impact of the COVID-19 global pandemic on our business, operations, clinical programs, manufacturing, financial results and other aspects of our business;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to develop and commercialize our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes, including when clinical trials will be initiated or completed, and when data will be reported or regulatory filings will be made;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital through the capital markets or through one or more corporate partnerships, equity offerings, debt financings, collaborations, licensing arrangements or asset sales;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits and future operation of our existing collaborations; </span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to recover the investment in our manufacturing capabilities;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our products;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization, marketing and manufacturing capabilities and strategy;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant competition in our industry;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic, political and other risks associated with our international operations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to receive research funding and achieve anticipated milestones under our collaborations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect and enforce patents and other intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss or retirement of key members of management;</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</span></div><div style="margin-bottom:6pt;padding-left:28pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to maintain effective internal controls.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_16"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMENTS</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_19"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:59.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNC0xLTEtMS0w_ce2f6018-eaa7-49c1-aea9-b8fb62bec2b6">201,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNC0zLTEtMS0w_6a1b15aa-f4cc-47ec-9e42-3e49a31ee231">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNS0xLTEtMS0w_25f44194-1f3e-4a64-96c5-ac65f7b0dfe0">79,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Investments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNS0zLTEtMS0w_177beb0f-3846-45de-a762-d51d230b811c">89,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNi0xLTEtMS0w_b564927f-151f-4cdb-880c-41d2fd8c1802">18,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNi0zLTEtMS0w_7ae836da-c9d6-4afe-b65b-61a3be23273f">12,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNy0xLTEtMS0w_d0e7bd42-7c2c-4951-bf28-6ff146977bc3">10,632</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNy0zLTEtMS0w_f3c76a89-f53d-4729-8df6-e736f3c1b104">11,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfOS0xLTEtMS0w_ddbc06e6-d08c-4dd2-b33f-5ea23e5d672c">310,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfOS0zLTEtMS0w_4d3d476f-2db8-405d-82d5-64a945ffd750">239,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTAtMS0xLTEtMA_192536db-67fc-46e1-be2d-e3d3fc9ed204">41,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTAtMy0xLTEtMA_864cae33-6b1d-4d6a-8337-9ca16a0cebe6">48,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTItMS0xLTEtMA_3bda5151-bb78-46a7-b567-ae2f0dfe39c2">22,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTItMy0xLTEtMA_d286f33a-bd18-4ba5-a353-2da69cfbea6b">24,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTMtMS0xLTEtMA_8ab2560e-f456-4756-8280-eaf0773f5924">374,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTMtMy0xLTEtMA_0e94c197-6a07-4630-9313-7521acfe326e">312,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTctMS0xLTEtMA_ad6e8623-7793-4758-b4a7-089982686816">4,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTctMy0xLTEtMA_e230e990-5a23-47ae-9540-13acfd6575ba">4,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTgtMS0xLTEtMA_c0fa8f5e-6689-43f4-abfc-4820ca51649e">32,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTgtMy0xLTEtMA_dea699e1-5ee3-4748-a062-71443af2dfce">27,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTktMS0xLTEtMA_ea89592b-f098-4191-b6c8-8e7c26fbeb2b">9,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTktMy0xLTEtMA_8ab3f06a-fab4-4bfe-9547-7358a37ea9f8">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjAtMS0xLTEtMA_cf5ddf22-f8d8-4edc-9028-6455a84e7201">3,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjAtMy0xLTEtMA_6cbb154e-fe35-4b89-8ea3-826eae3cb3d1">3,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjItMS0xLTEtMA_79810b02-ebff-4201-b5f3-0290364dc3f3">50,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjItMy0xLTEtMA_0153e471-aa0c-4398-b492-12791600c1a9">45,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjMtMS0xLTEtMA_c6e8396a-6581-416c-a828-fa3113277b4e">5,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjMtMy0xLTEtMA_8d0e1ccf-23a9-4c97-8b42-2a22ab4efcea">9,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjQtMS0xLTEtMA_63fdbac3-f670-44ab-87bf-a5e717ee25db">24,651</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjQtMy0xLTEtMA_9d26bc4c-c348-4f52-bebb-73e22a6ef776">27,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjUtMS0xLTEtMA_0e219cae-e9ab-4317-8b28-2e13a4eebd06">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjUtMy0xLTEtMA_21785c9f-c648-4ad7-987c-13bd480f7ce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjYtMS0xLTEtMA_699490bd-61c9-4741-881a-2b839cde40a4">82,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjYtMy0xLTEtMA_9a10c588-be9a-47a4-a557-67367709ebd0">81,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzE4_617d96f3-c901-46d4-900a-e238545d43a6"><ix:nonFraction unitRef="usdPerShare" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzE4_7653f4f9-2e13-4dc5-8641-82c9da1d1988">0.01</ix:nonFraction></ix:nonFraction> par value -- <ix:nonFraction unitRef="shares" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzM0_1e3e0079-35e3-4416-9c5c-81f3dbccbb88"><ix:nonFraction unitRef="shares" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzM0_c13354c6-1877-45b3-bb7b-c145dea9197b">125,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzU2_9e1144c8-15bc-478c-a29d-8451557e1228">56,174,932</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzYz_3e88063b-0e58-4fe2-8bb9-c1cd075dcacc">48,958,763</ix:nonFraction> shares outstanding at September&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMS0xLTEtMA_03674ce6-4129-4d64-87e8-5959801ee4eb">562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMy0xLTEtMA_333b89fa-eae6-4156-b399-81158a8110e9">490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjktMS0xLTEtMA_50803bf0-fe5e-4108-b405-d8df0a8094be">1,060,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjktMy0xLTEtMA_1927450c-c146-4f3c-a16b-f2f96b1e0820">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzAtMS0xLTEtMA_10b57935-131c-4c04-ac53-21d27bcf31f6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzAtMy0xLTEtMA_72774324-6ef9-4cb3-a2ee-657fc3a05dce">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzEtMS0xLTEtMA_ddd49956-421b-4c84-8e79-17e96b418a90">769,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzEtMy0xLTEtMA_2a35b6fb-fd1c-44a2-82b4-85fb90e743b1">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzItMS0xLTEtMA_e008e6be-e0c9-4b85-af2e-67990dde9fab">291,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzItMy0xLTEtMA_9aac9447-d8a9-40a9-906c-b10ac4c182b8">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzMtMS0xLTEtMA_84b0eee5-c8c4-4592-8619-b27761829abe">374,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzMtMy0xLTEtMA_25807df8-3a59-4a21-8e49-f216b24d9762">312,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.423%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11ab2ecbefa743f0831253b0bab43a2e_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy0xLTEtMS0w_3c5d3ec2-85ee-45d6-9e8a-523109002120">17,415</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cbc36cf427b4048bb3cd430116a3d18_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy0zLTEtMS0w_9b81b59d-4f84-42cd-9ca9-1e204a537863">17,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9aacc62ecec4769aef75e7e93eee7cb_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy01LTEtMS0w_766aeb24-021d-4589-ae8b-43ff5c177577">46,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f323311ba0f477e8a5eed6444e2f116_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy03LTEtMS0w_efb1db48-c4f4-414e-a150-490af31ff1c0">37,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0f0f42a48f649fb9adde86d8c8f3144_D20200701-20200930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC0xLTEtMS0w_c76d18ef-dcc7-403e-bea2-3571eaa63baf">838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice0dc1c1e98841ed97a1903b7430e16a_D20190701-20190930" decimals="-3" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC0zLTEtMS0w_2b09ec63-c9db-4eb7-9c6d-d65b01441702">757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f191c2ca22041aba70b10b4dc29f16c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC01LTEtMS0w_39e32326-ba76-4a51-aad1-d6a94a4df8f7">6,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef210ab30594a5c96c8265ceede1a54_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC03LTEtMS0w_b752d7e4-0259-4f69-b006-ef3659942704">1,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS0xLTEtMS0w_6e3eef16-6c84-455a-9048-83a57d44c758">18,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS0zLTEtMS0w_30a49870-2bd5-4313-aacf-034af325267e">18,741</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS01LTEtMS0w_0f02984c-a502-4dc5-b74b-4fd34b393c83">52,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS03LTEtMS0w_a16d45f4-c7fc-4c27-a7f8-9ca6dd2f6ae3">38,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy0xLTEtMS0w_e98eab5c-be7b-40f8-bcf6-552df5732d83">44,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy0zLTEtMS0w_d675960a-d4da-48d2-bf6f-5687c4fbb477">44,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy01LTEtMS0w_e417c632-3669-4a5b-ba53-53c5b4849aa4">150,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy03LTEtMS0w_59fc0f1f-93e1-4bc5-99c7-c41e38a563bb">143,352</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC0xLTEtMS0w_b96a4d2d-ab13-4ef4-9cfb-66c63c421a2d">9,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC0zLTEtMS0w_a258e614-7827-4a72-b42f-956e0d67e936">11,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC01LTEtMS0w_25b14f98-2270-49bc-9d75-7bdefa4f8624">30,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC03LTEtMS0w_641aab83-c6e5-4e30-948e-0689f2e139b5">34,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS0xLTEtMS0w_d9868b33-be00-47db-a796-49c7699cb107">54,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS0zLTEtMS0w_376bcd5d-f953-4f0f-a5b1-485875f95648">56,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS01LTEtMS0w_082d352f-e4f9-43e1-b840-f61e93cf39f3">181,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS03LTEtMS0w_531b73bd-42fd-42bf-a013-d33c7b37ae13">177,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtMS0xLTEtMA_efaa841a-3ec9-40b5-a864-1c4ea0b7e191">36,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtMy0xLTEtMA_a310b54b-58fa-4da0-b242-2efa7ea50d58">37,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtNS0xLTEtMA_acdbb600-3c98-4db5-b7ea-d7788cfd6c92">128,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtNy0xLTEtMA_b357b0c9-7e49-41f7-b7e8-dd576225161d">138,530</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtMS0xLTEtMA_a757f8b3-9b6f-4d14-8fb8-2a19c41ecfa8">92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtMy0xLTEtMA_4d6ca3e7-514d-4d88-b094-5f0f24cc335b">6,687</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtNS0xLTEtMA_7e81beb3-f0a8-428e-9283-eafdad60dc39">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtNy0xLTEtMA_3e6cf254-2db0-4588-ba9c-37459e61795f">17,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItMS0xLTEtMA_7684835d-c002-4957-8ad3-571312df3d62">36,043</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItMy0xLTEtMA_15e31ae0-e9ae-42c1-b31c-f3a637a6de65">44,631</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItNS0xLTEtMA_2b0868a0-d4bd-4e72-ae0c-998033f4ba3d">127,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItNy0xLTEtMA_8c17f6c3-36b8-40d5-84e4-e23666300d4b">121,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtMS0xLTEtMA_6146e3bb-b647-44f2-96cc-d80a6ea1bfb3">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtMy0xLTEtMA_98075aae-7021-4e00-bab8-cb313788e581">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtNS0xLTEtMA_f0e8a25d-4b88-4600-9bd9-64e3510efa20">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtNy0xLTEtMA_6c5151d6-598d-4fa2-81ba-05dd58976d80">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtMS0xLTEtMA_873a2484-c8ca-492d-a17d-b5b03a72ffd5">36,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtMy0xLTEtMA_8fb9af9f-f486-4621-868a-52621add0202">44,642</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtNS0xLTEtMA_8a87e23b-35f9-4241-a452-cf3a73655397">127,666</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtNy0xLTEtMA_aa7e2de3-3001-4396-aca2-b4172f2c268a">121,389</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per common share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctMS0xLTEtMA_b5254df2-6092-4405-9cff-807adc9440a6">0.66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctMy0xLTEtMA_dd34df70-d054-469e-9ca7-51c1e386c4df">0.91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctNS0xLTEtMA_33c6727f-bd88-4ba1-8058-3e8d0ce5016e">2.49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctNy0xLTEtMA_689ba82f-1123-4239-962a-84f608ae8d20">2.54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted weighted average common shares outstanding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtMS0xLTEtMA_7a8058a0-5c0e-477b-a45c-4ae2e5a55a86">54,463,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtMy0xLTEtMA_e362e7a4-e149-4de6-84b9-bca56bed6f18">48,902,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtNS0xLTEtMA_038d39c2-1c95-437c-a26b-b8cce3c1b8bb">51,176,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtNy0xLTEtMA_70e264b1-1f6d-4d30-90b5-a9fa9504ff9d">47,796,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:94.017%"><tr><td style="width:1.0%"></td><td style="width:19.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.368%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.450%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xLTEtMS0w_f00a51c6-11ea-433c-834f-a033c9ba16bd">48,958,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0zLTEtMS0w_21cd56ec-fcd2-4f13-ac5c-40424811833f">490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy01LTEtMS0w_9b567c52-d40c-4c7d-9c48-8c4f7483ef0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy03LTEtMS0w_5f6f7ce8-d402-4a4c-85b0-c2a8c9235f12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251ea0d889734a40a60b2db0510e4d30_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy05LTEtMS0w_33e0ad7a-8ebf-4111-b144-9c56a0f27bc9">872,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c7c0500c96d4870a7cda546e1d57804_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xMS0xLTEtMA_f50f0866-19de-4a7f-949b-776e99c515a8">642,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fbc608a7ebc4a189668ce0d769f101d_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xMy0xLTEtMA_b9665053-8b78-4d46-bd33-42ef9f116e7c">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xNS0xLTEtMA_6ea9271e-b16d-462e-80bc-bf5c17d40699">230,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNC05LTEtMS0w_b1b52361-3fcd-4925-a92f-fc017ecf088f">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNC0xNS0xLTEtMA_0eca097a-e769-4e78-a9b3-5d0709da2333">4,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0xLTEtMS0w_fe0f5225-3e51-4ad0-a9bb-bd4d512f8f1e">172,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0zLTEtMS0w_8dce5678-0293-4ec2-9f1e-660bf579f89f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi05LTEtMS0w_ba8529d8-8e81-4cc2-a1d4-8eb2f900c0b3">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0xNS0xLTEtMA_00a2614b-03e5-491b-af0a-7971941b87ba">162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fcac574cbe44ff598b04d63a009d245_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNy0xMy0xLTEtMA_00131269-fb6a-4a40-9700-9b06cf146e2d">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNy0xNS0xLTEtMA_a43788f9-3d00-418d-a5c1-5f08ca9c1212">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide541262618d4b8ca172e4936bda305e_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOC0xMS0xLTEtMA_4f51d3b7-271c-4630-8580-30e1c9d229ce">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOC0xNS0xLTEtMA_a0650c9f-6b69-4b1c-a116-85fa9156bd15">44,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iecd98e62333946d2bde73cd3927ee687_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xLTEtMS0w_3d807e6a-93ed-4517-bf8e-b1300ab6e7dc">49,131,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecd98e62333946d2bde73cd3927ee687_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0zLTEtMS0w_a8d17daa-b66d-4aa1-95e9-b4496c572d55">492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS01LTEtMS0w_43fcb16d-2e7c-4771-8b41-d604cb87d4e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS03LTEtMS0w_471c7d27-81c5-4078-bdf7-e14fa710b8e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678618f17ae24eca9cb47796aaaaadc4_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS05LTEtMS0w_3a24ea49-f28a-4a7a-8f8b-5007bbe4cab9">876,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5643da10e9664d89a666a86f3de255bf_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xMS0xLTEtMA_d57781e1-43f8-42ed-a867-9880007ad024">686,806</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44b26809617d43939a5329f6885680fd_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xMy0xLTEtMA_6f2c8003-caba-4255-8fe9-863c879d5af0">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b6082892bd94f66800a06bc094d50ff_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xNS0xLTEtMA_64dfd98d-863f-4711-b8b6-9ee8226aad39">190,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMS0xLTEtMA_72038cc9-bdcc-4e7d-bc30-e206cbcc4be4">4,060,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMy0xLTEtMA_5a2d75f5-0a4f-431c-9b12-c4354d163746">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtOS0xLTEtMA_f820a520-54a7-4ef9-8ecc-0ea7672ed964">96,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMTUtMS0xLTA_278bc417-f86b-4f8a-a633-3f2e013c4e53">96,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTEtOS0xLTEtMA_cb2ee657-d8d5-4098-8824-6643b5b4254a">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTEtMTUtMS0xLTA_f519f7c2-9d71-4c91-8c3b-274f42b74f42">5,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMS0xLTEtMA_ea090d33-8d88-47e8-9ca8-b049641b1604">173,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMy0xLTEtMA_db847d53-d9ce-43fb-b597-eb459178677c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItOS0xLTEtMA_b8e00f95-e1af-43f7-be7d-7e089296fefb">2,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMTUtMS0xLTA_d28cf94c-d383-4ce0-89cd-594e5a1a8373">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc8d7e7284994e3a8718cbc86dddc39c_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTMtMTMtMS0xLTA_41e88a55-776b-40ab-9a95-1308d5fc5408">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTMtMTUtMS0xLTA_cf19b4a8-c8b7-4588-b021-e00529ae5c31">55</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id2918b1588e24443b4687bb092493234_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTQtMTEtMS0xLTA_80d87122-9cb0-4db3-bcec-9663d533c89b">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTQtMTUtMS0xLTA_d3eb5d0f-d37f-4d2c-beb6-7ef8e228f898">46,885</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMS0xLTEtMA_159c5e57-b129-4f9b-8934-e0ff3008a0c9">53,365,003</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMy0xLTEtMA_e7a8293e-f13f-45ef-9dc2-841da3adb3bc">534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtNS0xLTEtMA_c6df2a6d-a705-4cd7-8da0-82b7f41dfafb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtNy0xLTEtMA_08170150-cd87-495f-a8e4-b7854f3aae11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i118dbb19ee294bef9dff06aee00e80a6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtOS0xLTEtMA_5bea8bca-e09f-4763-beb7-577758ea7855">980,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31c17d69a6f44a56a03595fa8f30ca05_I20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTEtMS0xLTA_5e0b5da4-b8c7-4237-877a-b9fa34f0d6d0">733,691</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i248e16c8b2404924963b17b9a022deea_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTMtMS0xLTA_6831a198-ea81-4b6c-9529-5554ef083554">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4a65ca63de24c97ba1095455858cfb6_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTUtMS0xLTA_e778c972-a71e-4846-a056-4d8dd3fe5fa2">247,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMS0xLTEtNDc2_66502aec-0dd7-47f5-b09a-ba0f10fd9ee6">2,552,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMy0xLTEtNDc2_6b753eed-589e-4b9d-b490-c5ee7802a8fd">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtOS0xLTEtNDc2_1793bc52-79fb-4b6b-a5d5-cc27138a7d8a">73,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMTUtMS0xLTUwMg_fa6689f6-88f8-4ed1-a937-0df9be0256a1">73,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtOS0xLTEtMA_2e6272e5-2a32-4c0d-894f-2a6333b977d8">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMTUtMS0xLTA_39133654-ab78-4964-b518-ff41f50fe033">5,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMS0xLTEtMA_18b795a8-5680-4906-9010-cf095d8dab80">257,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMy0xLTEtMA_b8acea12-8f29-4612-a731-b93fb7a72005">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctNS0xLTEtMA_e67806ee-d2d9-4bf6-8f18-2b20254c3051">74,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctNy0xLTEtMA_de283212-e77c-4adf-901a-be4029300dfa">2,012</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctOS0xLTEtMA_2704bffa-0195-4e44-abc7-eb777164c1ea">2,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMTUtMS0xLTA_dc2f35cf-0d26-4ec6-a936-6c0ea5e5a70d">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement of treasury stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktNS0xLTEtNDg2_05a7696b-3cd5-4efd-b510-fe73aa7c1c79">74,632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktNy0xLTEtNDg2_e57a80e4-0e47-470b-83de-35da1e63e29b">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktOS0xLTEtNDg2_315f31cd-fa83-4b07-a9f8-e7166403a766">2,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTUtMS0xLTQ5Mw_4fa6c29b-9295-4696-9da4-e76c1be07e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0034cf911ef4d0987f18fbcf9c12c54_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTgtMTMtMS0xLTA_d9348b4e-9cb7-4711-9011-2adeb93688a7">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTgtMTUtMS0xLTA_46691ed2-b2a7-418b-b57f-645230d40e6e">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i89a9947c99a4486786e7e887b223f9bb_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTEtMS0xLTA_b55d265f-6452-4533-89a0-b92f8e5d43e7">36,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTUtMS0xLTA_851cce80-83fa-4588-8e03-33138ec0f1cc">36,043</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5da47fec875b45ca8dc4ef858f3b3373_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMS0xLTEtMA_f89ed634-8435-4854-9310-1a01ae2dcfa7">56,174,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5da47fec875b45ca8dc4ef858f3b3373_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMy0xLTEtMA_09f21b03-88fb-47a7-98e4-3b25a52e3c1c">562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtNS0xLTEtMA_532ebafb-3308-4bb3-bbfd-a31cc3178b39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtNy0xLTEtMA_271223b0-04aa-4601-9610-e7b130b5ce54">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfbdee7a4f194e1f886e309d5f57e49c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtOS0xLTEtMA_394fc4b4-5e0f-40ab-97e4-bd4d87cfa8dd">1,060,755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f2fcd1d3d2f4c02a9ca03c84aba1084_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTEtMS0xLTA_5f23c13b-4d5e-4f32-9657-347289a370c5">769,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168d44892dc64bcfa877caa22d4d2f47_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTMtMS0xLTA_0d154991-16b9-4d99-a109-4799a06e5490">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTUtMS0xLTA_890908fd-05ed-49ec-abf1-0e6e51a2c29c">291,585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:91.773%"><tr><td style="width:1.0%"></td><td style="width:24.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.699%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.080%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.479%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99d089ec986c490e9d7a9fe9003fab25_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xLTEtMS0w_a1c80958-5d38-4f49-b3fb-bcc5f7be4340">42,353,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99d089ec986c490e9d7a9fe9003fab25_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0zLTEtMS0w_013f241f-3601-422a-8b32-94a1b2521e04">424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i772e75c235df4ee2ba9c5db15a74d268_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi05LTEtMS0w_31643560-0236-425b-9f91-21c0b14208e0">732,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99c4563ef8346599f6f5d683f3ab131_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xMS0xLTEtMA_627bae7a-fbd1-4ac3-b3e0-df7a1570a85c">490,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28c7c5e832994f4984a2b72a7c12a323_I20181231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xMy0xLTEtMA_56a8bf18-a672-48d9-8c5d-deccdafe8a99">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85172e0b52c945fcb48567a2d8cd5d66_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xNS0xLTEtMA_d2990a7e-bbf1-4046-9213-ed6f966788b4">242,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMy05LTEtMS0w_48141a9c-e3a4-4da4-a429-8bafe47db6b0">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMy0xNS0xLTEtMA_ba94e736-a280-4000-9815-eb9d980bf861">3,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0xLTEtMS0w_1a394016-e3b7-4193-b8a6-84b94796f6e4">6,325,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0zLTEtMS0w_ddaf502f-8d4f-4007-89d1-ee78505a32ad">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC05LTEtMS0w_ed725939-95b1-4b91-abf8-b162d15ce8ff">118,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0xNS0xLTEtMA_f1463d2f-db08-4734-9554-36644f18b739">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0xLTEtMS0w_69f09e1e-1b5e-44fc-b3f6-ab744c08a2f5">126,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0zLTEtMS0w_1e3a3923-1a7b-4a00-b172-3f09b32b002d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS05LTEtMS0w_73cbd9d1-9d15-4b61-aa14-719d17e55e6b">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0xNS0xLTEtMA_0d4a79e5-fdb5-4757-a537-c843a022f632">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i083e553805e84a4ab30278ee0b21eea1_D20190101-20190331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNi0xMy0xLTEtMA_d80fea2f-10b2-4f2b-9269-605694441ddd">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNi0xNS0xLTEtMA_71704bde-94bc-4c4b-ba42-bf0851ee33e1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86bc84252e164a12a5ef77a9c53239ab_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNy0xMS0xLTEtMA_c8548321-b7b2-49dd-8476-43f055214c62">45,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNy0xNS0xLTEtMA_e088db8b-c5c3-4796-980a-52009aedc90b">45,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a85c5a33a1940e686e68c93aa8752a8_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xLTEtMS0w_a209fde7-1b8d-4003-9cc1-1201ae405e61">48,805,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a85c5a33a1940e686e68c93aa8752a8_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0zLTEtMS0w_2d059e3b-72cf-481f-a21e-285f368af2d5">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad99730485234a69afe678ff8b091949_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC05LTEtMS0w_d01d460b-2053-4e74-ade7-c47b0dc9de3f">855,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4dde4cd27157467b873b883bcb26a3e4_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xMS0xLTEtMA_395005c8-9f9f-4604-8e7a-c40e567439c1">535,288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc1dbdce58a458eb5f7eb8d375ea1df_I20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xMy0xLTEtMA_f79d1ff2-f09c-4d1c-a90f-62601efd452a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242d9a69e198416fb1411637de6c71d0_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xNS0xLTEtMA_c8b8ec45-55f2-41dc-add7-a0171842fe9c">320,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOS05LTEtMS0w_5dc681c3-8998-4709-baf3-fe57b5794fdb">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOS0xNS0xLTEtMA_56aeebb3-64d6-48c7-b261-53ac55a2cf21">4,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMS0xLTEtMA_17bb3d00-ea7a-4d32-a212-d099756a3bb4">88,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMy0xLTEtMA_66d20526-8a68-4984-8f71-5159f988421a">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtOS0xLTEtMA_b34a8245-75ce-43d3-8e83-075be8077cae">633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMTUtMS0xLTA_13f308da-ba39-4db7-b73c-6b00c62ff7b7">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc1b1f56ad824f4d9f74ac2f6154dc3b_D20190401-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTItMTMtMS0xLTA_748c5577-31d4-44c3-9f7f-154ec41216b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTItMTUtMS0xLTA_e783c57e-95fc-4577-8e81-e27bf1092b1c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic22ad87081f44452b54967d211ab676d_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTMtMTEtMS0xLTA_ad4e5444-d26f-4202-b449-b431ac3bd441">31,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTMtMTUtMS0xLTA_c550c22e-b565-4df8-9c40-a5c03564d52e">31,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June 30, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMS0xLTEtMA_f0d13fc1-c141-45f5-abec-3be113837197">48,893,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMy0xLTEtMA_e6886dc2-415f-460f-9242-f1ed15b751a2">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5862997f33c54ac6981fb6685d18aa17_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtOS0xLTEtMA_b1778dad-52f4-453c-9843-e3187ca7b3cb">860,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idabb0d4b38a24297a10a88b8c412b614_I20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTEtMS0xLTA_1856ae7d-5611-4a21-b83f-17b2d3659c36">567,055</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabea7eedc8ed4974a97afbe70ef669e3_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTMtMS0xLTA_b8002a8e-859e-4f4f-ad78-6d0772fac2b3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52d6b5ad2eb1439ca7b9d6e530b4acd3_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTUtMS0xLTA_2841c2d3-94c4-492e-9d77-55a9de5b7a35">294,451</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTUtOS0xLTEtMA_0fbcc624-59c5-47e6-b406-6288e5de2e45">5,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTUtMTUtMS0xLTA_636795f7-4524-4fed-ac96-aef5234c3287">5,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock plan related activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89997c7fe90c43be8e6eac61d5f7f7ce_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtMS0xLTEtMA_6f62aac3-99e5-49d4-a2aa-49bb49e0ac6e">20,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtOS0xLTEtMA_124e03bb-beb1-493d-8dfa-7b7da09f69a0">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" name="us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtMTUtMS0xLTA_a72063ff-2672-43d1-bba4-6ab01a121412">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i508ac6b80ba5482fb20c800a957c919f_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTctMTMtMS0xLTA_ba21f8c2-39be-4f5e-8957-622e172a8954">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTctMTUtMS0xLTA_0a119fd6-537e-4e2d-b5d1-f72163602682">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a5362c6893440ed81f5656a8c74e7d1_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTgtMTEtMS0xLTA_bf50c6b8-6f58-4385-b060-89016ca68879">44,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTgtMTUtMS0xLTA_f29e6b08-fbf9-4dc1-be81-5dd166e19d14">44,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d97bb4ee6084712b486bea7a21d603e_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMS0xLTEtMA_334ff5a7-ac08-493a-9445-3c0ce2a4f7e7">48,914,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d97bb4ee6084712b486bea7a21d603e_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMy0xLTEtMA_867930ba-11a3-4221-ad87-8940fba39dee">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11cb9793489f45eeb9391db0da058532_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktOS0xLTEtMA_1db5a425-d508-4b8a-bc00-629ad78f49fb">866,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0fdf9d4e0da94e1194a5a8b2baceb2c0_I20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTEtMS0xLTA_397362a8-1fe2-438c-8d6c-1c7789a94c01">611,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia192c40bd1d344abbf5835f4a19906fd_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTMtMS0xLTA_9a97e6e9-9793-499c-bb29-40ed0b0a784c">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1781eeabb7431089fcd817959eee47_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTUtMS0xLTA_cb901ddc-e14d-4623-b938-ad7791e7aa78">255,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:68.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.732%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMy0xLTEtMS0w_1b39f1f7-d2e7-4eac-9cee-26057e3246f9">127,652</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMy0zLTEtMS0w_535c0e1c-e082-4f80-a679-c8b11297f909">121,415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNS0xLTEtMS0w_cfc7827e-db8d-4adb-afe8-a51601317951">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNS0zLTEtMS0w_27d0eb37-151f-445d-95bf-b2647b3f4f25">9,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNi0xLTEtMS0w_ce24182b-b0f1-4cec-a5e9-9f30045f5299">387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNi0zLTEtMS0w_9ac25814-57e5-44c5-ae79-7c632e5cd5c4">1,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNy0xLTEtMS0w_c9eed6ea-7473-4ad2-83e1-826b5b86201a">15,419</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNy0zLTEtMS0w_72a31af9-52fa-4616-ba78-12bb7b4db3d2">14,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfOS0xLTEtMS0w_94cd0a85-ac36-4aa0-8e2f-039953f8b353">6,033</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfOS0zLTEtMS0w_ec3fc70e-3d60-44d4-b9cd-64d4150fe0a4">20,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTAtMS0xLTEtMA_74ed6a08-0ac6-4257-b5b4-e08bed9d8529">654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTAtMy0xLTEtMA_90ea6401-66c5-41d9-a6b6-c7ec09a2a503">5,612</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTEtMS0xLTEtMA_0a4987ac-4d46-44e7-9efa-cd9016b1847f">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTEtMy0xLTEtMA_1d53c372-80d1-4c00-b41c-bf535ece141e">2,621</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTItMS0xLTEtMA_3132e7ff-3b18-4ce1-b110-42f29ad8b458">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTItMy0xLTEtMA_6bb232b3-1ce1-4372-b68e-c11acd5f5510">913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTMtMS0xLTEtMA_16dcf26a-91ea-4417-b938-60a56348c37d">5,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTMtMy0xLTEtMA_7912d293-5dda-4510-9751-25f4f907343b">4,678</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTQtMS0xLTEtMA_bc0314cb-c083-4082-bf64-8ed18d30e3d3">2,113</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTQtMy0xLTEtMA_7bd7b841-8c19-40b2-9b2a-3ed07bd7588e">3,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTUtMS0xLTEtMA_6ba8e841-c7d5-48ad-84c9-bdd37ecf3686">4,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTUtMy0xLTEtMA_e1617f57-faba-4393-b460-f0180e962f34">7,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTYtMS0xLTEtMA_58c61fe1-b7e3-45e5-8f83-97b2001d4f32">2,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTYtMy0xLTEtMA_7dc5a36a-c723-46b2-aa55-fefe0374a6ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTctMS0xLTEtMA_e653a6db-5550-4cec-9d3a-a58e5e75e7ba">106,365</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTctMy0xLTEtMA_567a0973-84bd-4705-9da5-70032130e58f">96,226</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTktMS0xLTEtMA_f33e2f93-cbb2-482d-97f7-a09df75afac8">151,230</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTktMy0xLTEtMA_ff1cd014-fbb2-4c48-a24b-2943c2b6a36d">214,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale and maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjAtMS0xLTEtMA_79f14aba-baf4-49d2-a545-976df7829cd7">161,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjAtMy0xLTEtMA_9d017467-c1d4-4e89-8ef0-0b41558f282d">130,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjEtMS0xLTEtMA_380d1bb2-5268-4764-9ede-55a895f3e9ac">2,346</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjEtMy0xLTEtMA_0a78e0b1-cd9d-4e35-a441-ec072f55e412">3,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjItMS0xLTEtMA_fbe06c56-18ae-4045-9880-a197d58f0f64">8,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjItMy0xLTEtMA_fd0735c2-c80e-4e50-9282-9ab130421717">86,984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjQtMS0xLTEtMA_843dd71b-edf0-4875-a217-95962cee9a88">170,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjQtMy0xLTEtMA_2518b2b7-d813-4b9c-806e-72612c2edd17">118,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and ESPP purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjUtMS0xLTEtMA_635d4080-04b8-4c54-8cfd-a9c1e276f810">4,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjUtMy0xLTEtMA_f364283f-fc27-4a21-8cb2-d075d8db421b">1,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="mgnx:RetirementOfTreasuryStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMS0xLTEtODE0_334805bf-dfb4-4532-933a-dfab0c02e14c">2,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="mgnx:RetirementOfTreasuryStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMy0xLTEtODE0_1080eb17-3f56-4d91-9a98-e96439130b89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMS0xLTEtMA_f66266bd-00b5-4ee0-a8bf-2d9d81087951">173,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMy0xLTEtMA_f74d0017-6949-4d01-992f-5d891bc9dbae">119,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjctMS0xLTEtMA_c0d68bac-5745-4dc2-a1f3-b6c879c78045">75,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjctMy0xLTEtMA_300a1d62-f36c-4ccb-b4b7-bd502f902917">63,535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjgtMS0xLTEtMA_03784b8c-0c8c-4032-89b3-e16030808bb4">126,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85172e0b52c945fcb48567a2d8cd5d66_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjgtMy0xLTEtMA_a6bbfb69-dcca-4866-a94b-29caf3a23dd9">220,128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjktMS0xLTEtMA_a75aeaa7-2ee0-4843-b661-ad8b9a947551">201,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f1781eeabb7431089fcd817959eee47_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjktMy0xLTEtMA_b5d8681e-caee-43f3-822d-4bff400ef90b">156,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:13pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets modified in exchange for operating lease obligations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMzItMS0xLTEtMA_4565438e-c593-4763-988e-11e83590742e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMzItMy0xLTEtMA_81b9cb73-8cff-4c0c-ac53-2cad755bbca1">6,408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_31"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MACROGENICS, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_34"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNC9mcmFnOjdhODgyOTE5MTc3MTRkNTM5YWRjMmVhZjhiODAzMjY2L3RleHRyZWdpb246N2E4ODI5MTkxNzcxNGQ1MzlhZGMyZWFmOGI4MDMyNjZfMzAxMw_e0f3a4a4-4cc3-43a1-a7d4-3491ca48ea01" continuedAt="id3bcb44e51004d669dbf28c9af7d18fa" escape="true">Basis of Presentation and Risks and Uncertainties</ix:nonNumeric></span></div><ix:continuation id="id3bcb44e51004d669dbf28c9af7d18fa"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNC9mcmFnOjdhODgyOTE5MTc3MTRkNTM5YWRjMmVhZjhiODAzMjY2L3RleHRyZWdpb246N2E4ODI5MTkxNzcxNGQ1MzlhZGMyZWFmOGI4MDMyNjZfMzAxMA_c55df289-40f0-4818-bf10-fea4da0dd2a8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2020.</span></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. To date, although there has been some negative impact on the Company's business and operations, including, for example, slowed clinical trial enrollment, the Company has been able to mitigate against more severe impacts of COVID-19 on its business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on the Company's business in the future depending on the depth of the effects and the duration of the crisis. The COVID-19 pandemic is an evolving situation and the Company continues to monitor its business very closely to try and mitigate any potential impacts. Significant delays in the timing of the Company's clinical trials and in regulatory reviews could adversely affect its ability to commercialize the product candidates in the Company's pipeline. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Company cannot precisely predict the impact that COVID-19 will have in the future due to numerous uncertainties, including the severity of the disease, the duration of the outbreak, actions that may be taken by governmental authorities, and the impact to the business of the Company's supply chain. Given these uncertainties, COVID-19 could disrupt the business of certain of the Company's collaborators and impact the Company's business operations and its ability to execute on the Company's associated business strategies and initiatives, and adversely impact the Company's consolidated results of operations and/or the Company's financial condition in the future. The Company will continue to closely monitor and evaluate the nature and extent of the impact of COVID-19 to its business, consolidated results of operations, and financial condition.</span></div></ix:continuation><div id="i837d975c068f41aa997c97c40d8bbcd5_37"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNy9mcmFnOmExNzk1Nzg2ODcyMzRlMWY5MjBjYTA5MTZmYmY1M2FlL3RleHRyZWdpb246YTE3OTU3ODY4NzIzNGUxZjkyMGNhMDkxNmZiZjUzYWVfNDAyNA_ce1def6c-8e6a-4ea6-ba63-f2603a30766a" continuedAt="i084a5d2eef774996883a865236276809" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i084a5d2eef774996883a865236276809" continuedAt="i11186633e23d46428dc023df38c96393"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13) during the nine months ended September 30, 2020, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNy9mcmFnOmExNzk1Nzg2ODcyMzRlMWY5MjBjYTA5MTZmYmY1M2FlL3RleHRyZWdpb246YTE3OTU3ODY4NzIzNGUxZjkyMGNhMDkxNmZiZjUzYWVfNDAyNQ_d59bc1fd-f8c1-4558-bfea-00132ba8f076" continuedAt="iba7834f38b964454b5f750f4e86c133c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i11186633e23d46428dc023df38c96393"><ix:continuation id="iba7834f38b964454b5f750f4e86c133c" continuedAt="i35171952912141e1b5f22e682befe941"><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 4, Marketable Securities, for additional information.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a prospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a retrospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div></ix:continuation><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i35171952912141e1b5f22e682befe941">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</ix:continuation>.</span></div></ix:continuation><div id="i837d975c068f41aa997c97c40d8bbcd5_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMzEzNA_fb8795f6-7154-480d-b1cf-2bd49714bf4e" continuedAt="if31d3f7efb4a42658a0ad48e584682a7" escape="true">Fair Value of Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="if31d3f7efb4a42658a0ad48e584682a7" continuedAt="iec8cbf6d1b40486f98bb465527479a3f"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iec8cbf6d1b40486f98bb465527479a3f"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMzEzNg_6abea33a-e684-47f6-b079-9cbc338be5e8" escape="true"><div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:29.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.692%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3d327578eb4a8fad5a02f88b706a81_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC0xLTEtMS0w_0bcf9e8d-64d4-4545-a2aa-977fe2af7d5a">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61390568815449f1b203b09838077cfd_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC0zLTEtMS0w_2bfed584-4730-4be2-8241-efb72e39a042">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifef9401807084084b4cfcd1497fbd03b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC01LTEtMS0w_53970d09-e5c4-4831-8c45-395994272ed0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18bc51ed445347d490417a0086d4ec6c_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC03LTEtMS0w_14f6a226-8fd2-4a7e-80af-f29994c593bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1f44ee2b6604e6faceef147adab156b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS0xLTEtMS0w_cf31e817-c614-4b66-97dc-3311b49f26c6">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib02652ca68b840fdb8345db6c3943506_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS0zLTEtMS0w_567df5c3-f665-4c58-abcc-c34ebfb1739a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95c791bd80414458bf798e3a5c8371ca_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS01LTEtMS0w_266a4158-7355-4d59-bbf5-2b3a1f716e16">60,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53df1531613345a4a20cd107a152c452_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS03LTEtMS0w_a7d600e7-6175-4fc2-bf2e-575ba40645be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50a90c0416934ef191dae9248e6bd343_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi0xLTEtMS0w_de293367-0f0c-42bf-b5e1-b2ee35575f04">14,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cd3e5b6f3bb423cb9c8241c4629352a_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi0zLTEtMS0w_4a5855cc-4104-4806-a11b-bb6ec64b29c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i853b145d4b5d4ff887fe3c813723757a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi01LTEtMS0w_370d3450-9fea-4e27-890e-62a74c61e7c3">14,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia965ddea0c0d4929bcaaf10ab3dce00d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi03LTEtMS0w_0e390615-cf6c-4e88-ab87-b2bc2bffb393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i429a8d866ab94f0887344d549058d4a7_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy0xLTEtMS0w_4e56a813-ec58-4f73-88b1-8603f1f487e9">23,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i367e0e3322684eb693f6e0db308b49be_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy0zLTEtMS0w_7edb4668-c366-4fc8-b129-1e31e1996fc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd66a09550047b488eecee849d1ab89_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy01LTEtMS0w_da325c16-bae6-40cf-8296-3763fc3faaba">23,759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i351eacc89eba4a779a3a805096b50266_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy03LTEtMS0w_7ed813c8-2eae-4c3e-b656-aa93739f81b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e1427f09d0a4d849022fa592d4e2510_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS0xLTEtMS0w_a2eba3ce-5806-4072-a34f-f19cd2169217">143,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd24cb204af040a1896e0e2e134b823c_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS0zLTEtMS0w_4b3bece0-9c2a-4539-a26c-73328f566c59">45,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eee048bc9214fcebfa85d929a62359a_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS01LTEtMS0w_efa9a05e-1e18-4f13-b55d-1845a72aab94">97,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5637258cb9f467daa8468f96fe90010_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS03LTEtMS0w_6aa913bf-8984-455b-8b6e-f5a8528543f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76651544b7ed4a3aaf1e1ad08d30d686_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC0xLTEtMS0w_4886a80c-cf32-4832-90d2-084a4cc6e514">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96cf5c6e27734accb1a3e05be19371c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC0zLTEtMS0w_66d86f52-43a0-462c-864e-0e996129d3da">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i631c1559593f4350a22a93d85ffed1de_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC01LTEtMS0w_f95f5aa9-8b6c-4e16-8318-c8170c42f458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i661301857c8140fcace77bc9000a2645_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC03LTEtMS0w_0d01522c-6eb2-483b-9d39-31f6a77f9583">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4617b92aae94471a82ddc03195cb0603_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS0xLTEtMS0w_c86a0fd9-0b3b-4fc1-b38b-bdc139869266">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifff3a59bcb8f40719209839b68d4b087_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS0zLTEtMS0w_644192b1-8ead-4337-9719-d6c400a96054">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cdb49cd71144059cc61727bd2504b3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS01LTEtMS0w_192032ae-74ae-45e8-b3ba-02ba98c93eae">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07e730e5685e4559a024b11728b95988_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS03LTEtMS0w_2a3b3a67-7062-4f3c-b154-79a3665a9c90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ac12fb37dda4afa812ff75ecbb55b47_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi0xLTEtMS0w_c8b6edbd-5096-4ae0-bcef-2db73549904f">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i930b7f72b4454a8986e9888ac10ffc56_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi0zLTEtMS0w_fcd0529a-677c-4678-be7c-dbd0f9c3e16e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dc5e6a1bc8c48528ef4028801eaf60f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi01LTEtMS0w_48df6d5c-9dcf-496f-bfb8-e30d26cab997">103,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b7234ef3f94f8f922de6a29f863ef0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi03LTEtMS0w_8019cbbe-fb7f-46af-9725-0d002e70e107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy0xLTEtMS0w_c402f025-19fe-41fc-a37f-5d7ce02144a6">162,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac0308dd5c1146fd864acc4473bd9d02_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy0zLTEtMS0w_2a8616e7-e06c-44fe-98da-c27a91358386">46,149</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id98a1eb125924f9ebae87f7340768587_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy01LTEtMS0w_e9fc825c-45e4-4c87-88ce-4f9c8a0591fe">116,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4064a77523204a5c97651a32d316bd67_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy03LTEtMS0w_5f85afad-8654-4538-b422-4deaa301374d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2020 includes approximately $<ix:nonFraction unitRef="usd" contextRef="i0e1427f09d0a4d849022fa592d4e2510_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMjUzNg_a0164729-7e5d-4d5f-9d2a-b929f9143ece">64.5</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $<ix:nonFraction unitRef="usd" contextRef="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMjY4MQ_078c632b-bf48-4cfb-9d38-2ef5a13960fa">73.2</ix:nonFraction> million reported in cash and cash equivalents on the consolidated balance sheet.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented.</span></div></ix:continuation><div id="i837d975c068f41aa997c97c40d8bbcd5_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfMTE3Ng_4c8d4dcc-b602-46f8-b760-baf29a754297" continuedAt="i476066ea1aee4e5aac37c600c15af9e9" escape="true">Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="i476066ea1aee4e5aac37c600c15af9e9" continuedAt="ia65c3ae661274c8c9e7bba14b738597a"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:AvailableForSaleSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfMTE3Nw_cd1564a2-d939-4416-a4b5-1d5e4910f74b" continuedAt="i6f27ea91a0fe4e86af6397b47d23f9e0" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.307%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.297%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.247%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.297%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.307%"></td><td style="width:0.1%"></td><td style="width:0.0%"></td><td style="width:0.297%"></td><td style="width:0.0%"></td><td style="width:1.0%"></td><td style="width:3.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi0xLTEtMS0w_cd7ddf8e-32e7-4e9c-b222-1c6d90fd2149">60,003</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi0zLTEtMS0w_2e46a61b-baf6-4494-b629-562b6f032594">2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi01LTEtMS0w_9add6272-7fb5-44a4-9857-03608984e3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi03LTEtMS0w_a8a90f8d-7be0-42dc-8ad4-6e8cd68e1166">60,005</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bf751d79c94691b038938d560d3571_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy0xLTEtMS0w_1be289fb-bcd3-416d-abd1-cc322bcf2f48">14,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bf751d79c94691b038938d560d3571_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy0zLTEtMS0w_29a673e3-8811-49ce-9c51-bf842253b2c0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bf751d79c94691b038938d560d3571_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy01LTEtMS0w_e7218f50-8e51-4653-97e2-0a1863d8a0ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57bf751d79c94691b038938d560d3571_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy03LTEtMS0w_519a4e15-cfb4-4729-9da0-168a42479360">14,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC0xLTEtMS0w_5b7b7c73-24dd-4e54-9c0d-ff9c5300b296">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC0zLTEtMS0w_15ae06bf-44ca-4658-a271-bc7addba0f0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC01LTEtMS0w_443643b9-908f-467c-8975-b0bf32c3b937">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC03LTEtMS0w_b0c352fa-0edf-4951-a20d-9c706171ff0f">5,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS0xLTEtMS0w_bad3a63c-6247-463b-baa0-828134561c78">79,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS0zLTEtMS0w_a9b0b75c-dd82-464d-a077-8e5fed5de066">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS01LTEtMS0w_166d5476-e896-40f5-b4d0-e00c1354ba91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS03LTEtMS0w_e11dddaf-0e19-4b4d-ac3d-7a21641f1ee4">79,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><ix:continuation id="ia65c3ae661274c8c9e7bba14b738597a" continuedAt="iadbce4639d8e415ba8841581d384a01d"><ix:continuation id="i6f27ea91a0fe4e86af6397b47d23f9e0"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:53.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.798%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.801%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi0xLTEtMS0w_6912cbd3-65ff-44d9-bf03-a35051dc5d45">13,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi0zLTEtMS0w_efefe1cb-96ed-4054-809b-eab9c28c1fc1">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi01LTEtMS0w_f437d520-4ca6-482b-aa91-ecf929c8a3aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi03LTEtMS0w_d649b639-fb99-47d9-ae38-c42060c6cbc1">13,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy0xLTEtMS0w_bb4e403d-e937-4c68-b7b9-523d5d57a3ab">76,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy0zLTEtMS0w_91d076db-ba6f-43af-8f6c-f8672dd8e9d5">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy01LTEtMS0w_44604e36-a5ef-44e7-83c9-2fbaa3e5bc84">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy03LTEtMS0w_51828cfe-d662-4960-9532-f78697bd576f">76,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC0xLTEtMS0w_2bd91a92-8f8c-4a90-bf80-b099b5511ba7">89,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC0zLTEtMS0w_e6e4415b-b42b-49a9-b4a6-ffb561bee910">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC01LTEtMS0w_1fe808ac-8880-4302-8293-468a3847fe49">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC03LTEtMS0w_a8659ffb-0bd3-4b84-abb5-7d4384495346">89,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iadbce4639d8e415ba8841581d384a01d">All available-for-sale marketable debt securities held as of September&#160;30, 2020 and December&#160;31, 2019 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, <ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfNjgy_4e16a7b9-5193-4df1-939c-90a6f90dd0f1">no</ix:nonFraction> allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the nine months ended September 30, 2020. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. <ix:nonFraction unitRef="usd" contextRef="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfOTk4_3afeda88-0f1f-46c1-8153-5bd77ca6a166">No</ix:nonFraction> losses related to other-than-temporary impairments of our available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended December&#160;31, 2019</ix:continuation>.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_46"></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTUzMg_0c27e777-1473-47fb-8585-539de16f89a9" continuedAt="ice6251851993441aaa97932ac3a0a396" escape="true">Stockholders' Equity</ix:nonNumeric></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:3pt;text-indent:36pt"><ix:continuation id="ice6251851993441aaa97932ac3a0a396" continuedAt="if041d3ff1c2643f8a438e705cc438458"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company completed a </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">firm-commitment underwritten public</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offering, in which the Company sold <ix:nonFraction unitRef="shares" contextRef="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTQ0_024f218e-3d00-482e-9137-bbab5cc417ea">5,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="iec648d78c60f46bdb12dc3ce89f30a15_I20190228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTg4_3fcd6491-9f86-485f-9836-96ddcaaaf05d">20.00</ix:nonFraction> per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional <ix:nonFraction unitRef="shares" contextRef="i97dd199628d2445cb4a47064a0b74d6a_D20190201-20190228" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMzQ1_a1f62f33-a586-4819-90f6-3f441278d2f2">825,000</ix:nonFraction> shares of the Company&#8217;s common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i44e22609aae84c4ba9ad609e47840e0d_I20190228" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMzk5_32cf95ce-e6bc-4bb5-97d2-321578691d8c">20.00</ix:nonFraction> per share. The Company received net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfNDY0_703aa4ef-23e3-4bc8-90e5-ae1e1765f34a">118.7</ix:nonFraction> million from this offering, net of underwriting discounts and commissions and other offering expenses.</span></ix:continuation></div><div style="margin-top:3pt;text-indent:36pt"><ix:continuation id="if041d3ff1c2643f8a438e705cc438458" continuedAt="i3fbb1bc8db51424eb7aeb746b28ed1da"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i6514c468c9e740d6b1d05c92467a1618_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfNzEy_078d2e58-a6c4-4d94-acf9-dd9466990341">50.0</ix:nonFraction> million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $<ix:nonFraction unitRef="usd" contextRef="ia2d7928761a04561a98b1772b844011e_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CommonStockMaximumAmountAvailableForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfOTI2_4e96a68d-8d83-4463-9b4c-b215b88dbedb">175.0</ix:nonFraction> million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on December 23, 2019. During the nine months ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3fbb1bc8db51424eb7aeb746b28ed1da">, the Company sold <ix:nonFraction unitRef="shares" contextRef="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTE4OA_4fa0b3e2-4344-4635-93c0-c0a8d6c32dc4">6,612,815</ix:nonFraction> shares of common stock at a weighted average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2f6e1c1422a241b7865adbaac8d439a6_I20200930" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTI1NQ_ac71a723-b7b5-43cd-a7b1-d1f496259e9d">26.46</ix:nonFraction>, resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTMwMg_656f4897-b851-4adb-8cdc-f48a69b82cb5">170.5</ix:nonFraction> million, pursuant to the ATM Offering.</ix:continuation>  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjQ2Mzk_d7e5949e-302f-4130-8fdc-00a72d29c8d0" continuedAt="if63b1aa01a6a41a5b6c833202aa557ff" escape="true">Collaboration and Other Agreements </ix:nonNumeric></span></div><ix:continuation id="if63b1aa01a6a41a5b6c833202aa557ff" continuedAt="id1c6dd2f21bd4d378ad45639fe608a3e"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i2a91773145ff4dc6bed1e4e7d3de5929_D20171001-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk3_b38063a4-9e36-425e-bfe3-cac97175fef1">150.0</ix:nonFraction> million in 2017.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfOTM5_396def02-00a5-486c-8f77-d711949953e2">420.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfOTkz_24daf51a-8070-4f9c-90e2-df531e40b847">330.0</ix:nonFraction> million in commercial milestones. From its inception through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="ic13ad679ef8a4def92ebbc15dce2b871_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA2Mw_5c16007d-4bb0-4bd0-9b5f-0a5eed39a4a5">30.0</ix:nonFraction> million in development milestones under the Incyte License Agreement.  If retifanlimab is commercialized, the Company would be eligible to receive tiered royalties of <ix:nonFraction unitRef="number" contextRef="i9e29c2c5bc4b44648d0a8b577e42de39_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI0Mg_5c2377da-cd92-434d-9daa-268997f9317d">15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="if59acebf30ba44029fdad1f534a68269_D20171001-20171031" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI0OA_3c0c2478-ac65-4842-9b59-c042b60ca012">24</ix:nonFraction>% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="id1c6dd2f21bd4d378ad45639fe608a3e" continuedAt="ic470fa78184c4cc1a75d42da04042b39"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $<ix:nonFraction unitRef="usd" contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjg3NQ_7b24288c-888b-4b1f-b83b-e2f135c0f7e9">154.0</ix:nonFraction> million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling $<ix:nonFraction unitRef="usd" contextRef="ia791781a92464af29c8f02db3c401ab8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDQ3OQ_a60358fc-4cab-44b5-a828-e44213d747e1">15.0</ix:nonFraction> million related to retifanlimab meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three months ended September 30, 2020, it became probable that a significant reversal of cumulative revenue would not occur for a $<ix:nonFraction unitRef="usd" contextRef="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA3OA_24130a8f-a2a4-40c2-bd76-0928899df77b"><ix:nonFraction unitRef="usd" contextRef="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA3OA_f0636448-7266-4f47-a14f-e9855b3500ee">15.0</ix:nonFraction></ix:nonFraction> million development milestone related to the initiation of a Phase 3 clinical trial of retifanlimab.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  The Company recorded a receivable as of September 30, 2020 and the milestone payment was received in October 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $<ix:nonFraction unitRef="usd" contextRef="i88964468ab69431eaebd92a52277944f_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDgwMw_04323558-e59a-49b5-8792-ea9970565e01">150.0</ix:nonFraction> million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $<ix:nonFraction unitRef="usd" contextRef="i4e228120dad34e57a7e7cdf18d7fa48d_D20171001-20171031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDkyOA_dd70c239-ae21-47af-8417-6d8ebae729ed">4.0</ix:nonFraction> million allocated to the clinical activities was recognized over a period spanning 2017 and 2018.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MTYxOA_24130a8f-a2a4-40c2-bd76-0928899df77b"><ix:nonFraction unitRef="usd" contextRef="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MTYxOA_f0636448-7266-4f47-a14f-e9855b3500ee">15.0</ix:nonFraction></ix:nonFraction> million in development milestone revenue during the three and nine months ended September 30, 2020.  <ix:nonFraction unitRef="usd" contextRef="iea44bd2966be41888177853b425961ff_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTAyMg_8fd253d6-134d-41ec-ad13-cd928b469c2a"><ix:nonFraction unitRef="usd" contextRef="i8bc7d94081d340628b9b2a71457956e1_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTAyMg_e6a8d026-8449-4fa5-aea3-2aadb2e90ca6">No</ix:nonFraction></ix:nonFraction> revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2019.   </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8aff2b8c451a486ca958bc76fd5a67bb_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTk2NQ_b7d67b0c-ba4e-4028-8d29-3701190cd24c">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4a340d54cb3d485989696d575daa8669_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTk3Mg_ace10586-ffe3-499f-a4d8-c9d283576b4b">4.9</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="ie54ccd6d1f4249b7b4f1ac381f526911_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjExNA_517f7e12-a1dc-4f2b-9484-ab5b860d241d">8.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61e7d81a9da347bb85af6348231a2bab_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjEyMQ_38acd4ae-7c3c-45c4-b01a-d5fb2decc70f">13.1</ix:nonFraction> million, respectively, for services performed under the Incyte Clinical Supply Agreement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2020, the Company entered into a commercial supply agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Incyte Commercial Supply Agreement also includes customary provisions relating to, among others, production forecasting, delivery, inspection procedures, warranties, confidentiality and indemnification.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly MGD013), a bispecific DART</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ic470fa78184c4cc1a75d42da04042b39" continuedAt="i73476a29a33e45499974cd8844a561fc"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk4Ng_d13cf34c-d7f0-487f-9fa6-1d27794d8a27">25.0</ix:nonFraction> million ($<ix:nonFraction unitRef="usd" contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk5MA_5b419c1c-3fc5-47e5-9407-125d4f5f38a2">22.5</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundablePaymentTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzAzOQ_36073dc1-a9ff-42e0-9efc-9558a291406e">2.5</ix:nonFraction> million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzE4MA_33e84f4b-ab9a-4965-86ce-38b7b4e2f1f5">140.0</ix:nonFraction> million in development and regulatory milestones, $<ix:nonFraction unitRef="usd" contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzIyNQ_588ba1f9-7ed0-4168-9c8e-c64d702f7d2e">4.0</ix:nonFraction> million of which ($<ix:nonFraction unitRef="usd" contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzIzOA_37905c2b-efe4-4c1b-bbfa-e56fb32f4fc0">3.6</ix:nonFraction> million after netting value-added tax withholdings of $<ix:nonFraction unitRef="usd" contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzI4Nw_61a89bae-86e1-4bdf-9292-33cb7ab7f4a4">0.4</ix:nonFraction> million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to <ix:nonFraction unitRef="number" contextRef="if3132c81f87a4d99ba4f564ef87782a6_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzQxMw_6c05ab87-58a1-42e1-b9b2-385d123b2bb6">20</ix:nonFraction>% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and <ix:nonFraction unitRef="number" contextRef="i2b16f811de98474199d531dece74437d_D20181101-20181130" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzUzMQ_d0c2bb17-f6d6-4eb9-8aea-f7170cf04e6d">10</ix:nonFraction>% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $<ix:nonFraction unitRef="usd" contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfODgyMQ_5b419c1c-3fc5-47e5-9407-125d4f5f38a2">22.5</ix:nonFraction> million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  The Company recognized <ix:nonFraction unitRef="usd" contextRef="ifd4f369c54f94171ad9af39bc0da5bbe_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA4MDg_351fc606-6871-4d60-b248-b5edf114a657">no</ix:nonFraction> revenue during the three months ended September 30, 2020 and recognized revenue of  $<ix:nonFraction unitRef="usd" contextRef="id2a7aa88cb654aa884f7e855835ec390_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA4NjA_3a011e0c-454d-462f-b7c9-59d4dca7b135">4.0</ix:nonFraction> million during the three months ended September 30, 2019 under the Zai Lab Agreement.  The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i8f6d41510162452d9a466e6c347714d1_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA5NDE_6fe6efd9-affb-48d1-80c5-019f49a55450">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i61ca4c82e803497f86944bb5582a02f0_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenuesNetOfTaxWithholding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA5NDg_d4ca4e19-32ed-47e0-8b6a-cfc5c7628f61">12.1</ix:nonFraction> million during the nine months ended September&#160;30, 2020 and 2019, respectively, under the Zai Lab Agreement.  Revenue recognized during the nine months ended September 30, 2020 reflected milestone revenue, whereas revenue during the nine months ended September 30, 2019 was the recognition of the deferred upfront payment.  At September&#160;30, 2020 and December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i5e461a0cdef74333a6a3069cedba5031_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTExOTM_454da658-f5ff-457c-b3ef-a939c3b72b17"><ix:nonFraction unitRef="usd" contextRef="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTExOTM_9577764b-e9c9-4970-8b95-63d38510cf76">5.0</ix:nonFraction></ix:nonFraction> million of revenue was deferred under this agreement, all of which was current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2020, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i107f7d71e8f24667bb86b994ab1d73a1_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIxNTA_e5b01eb1-b2af-438e-b033-e5cda6f4bde5">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i314a584979b14a389f3c5d964af2863f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIxNTc_92f38317-cbc9-468f-8e01-42f6f75bf949">1.9</ix:nonFraction> million, respectively, related to the Zai Lab Clinical Supply Agreements.  <ix:nonFraction unitRef="usd" contextRef="i36d284e79f3044a3ac9625ecf4e891e2_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIyMjc_64776b78-7dce-429a-8cf5-c9cd7d4595a7"><ix:nonFraction unitRef="usd" contextRef="ib1ac8ba9b2e14e9493c732eb3111af36_D20190701-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIyMjc_8e4b07c7-2f51-4a41-9b72-7a2630954655">No</ix:nonFraction></ix:nonFraction> such revenue was recognized during the three and nine months ended September 30, 2019.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i73476a29a33e45499974cd8844a561fc" continuedAt="iccdcc45096944a0ab80adf6cc4b9b6e2"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI5NTU_d92bdd92-b6de-4de5-acfe-9ba1c49b42f2">15.0</ix:nonFraction> million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $<ix:nonFraction unitRef="usd" contextRef="i3ea3b158fb7c41879720382aa02de77b_I20190709" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTMwNjQ_ed175b0b-b4e6-4da1-9608-b85a76990391">135.0</ix:nonFraction> million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to <ix:nonFraction unitRef="number" contextRef="i5f9cc003f349478ca3ed4fe7c6abc14e_D20190701-20190731" decimals="2" name="mgnx:ProceedsfromRoyaltiesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTMxOTM_8cf07965-3159-4b8b-b086-f06e148d66d0">20</ix:nonFraction>% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territory, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $<ix:nonFraction unitRef="usd" contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTM5OTQ_d92bdd92-b6de-4de5-acfe-9ba1c49b42f2">15.0</ix:nonFraction> million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $<ix:nonFraction unitRef="usd" contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731" decimals="-5" format="ixt:numdotdecimal" name="mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTQ0MDk_6feee8db-7d45-4cb6-99ab-3c1caf7a7872">1.0</ix:nonFraction> million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i695b50b168414938849dea296be40228_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU4MzI_44c0fbba-01f7-4392-b059-c5036437799b">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie164583eab6942249da5bef115ef55e3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MjgzMQ_30544851-904d-4c22-93b7-50f4d899f23d">0.6</ix:nonFraction> million, respectively, under the I-Mab Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i68ecfdcfeec84c4ea913ab203c146751_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MzAxNg_d2254e3a-5d76-44e5-ae7e-3d0f218fbaa2">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia8369f5a9bc24605bd6959601bb26575_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MzAyMQ_2de57425-9283-4860-97f7-bf2268cfb145">0.6</ix:nonFraction> million, respectively, under the I-Mab Agreement. At September&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU5NDg_1309d1bd-1e2a-4f09-8624-39c83ad89036">10.0</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU5OTc_6ca39ac5-2596-46fd-b94a-6b046f5cb980">4.3</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYwMjU_07b2ca5d-783e-4bd9-b0ef-2634028eac12">5.7</ix:nonFraction> million of which was non-current.   At December&#160;31, 2019, $<ix:nonFraction unitRef="usd" contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYwNjM_3b51a75b-5024-4adf-b5c9-ac084e0c94ee">13.5</ix:nonFraction> million of revenue was deferred under this agreement, $<ix:nonFraction unitRef="usd" contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYxMTI_0fa267da-e726-4f7c-b0c5-34afc1cb26ef">4.4</ix:nonFraction> million of which was current and $<ix:nonFraction unitRef="usd" contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYxNDA_41e0c435-68a3-4cdb-a7bc-3077b8825e78">9.1</ix:nonFraction> million of which was non-current.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib280116fa7124f13b35c12a7dd273e86_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY3MzY_9b75d7ab-1c51-4f77-adfa-8de11747909c">2.50</ix:nonFraction> per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i57e35a0253554ab4b773d0e5048648bb_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY4OTY_e3eb9186-9f51-461d-bfd8-b9adfa4570bb">65.0</ix:nonFraction> million in development and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i57e35a0253554ab4b773d0e5048648bb_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY5NTA_d122b48a-0ef5-4108-87f1-5ed07c143108">225.0</ix:nonFraction> million in commercial milestones.  As of September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of  $<ix:nonFraction unitRef="usdPerShare" contextRef="i398326bccf184051bda69d4a3c8a1a33_D20180531-20180531" decimals="INF" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTc5Nzk_8fe48a58-9903-45a1-9457-afdaec4320fd">2.50</ix:nonFraction> per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTgxMzg_5b9ac2d6-7547-4fd9-b130-2cea6c55de11">170.0</ix:nonFraction> million in regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialCommercialMilestonePaymentsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTgxNzY_60b599d0-f344-4fd5-88d4-1e8bf3412268">225.0</ix:nonFraction> million in commercial milestones.  As of </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="iccdcc45096944a0ab80adf6cc4b9b6e2" continuedAt="ia1f7ed3251da4729aece72c9b0242df5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $<ix:nonFraction unitRef="usd" contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTg2MzM_54803e41-c199-4a0f-904f-9e28547fc8a8">1.3</ix:nonFraction> million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified <ix:nonFraction unitRef="performance_obligation" contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfPerformanceObligations" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTkyMzU_e6a7977d-d196-4699-8823-469cb85d837d">two</ix:nonFraction> performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $<ix:nonFraction unitRef="usd" contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531" decimals="-5" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTk0Mjg_d5c4db7f-e416-40a3-b6af-49ee9e4db3be">6.1</ix:nonFraction> million, based on the Black-Scholes valuation of the warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTk0OTc_97be503d-04df-4177-b031-ab84581135d7">2,432,688</ix:nonFraction> shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $<ix:nonFraction unitRef="usd" contextRef="i709d5a4375bc46bfa8eb06e60b804476_D20180701-20180930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjA0MzU_0fd786a1-98c6-44f9-aa2f-3bd26befc7ae">6.1</ix:nonFraction> million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale in July 2019. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to <ix:nonFraction unitRef="molecule" contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjEzNDg_70f1794d-b07d-4a05-bdd7-2ee6117fdc95">two</ix:nonFraction> DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NIAID Contract includes a base period of up to $<ix:nonFraction unitRef="usd" contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915" decimals="-5" format="ixt:numdotdecimal" name="mgnx:FundedValueOfBasePeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjE5MTQ_6e4485d9-dc1b-4b13-8f74-37e828895823">7.5</ix:nonFraction> million to support development of MGD014 through Investigational New Drug application submission with the U.S. Food and Drug Administration, as well as up to $<ix:nonFraction unitRef="usd" contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIwNjc_435647ab-d601-4611-8b0c-ed6d447ec443">17.0</ix:nonFraction> million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915" decimals="INF" format="ixt:numdotdecimal" name="mgnx:TotalPotentialValueUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIyMTU_c9513d20-f0b3-4278-8b40-fab435f3f672">24.5</ix:nonFraction> million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024.  In 2017, NIAID exercised the first option in the amount of up to $<ix:nonFraction unitRef="usd" contextRef="i17e4e3bc99de4302af0c36215cc08f6f_D20170101-20171231" decimals="-5" format="ixt:numdotdecimal" name="mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIzNjY_9d18b83f-7d45-408d-a98f-9d3623c98075">10.8</ix:nonFraction> million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  The Company recognized revenue  under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="i084bc672cb2542ee93482822566c90cd_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI1NTE_b93c7368-2897-4fa6-84ad-c71f2183e2e0"><ix:nonFraction unitRef="usd" contextRef="i8ec7e2284b474d4997d8410cdd14f1b7_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI1NTE_fac37b82-fa54-427d-86dc-9fdae6dbdb92">0.8</ix:nonFraction></ix:nonFraction> million during each of the three month periods ended September&#160;30, 2020 and 2019.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue under the NIAID Contract of $<ix:nonFraction unitRef="usd" contextRef="ied5a5d5f59e0443393b8732129f9e130_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI2NTk_f835e8d7-276b-4c70-b18e-45f2e6639206">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8e1a76d57ce94e01be30cf3cfa42cd5e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI2NjY_1755c02a-3135-4b77-87b4-560dbd4cf2a6">1.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ia1f7ed3251da4729aece72c9b0242df5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a <ix:nonNumeric contextRef="i8e5332870f4e4706a838787952f9124b_D20101001-20151031" format="ixt-sec:durwordsen" name="mgnx:CollaborationAndLicenseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzE0NjgyNTYxMzQ4MQ_548736bb-4990-4846-9b83-39619acf921f">five-year</ix:nonNumeric> period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected <ix:nonFraction unitRef="numberofproductcandidates" contextRef="ib37d01f8e8ec44a3b82be406e14e4895_I20151031" decimals="INF" format="ixt-sec:numwordsen" name="mgnx:NumberOfProductCandidates" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjMyNjc_24d5438c-41fa-41a4-a571-bef9fb6a1912">two</ix:nonFraction> product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i8e5332870f4e4706a838787952f9124b_D20101001-20151031" decimals="-5" format="ixt:numdotdecimal" name="mgnx:NonRefundableUpfrontFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM0MDE_fbed070d-edb6-47e1-975d-c8156a20b482">15.0</ix:nonFraction>&#160;million which was fully recognized prior to the adoption of ASC Topic 606 on January 1, 2018. The remaining obligations under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   In June 2020, BII agreed to a payment of $<ix:nonFraction unitRef="usd" contextRef="i5be796f261a24d47bb6a08dee44be3f7_D20200601-20200630" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentMilestonesAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM3MTg_b1370e0a-a9ba-4d55-8286-dc5d60126845">12.0</ix:nonFraction> million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="ic8506fff30e343c0a108eac7ddb6eb91_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM4NDE_9765df0e-5a90-47ce-8fac-44f4dee1e069"><ix:nonFraction unitRef="usd" contextRef="i682bc99e203a470fadd9467ce13ac26a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM4NDE_acf9b8b3-d0d1-48a8-832e-d789afe17191">12.0</ix:nonFraction></ix:nonFraction> million during the nine months ended September 30, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div></ix:continuation><div id="i837d975c068f41aa997c97c40d8bbcd5_52"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzMg_76b6253f-7c93-4ca4-bf75-b774603456cf" continuedAt="i3878007a5a264fad8ddf2ba4651d459e" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i3878007a5a264fad8ddf2ba4651d459e" continuedAt="ie9e2b1ae0e4e4095a14e4df44e1ae2aa"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved <ix:nonFraction unitRef="shares" contextRef="i651dacb02b694c7cab3fc1042896bf4d_I20170531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDI3_8d90901b-c5b3-4289-8ec7-671d6d485efe">800,000</ix:nonFraction> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531" decimals="INF" name="mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNjI2_a6b7510a-da76-483e-80a8-8341034a5f7d">10</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="number" contextRef="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfODcz_80c3b7a7-0555-49a7-92c0-cc36fdcf5ebc">85</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTAwMw_3e7c6e7c-5875-414c-9383-29cc8e595566">18,304</ix:nonFraction> shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTExMw_492abd2d-0d2b-4be8-9517-5de72fe3230e">0.3</ix:nonFraction>&#160;million.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2020, under the 2003 Plan, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i4659cc916dd3432aa5e78628aca3effd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTk3Nw_d5b36a01-ded1-4da9-88bf-6f1fa2cf6883">259,904</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4659cc916dd3432aa5e78628aca3effd_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjA1NQ_588131ad-b865-4981-b5c5-418b9c97fa52">2.73</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) <ix:nonFraction unitRef="shares" contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930" decimals="INF" format="ixt:numdotdecimal" name="mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjQ2Nw_f3630760-ab81-4abe-be7b-f6deac8fa8a5">1,960,168</ix:nonFraction> shares, (b) <ix:nonFraction unitRef="number" contextRef="i35072c1e740040a296f33ad007daa74c_D20200101-20200930" decimals="3" name="mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjQ4Mg_91973734-ff0e-48b6-a14d-20b019649244">4.0</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to <ix:nonFraction unitRef="shares" contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjgzNA_ea128ab6-b9ba-485f-9eb8-3ec53f9b9515">11,896,613</ix:nonFraction>.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2020, there were options to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMzQxMA_60e9db47-52b1-410f-9b95-4f05cb7bcbf2">7,079,313</ix:nonFraction> shares of common stock outstanding at a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMzQ4OA_5675c424-5b36-485c-8350-0fc70d6bd31a">22.10</ix:nonFraction> per share under the 2013 Plan.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="ie9e2b1ae0e4e4095a14e4df44e1ae2aa" continuedAt="i19d89ba2eafc4cd18ad352630bcbd648"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkyOA_013e3f37-5846-4260-b262-c1523194f6c4" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:2.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.441%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d3cb74cabac4267807f2a0c571ab8f3_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi0xLTEtMS0w_7d9ba0eb-c930-4753-acff-c93804b1d736">3,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3c10bc20e144f36b196b86ec9fb610e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi0zLTEtMS0w_11f8b06d-2a01-4d92-808d-a23cba4bae5c">2,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba2e860df1846c29d00f140ae5dfa0e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi03LTEtMS0w_0f6367b8-96ef-4c26-bc88-f8cefc79a361">8,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i267ca7ed35444cc1a4d6d12768b9c471_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi05LTEtMS0w_b5a7a5b9-26c6-47bf-9c3a-b7072e6a5301">7,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3041645d5148e2885536c8ef463ce0_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy0xLTEtMS0w_6e09f41e-eef0-4c1e-a749-71b976cd4308">2,773</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie09d12dbaa6c4616ae1d1ef7740fb483_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy0zLTEtMS0w_3d4b34a1-c014-4ffe-9376-cdeabfae4cbc">2,633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b36cc5e5fa4780a5d86d9a4a7471c5_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy03LTEtMS0w_d36ee2d5-8895-4eb0-ab12-8f64e72da926">7,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328732a3cf7940cca770d218ab8234b5_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy05LTEtMS0w_7fefd8e9-c534-4ca0-9c56-3cda18ebcd3a">7,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC0xLTEtMS0w_d523a1da-ad5e-4b45-9c6e-aff0f954138b">5,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC0zLTEtMS0w_45c9d45d-9b50-4903-b201-b9b8bb2e6150">5,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC03LTEtMS0w_663095ef-9483-4609-8def-00bc157ca0e4">15,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC05LTEtMS0w_c305ac69-df20-43fa-b86c-4953748896c9">14,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNA_b2e116db-e905-4df0-9a61-dc78f153d602" escape="true"><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMi0xLTEtMS0w_9745c0c1-3596-4357-87ac-1c72c5db5b2b">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMi0zLTEtMS0w_292208cd-c1f9-4c3b-8e9b-eb580d0a1fb3">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0xLTEtMS0wL3RleHRyZWdpb246NjdjYzlmNTJmODY4NDVjZmI5OGI0NzYwYjlhNDkwNjZfNA_61d1355e-fe40-4140-b828-fbc9381c6284">67.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0xLTEtMS0wL3RleHRyZWdpb246NjdjYzlmNTJmODY4NDVjZmI5OGI0NzYwYjlhNDkwNjZfOQ_4e4e890f-d679-4221-94c2-e6eefefacab8">109</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0zLTEtMS0wL3RleHRyZWdpb246NDQ0YjkyYjlkMDUzNDFjN2I0N2Y1NGZhYWYwMzVkMjZfNA_53421dff-00b3-4c47-86a1-63a4ee9c9c09">73.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0zLTEtMS0wL3RleHRyZWdpb246NDQ0YjkyYjlkMDUzNDFjN2I0N2Y1NGZhYWYwMzVkMjZfOQ_946ecaa8-34d7-4314-84f1-32da891d37ba">76.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0xLTEtMS0wL3RleHRyZWdpb246NDBhYzI4MzU4MjQwNDU1Njg4MjIwYjVjMmM0ZmIzMTFfNA_28d0290f-526d-4abb-b724-e290f0403666">0.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0xLTEtMS0wL3RleHRyZWdpb246NDBhYzI4MzU4MjQwNDU1Njg4MjIwYjVjMmM0ZmIzMTFfOQ_a40af749-db8b-427c-a6fa-3e3c90ca2067">1.8</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0zLTEtMS0wL3RleHRyZWdpb246YzUzOTg2ZjY3MjgyNDBjN2FiMzFiZGYzZTQ3MzlmNDNfNA_166883c7-fd5d-4544-a441-0f151d90c203">1.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0zLTEtMS0wL3RleHRyZWdpb246YzUzOTg2ZjY3MjgyNDBjN2FiMzFiZGYzZTQ3MzlmNDNfOQ_352c2ce9-4c93-4f07-90fb-b6d87893ffeb">2.6</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNS0xLTEtMS0w_0b613e4b-2541-41da-96e1-e3ba02b88b35">6.25</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNS0zLTEtMS0w_fe1b829e-53ae-4090-8fa7-83f9cdca870e">6.25</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNQ_b56ccca3-d1bb-4c92-9688-8b4276fd94bf" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:27.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS0xLTEtMS0w_257cf022-b2f8-4806-a86e-944b768a1d75">6,706,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id03af012974e455383bba3223db02d75_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS0zLTEtMS0w_f75807d0-924d-418d-b995-5113631295e1">22.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS01LTEtMS0w_61aa6698-7684-4914-be8c-827e6ea14fe6">6.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMi0xLTEtMS0w_af45b475-4987-4300-9b06-9733f1a482eb">1,816,277</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMi0zLTEtMS0w_3b259571-ea8c-45be-b7c1-06d6bdde3314">14.97</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMy0xLTEtMS0w_60a35602-c0ac-4579-817e-53555d42825b">448,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMy0zLTEtMS0w_97a6a12f-e940-4983-9e9d-d9a6f36805a2">9.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNC0xLTEtMS0w_8da24896-ab65-4cb9-9981-2c45f0f26cae">735,322</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNC0zLTEtMS0w_6c263d7d-13ab-4261-966a-141d9a7f0e6e">20.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS0xLTEtMS0w_2e830dad-9e86-46ef-ba0f-d33e9f003f22">7,339,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS0zLTEtMS0w_80dbedc5-ed31-4071-a162-552de44d3f12">21.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS01LTEtMS0w_54a500fb-ca27-4d56-8f30-1ed37a88bb86">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS03LTEtMS0w_e3ab26a0-8321-4bc0-92d2-fcd71a9adeaf">39,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy0xLTEtMS0w_7da8ceae-d97d-4517-b759-5e74a4ce1fec">4,407,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy0zLTEtMS0w_ca540fdc-4b59-49f9-8881-2172ddc5e5f1">23.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy01LTEtMS0w_27ec35fc-adf5-4897-9a97-454a77e48269">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy03LTEtMS0w_57bdb772-04f1-411a-8ff2-d2c68a42d7b4">18,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC0xLTEtMS0w_af8a58f3-026b-410a-ae01-db64b06e926b">7,027,237</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC0zLTEtMS0w_9a88fe6f-0669-41db-b49d-49fcf4c09533">21.50</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC01LTEtMS0w_1a18f6a2-9625-4da9-a472-7d0367539a6b">7.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC03LTEtMS0w_7af57eca-27af-404a-ba0b-a1fb811194fb">36,973</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $<ix:nonFraction unitRef="usdPerShare" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDU3Mg_3dfae3f0-13e4-4658-970c-58f339b8d873">10.50</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDU3OQ_0d242eeb-f7d7-48f8-a843-ecfdbc2ee964">14.33</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDcxNA_257cc411-69d1-4d1e-8fef-aa3f25d92a7a">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTA5OTUxMTYzMzgzNg_4586cd7c-c1d5-4381-b167-40bcaa35b44c">2.8</ix:nonFraction> million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDgyMA_1ebf86ad-58b2-438f-b2fb-eda945842e5f">4.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDgyNw_61e812bc-5b6c-4460-bee9-3766d7265baf">0.7</ix:nonFraction> million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2020 and 2019 was approximately $<ix:nonFraction unitRef="usd" contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDkzNQ_fdfddc5e-630f-4483-8d90-1e1b812dc7c8">12.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDk0Mg_e62b3545-11a6-4279-a3ab-51eeaf23402a">12.8</ix:nonFraction> million, respectively. As of September&#160;30, 2020, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $<ix:nonFraction unitRef="usd" contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTEwNA_d0a8e77c-5d62-47fb-baec-d93848323da6">31.7</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of approximately <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTE5NQ_30740122-a96c-4041-b8a7-afd96268495e">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><ix:continuation id="i19d89ba2eafc4cd18ad352630bcbd648"><ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNg_920d18de-4013-4a9c-acc0-40a92306c35e" escape="true"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"></td><td style="width:52.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.330%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied85acb778bf4e98a18112866d8afde5_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMS0xLTEtMS0w_d39d846d-ea2a-4dea-adff-e349df15c3d9">452,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ied85acb778bf4e98a18112866d8afde5_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMS0zLTEtMS0w_2f90164c-e14c-45e5-b9c1-f483b570e2e3">15.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMi0xLTEtMS0w_11835122-ea34-4a14-af65-771c4a8a0b36">15,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMi0zLTEtMS0w_f5417f51-1fdb-41bb-9e9a-9a7e1f26f177">23.68</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMy0xLTEtMS0w_0d4067f3-5ebc-4ca4-bf7d-2052c26df18e">210,950</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMy0zLTEtMS0w_45bb7b18-6ac5-4930-b9c2-43c625b75d32">15.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNC0xLTEtMS0w_783eaa4c-212d-4fd9-8067-40c8e6eabd91">40,950</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNC0zLTEtMS0w_e478d2dc-5095-4472-8200-e8481e48b43b">15.32</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNS0xLTEtMS0w_e4f2191f-3d42-4b2c-b218-7834296564f3">215,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNS0zLTEtMS0w_86888352-3925-450c-a286-57b920932dbf">15.90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTc2OA_e22334cb-ed0a-430f-a680-d8a1d79bcda3">2.8</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNzE0NjgyNTU4Njc2NA_dd094552-319e-4b17-abad-faaf1642cd24">one year</ix:nonNumeric>.</span></div></ix:continuation><div id="i837d975c068f41aa997c97c40d8bbcd5_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81NS9mcmFnOjg5NGFlNWZhMjdkNjQ5YzM4YjhjMjQzZWM2ODM4MWJlL3RleHRyZWdpb246ODk0YWU1ZmEyN2Q2NDljMzhiOGMyNDNlYzY4MzgxYmVfOTY1_bf346bcb-5bed-4fb3-ae82-6d96cd1df0ba" continuedAt="i60b6d1fae1cd4d9e96dd8f14466e6535" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i60b6d1fae1cd4d9e96dd8f14466e6535">On September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</ix:continuation>   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with U.S. generally accepted accounting principles (GAAP), for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. We currently have a pipeline of product candidates in human clinical testing, including seven immuno-oncology programs, that have been created primarily using our proprietary, antibody-based technology platforms. We believe our product candidates have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We are currently preparing for the commercialization of margetuximab, if it is approved, which has a Prescription Drug User Fee Act (PDUFA) target action date for the Biologics License Application (BLA) of December 18, 2020.  We do not currently intend to develop an internal sales force to commercialize margetuximab.  We expect to enter into agreements with third-party providers of sales and marketing, market access, distribution and logistics and other services.  We may also enter into collaborations with third-party biopharmaceutical firms for the commercialization of margetuximab. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160;Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September&#160;30, 2020, combined with the $15.0 million received from Incyte Corporation (Incyte) subsequent to September 30, 2020, and anticipated and potential collaboration payments, should enable us to fund our operations into 2023, assuming our programs and collaborations advance as currently contemplated. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through September&#160;30, 2020, we had an accumulated deficit of $769.7 million. We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the outbreak of a novel strain of coronavirus (COVID-19) as a pandemic, which continues to spread throughout the world. Developments have been occurring rapidly with respect to the spread of COVID-19 and its impact on human health and businesses. To date, the COVID-19 pandemic has negatively impacted the global economy, created significant financial market volatility, disrupted global supply chains, and resulted in a significant number of infections and deaths worldwide.  In addition, several national, state and local governments have placed restrictions on people from gathering in groups or interacting within a certain physical distance and in certain cases, have ordered businesses to close, limit operations or mandate that people stay at home. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, although there has been some negative impact on our business and operations, including, for example, slowed clinical trial enrollment, we have been able to mitigate against more severe impacts of COVID-19 on our business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on our business in the future depending on the depth of the effects and the duration of the crisis. In response to the COVID-19 pandemic, we have been focused on keeping our employees safe, continuing patients on trials, and maintaining our manufacturing capabilities and research efforts.  The COVID-19 pandemic is an evolving situation and we continue to monitor our business very closely to try and mitigate any potential impacts. We expect the pandemic to continue to have some near-term impact on the initiation of new studies and on clinical trial enrollment. For example, in consideration of the current COVID-19 pandemic, we delayed our planned Phase 2 study of enoblituzumab, an investigational, Fc-engineered, anti-B7-H3 monoclonal antibody, in combination </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with checkpoint blockade in patients with advanced head and neck cancer until the first quarter of 2021. In addition, we stopped enrollment in a Phase 1/2 study combining flotetuzumab with retifanlimab in patients with relapsed or refractory acute myeloid leukemia being conducted outside of the U.S. We anticipate resuming the study and initiating activity at U.S. sites in the future.  Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize the product candidates in our pipeline. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, we cannot precisely predict the impact that COVID-19 will have in the future due to numerous uncertainties, including the severity of the disease, the duration of the outbreak, actions that may be taken by governmental authorities, the impact to the business of our supply chain, and other factors identified in Part II, Item 1A. &#8220;Risk Factors&#8221; in this Form 10-Q and our Annual Report on Form 10-K. Given these uncertainties, COVID-19 could disrupt the business of certain of our collaborators and impact our business operations and our ability to execute on our associated business strategies and initiatives, and adversely impact our consolidated results of operations and/or our financial condition in the future. We will continue to closely monitor and evaluate the nature and extent of the impact of COVID-19 to our business, consolidated results of operations, and financial condition. </span></div><div><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborations</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Our current collaborations include the following:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Incyte. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into an exclusive global collaboration and license agreement with Incyte for retifanlimab, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while we retain the right to develop our pipeline assets in combination with retifanlimab. Incyte paid us an upfront payment of $150.0 million under the terms of the agreement. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab. Assuming successful development and commercialization of retifanlimab by Incyte, we could receive development and regulatory milestones of up to approximately $420.0 million and up to $330.0 million in commercial milestones.   Of the $420.0 million in development and regulatory milestones, $30.0 million has already been recognized, $15.0 million of which was recognized during the three months ended September 30, 2020 and was received in October 2020.   If retifanlimab is commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote retifanlimab with Incyte. We retain the right to develop our pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and us commercializing our asset(s), if any such potential combinations are approved. We also have an agreement with Incyte under which we are to perform development and manufacturing services for Incyte's clinical needs of retifanlimab (Incyte Clinical Supply Agreement). In addition, subsequent to September 30, 2020, we entered into a commercial supply agreement with Incyte pursuant to which we are entitled to manufacture a portion of the global commercial supply needs for retifanlimab. </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12.53pt">Zai Lab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In 2018, we entered into a collaboration and license agreement with Zai Lab Limited (Zai Lab) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly MGD013), a bispecific DART molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development (Zai Lab Agreement). Zai Lab will lead clinical development in its territory. </span></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Zai Lab paid us an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, we could receive up to $140.0 million in development and regulatory milestones, of which we have already earned $4.0 million ($3.6 million after netting value-added tax withholdings of $0.4 million). In addition, Zai Lab would pay us tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">I-Mab Biopharma.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2019, we entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates our proprietary Fc Optimization technology platform (I-Mab Agreement). I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by us. <br/><br/>Under the terms of the agreement, I-Mab paid us an upfront payment of $15.0&#160;million. Assuming successful development and commercialization of enoblituzumab, we could receive up to $135.0&#160;million in development and regulatory milestones. In addition, I-Mab would pay us tiered royalties ranging from mid-teens to 20% on annual net sales in its territories.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:15pt;text-indent:39pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our consolidated financial statements. A summary of our critical accounting policies is presented in Part II, Item&#160;7, of our Annual Report on Form 10-K for the year ended December&#160;31, 2019. There have been no significant changes to our critical accounting policies and estimates during the nine months ended September 30, 2020. </span></div><div style="text-indent:39pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our revenue for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:32.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.903%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.957%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.360%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other agreements</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from government agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in revenue of $0.5 million for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $4.7 million in revenue recognition of the deferred flotetuzumab license grant fee from Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier) due to Servier's notice of their intention to terminate the agreement effective January 15, 2020;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $4.2 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $4.0 million in revenue recognition of the deferred upfront payment under the Zai Lab Agreement  during the three months ended September 30, 2020 as the recognition period ended in 2019;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of $1.8 million in revenue recognition during the three months ended September 30, 2020 of the deferred upfront payment  from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) as the recognition period ended in 2019.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were offset by recognition of a $15.0 million development milestone from Incyte related to the initiation of a Phase 3 clinical trial of retifanlimab.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in revenue of $13.2 million for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $15.0 million development milestone from Incyte related to the initiation of a pivotal study of retifanlimab;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of a $12.0 million payment from Boehringer Ingelheim International GmbH (BII) for retention of rights to two DART molecules;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of approximately $4.6 million in revenue recognized under the National Institute of Allergy and Infectious Diseases (NIAID) contract due to increased clinical trial activity of MGD014 and development of the second DART molecule; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognition of $3.6 million in milestones under the Zai Lab Agreement and approximately $1.9 million related to manufacturing services performed under the Zai Lab Clinical Supply Agreements; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase of approximately $2.9 million of the deferred upfront payment under the I-Mab Agreement compared to the nine months ended September 30, 2019 because the agreement was executed in July 2019.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:  </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $12.1 million in revenue recognition of the deferred upfront payment under the Zai Lab Agreement during the nine months ended September 30, 2020 as the recognition period ended in 2019;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $4.1 million in revenue recognition of the deferred flotetuzumab license grant fee from Servier due to Servier's notice of their intention to terminate the agreement effective January 15, 2020;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $3.8 million in revenue recognition during the three months ended September 30, 2020 of the deferred upfront payment  from Roche as the recognition period ended in 2019; and</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decrease of approximately $5.0 million in revenue recognized under the Incyte Clinical Supply Agreement due to decreased development activity.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following represents a comparison of our research and development expense for the three and nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:33.181%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.486%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.834%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Margetuximab</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Flotetuzumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(a)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retifanlimab</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tebotelimab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MGC018</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enoblituzumab</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MGD019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MGD009</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MGD007</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other pipeline programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)   For the three and nine months ended September 30, 2019, expenses are shown net of reimbursements from collaborator.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the three months ended September 30, 2020 decreased by $0.2 million compared to the three months ended September 30, 2019 primarily due to:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">decreased development costs related to tebotelimab due to timing of manufacturing activities; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial costs related to our enoblituzumab studies; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial costs related to MGD007 and MGD009 as these programs have been discontinued.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These decreases were partially offset by:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased flotetuzumab development costs due to increased clinical trial enrollment and regulatory costs, and the end of cost sharing with Servier;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased clinical trial costs related to our MGC018 Phase 1 study.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expense for the nine months ended September 30, 2020 increased by $7.5 million compared to the nine months ended September 30, 2019 primarily due to:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased flotetuzumab development costs due to increased clinical trial enrollment and regulatory costs, and the end of cost sharing with Servier;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased development and manufacturing costs related to retifanlimab due to timing of manufacturing activities for Incyte; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.53pt">increased clinical trial and development costs related to our ongoing tebotelimab Phase 1 study.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial and BLA preparation costs for margetuximab; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased clinical trial costs related to MGD007 and MGD009 as these programs have been discontinued.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses decreased by $2.1 million and $4.0 million for the three and nine months ended September 30, 2020 compared to the three and nine months ended September 30, 2019, respectively, due primarily to decreased spend on external expenses, including consulting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change from other expense for the three months ended September 30, 2019 to other income for the three months ended September 30, 2020 and the decrease in other income for the nine months ended September 30, 2020  compared to the nine months ended September 30, 2019 is primarily due to decreased investment income and the revaluation at June 30, 2019 of the warrants received under the Provention License Agreement and Asset Purchase Agreement.  These warrants were exercised, and the acquired shares subsequently sold, during 2019, therefore no such revaluation is reflected in other income during the three and nine months ended September 30, 2020.</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_73"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple product candidates currently under development will require significant additional research and development efforts that include extensive preclinical studies and clinical testing, and regulatory approval prior to commercial use.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a clinical-stage biotechnology company, we have primarily funded our operations with proceeds from the sale of our common stock in equity offerings, revenue from our multiple collaboration agreements, and contracts and grants from NIAID.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management regularly reviews our available liquidity relative to our operating budget and forecast to monitor the sufficiency of our working capital, and anticipates continuing to draw upon available sources of capital to support our product development activities. There can be no assurances that new sources of capital will be available to us on commercially </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acceptable terms, if at all. Also, any future collaborations, strategic alliances and marketing, distribution or licensing arrangements may require us to give up some or all rights to a product or technology at less than its full potential value. If we are unable to enter into new arrangements or to perform under current or future agreements or obtain additional capital, we will assess our capital resources and may be required to delay, reduce the scope of, or eliminate one or more of our product research and development programs or clinical studies, and/or downsize our organization.  Although it is difficult to predict our funding requirements, we anticipate that our cash, cash equivalents and marketable securities as of September&#160;30, 2020, combined with the  $15.0 million received from Incyte subsequent to September&#160;30, 2020, and anticipated and potential collaboration payments, should enable us to fund our operations into 2023, assuming our programs and collaborations advance as currently contemplated.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the other risk factors pertinent to our business, the COVID-19 outbreak might unfavorably impact our ability to generate such additional funding. Given the uncertainty in the rapidly changing market and economic conditions related to the COVID-19 pandemic, we will continue to evaluate the nature and extent of the impact of the outbreak on our business and financial position. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a summary of our cash flows for the nine months ended September&#160;30, 2020 and 2019:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:64.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.494%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities.  The principal use of cash in operating activities for all periods presented was to fund our net loss, adjusted for non-cash items.  The nine months ended September 30, 2020 benefited from the $12.0 million payment from BII for their retention of rights to two DART molecules, and the nine months ended September 30, 2019  benefited from the $22.5 million upfront payment from Zai Lab and the $15.0 million upfront payment from I-Mab.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities during the nine months ended September 30, 2020 is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities.  Net cash used in investing activities during the nine months ended September 30, 2019 is primarily due to purchases of marketable securities, partially offset by maturities of marketable securities.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the nine months ended September 30, 2020 is primarily due to the proceeds from our ATM Offering of approximately $170.5 million and proceeds from stock option exercises.  Net cash provided by financing activities for the nine months ended September 30, 2019 is primarily due to the proceeds from our firm-commitment underwritten public offering of approximately $118.7 million.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission (SEC).</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of September&#160;30, 2020, we had cash, cash equivalents and marketable securities of $280.7 million.&#160;&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_82"></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:7.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.150%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONTROLS AND PROCEDURES</span></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September&#160;30, 2020. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in our periodic reports filed with the SEC (such as this Quarterly Report on Form 10-Q) has been appropriately recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. Based on their evaluation of our disclosure controls and procedures as of September&#160;30, 2020, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in the Company's internal control over financial reporting that occurred during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially effect, the Company's internal control over financial reporting.</span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_85"></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.  Legal Proceedings</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we are or may be involved in various legal or regulatory proceedings, claims or  class actions related to alleged patent infringements and other intellectual property rights, or alleged violation of commercial, corporate, securities, labor and employment, and other matters incidental to our business. We do not, however, expect such legal proceedings to have a material adverse effect on our business, financial condition or results of operations. However, depending on the nature and timing of a given dispute, an eventual unfavorable resolution could materially affect our current or future results of operations or cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">See note 8, Commitments and Contingencies, to the consolidated financial statements for more information.  </span></div><div id="i837d975c068f41aa997c97c40d8bbcd5_91"></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:7.792%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.008%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Risk Factors</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There have been no material changes in the risk factors described in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K for the year ended December&#160;31, 2019, aside from the risk factors included below:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business interruptions resulting from the COVID-19 outbreak or similar public health crises could cause a disruption of the development of our product candidates and adversely impact our business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Public health crises such as pandemics or similar outbreaks could adversely impact our business. In December 2019, a novel strain of a virus named SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), or coronavirus, which causes coronavirus disease, or COVID-19, was reported to have surfaced in Wuhan, China and has reached multiple other regions and countries, including Europe and the United States. The COVID-19 pandemic is evolving, and to date has led to the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">implementation of various responses, including government-imposed quarantines, work and travel restrictions and other public health safety measures at the federal, state and local levels. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continued spread of COVID-19 or other global health crises, such as pandemics, has had, and may continue to have, an adverse impact our clinical trials, preclinical studies, and other aspects of our business or that of our third-party partners. For instance, the COVID-19 outbreak has impaired our ability to enroll patients in clinical trials, continue ongoing clinical trials or activate clinical trial sites, due to, for example, heightened exposure to COVID-19 if an outbreak occurs in a specific geography, the shifting of healthcare resources toward the outbreak or the closing of or limiting of access to clinical facilities.  Furthermore, patients may be unable or unwilling to enroll in our clinical trials or be unable to comply with clinical trial protocols if COVID-19 related restrictions impede patient movement or interrupt healthcare services.  Government-imposed quarantines and other restrictions may also require us to temporarily suspend activity at our clinical sites.  COVID-19 may also negatively affect the operations of third-party contract research organizations that we rely upon to carry out our clinical trials, or the operations of other service providers, which could result in delays or disruptions in the supply of our product candidates or other aspects of our business or that of our collaborators. Any negative impact COVID-19 has on patient enrollment or treatment or the timing and execution of our clinical trials could cause delays to our clinical trial activities, which could adversely affect our ability to seek and obtain regulatory approval for and to commercialize any approved product candidates, increase our operating expenses and have a material adverse effect on our business and financial results.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the outbreak of COVID-19 has increased the risk that a portion of the workforce, including ours, may suffer illness or otherwise be unable to work.  We have implemented stay-at-home orders consistent with the requirements of the jurisdictions in which we operate, with arrangements such as remote work and flexible schedules for certain functions, as well as other measures intended to reduce the risks to our employees from the impact of the pandemic while maintaining our operations.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also face increased cybersecurity risks due to the shifting of a majority of our corporate functions operating remotely in regions impacted by stay-at-home orders. Increased levels of remote access may create additional opportunities for cybercriminals to attempt to exploit vulnerabilities, and our employees may be more susceptible to phishing and social engineering attempts. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 impacts our operations or those of our collaborators will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, new information that may emerge concerning the severity of COVID-19 or the effectiveness of actions to contain COVID-19 or treat its impact, among others. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions. If we or any of the third parties with whom we engage experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_94"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:92.251%"><tr><td style="width:1.0%"></td><td style="width:6.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.452%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.017%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-1q32020.htm">Rule 13a-14(a) Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit31-2q32020.htm">Rule 13a-14(a) Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-1q32020.htm">Section 1350 Certification of Principal Executive Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit32-2q32020.htm">Section 1350 Certification of Principal Financial Officer</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Schema Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Calculation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Definition Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Labels Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Presentation Linkbase Document</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data (formatted as Inline XBRL and contained in Exhibit 101 filed herewith)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+ Indicates management contract or compensatory plan.</span></td></tr></table></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i837d975c068f41aa997c97c40d8bbcd5_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.873%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.235%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MACROGENICS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Scott Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scott Koenig, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Karrels</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 4, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>exhibit31-1q32020.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic7fb251b586f496aa7ebe2b50eb08d99_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2020 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Executive Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;4, 2020 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>exhibit31-2q32020.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ic343ed58d5a4438cb540a3216cbde2ee_1"></div><div style="min-height:63pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&#160;30, 2020 of MacroGenics, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior Vice President and Chief Financial Officer</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; November&#160;4, 2020 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>exhibit32-1q32020.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="idc83dda9734145c991beae82fa5928d0_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2020&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div style="padding-left:22pt;text-indent:-22pt"><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Scott Koenig</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; Scott Koenig, M.D., Ph.D.</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020 </font></div><div style="padding-left:252pt"><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>exhibit32-2q32020.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="if3aec08200eb464a9a524fbe3257bc4d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EXHIBIT 32.2</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification of Principal Financial Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to 18 U.S.C. 1350</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the Registrant), certify, to the best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended&#160;September&#160;30, 2020&#160;of the Registrant (the Report), that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The Report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name&#58; James Karrels</font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; November&#160;4, 2020 </font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>mgnx-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://macrogenics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandRisksandUncertainties" roleURI="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties">
        <link:definition>2101101 - Disclosure - Basis of Presentation and Risks and Uncertainties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2102102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstruments" roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments">
        <link:definition>2104103 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsTables" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables">
        <link:definition>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueofFinancialInstrumentsDetails" roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails">
        <link:definition>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2107104 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2308302 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2409402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2110105 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2411403 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements">
        <link:definition>2112106 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails">
        <link:definition>2413404 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsZaiLabDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails">
        <link:definition>2414405 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsIMabBiopharmaDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails">
        <link:definition>2415406 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsProventionBioIncDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails">
        <link:definition>2416407 - Disclosure - Collaboration and Other Agreements - Provention Bio, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsNIAIDContractDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails">
        <link:definition>2417408 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
        <link:definition>2418409 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2119107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2320303 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockbasedCompensationRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails">
        <link:definition>2424413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://macrogenics.com/role/CommitmentsandContingencies">
        <link:definition>2125108 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementTerm" abstract="false" name="CollaborationAndLicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementTransactionPrice" abstract="false" name="CollaborativeAgreementTransactionPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" abstract="false" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementMember" abstract="true" name="IncyteMGA012AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProceedsfromRoyaltiesPercent" abstract="false" name="ProceedsfromRoyaltiesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" abstract="false" name="DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenueFromCollaborativeAgreementsMember" abstract="true" name="RevenueFromCollaborativeAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenuesNetOfTaxWithholding" abstract="false" name="RevenuesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RevenuesFromLicenseAgreementsMember" abstract="true" name="RevenuesFromLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteCorporationMember" abstract="true" name="IncyteCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" abstract="true" name="IMabBiopharmaCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenuesFromGrantsMember" abstract="true" name="RevenuesFromGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_AssetPurchaseAgreementMember" abstract="true" name="AssetPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" abstract="false" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_ProventionLicenseAgreementMember" abstract="true" name="ProventionLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NonRefundableUpfrontFees" abstract="false" name="NonRefundableUpfrontFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TotalPotentialValueUnderAgreement" abstract="false" name="TotalPotentialValueUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueFromGovernmentAgreementsMember" abstract="true" name="RevenueFromGovernmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" abstract="false" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_RetirementOfTreasuryStock" abstract="false" name="RetirementOfTreasuryStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV3279Member" abstract="true" name="ProventionPRV3279Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" abstract="false" name="ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHMember" abstract="true" name="BoehringerIngelheimInternationalGmbHMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabCollaborationAndLicenseAgreementMember" abstract="true" name="ZaiLabCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" abstract="true" name="BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" abstract="false" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" abstract="false" name="CollaborationAndOtherAgreementsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementClinicalActivitiesMember" abstract="true" name="IncyteMGA012AgreementClinicalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" abstract="false" name="RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_StockIncentivePlan2013Member" abstract="true" name="StockIncentivePlan2013Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_NumberOfPerformanceObligations" abstract="false" name="NumberOfPerformanceObligations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" abstract="false" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" abstract="true" name="ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" abstract="false" name="CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" abstract="false" name="NonrefundableUpfrontFeesNetOfTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" abstract="true" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_DevelopmentMilestonesAmount" abstract="false" name="DevelopmentMilestonesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ZaiLabMember" abstract="true" name="ZaiLabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ZaiLabClinicalSupplyAgreementsMember" abstract="true" name="ZaiLabClinicalSupplyAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" abstract="false" name="RevenueInformationUsedToAssessVariableConsiderationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_ProventionPRV031Member" abstract="true" name="ProventionPRV031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_FollowOnEquityOfferingMember" abstract="true" name="FollowOnEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IMabBiopharmaMember" abstract="true" name="IMabBiopharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_IncyteMGA012AgreementServicesMember" abstract="true" name="IncyteMGA012AgreementServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_RevenuesTaxWithholding" abstract="false" name="RevenuesTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" abstract="true" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" abstract="false" name="PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_NonrefundablePaymentTaxWithholding" abstract="false" name="NonrefundablePaymentTaxWithholding" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_FundedValueOfBasePeriod" abstract="false" name="FundedValueOfBasePeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" abstract="false" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mgnx_A2003StockIncentivePlanMember" abstract="true" name="A2003StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_ProventionBioInc.Member" abstract="true" name="ProventionBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" abstract="false" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="mgnx_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>mgnx-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b80e9c4c-1b3a-46c7-89c8-e9eb8984018c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e89605b8-b80e-4146-859f-15b42dcc1d1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b80e9c4c-1b3a-46c7-89c8-e9eb8984018c" xlink:to="loc_us-gaap_AssetsCurrent_e89605b8-b80e-4146-859f-15b42dcc1d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_577e5f40-80dd-4611-8a7a-45c60d3eb666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b80e9c4c-1b3a-46c7-89c8-e9eb8984018c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_577e5f40-80dd-4611-8a7a-45c60d3eb666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f2ad684d-21da-47fd-b8bc-67ef3c658e50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b80e9c4c-1b3a-46c7-89c8-e9eb8984018c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f2ad684d-21da-47fd-b8bc-67ef3c658e50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cef272d2-6ee5-4862-87f5-51e6ba75ee5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_9a6e3ee0-8338-468b-b794-312a9b1ed489" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cef272d2-6ee5-4862-87f5-51e6ba75ee5a" xlink:to="loc_us-gaap_Liabilities_9a6e3ee0-8338-468b-b794-312a9b1ed489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5acee71e-29c0-47e8-97bc-d37103607bf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cef272d2-6ee5-4862-87f5-51e6ba75ee5a" xlink:to="loc_us-gaap_StockholdersEquity_5acee71e-29c0-47e8-97bc-d37103607bf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d7ebbbf5-fc01-4ac3-8260-e3961ad60a56" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1f709a8e-0838-4e02-9e24-937c19cda4f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7ebbbf5-fc01-4ac3-8260-e3961ad60a56" xlink:to="loc_us-gaap_AccountsPayableCurrent_1f709a8e-0838-4e02-9e24-937c19cda4f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f24890e9-5b84-4e4b-b135-455d78c71213" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7ebbbf5-fc01-4ac3-8260-e3961ad60a56" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f24890e9-5b84-4e4b-b135-455d78c71213" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_352badb2-2d6d-4559-ac02-b9240b46a371" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7ebbbf5-fc01-4ac3-8260-e3961ad60a56" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_352badb2-2d6d-4559-ac02-b9240b46a371" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbff499b-ccc1-4f23-9f31-c75f1ae2eb44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_d7ebbbf5-fc01-4ac3-8260-e3961ad60a56" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_cbff499b-ccc1-4f23-9f31-c75f1ae2eb44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_23f43896-e70e-4f9a-a808-71bcedf36cd8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_83cd36c2-0321-4274-ab0c-17305f48984e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23f43896-e70e-4f9a-a808-71bcedf36cd8" xlink:to="loc_us-gaap_CommonStockValue_83cd36c2-0321-4274-ab0c-17305f48984e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b53c5149-6f11-4491-b03f-bd28d5736511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23f43896-e70e-4f9a-a808-71bcedf36cd8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b53c5149-6f11-4491-b03f-bd28d5736511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71d2c1ff-1dca-4eb3-b281-a196e706ac01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23f43896-e70e-4f9a-a808-71bcedf36cd8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_71d2c1ff-1dca-4eb3-b281-a196e706ac01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_78cf7298-3d38-4ca3-8905-5f9adde4b6b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_23f43896-e70e-4f9a-a808-71bcedf36cd8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_78cf7298-3d38-4ca3-8905-5f9adde4b6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_58e9d373-66c2-4391-8c3e-955ba19596ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f17843fe-7438-4481-9383-bc1753cb20b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_58e9d373-66c2-4391-8c3e-955ba19596ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_f17843fe-7438-4481-9383-bc1753cb20b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_045d0e66-9b64-4da3-9a26-789acdc68c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_58e9d373-66c2-4391-8c3e-955ba19596ab" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_045d0e66-9b64-4da3-9a26-789acdc68c22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d2ba220-6f67-46a8-aa73-6209c71cc507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_58e9d373-66c2-4391-8c3e-955ba19596ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7d2ba220-6f67-46a8-aa73-6209c71cc507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b5380b57-31fe-4471-b185-88049bbc2425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_58e9d373-66c2-4391-8c3e-955ba19596ab" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b5380b57-31fe-4471-b185-88049bbc2425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_16ab898e-2196-47f2-b1e8-5007da9a0645" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97ac682a-9889-4eb4-95a3-18009e46dc7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_16ab898e-2196-47f2-b1e8-5007da9a0645" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_97ac682a-9889-4eb4-95a3-18009e46dc7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_f61a543c-f403-4747-9e94-e1ad12dede60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_16ab898e-2196-47f2-b1e8-5007da9a0645" xlink:to="loc_us-gaap_Investments_f61a543c-f403-4747-9e94-e1ad12dede60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_cb66c700-587c-4fcc-93d0-05d942167b93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_16ab898e-2196-47f2-b1e8-5007da9a0645" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_cb66c700-587c-4fcc-93d0-05d942167b93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_a98b2048-0694-4863-b514-04375e666799" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_16ab898e-2196-47f2-b1e8-5007da9a0645" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_a98b2048-0694-4863-b514-04375e666799" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_55fbce9d-f303-4c3a-941c-a3a1fc135305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_991e205e-65bb-465c-b5af-2c6533ed43f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_55fbce9d-f303-4c3a-941c-a3a1fc135305" xlink:to="loc_us-gaap_NetIncomeLoss_991e205e-65bb-465c-b5af-2c6533ed43f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aea7b76f-159e-4f2c-83b3-d92a69f3e713" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_55fbce9d-f303-4c3a-941c-a3a1fc135305" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_aea7b76f-159e-4f2c-83b3-d92a69f3e713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7a101923-7b56-4aff-b01d-7e03979674b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_87dcbd2f-37ab-45b8-b288-a2769c5d559e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7a101923-7b56-4aff-b01d-7e03979674b3" xlink:to="loc_us-gaap_Revenues_87dcbd2f-37ab-45b8-b288-a2769c5d559e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_89106e67-8629-4d48-b231-ae17faca7289" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_7a101923-7b56-4aff-b01d-7e03979674b3" xlink:to="loc_us-gaap_CostsAndExpenses_89106e67-8629-4d48-b231-ae17faca7289" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_38e2dd13-3241-4a77-bbde-b7f3516ff4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_93705d56-4b99-48a7-97ff-e2137ab3374d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38e2dd13-3241-4a77-bbde-b7f3516ff4a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_93705d56-4b99-48a7-97ff-e2137ab3374d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b0629ae6-6238-40c9-8e5a-b1661388d66d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_38e2dd13-3241-4a77-bbde-b7f3516ff4a4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b0629ae6-6238-40c9-8e5a-b1661388d66d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_712fe3ae-463d-46fe-aeab-024630b24b2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f35c4cb9-e56c-4235-983d-39706f73b63f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_712fe3ae-463d-46fe-aeab-024630b24b2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f35c4cb9-e56c-4235-983d-39706f73b63f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_69610175-cff7-467e-88dc-f49bc83f885a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_712fe3ae-463d-46fe-aeab-024630b24b2a" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_69610175-cff7-467e-88dc-f49bc83f885a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa6147a9-7488-4de0-b94a-c18108f74020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb6523e7-d976-44c5-a66b-1ac4823492fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa6147a9-7488-4de0-b94a-c18108f74020" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fb6523e7-d976-44c5-a66b-1ac4823492fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b14a6c9-0436-4cb0-9a87-409fde7867bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa6147a9-7488-4de0-b94a-c18108f74020" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7b14a6c9-0436-4cb0-9a87-409fde7867bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_11d52cab-b012-4fc8-900e-edb717771ec8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fa6147a9-7488-4de0-b94a-c18108f74020" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_11d52cab-b012-4fc8-900e-edb717771ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95acbf2a-82b5-4b7f-a216-fd5f206ce2ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12304aaf-3a59-45f4-8bd0-3c7cfdced23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95acbf2a-82b5-4b7f-a216-fd5f206ce2ae" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_12304aaf-3a59-45f4-8bd0-3c7cfdced23f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fd1a9ec0-441d-4df2-a0ff-cfc9c349bb82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95acbf2a-82b5-4b7f-a216-fd5f206ce2ae" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_fd1a9ec0-441d-4df2-a0ff-cfc9c349bb82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21d3fbe7-0591-480d-a6d8-5633284f9dd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_95acbf2a-82b5-4b7f-a216-fd5f206ce2ae" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_21d3fbe7-0591-480d-a6d8-5633284f9dd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d9be7cc-2a2c-4c05-afb0-f5e26d764427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_NetIncomeLoss_9d9be7cc-2a2c-4c05-afb0-f5e26d764427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d8721363-c2e5-4c46-a28b-5f54258ca52d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_Depreciation_d8721363-c2e5-4c46-a28b-5f54258ca52d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_78bcf8f4-18ac-4ad5-9f78-76162dab9ad0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_78bcf8f4-18ac-4ad5-9f78-76162dab9ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_57378643-6136-45d4-855c-0b7a78bb6204" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_ShareBasedCompensation_57378643-6136-45d4-855c-0b7a78bb6204" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1ea083f3-2b0b-4e3d-8ae0-ceecbefa9089" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_1ea083f3-2b0b-4e3d-8ae0-ceecbefa9089" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_340466c0-73ca-427a-966b-f034987f7660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_340466c0-73ca-427a-966b-f034987f7660" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_50633cdf-73c7-4505-b9df-f0cf03a842ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_50633cdf-73c7-4505-b9df-f0cf03a842ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_0fc959e5-71e5-458b-be9a-09ff303f55ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_0fc959e5-71e5-458b-be9a-09ff303f55ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b113a9e7-88fb-460b-9c13-7d14aee45f01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_b113a9e7-88fb-460b-9c13-7d14aee45f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_e81d7a8d-8b52-480b-a2cd-5d98052be8c3" xlink:href="mgnx-20200930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_e81d7a8d-8b52-480b-a2cd-5d98052be8c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b83d2b2e-8a97-4ba0-a32a-5bef05d96b50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b83d2b2e-8a97-4ba0-a32a-5bef05d96b50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_8ab241be-4115-408f-a4d7-cdfd0c829816" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_46b60ed0-dacb-4b29-b6f7-5d723d74f20b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_8ab241be-4115-408f-a4d7-cdfd0c829816" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a73780ad-a683-4c39-920a-4e9fdfb45468" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2f1721e2-e43f-4245-a43b-31c308536cbb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a73780ad-a683-4c39-920a-4e9fdfb45468" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2f1721e2-e43f-4245-a43b-31c308536cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_f8fd7257-5a94-4bf3-950e-935d98ac121a" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a73780ad-a683-4c39-920a-4e9fdfb45468" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_f8fd7257-5a94-4bf3-950e-935d98ac121a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock_ead902dd-94d3-4dfb-898d-3a16554e36eb" xlink:href="mgnx-20200930.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a73780ad-a683-4c39-920a-4e9fdfb45468" xlink:to="loc_mgnx_RetirementOfTreasuryStock_ead902dd-94d3-4dfb-898d-3a16554e36eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="simple" xlink:href="mgnx-20200930.xsd#BasisofPresentationandRisksandUncertainties"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstruments"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7bea7105-7408-4748-921f-00255cc9cad3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_925e496d-ecf0-48ec-aa08-0a438a92f192" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7bea7105-7408-4748-921f-00255cc9cad3" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_925e496d-ecf0-48ec-aa08-0a438a92f192" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37512f67-a7f8-4daf-9397-c8a8c65b0523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_7bea7105-7408-4748-921f-00255cc9cad3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_37512f67-a7f8-4daf-9397-c8a8c65b0523" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecurities"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ce0ec140-0604-461c-a163-db20f0a1cfa2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cbcbf6f3-b313-486a-8c98-63537cc5181d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ce0ec140-0604-461c-a163-db20f0a1cfa2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cbcbf6f3-b313-486a-8c98-63537cc5181d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c61be224-e84c-4a9f-9cec-b9a47b469b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ce0ec140-0604-461c-a163-db20f0a1cfa2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c61be224-e84c-4a9f-9cec-b9a47b469b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832281da-323b-4e66-aff5-6d495d0551d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ce0ec140-0604-461c-a163-db20f0a1cfa2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_832281da-323b-4e66-aff5-6d495d0551d1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreements"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsProventionBioIncDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>mgnx-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended" id="i10c2db5df12e41c6b19f85fa9cc99bec_CoverPage"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended" id="i0d16c54d20d84d3a8b13bf05e1dea5a8_CONSOLIDATEDBALANCESHEETS"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended" id="ic8fc813ce00e492995fd92920fa15af0_CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="i126bacc67c1d45b29c0955e369f624e5_CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_87b5f366-0a4a-4b25-85f4-19c5d29f4d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:to="loc_us-gaap_Revenues_87b5f366-0a4a-4b25-85f4-19c5d29f4d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c7e4a444-21d8-4315-ac79-5edb8df14f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c7e4a444-21d8-4315-ac79-5edb8df14f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bc1f1bbe-650b-4c73-a28e-4c0c83ac064b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bc1f1bbe-650b-4c73-a28e-4c0c83ac064b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_27d08f76-8ebe-47c5-93a6-f83798ee61c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_CostsAndExpenses_27d08f76-8ebe-47c5-93a6-f83798ee61c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce84c500-53fb-4422-80b5-135075c15b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce84c500-53fb-4422-80b5-135075c15b0d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_894013c7-5d06-4526-988a-c25cfea44409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_894013c7-5d06-4526-988a-c25cfea44409" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a94355fd-09fc-4fd6-84ca-ac71175e982e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_NetIncomeLoss_a94355fd-09fc-4fd6-84ca-ac71175e982e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38d683a5-7a48-4cab-be19-e7815f09ee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38d683a5-7a48-4cab-be19-e7815f09ee55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c992fbd1-e8b7-4ec1-a956-745f527f9f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c992fbd1-e8b7-4ec1-a956-745f527f9f1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2b91dd80-56da-41ab-bf58-86fd67c1abe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2b91dd80-56da-41ab-bf58-86fd67c1abe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_930913bc-573b-4520-8013-14b7ea9b4201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_930913bc-573b-4520-8013-14b7ea9b4201" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:to="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f8d526a6-09f3-4744-a462-9f43a27bfd25_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:to="loc_srt_ProductsAndServicesDomain_f8d526a6-09f3-4744-a462-9f43a27bfd25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:to="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c3f60f4f-62fc-49a3-9953-9b9ce0f9b0af" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c3f60f4f-62fc-49a3-9953-9b9ce0f9b0af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_b9960263-eec2-4019-9dae-047fa36c1098" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_b9960263-eec2-4019-9dae-047fa36c1098" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="ic7922a02c5e048daa8deeaf3360101dd_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c2b1e056-0051-4504-af0e-2cdca3c363e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_SharesIssued_c2b1e056-0051-4504-af0e-2cdca3c363e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5505a87e-5ef9-485f-b44b-c265b931105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5505a87e-5ef9-485f-b44b-c265b931105f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb716923-de80-492f-a728-734fdb156d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb716923-de80-492f-a728-734fdb156d5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b469788d-0ff9-4140-b5b6-0ac00c0cf101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b469788d-0ff9-4140-b5b6-0ac00c0cf101" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_573e1cd2-0799-42c5-b23b-9caa0892744b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_573e1cd2-0799-42c5-b23b-9caa0892744b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_48fde7b9-fe5c-4ed5-a4d1-f6b29e26a725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_48fde7b9-fe5c-4ed5-a4d1-f6b29e26a725" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_65f48337-8718-4fdf-bf90-697d19279632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_65f48337-8718-4fdf-bf90-697d19279632" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_05203c17-2578-4849-b898-1b08b3d51de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_05203c17-2578-4849-b898-1b08b3d51de7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d08eaed-eed2-4974-a3ca-8c1503bf2f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d08eaed-eed2-4974-a3ca-8c1503bf2f19" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_bd019d7c-134b-4c11-8c2e-9bcc36e23a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_bd019d7c-134b-4c11-8c2e-9bcc36e23a04" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_501da499-c653-4c5e-86df-f9c24e256dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_NetIncomeLoss_501da499-c653-4c5e-86df-f9c24e256dc6" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_62d6ac8a-4a4c-4bbd-810e-aa638aca3643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a381bf76-e084-468a-be40-a76e6655a769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:to="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c005fc81-59c5-4832-b2e7-4a506e06626a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:to="loc_us-gaap_EquityComponentDomain_c005fc81-59c5-4832-b2e7-4a506e06626a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:to="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a68cc97-6527-4c6b-9bb5-f7f0a96540e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_CommonStockMember_1a68cc97-6527-4c6b-9bb5-f7f0a96540e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_dafc219d-bd93-4565-898e-a3edf8829db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_TreasuryStockMember_dafc219d-bd93-4565-898e-a3edf8829db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9aaa0c1f-4d9f-4b36-b929-cb382698cccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9aaa0c1f-4d9f-4b36-b929-cb382698cccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e8291510-c698-448f-b638-e11fe0ef5e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_RetainedEarningsMember_e8291510-c698-448f-b638-e11fe0ef5e94" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d18d2821-047d-4e30-980a-92d1e508edf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d18d2821-047d-4e30-980a-92d1e508edf1" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended" id="iae587ec4dc144e14b606d82d642ab3d4_CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="simple" xlink:href="mgnx-20200930.xsd#BasisofPresentationandRisksandUncertainties"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="extended" id="i66646dba3a5943858343455882729998_BasisofPresentationandRisksandUncertainties"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="iebd2b83b8a034e2da06c434abf79fa26_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="id123107615bc4c80a5c8d5f789e23890_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstruments"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended" id="ieb4c6a7d49c84d83a8fc9897e10d63e7_FairValueofFinancialInstruments"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended" id="id859e216af664bf79c0e749f564ff642_FairValueofFinancialInstrumentsTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended" id="i0732acc19e10405dbd82b6b4d6c228b3_FairValueofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bfff63c2-1e13-4e80-afa5-a31a16bc7351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bfff63c2-1e13-4e80-afa5-a31a16bc7351" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ec0fe75-7a8a-4d05-8304-35ab402d30d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ec0fe75-7a8a-4d05-8304-35ab402d30d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3b6ab686-dec2-4a10-a70e-65ba9493a263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3b6ab686-dec2-4a10-a70e-65ba9493a263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_04044956-ced6-4aab-9c73-417dd090e83f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_04044956-ced6-4aab-9c73-417dd090e83f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_188f0288-dec0-4f31-bac1-e5d6da49e0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_188f0288-dec0-4f31-bac1-e5d6da49e0b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1d220c31-6d10-4049-933f-ed564297989c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1d220c31-6d10-4049-933f-ed564297989c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3847a81f-af12-45cd-871e-b561e4c9f130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3847a81f-af12-45cd-871e-b561e4c9f130" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_20b516f2-53df-43de-b3a8-43337e43e5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_20b516f2-53df-43de-b3a8-43337e43e5e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239036f0-d0df-4665-b72d-bd14e49b739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239036f0-d0df-4665-b72d-bd14e49b739f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5d1baa55-0913-41f7-b84e-b6cec2b35e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5d1baa55-0913-41f7-b84e-b6cec2b35e7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34da17a3-8684-4361-9784-4b78716c14f4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_34da17a3-8684-4361-9784-4b78716c14f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21f35501-6085-4157-9086-6a6b955adb13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21f35501-6085-4157-9086-6a6b955adb13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1e00270-8ccb-489e-98d1-d631d7293f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1e00270-8ccb-489e-98d1-d631d7293f40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f61b03e6-ccb0-4b69-a2de-46e9a4d5852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f61b03e6-ccb0-4b69-a2de-46e9a4d5852e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecurities"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" id="iab691d5b3d1045958f837aeae1fe667c_MarketableSecurities"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" id="idb692c0b91394023af5b63e78ae13e5f_MarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended" id="i3d0ae34d43cb475eae6d19ce3a2e8222_MarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b630fd4-bc57-478a-b5f4-9841310e80d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b630fd4-bc57-478a-b5f4-9841310e80d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1004b490-4b33-4949-8e31-4b98db87e4c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1004b490-4b33-4949-8e31-4b98db87e4c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c361bb6a-4440-4c50-91db-80255129aec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c361bb6a-4440-4c50-91db-80255129aec4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d63cbd21-93c4-487b-9023-9f958cab92d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d63cbd21-93c4-487b-9023-9f958cab92d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_271ce433-f2a5-439f-880a-89ef29aca7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_271ce433-f2a5-439f-880a-89ef29aca7e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b12933f4-0e17-4680-b0ac-ffef15be1b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b12933f4-0e17-4680-b0ac-ffef15be1b28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_78c0df71-03ec-49ae-813b-c6e848b459fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_78c0df71-03ec-49ae-813b-c6e848b459fd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" id="i9b2b805643af492bbd6028dcd2281326_StockholdersEquity"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" id="ib7521b6a5781407692e86c0c455aac14_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6cf2f2d4-066a-4d19-b7e1-67a4ecb3b901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6cf2f2d4-066a-4d19-b7e1-67a4ecb3b901" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f9eccef-eb10-45af-980a-8039741cca9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f9eccef-eb10-45af-980a-8039741cca9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79e3048d-ff5b-41d1-b021-8e7c3def37c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79e3048d-ff5b-41d1-b021-8e7c3def37c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_fbd2007a-33e2-45d5-8ae7-64df3bd09422" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_fbd2007a-33e2-45d5-8ae7-64df3bd09422" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ae737148-6172-4c65-b51e-ab221b169f9c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ae737148-6172-4c65-b51e-ab221b169f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_16aa5a53-0b92-4157-b1b1-299d25ed7962" xlink:href="mgnx-20200930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_16aa5a53-0b92-4157-b1b1-299d25ed7962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_739eb95f-fa86-472b-a361-090a9add5232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_739eb95f-fa86-472b-a361-090a9add5232" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_5cf40e35-abd8-42b8-ba49-d88be0864626" xlink:href="mgnx-20200930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_mgnx_AtTheMarketOfferingMember_5cf40e35-abd8-42b8-ba49-d88be0864626" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreements"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended" id="if8b616249f3942b58ac46d58c4703f5a_CollaborationandOtherAgreements"/>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended" id="ifc7914f9c2e246fcb8a195b9649d2d3a_CollaborationandOtherAgreementsIncyteCorporationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f6e8846e-d416-462e-9434-f505c031b2df" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f6e8846e-d416-462e-9434-f505c031b2df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29a2afb4-2471-4975-be99-7abc43224c4a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29a2afb4-2471-4975-be99-7abc43224c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_396e599e-535e-432d-9aa2-f0d72a1efe7a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_396e599e-535e-432d-9aa2-f0d72a1efe7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e3d54376-34db-4f9f-ba8e-47d961faf922" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e3d54376-34db-4f9f-ba8e-47d961faf922" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_3a935d93-e87b-414b-8d9f-bec557e9b624" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_3a935d93-e87b-414b-8d9f-bec557e9b624" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_f1387007-3497-478d-9bcd-7f2d2851935d" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_NumberOfPerformanceObligations_f1387007-3497-478d-9bcd-7f2d2851935d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ce704086-12ee-47fd-92b7-5be6eb09f77a" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ce704086-12ee-47fd-92b7-5be6eb09f77a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_077744cc-2e46-4974-b5a2-e24f6041a879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_us-gaap_Revenues_077744cc-2e46-4974-b5a2-e24f6041a879" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_afecbece-db79-494d-ad95-092669a28f45" xlink:href="mgnx-20200930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_afecbece-db79-494d-ad95-092669a28f45" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_31e52791-4ae1-4aa7-bf59-3c5ef25fec59_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:to="loc_srt_ProductsAndServicesDomain_31e52791-4ae1-4aa7-bf59-3c5ef25fec59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:to="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c3017abc-2a34-4453-b4e3-b3059b22c3f9" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c3017abc-2a34-4453-b4e3-b3059b22c3f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:to="loc_srt_RangeMember_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:to="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd88244b-1c07-4458-8152-3889a6544c65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:to="loc_srt_MaximumMember_dd88244b-1c07-4458-8152-3889a6544c65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef7b7ed8-c5cf-4dc7-b72a-28248dccd4ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:to="loc_srt_MinimumMember_ef7b7ed8-c5cf-4dc7-b72a-28248dccd4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_258176ae-3654-44ee-ac1f-54bf35e37108_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_258176ae-3654-44ee-ac1f-54bf35e37108_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_083080c1-97c2-4646-b3a7-b94821b61559" xlink:href="mgnx-20200930.xsd#mgnx_IncyteCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:to="loc_mgnx_IncyteCorporationMember_083080c1-97c2-4646-b3a7-b94821b61559" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35878135-fde0-463c-bcd9-7746d50de7a4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_35878135-fde0-463c-bcd9-7746d50de7a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5793423c-c00f-424f-b46e-039bf155d447" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5793423c-c00f-424f-b46e-039bf155d447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_1e6c60f7-9c96-457e-a1e1-dbd12ef5d278" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_1e6c60f7-9c96-457e-a1e1-dbd12ef5d278" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended" id="ifd9b7af843174e9f9c670804860bb389_CollaborationandOtherAgreementsZaiLabDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_393d9c37-9523-49a7-88f0-6f35b5c83104" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonRefundableUpfrontFees_393d9c37-9523-49a7-88f0-6f35b5c83104" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_04cf5e93-3a71-4930-8e1e-86845be809b6" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_04cf5e93-3a71-4930-8e1e-86845be809b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_d1e46157-53b3-4bfc-bd4b-2b826aa82e3c" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_d1e46157-53b3-4bfc-bd4b-2b826aa82e3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ffd7a11b-cabc-4605-9625-bcea21d5a672" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ffd7a11b-cabc-4605-9625-bcea21d5a672" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b42c0376-edc5-4c95-b825-47c71832b0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_us-gaap_Revenues_b42c0376-edc5-4c95-b825-47c71832b0b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_3ed99c37-743a-4a71-8745-1283e4597553" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_3ed99c37-743a-4a71-8745-1283e4597553" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_6ef33076-fae0-4a92-a301-53269b196c71" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_RevenuesTaxWithholding_6ef33076-fae0-4a92-a301-53269b196c71" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_17e1fab1-468c-4fec-8b93-d667263dff9d" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_17e1fab1-468c-4fec-8b93-d667263dff9d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f46a3fa2-8355-4322-bb69-5aca0a0873ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f46a3fa2-8355-4322-bb69-5aca0a0873ac" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_564fb295-c892-474d-afbb-1ff08a51d213_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:to="loc_srt_ProductsAndServicesDomain_564fb295-c892-474d-afbb-1ff08a51d213_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:to="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_fffff82d-c1e0-476a-b2ad-95d1e743e480" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_fffff82d-c1e0-476a-b2ad-95d1e743e480" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5709f337-94d1-4b74-aa90-1ecf9214dc64_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_5709f337-94d1-4b74-aa90-1ecf9214dc64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_1c1b9280-6dec-4565-8a6b-c0cf9c6d9f71" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_1c1b9280-6dec-4565-8a6b-c0cf9c6d9f71" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a040325c-5399-4811-a6bb-b0295f25da0c" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a040325c-5399-4811-a6bb-b0295f25da0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_ebf4fc15-9034-4d76-8e6f-513cb964df42" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_ebf4fc15-9034-4d76-8e6f-513cb964df42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_150afcca-1dc7-4e2f-9da4-a3a06f5fc418" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_150afcca-1dc7-4e2f-9da4-a3a06f5fc418" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00379a6a-0126-432d-a04b-c8f0ac134f9b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_00379a6a-0126-432d-a04b-c8f0ac134f9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_50aac22c-a354-41c8-a9fb-744b37ceb101" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:to="loc_mgnx_ZaiLabMember_50aac22c-a354-41c8-a9fb-744b37ceb101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7da83125-87a7-431b-b531-590a93111bfb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:to="loc_srt_RangeMember_7da83125-87a7-431b-b531-590a93111bfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:to="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb5a9945-ed34-4d65-9faf-4d7d318775d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:to="loc_srt_MaximumMember_fb5a9945-ed34-4d65-9faf-4d7d318775d1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended" id="i0a68710cc33645098aa07d3dd1b43a19_CollaborationandOtherAgreementsIMabBiopharmaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_12317d0c-946f-41cc-88ee-3624273c06b5" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_12317d0c-946f-41cc-88ee-3624273c06b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f661440d-bd55-4184-b38f-4319c77c2df9" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f661440d-bd55-4184-b38f-4319c77c2df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_3b3d6783-23f3-4330-913a-ebd86976800b" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_3b3d6783-23f3-4330-913a-ebd86976800b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_be945536-a493-4990-98f3-1a8780ffec12" xlink:href="mgnx-20200930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_be945536-a493-4990-98f3-1a8780ffec12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b7af7f41-768f-4052-a72a-79defdf10df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_Revenues_b7af7f41-768f-4052-a72a-79defdf10df0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0f1df097-4e44-4b3a-bbb7-8c2f454f5456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0f1df097-4e44-4b3a-bbb7-8c2f454f5456" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9988c95c-0cd8-474a-9b2f-d68a54ee3474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9988c95c-0cd8-474a-9b2f-d68a54ee3474" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_98002763-b687-4ad9-a199-e78ab5cbf86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_98002763-b687-4ad9-a199-e78ab5cbf86a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e1b988a-4eef-4a5f-851a-91b5977d8c8e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7e1b988a-4eef-4a5f-851a-91b5977d8c8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_15227145-4d43-4ed3-8262-78e906ede173" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:to="loc_mgnx_IMabBiopharmaMember_15227145-4d43-4ed3-8262-78e906ede173" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02a49108-a661-4787-82cc-b21d0e227dc8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_02a49108-a661-4787-82cc-b21d0e227dc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5b981b44-e583-485f-97cc-b88de0e4467b" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5b981b44-e583-485f-97cc-b88de0e4467b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f6ec4687-22d9-4b41-85f1-ec4efef3e313_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:to="loc_srt_RangeMember_f6ec4687-22d9-4b41-85f1-ec4efef3e313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:to="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_322de2dc-53e8-4fd1-ab0a-35c624506eef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:to="loc_srt_MaximumMember_322de2dc-53e8-4fd1-ab0a-35c624506eef" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsProventionBioIncDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="extended" id="iabae785500a544c193e74af6f33b7d91_CollaborationandOtherAgreementsProventionBioIncDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_89bb700a-3042-4004-86de-b3352329d8a2" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_89bb700a-3042-4004-86de-b3352329d8a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_aa79bbe9-728d-4826-a4d2-b4ecdcd96d9a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_aa79bbe9-728d-4826-a4d2-b4ecdcd96d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4e9a3b3d-75bc-44ee-9a4d-520429c5a721" xlink:href="mgnx-20200930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4e9a3b3d-75bc-44ee-9a4d-520429c5a721" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_2c538904-3f43-4513-8b70-478432653667" xlink:href="mgnx-20200930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_2c538904-3f43-4513-8b70-478432653667" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_ae56049f-3fde-46d5-afd4-612575cd74a5" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_NumberOfPerformanceObligations_ae56049f-3fde-46d5-afd4-612575cd74a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_bed3fafd-096f-48bb-b655-6f2a845cae1e" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_bed3fafd-096f-48bb-b655-6f2a845cae1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_f8c44f09-8f83-4c67-8b30-2cb9e7705af6" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_f8c44f09-8f83-4c67-8b30-2cb9e7705af6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_60ac0227-e460-4dab-96db-9e89231b8a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_us-gaap_Revenues_60ac0227-e460-4dab-96db-9e89231b8a1e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1574e8a-4e6f-4074-bcea-a0e3dde7380b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1574e8a-4e6f-4074-bcea-a0e3dde7380b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb6cca9f-1cda-4134-a634-7c39b070fb08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_fb6cca9f-1cda-4134-a634-7c39b070fb08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f731ecea-40cc-44d6-a202-cf4a6e8c46e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f731ecea-40cc-44d6-a202-cf4a6e8c46e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a6ff5b1c-f965-417e-a63d-457544257a42_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:to="loc_srt_ProductsAndServicesDomain_a6ff5b1c-f965-417e-a63d-457544257a42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:to="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7246a072-47d9-41b9-a110-a3cbe0e96bb4" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7246a072-47d9-41b9-a110-a3cbe0e96bb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_083b2e31-ab83-4846-a70f-11f317c05f80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_083b2e31-ab83-4846-a70f-11f317c05f80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_f2940b9f-2366-4364-813e-f9ed452c2344" xlink:href="mgnx-20200930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_f2940b9f-2366-4364-813e-f9ed452c2344" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_7aaf19b3-e6b5-4330-b6af-d2c48a384fae" xlink:href="mgnx-20200930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_7aaf19b3-e6b5-4330-b6af-d2c48a384fae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e06e0544-530e-4f83-815d-a479c3e6640b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e06e0544-530e-4f83-815d-a479c3e6640b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_aa14822e-e519-4e2a-a3a8-aefd63c86929" xlink:href="mgnx-20200930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:to="loc_mgnx_ProventionBioInc.Member_aa14822e-e519-4e2a-a3a8-aefd63c86929" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_071572a5-8843-487c-b2a2-fd04a9cd1d87_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_071572a5-8843-487c-b2a2-fd04a9cd1d87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_deff683c-a43c-4667-b544-d9b50288d934" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:to="loc_mgnx_ProventionPRV3279Member_deff683c-a43c-4667-b544-d9b50288d934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_6ff48fc6-5076-47ce-b13d-b2eb8de52c26" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:to="loc_mgnx_ProventionPRV031Member_6ff48fc6-5076-47ce-b13d-b2eb8de52c26" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended" id="iad25efa1cb19422f9a45cf4e1452058c_CollaborationandOtherAgreementsNIAIDContractDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_3ef9dde5-fa75-4892-ad1d-3efebc3cb63a" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_3ef9dde5-fa75-4892-ad1d-3efebc3cb63a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_9f11c93d-0ef6-439b-a7dd-053cbedc32fc" xlink:href="mgnx-20200930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_FundedValueOfBasePeriod_9f11c93d-0ef6-439b-a7dd-053cbedc32fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_35279502-df8b-4b5b-b5e8-a1f7d48deaad" xlink:href="mgnx-20200930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_35279502-df8b-4b5b-b5e8-a1f7d48deaad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_b430a93b-5072-4ad5-9302-9384746a4d0e" xlink:href="mgnx-20200930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_b430a93b-5072-4ad5-9302-9384746a4d0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_b872538f-8794-48cb-b409-661c4ba6331e" xlink:href="mgnx-20200930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_b872538f-8794-48cb-b409-661c4ba6331e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7ca0359a-1ad4-4e2e-b5e8-424c75d9345f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_us-gaap_Revenues_7ca0359a-1ad4-4e2e-b5e8-424c75d9345f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63ced5cb-0c62-4315-80d3-597e06558e7b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:to="loc_srt_ProductsAndServicesDomain_63ced5cb-0c62-4315-80d3-597e06558e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:to="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_25d0d5ff-a0e9-40d5-9245-791ec39f2547" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:to="loc_mgnx_RevenuesFromGrantsMember_25d0d5ff-a0e9-40d5-9245-791ec39f2547" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0539a142-93ed-427e-9ac9-e77283ea9559_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0539a142-93ed-427e-9ac9-e77283ea9559_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0e6a5755-e614-45bb-8d8d-2c58cbd48053" xlink:href="mgnx-20200930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0e6a5755-e614-45bb-8d8d-2c58cbd48053" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a49fa168-57f5-4ddf-befb-f1a0c44bca9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:to="loc_srt_RangeMember_a49fa168-57f5-4ddf-befb-f1a0c44bca9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:to="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_522ced2e-f653-400e-9baa-57c827d7c781" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:to="loc_srt_MaximumMember_522ced2e-f653-400e-9baa-57c827d7c781" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended" id="i7fdcb7fff7174dae9617c91f9e89a544_CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_658ee993-1de4-48a5-b8e5-2de23f93435a" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_658ee993-1de4-48a5-b8e5-2de23f93435a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_66809b36-4367-420b-8eb5-cd118288549e" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_NumberOfProductCandidates_66809b36-4367-420b-8eb5-cd118288549e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_65abc63e-beea-4fc6-a7f6-5f5088c830d2" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_65abc63e-beea-4fc6-a7f6-5f5088c830d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_06e21e42-734c-4aba-b885-d6b21f63c7e1" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_06e21e42-734c-4aba-b885-d6b21f63c7e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_acae437b-db44-473e-a08e-69bd424350dc" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_acae437b-db44-473e-a08e-69bd424350dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1fd5a01-9394-46ba-9be2-fe07b58c492a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f1fd5a01-9394-46ba-9be2-fe07b58c492a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_392ed648-b338-4afe-af12-f34f393a1898" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_392ed648-b338-4afe-af12-f34f393a1898" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:to="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82f4e0f2-2451-4074-b9c5-97e1c312658d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82f4e0f2-2451-4074-b9c5-97e1c312658d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_020e950a-eff7-4c20-8f94-d52c563af193" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_020e950a-eff7-4c20-8f94-d52c563af193" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" id="i6fff8dbf8a754fd1b6ea5175eef17504_StockBasedCompensation"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" id="i19bf522d114a4a1c8409f60321d6dac1_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ie9b2bc1f52154b859d6309670517925b_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8532d14c-c9b1-4716-a6b9-bd6e0d58268f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8532d14c-c9b1-4716-a6b9-bd6e0d58268f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_187f825b-fe9a-491b-a6ba-63bdfa3b5def" xlink:href="mgnx-20200930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_187f825b-fe9a-491b-a6ba-63bdfa3b5def" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cc5466a3-fcdb-4ed2-a7c6-f3220009e582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cc5466a3-fcdb-4ed2-a7c6-f3220009e582" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_22ebdb4d-0aa2-47ae-b8b3-22bf1b3004fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_22ebdb4d-0aa2-47ae-b8b3-22bf1b3004fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_05bc974d-0a48-490d-a872-e82f53420c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ProceedsFromStockPlans_05bc974d-0a48-490d-a872-e82f53420c4e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_a7958380-21dd-4f28-9be3-74eb26ac2320" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_a7958380-21dd-4f28-9be3-74eb26ac2320" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_bd27e2b1-acc8-4f75-b887-240652f74182" xlink:href="mgnx-20200930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_bd27e2b1-acc8-4f75-b887-240652f74182" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_961d3b17-290e-40b8-8e77-cdfee272feeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_961d3b17-290e-40b8-8e77-cdfee272feeb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_106e4975-1f56-4956-9d2c-03835100f338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_106e4975-1f56-4956-9d2c-03835100f338" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:to="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_39ed5c21-895c-49fd-82cb-6536345aa711_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:to="loc_us-gaap_PlanNameDomain_39ed5c21-895c-49fd-82cb-6536345aa711_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:to="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_ac895017-5d91-48bf-a880-6f5b5ca585e6" xlink:href="mgnx-20200930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_ac895017-5d91-48bf-a880-6f5b5ca585e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_d5a26370-63d6-4ee6-bd60-26754797ed26" xlink:href="mgnx-20200930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_d5a26370-63d6-4ee6-bd60-26754797ed26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_84934f28-ff4f-4ec7-8978-62602c03f9b2" xlink:href="mgnx-20200930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_StockIncentivePlan2013Member_84934f28-ff4f-4ec7-8978-62602c03f9b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22fcbcf8-b644-4c39-90a7-268ad1e1372d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22fcbcf8-b644-4c39-90a7-268ad1e1372d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_75acc261-c6fc-435f-911c-7c86baec59a9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_75acc261-c6fc-435f-911c-7c86baec59a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba43c289-8145-41df-8bd8-ccab93439e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba43c289-8145-41df-8bd8-ccab93439e62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6cd1b5d-4413-4169-97f7-0e142aca07fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6cd1b5d-4413-4169-97f7-0e142aca07fe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" id="iffe2993efe7c406ca59b6dedd4364865_StockBasedCompensationOptionPricingAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90b82696-0012-4da8-bc4f-a5a57871fb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90b82696-0012-4da8-bc4f-a5a57871fb52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf381d80-e6c1-4638-ad29-8e5f1794f65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf381d80-e6c1-4638-ad29-8e5f1794f65e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_deff7401-9014-4d92-b741-9ae56f53f818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_deff7401-9014-4d92-b741-9ae56f53f818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1409078e-f077-4b9f-b9e9-196b6c43f2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1409078e-f077-4b9f-b9e9-196b6c43f2ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:to="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_66448558-d2b0-44e9-a059-043a060a14d0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:to="loc_srt_RangeMember_66448558-d2b0-44e9-a059-043a060a14d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:to="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f44c0f47-6086-48b6-beab-2dd27e036ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:to="loc_srt_MinimumMember_f44c0f47-6086-48b6-beab-2dd27e036ff0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_658cdefa-57e0-4422-baa9-dcad2dcbfc11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:to="loc_srt_MaximumMember_658cdefa-57e0-4422-baa9-dcad2dcbfc11" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i9bf9d9cc927148c78cd8ad262efe9dcf_StockBasedCompensationStockOptionActivityDetails"/>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended" id="if7d39096b0a040368c483ef03c1b8783_StockbasedCompensationRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4521ea14-1520-426d-8ee1-370aa27683b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4521ea14-1520-426d-8ee1-370aa27683b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3bd8f1b-9312-4b4d-add3-c2a39e3f6050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3bd8f1b-9312-4b4d-add3-c2a39e3f6050" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_32037f3f-18b6-428e-a454-cb954226857d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_32037f3f-18b6-428e-a454-cb954226857d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07d38954-8102-488f-af3b-5f932df5aa11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07d38954-8102-488f-af3b-5f932df5aa11" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18c92f03-387b-49d8-9689-9417836a041f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52cad51b-8dbd-4755-aeeb-69539fc6aa06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52cad51b-8dbd-4755-aeeb-69539fc6aa06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fad09b4c-0efb-4d25-afb5-a121bb1b9a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fad09b4c-0efb-4d25-afb5-a121bb1b9a0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5851e5d-989f-4f28-a07e-8c2387756b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5851e5d-989f-4f28-a07e-8c2387756b05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ddce5d5-fc93-4847-8f09-e3b6ba0f2abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ddce5d5-fc93-4847-8f09-e3b6ba0f2abe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7aad1d4c-70f8-4d0a-88fa-276ad59dddb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14900b70-38c6-4630-bd15-ebec569e6f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7c71050f-4bcd-4f71-bb23-ae2216c6f4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7c71050f-4bcd-4f71-bb23-ae2216c6f4dc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ec8883c-5f5c-4cde-b6f8-504cbbcca32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ec8883c-5f5c-4cde-b6f8-504cbbcca32a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:to="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7372aa2d-5a05-4899-82b6-50aa8c42fbc0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7372aa2d-5a05-4899-82b6-50aa8c42fbc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cdb9bc42-2185-40e0-8f5d-33851f475d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cdb9bc42-2185-40e0-8f5d-33851f475d93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:to="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:to="loc_us-gaap_PlanNameDomain_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:to="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_432276f0-98c8-4f56-bd2f-637873e20b16" xlink:href="mgnx-20200930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:to="loc_mgnx_StockIncentivePlan2013Member_432276f0-98c8-4f56-bd2f-637873e20b16" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended" id="if60ef0bac8cd4003b30bdfe5e9911828_CommitmentsandContingencies"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>mgnx-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a3bb2fbe-ec40-4643-b5e5-df86af448060_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_49353215-4730-4698-a7c8-a39166e0854e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards granted in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6531f364-9133-4e8b-a728-832d53e92d22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_59fbebfe-cbce-4842-9b14-d17f2e61cc46_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_4a6d8a3f-ec9f-434f-a692-22a453bf42f7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_3b3bef08-0135-4c37-8be0-64f695bad602_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_d3119706-bb87-40dc-8e49-863281647230_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_15d2cff4-04bc-467d-9a28-205cf5bd056f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionBioInc.Member_8eaa1672-84a9-4922-9585-3b0f3656a612_terseLabel_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention</link:label>
    <link:label id="lab_mgnx_ProventionBioInc.Member_label_en-US" xlink:label="lab_mgnx_ProventionBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionBioInc.Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member" xlink:href="mgnx-20200930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionBioInc.Member" xlink:to="lab_mgnx_ProventionBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_28862e52-1822-4d80-a1b7-19051ac45582_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_bade8ca2-d4ee-4e5a-addd-81c9e9245eba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired" xlink:to="lab_us-gaap_TreasuryStockSharesRetired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_ea3b0fab-d882-4e7d-a650-43b0db4d3db6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_0353cd8b-b1f0-433e-aa57-6d3bc7e0ff49_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercial milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialCommercialMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_d06c2461-307a-4f09-9e3f-bf6c183de018_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d9598c35-15b8-44c2-a365-a6e8578a9e94_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3e095c4e-ddff-407a-abe0-105da1d53246_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1e7e52ca-7f50-477b-92f3-045d9d577ee9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_c7ac787c-36dd-4794-b3fc-d01a4e4df326_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a730952b-f55d-4c54-b356-d524c5aca5f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_27d14a0a-b71c-4d47-97e8-b42f2fba9c01_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4bc5c4f3-caa2-4031-9a40-35e4c9a364f4_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ca55ae52-32de-49d8-a524-dac36cf31cd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_85a401fe-a23e-4cf4-851a-405c8dc3b02c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_37513155-b52b-4977-96ce-76155d685da8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_b12a2021-42f5-4908-a1cb-45d1c42ea43d_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:href="mgnx-20200930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_mgnx_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_867a0f72-9f7d-455f-aa92-172a1ce894c0_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential proceeds from royalties (percent)</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromRoyaltiesPercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_79cbbdda-58d1-453a-8bef-e03f49a768ea_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0597627a-0cd7-4f51-94ef-1a9cca327393_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_7d2eed44-224d-4028-8441-681483130cbc_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Services</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementServicesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementServicesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementServicesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7dee7c78-039b-4c4d-ad60-725e279ea983_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_c08c7d9a-aa3b-42b4-ac98-8945cabe8da3_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9185e9b0-9665-4f3f-90f5-381ef1da4fb1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_20dd8fe6-f021-46e3-81fe-3b3a0379d875_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_75b207e8-4f04-4947-8d67-5758a58e73ae_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NationalInstituteOfAllergyAndInfectiousDiseasesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:href="mgnx-20200930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_05812568-ad87-4d65-a1fc-35c9472ee99c_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_179892b4-f8bf-4f2a-bfbb-ebd70c8bbd6d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_62e4dc73-c32d-487c-b328-8900e0e48e8c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2a21dcb8-e4e3-4f08-a628-7a46aca783c2_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_6584796d-3c43-49a3-a4f4-5fa3eaee0db1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7e6e59c4-b73e-4a29-a77e-6052d999f058_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bc3798d9-f516-46f6-ba4d-e069a51d2f24_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_9dbd4e20-6917-4671-a310-132b31365671_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment, net of tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Upfront Fees, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:to="lab_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e5327228-a0a7-486b-a18b-abda80415837_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_0e982dcc-a4e6-4dbd-8a47-2088ce15d11b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_5a064633-2a8c-475f-acd6-99f59b6722b4_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_417d8482-4c13-4736-8744-231aa5dcb3ff_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a8c8b114-5126-43a3-9bc1-cf4d46b432f3_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_60408d4c-09d6-4975-a99b-1ce0c239513a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a29300a7-1aa2-45cc-9e82-6003555275bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7a0925be-d013-430f-aa80-880229b1537f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_e3dfaecd-5bbe-4234-b5b1-5911b4257bb7_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesTaxWithholding" xlink:to="lab_mgnx_RevenuesTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cc48de09-8193-40a3-838a-948bdd0b1cdc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_ad7eff18-813b-4c40-941a-55b41752fbad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_77f2c98c-1b35-4b69-9770-29c0e70e21a2_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember" xlink:to="lab_mgnx_IncyteMGA012AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_7fb7c12e-a853-406c-ab7d-22c21221b363_terseLabel_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5ecfa629-c09a-46be-ba48-a07ffcb4c910_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_83fabc7f-d498-4e75-ad75-6243020d33ff_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_b6f8324f-ef77-4859-8012-d33af5016f0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1b9e5a80-65da-49aa-8259-cf2b4aba5f8b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_417568ca-515f-48a5-a353-2c382f327c33_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a0fb91f6-9eb9-4604-bad4-03c2bfced02d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_881d09f3-2708-45a0-86cb-f0c159df0cf5_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9614af7f-4f22-44da-bc6b-e8cec032f01d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_3cf43762-de97-4024-95f6-d4ff8fc2c35c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Losses related to other-than-temporary impairments of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_94757ed8-43f4-4c1b-9c43-efff722f32d6_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="mgnx-20200930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3b2d1655-4d1e-412e-ad02-e4418e3bb0f1_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a4163a5a-2838-43d1-9032-9f3718c43da8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_16b3147d-e540-4e05-b316-188eb21ff98e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2518b781-bf14-477a-a409-8433833e6679_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e97d8a2-a35c-4d75-a289-7261af23f048_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_0259639f-421d-4246-8f24-dd6032b35e08_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_fde74c11-c6d7-432c-ac80-4a7c4f8e41eb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_aea03619-efdb-41fd-96f8-2c2dd11ebda8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_e51a66a5-bb62-47d8-b73d-0980b4d4cb70_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_26bab89f-5a1c-4956-9214-d16a8c013237_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent of the fair market value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_c489cee1-04ea-4726-b2ff-e0b90b49e7fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_15fdc0b2-ad2a-4d01-abbb-f07415b05f38_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NonRefundableUpfrontFees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees" xlink:to="lab_mgnx_NonRefundableUpfrontFees" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_1a7349b4-d127-44dd-927e-d6cfcfa1ade4_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_41f7849d-7c15-42e4-a318-6545767ec97d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_cbc4886d-dd2b-41b7-ab2e-c8519e645ca0_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f012e164-ba77-4189-a778-45b2c050043b_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_f68242ec-51d0-4f5d-b19a-ad3d4e1aaf3a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e1105d8b-5ad0-4589-9408-6c2ba204d66f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3463c092-404a-4148-9da5-cbfca4089920_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_4bfd8b88-67a4-4e32-8630-aa67783d2ced_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_88879621-e944-4790-9aa6-0de016c3e8b4_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2e87c49f-42ce-48dc-ad24-2257195e1151_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a6b118c3-c9a7-4e6c-8087-9279b5b77236_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV3279Member_23012b80-3fc1-4035-b970-8747ffb7ebec_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-3279</link:label>
    <link:label id="lab_mgnx_ProventionPRV3279Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV3279Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV3279Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV3279Member" xlink:to="lab_mgnx_ProventionPRV3279Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_56fd2974-ab81-4d04-905e-6c92a0324a20_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_dfb7d3b9-f6cd-482e-94f2-1f29a4ab40a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_fcba4fa6-b6fe-4f1a-90d4-9ea6137f2e29_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_d47a4ccd-d51b-4085-8604-79f9cd32826a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_db625cb0-353e-4d79-9c97-7442c74e5cdf_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_38a373de-102d-4f54-be86-dd6eb911617d_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in years)</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementTerm_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementTerm" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_eff31ddf-eed6-4dc4-a784-8dc3a291321f_verboseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProceedsfromStockOptionsExercisedAndESPPPurchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a1e81b4b-3ffc-4461-a20c-a6bbea0534a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0b8b6ef5-e8fb-423a-aa06-bc84806748ce_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_3e3a75ad-492c-401d-936c-5942e4a67d83_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte MGA012 Agreement - Clinical activities</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteMGA012AgreementClinicalActivitiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:to="lab_mgnx_IncyteMGA012AgreementClinicalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_4e21df2d-32b1-47fd-ad16-2353a3204876_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockMaximumAmountAvailableForIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_edf29252-e5ab-412a-b0ee-860b2c398457_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_c9e2a160-2198-46be-b5e3-d1e1bf253c6a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_631933ea-6dce-4643-8462-5648d98d2d58_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_ccef6880-1ce1-4384-ac9a-e2074f7f17c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_4c7b5213-7a0b-4ffe-8f79-91228bea5de4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01f282f3-5c14-4c73-bfe9-cb94cb6ac04e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_33ae715c-8b4a-4e12-8027-c89ad9eb0174_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6b99f887-a63a-4096-8c51-5da6f41d2888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Collaboration Agreements [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_fe168f19-b57d-48b9-9e3f-ac90895737d8_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e0355445-04e7-4539-822e-0ff3566fee0e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c04a672e-4c7b-40eb-8598-142b2bfd3151_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_d56b7fa6-abed-447b-ba17-1fd51aa0544f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bae6d1e2-decd-494d-bff3-cd0fe5c9ce2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfProductCandidates_df5ea468-c00a-43e0-81a7-ca073e36589e_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates to develop</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_label_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_mgnx_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_mgnx_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfProductCandidates" xlink:to="lab_mgnx_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_21839eaf-c9c2-466b-9cd8-a636929115cd_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d6fd7b98-306d-4f98-b412-354ff06626d1_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_e80f1880-a9e5-4787-a3fb-9c8dccd13dc8_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_3e18380e-6dfe-457f-a114-9083022f2446_negatedLabel_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_label_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:label id="lab_mgnx_RetirementOfTreasuryStock_documentation_en-US" xlink:label="lab_mgnx_RetirementOfTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Of Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock" xlink:href="mgnx-20200930.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RetirementOfTreasuryStock" xlink:to="lab_mgnx_RetirementOfTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_0b03959f-809a-4e37-aa95-95f01eb7e2ac_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_af685a01-093a-43a2-935a-c94e30c86273_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,174,932 and 48,958,763 shares outstanding at September&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_5c1c9b40-44a1-4b97-b9f3-61be3762cc8f_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AtTheMarketOfferingMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember" xlink:href="mgnx-20200930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember" xlink:to="lab_mgnx_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_8be6f9e6-af79-48a9-b68e-f3158fc2ada0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per common share (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_2e7c4d20-ae8c-4e9f-90d1-20238be77420_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_062cd48e-9d95-4dc2-a5f5-0495bd03246c_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_bd6d6a80-b820-4809-951a-37bbe6c87fff_terseLabel_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement</link:label>
    <link:label id="lab_mgnx_AssetPurchaseAgreementMember_label_en-US" xlink:label="lab_mgnx_AssetPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AssetPurchaseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AssetPurchaseAgreementMember" xlink:to="lab_mgnx_AssetPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_55d110f9-400f-4909-9e34-615ad031b8eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_11b24423-47b9-4762-a72f-45294371ef82_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_efd8c1d1-6742-428b-be98-9461fea10d03_terseLabel_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable payment tax withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_label_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:label id="lab_mgnx_NonrefundablePaymentTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonrefundable Payment Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonrefundablePaymentTaxWithholding" xlink:to="lab_mgnx_NonrefundablePaymentTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9c79df9b-ce59-4c89-b869-ba7bfb909ca1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_945227c5-fff8-4b48-883a-5964ec8af894_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_f2f79ade-315b-4e2e-ae3e-9c3f3d82f6c7_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9a3bf7da-fb5e-4722-a0e0-cb84430b40df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f98dac37-c4b2-4f96-aae2-f18f07262b98_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9dcd9115-b1b8-45a5-ba66-c28adcd897b8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_772fb8f5-54a8-4532-9101-b221f05819ed_terseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FundedValueOfBasePeriod</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod" xlink:href="mgnx-20200930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod" xlink:to="lab_mgnx_FundedValueOfBasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_bdb31249-2542-43bf-a5ba-1fab64013e30_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_267a788c-014e-40fc-aa65-5ebefde20a0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_44a410a5-e03c-4edc-b31b-dafeaa6cb3ba_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_e1f7bee3-b2c7-4d59-ad29-1e8956e4e1e2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4c668aad-b320-49ba-ad46-71c84b3e7898_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_fc5e8732-4667-4abd-8043-a013bc58d198_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_acc1a391-e81f-4a84-9796-edf3250ff733_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_818872fd-4b85-4017-9058-5ef9b3fadaa3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_fe50fe6c-2bb4-47be-90bf-36775308fba9_terseLabel_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated variable consideration</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_label_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:label id="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Information Used To Assess Variable Consideration, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:href="mgnx-20200930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:to="lab_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_c634ada8-f3e3-4406-a5cb-8a48b9e4bb2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_775e5f4d-37c7-4a50-a4d5-4afff41b52df_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaborative Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromCollaborativeAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromCollaborativeAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:to="lab_mgnx_RevenueFromCollaborativeAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_c0a982d4-732c-456f-b77b-dc06881342d8_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_label_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Clinical Supply Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:to="lab_mgnx_ZaiLabClinicalSupplyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_706ab84f-82ce-4f23-a85a-7a460faf5d16_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_e904940d-2b4c-43f3-8ce0-4f710750551c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_ed189b4d-3a6d-4ffb-8987-c933fe2dab99_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_761926a7-b1b0-4acf-a4a5-c5fe50fae3fa_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, TRIDENT molecule</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, TRIDENT molecule</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0a27cffe-20a6-4ad4-ae02-1e3024193413_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_8d3cf4b2-a593-4a2c-891b-05162983e4e0_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments to third parties</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:to="lab_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_50e73f3c-3624-4423-8670-f9498e1c62c4_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7ed74e83-5999-4a43-9840-e0c99035a684_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_bc3a810b-e198-43e6-a84e-41c02ba18e80_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_35cf5aaa-a537-4e12-bbdb-aacdf80d95b0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_38944234-69e0-43db-96d6-0b0dabcb5d3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_cd7464ca-6e3c-495a-84c9-51404da5f0d8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b5920999-0c3c-4672-9817-462db02ebe96_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_94caf91d-6337-4af6-9dbb-9fe82c2428a3_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_label_en-US" xlink:label="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:to="lab_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_436c0291-c830-4e49-a261-fc435dcb5696_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0fdaa7c7-b9c2-4718-bf94-39c169275416_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2152e482-89a3-40c3-a431-0d283e64f44b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d61be04-ee14-4456-b493-b63d90e2ad8d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_7aaf0a56-36b6-406b-afdf-90d9f69f2b7c_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_label_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:label id="lab_mgnx_DevelopmentMilestonesAmount_documentation_en-US" xlink:label="lab_mgnx_DevelopmentMilestonesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Milestones, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentMilestonesAmount" xlink:to="lab_mgnx_DevelopmentMilestonesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_d732b067-4c1d-4bb8-a09f-f0c0e61774a2_terseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and regulatory milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e28fc75c-a97a-4341-a77c-5edb87a0bdfd_verboseLabel_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development milestones recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_label_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:label id="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_documentation_en-US" xlink:label="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development And Regulatory Milestone Payments Under Agreement, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:to="lab_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_6f899bcb-3657-44ff-9865-7fa7b5eb084d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_760b4fd7-4c54-4fa6-92bc-11027d8906fb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9931400a-e0b6-43d1-af2c-5fc8ea2b143b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7ddac857-657c-4a65-9fb4-e074700f07a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_3d18f5da-9905-4d74-9577-ec41af28c76f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_01927937-29a0-45d0-b40f-61ea2d071cc2_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement, Margetuximab</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs Collaboration And License Agreement, Margetuximab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:to="lab_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_445e1674-e1d0-40db-ab54-6d9558c0c866_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef7df86c-73ce-464b-9770-517ab6fb701d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_13c24774-af0a-45c1-b613-571bac919c59_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a91422e6-6a5d-4e2b-a6b6-8d5823fe5ba0_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_e5633db7-6be9-428b-a25d-0b3e9244178e_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TwoThousandSixteenEmployeeStockPurchasePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:href="mgnx-20200930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e4a099ae-47dc-4edb-9d4a-bffeeeccf15d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_9e2c0a08-fb28-46c4-8530-837d95a1f3b0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f8e454d7-57f3-46fb-8a33-a23e80cb6405_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_70aa5510-828f-44b7-bb0d-b9b44cb29997_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_48c35e57-f749-4d1d-91b3-8133f91073a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a4befbdf-9acb-4693-8b0c-1e32c732b4bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_b9d3d91e-484c-4d6e-977e-c292af8b81e3_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_628793dd-036c-4a7d-9a54-1fc377ee7c71_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9445d898-587c-4951-9063-379f63fe349b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a53c0a19-cf51-41f0-9b36-e3e371b656c9_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_96b39d2f-6be0-4892-88a0-7ab3d47b7500_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7bb44fed-7916-4150-a9d3-0929ce202b08_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_f1bcd8c0-e28e-4044-8d59-5876f57d95ff_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_7ef973cc-7704-4a79-acff-b61e8b6b320c_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cc0cc7d7-a83f-44db-87ef-50bcd0df1ad8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7e2bbc43-607b-42de-9c87-c0f151993ffb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IncyteCorporationMember_a9209e5e-87aa-4824-9e64-b6e429c72e55_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incyte Corporation</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IncyteCorporationMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember" xlink:href="mgnx-20200930.xsd#mgnx_IncyteCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember" xlink:to="lab_mgnx_IncyteCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_6c695a94-0f1b-4184-b7ed-afea5719457e_terseLabel_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_label_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering [Member]</link:label>
    <link:label id="lab_mgnx_FollowOnEquityOfferingMember_documentation_en-US" xlink:label="lab_mgnx_FollowOnEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Follow-On Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember" xlink:href="mgnx-20200930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FollowOnEquityOfferingMember" xlink:to="lab_mgnx_FollowOnEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_35a35e0f-fe14-46b3-a9bd-dbd0b78ad5bb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_f83f5659-ba07-4ead-a351-7e6a782b5147_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_label_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:label id="lab_mgnx_RevenuesNetOfTaxWithholding_documentation_en-US" xlink:label="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Net Of Tax Withholding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesNetOfTaxWithholding" xlink:to="lab_mgnx_RevenuesNetOfTaxWithholding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2a713f62-9107-4c92-ab60-ebcdc6f9cf91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_998ed59e-6d30-4a96-abe9-0ea9ba4d1d0e_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From Grants</link:label>
    <link:label id="lab_mgnx_RevenuesFromGrantsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromGrantsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromGrantsMember" xlink:to="lab_mgnx_RevenuesFromGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a6f94545-4157-4349-87ac-066d12a6cf89_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f7d6e987-d60b-47e8-999c-dd8795d5484f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_d622083c-0f59-45cd-9421-9d9e35b63076_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:href="mgnx-20200930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_308b8d93-64ca-4a77-965a-e15cd39c80a4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_3172d34e-7da4-4fd7-88f7-0ab76ddea1a3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_f2595704-1188-4f31-9072-107442bb667e_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll deduction discount</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="mgnx-20200930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_40fb2653-f5bf-4fef-b76a-501b82a4ed69_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_189e343c-d94f-48ba-bf3c-e1adab7db133_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_e067fa90-6b10-44f1-811f-90cb90066482_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_e39f336e-2a7c-435f-a0c2-d844bf15454b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_dd71ccc7-472f-47b9-bda3-87deaa0deacb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6b881157-dc50-41f4-9762-e014bf07e0a1_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_3ccd7ce9-f08c-4876-ac76-47a20417345c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_15810894-f71c-4937-a811-dbba5457ba2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6fd9c4ab-6d84-4ec8-a589-edd5d275a3c8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0bd5cc02-4d73-4b24-abcf-d0958e8c2327_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_30c803ec-fa5c-4de5-b4a6-6be40daf7ac5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9c7a6bbb-6590-492f-a1cc-f4f5c23f5719_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ce93a0c2-3c4f-41ff-b938-ab8271f05f01_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_2c4cab56-ea17-4161-bf27-99fbc3b2dded_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_fc9e9c37-8926-47ac-978f-f7275717bb74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_51a99d9c-564d-4388-b6cf-e13a68c1f451_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_53ead7e3-58e8-4d9c-abeb-a20eee442cdc_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AdditionalDevelopmentFundingOptionsUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_5e643fce-05ff-4c40-b46d-193e3ab5c351_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24ea1261-d659-4035-a7e4-78fcd2c7b13b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaMember_f6d61565-f576-436c-b8ba-c911316befde_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaMember" xlink:to="lab_mgnx_IMabBiopharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_e6613789-e3e6-4b49-b84d-edab5c357e8c_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1faca233-4f63-4a80-8141-7cb02a4c7939_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_29c299ce-39e7-4dba-ae49-c3205bf41617_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ec6da65d-77ec-47c8-bfb3-37b3d445048d_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_36ef79a5-75f0-4ac6-9b9e-c2eb25451cf7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_adca461f-eea9-4a93-b381-17ec16440b87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_746a18db-7772-4b23-9a12-a2cfabdf5d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_7ca500ff-ff26-4514-97a7-f4c103553920_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimInternationalGmbHMember_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Boehringer Ingelheim International GmbH</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:to="lab_mgnx_BoehringerIngelheimInternationalGmbHMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0065287a-7f11-41fd-a2d6-e4cbea37a5a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_6165bd28-b3f0-43e0-9c4f-c7de0bb1971b_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_db0d68aa-bef6-4ed8-bae5-976c3a99f71c_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ec0ea050-3d73-4e93-947e-94b599210707_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7dfdca4-5a8b-475f-8f9a-07bb9088d8de_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionPRV031Member_f0c73e42-b38f-4f7d-a9e2-d4615e186416_terseLabel_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provention PRV-031</link:label>
    <link:label id="lab_mgnx_ProventionPRV031Member_label_en-US" xlink:label="lab_mgnx_ProventionPRV031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionPRV031Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionPRV031Member" xlink:to="lab_mgnx_ProventionPRV031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_292b3b62-9e7e-4a3b-b790-d97b989b6a47_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Agreement</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_ZaiLabCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c92d7f96-d9dd-41b4-a8ec-49373dab65c1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c15b67ed-3317-43ef-bff7-cf04db4e7a1c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_ac263738-59fb-439e-a0f9-c95ad59f8c6a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1a853134-8c07-4acc-b957-331ee459c839_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_581460ea-0971-4327-a21e-b88397ffa17a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b532f1c4-3680-495f-b382-bf32ef47e68f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_296b229d-2292-439e-bc96-d8368542f527_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average exercise price of stock options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8149be3e-dc6e-4f0f-a7cb-5d49db5a2e84_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0f77c363-a36e-4ca9-a6c8-83d817af30b1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8cf985f3-c753-4ce0-813c-d21cc63d6065_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_66baa604-6e0e-4a6f-91f1-947944b37376_terseLabel_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration and License Agreement</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">I-Mab Biopharma Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:to="lab_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_39fbc1bf-6bb1-490e-8163-31ead4657ce1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_c3beafcc-2501-4b2e-ba00-7560b2f74f1f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0ae520be-5bf3-4a1b-a996-d8986107f0d8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_79f9bb7b-069e-4969-81c8-13c49e99c0c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7ff03e01-4e98-4b41-bb3a-0e9acd0a6d50_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_beb5d396-77ed-48b9-87c7-dd3381fd0fe8_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_ff26b92c-5f2e-451f-a87d-795226456938_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available under warrants (in shares)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_532ddc43-e8d3-4d3e-b51e-969535310d13_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets modified in exchange for operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_4aab7ae9-4446-4aa2-8e5e-5993b9be16a5_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_54a2fac3-1d51-4def-ac60-10a77d3c9319_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_40b45519-be15-4d4a-aa47-f6d0a8731023_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f0e76c70-16a0-4dfe-ba16-2cf1c6104b7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1f27ae22-cbf0-484f-bbed-4fee0a45ffc1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_1191da83-9836-4bb7-991b-50cb9123d8d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_30eead8b-5abc-4a49-8131-dcf748d5e2ef_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement transaction price</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementTransactionPrice_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementTransactionPrice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementTransactionPrice" xlink:to="lab_mgnx_CollaborativeAgreementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_86ea912d-2e77-4c1d-8167-0d20a921f82f_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-allotment option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_94fde25a-d545-42fd-a0d7-65748573c5e1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e6cd6d26-c4a6-4f35-843b-15dee9c69180_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_adfcc871-9dfb-4a09-bfe2-bedc920ee34c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_bd0cbc6b-ce2f-4f36-b1c4-4375f0348d77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ZaiLabMember_7f83a813-9ace-47d6-b32b-21c74cae67c5_terseLabel_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Labs</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_label_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab [Member]</link:label>
    <link:label id="lab_mgnx_ZaiLabMember_documentation_en-US" xlink:label="lab_mgnx_ZaiLabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Zai Lab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ZaiLabMember" xlink:to="lab_mgnx_ZaiLabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_f0c364fe-ddfa-4087-aa1e-222464f01b4a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_556f4758-a7ac-4df7-bcff-7f3063d421e0_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e3747c2c-75db-4af1-8354-f54b2749200f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_438000c4-3b5e-4ffc-acc6-56da9e17feb6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5925ed81-ee22-44cd-9c9b-8cbdfe1061e9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_de77e19e-d0f3-44ef-85c1-6ce4709e30e6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aced55cb-52ac-4754-a25f-c5df7ea19ec5_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_eee45200-e21b-48da-b938-6e270dcd783e_terseLabel_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues From License Agreements</link:label>
    <link:label id="lab_mgnx_RevenuesFromLicenseAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenuesFromLicenseAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenuesFromLicenseAgreementsMember" xlink:to="lab_mgnx_RevenuesFromLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_f9ffb828-566f-4729-a218-e828f33eaa6b_terseLabel_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Government Agreements</link:label>
    <link:label id="lab_mgnx_RevenueFromGovernmentAgreementsMember_label_en-US" xlink:label="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RevenueFromGovernmentAgreementsMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueFromGovernmentAgreementsMember" xlink:to="lab_mgnx_RevenueFromGovernmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4486fd9e-a9ed-4f2a-99ca-47f35181e9eb_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_61d91df9-fe73-44cf-a09e-a8374fc794e2_terseLabel_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant to purchase shares of common stock, exercise price (in dollars per share)</link:label>
    <link:label id="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_label_en-US" xlink:label="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:to="lab_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_16c9cc94-8879-404a-ad12-f785f3f49a98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_bbb656d8-f466-48de-88b5-e9b7061c6b40_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_cd91ec94-e53f-4945-8c5b-f285408a9efb_terseLabel_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2003 Stock Incentive Plan</link:label>
    <link:label id="lab_mgnx_A2003StockIncentivePlanMember_label_en-US" xlink:label="lab_mgnx_A2003StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2003StockIncentivePlanMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember" xlink:href="mgnx-20200930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_A2003StockIncentivePlanMember" xlink:to="lab_mgnx_A2003StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_63cae8a0-911c-4bd3-a58e-ec3b396fba5d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_b868e2e9-409d-41e8-943f-52673446b896_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_86c5d5fc-48f0-4c16-bab3-e583e5e6da85_terseLabel_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement</link:label>
    <link:label id="lab_mgnx_ProventionLicenseAgreementMember_label_en-US" xlink:label="lab_mgnx_ProventionLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ProventionLicenseAgreementMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember" xlink:href="mgnx-20200930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProventionLicenseAgreementMember" xlink:to="lab_mgnx_ProventionLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_44ed48a8-f80f-48dd-9da4-f637ba3c272d_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of performance obligations</link:label>
    <link:label id="lab_mgnx_NumberOfPerformanceObligations_label_en-US" xlink:label="lab_mgnx_NumberOfPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NumberOfPerformanceObligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfPerformanceObligations" xlink:to="lab_mgnx_NumberOfPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_a3fa8565-947b-4fd4-8e2b-1c2a11231a36_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_e784f17c-e785-4fd4-b3dc-fffa35f55363_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_314b3bfc-409f-42cc-b32c-a237e8736dd8_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3de38bbb-e9ed-4661-8dad-2c0ad662eb20_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_5d409354-7111-432f-80d7-aca4e25394df_terseLabel_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration recognized</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_label_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:label id="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_documentation_en-US" xlink:label="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:href="mgnx-20200930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:to="lab_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_19019e80-6646-4b62-af4f-fc8d17bbf155_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_f8572941-5c08-4301-8cb9-372e6c549d1e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_057e4224-606e-4679-9c9d-de64e87a5762_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_4c82fa5b-6974-46d0-98fd-5975f98827aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_41affeae-c20b-4c27-8b59-f97a94cf6893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_3e60c390-3fbc-4e99-aab1-d75aa61adddc_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a1d3da0f-11c2-483c-ac8a-0c48c6913fcf_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0922d02a-121e-4a4c-a0a7-82d8df666180_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_55b85bde-d8de-4033-9b5c-3089f802e779_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9acf1dfa-15de-4152-b183-125e888eed54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_26fdab7c-c5a6-4078-8c14-b0fbaf1343b3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_77f2762f-3cfe-46b9-852b-70c35821635e_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TotalPotentialValueUnderAgreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:href="mgnx-20200930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_cb0279d2-644e-4691-a078-33c2de0a0b8e_terseLabel_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:to="lab_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6edc0ef4-1407-4b0f-abff-9075eb0738e6_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_d93e4b48-a0a7-4657-aa9c-462c9b4262d6_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b538c6fa-429a-4f06-9813-d53af36df25e_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_54c1e44a-4df1-4ca2-9d50-91400563c4e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_b41f912f-ce8f-4f2e-8fb7-bd2f25adc2d4_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential annual increase in shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_3b5f04db-311d-4a2b-87b5-8e889a884600_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_bb9f9848-4e80-482c-b765-01038779d9fd_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">StockIncentivePlan2013Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member" xlink:href="mgnx-20200930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member" xlink:to="lab_mgnx_StockIncentivePlan2013Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dd03ecb2-e4a5-4a47-b241-672fa72ac94b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_a2409d19-78f7-4abe-855b-7f4557777475_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US"></link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_32683b80-a4e4-4699-9018-97d20d47b5cd_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_84795cb3-fea8-4e56-b344-b11dcede1f4c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_49edba59-2f79-48c3-b771-9d53fb2fb544_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_99a61a3c-3149-417f-86ad-ec63b546ea98_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>mgnx-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:b3ee28dd-532e-4994-b816-5e6485c9006a,g:1e034e00-673e-4b93-abb8-5dcde03f7bfe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://macrogenics.com/role/CoverPage" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d018cee7-c45a-4c30-aa21-f15d2f386e0d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentType_d018cee7-c45a-4c30-aa21-f15d2f386e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_7f5461e5-83cd-4dc8-bd4f-56300e3f91b4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentQuarterlyReport_7f5461e5-83cd-4dc8-bd4f-56300e3f91b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cf6b418f-fb13-480f-9b62-b12b42c0c07e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentPeriodEndDate_cf6b418f-fb13-480f-9b62-b12b42c0c07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b85f7bcb-deed-4ce1-b012-ba1211af1f65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentTransitionReport_b85f7bcb-deed-4ce1-b012-ba1211af1f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_16e889b6-d8b7-46e8-a536-4254ecda225c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityFileNumber_16e889b6-d8b7-46e8-a536-4254ecda225c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_cbfd5710-6d88-4637-98df-22413dd5bfa4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityRegistrantName_cbfd5710-6d88-4637-98df-22413dd5bfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_859f43c3-d78e-46b7-91ab-9e68f4398db9" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityIncorporationStateCountryCode_859f43c3-d78e-46b7-91ab-9e68f4398db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_969bb6f2-51b9-44f4-ae92-01a05b7a901e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityTaxIdentificationNumber_969bb6f2-51b9-44f4-ae92-01a05b7a901e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a0fc8a48-2027-4950-a2fe-5ad9943ee058" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityAddressAddressLine1_a0fc8a48-2027-4950-a2fe-5ad9943ee058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_635d0498-c6a6-4fae-9986-35fd861a09ff" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityAddressCityOrTown_635d0498-c6a6-4fae-9986-35fd861a09ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_1c333f56-ec82-432c-b444-59a47b553c01" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityAddressStateOrProvince_1c333f56-ec82-432c-b444-59a47b553c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_ad37d278-9a00-403a-8c7f-39d63402811f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityAddressPostalZipCode_ad37d278-9a00-403a-8c7f-39d63402811f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_46df3238-f3ec-40a8-905b-5013bdb001fe" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_CityAreaCode_46df3238-f3ec-40a8-905b-5013bdb001fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_6aa1ac8f-9ea1-4925-aa7e-8a239bc90e0a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_LocalPhoneNumber_6aa1ac8f-9ea1-4925-aa7e-8a239bc90e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bbdd4689-739f-49e2-b6a4-cc25fe146099" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_Security12bTitle_bbdd4689-739f-49e2-b6a4-cc25fe146099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_22acfdba-5d39-46fc-b312-a6047fa1d50e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_TradingSymbol_22acfdba-5d39-46fc-b312-a6047fa1d50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_3a80dc9a-cc14-4689-b8b8-098dd2550811" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_SecurityExchangeName_3a80dc9a-cc14-4689-b8b8-098dd2550811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_648fd4c0-689f-4f8f-b29b-56398ef4a3d6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityCurrentReportingStatus_648fd4c0-689f-4f8f-b29b-56398ef4a3d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f5bc1207-c89c-474b-8289-91fef342f98f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityInteractiveDataCurrent_f5bc1207-c89c-474b-8289-91fef342f98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_7360c9a7-0574-47b2-abdd-c7f23653d661" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityFilerCategory_7360c9a7-0574-47b2-abdd-c7f23653d661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_783d0a88-68ab-4fb1-9a6a-1a1f3ba2c5cc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntitySmallBusiness_783d0a88-68ab-4fb1-9a6a-1a1f3ba2c5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_8c6a6c3d-0fc3-4f17-b1da-5ae91c827a26" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityEmergingGrowthCompany_8c6a6c3d-0fc3-4f17-b1da-5ae91c827a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_cb9b226c-ef2d-4f51-9dd7-e1a35e7e199a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityShellCompany_cb9b226c-ef2d-4f51-9dd7-e1a35e7e199a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ff00be4c-2886-41d0-b0aa-4cf6cbd7219c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ff00be4c-2886-41d0-b0aa-4cf6cbd7219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_3f521093-5423-4b06-88fe-6c9960cff120" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_AmendmentFlag_3f521093-5423-4b06-88fe-6c9960cff120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_a747b303-20a8-4184-95cc-b5c83f50b308" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentFiscalYearFocus_a747b303-20a8-4184-95cc-b5c83f50b308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9a1121d2-0d4e-4621-bb9f-f19ad9fe19b6" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9a1121d2-0d4e-4621-bb9f-f19ad9fe19b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_78c400b5-78c1-410f-8ded-83cb096f46a5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_EntityCentralIndexKey_78c400b5-78c1-410f-8ded-83cb096f46a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_2a6e5566-afb3-40fb-a1a7-97b58962ec09" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c553d9fc-59ef-495a-b331-4a51948b93de" xlink:to="loc_dei_CurrentFiscalYearEndDate_2a6e5566-afb3-40fb-a1a7-97b58962ec09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3a2a5776-0154-4f72-9071-e0a5e50ce8e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3a2a5776-0154-4f72-9071-e0a5e50ce8e9" xlink:to="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:to="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5188111-b40a-4865-9ea6-ed8ecb50cc63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5188111-b40a-4865-9ea6-ed8ecb50cc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_d4f465cd-60f5-4fa3-b3a3-a492ceae4ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:to="loc_us-gaap_Investments_d4f465cd-60f5-4fa3-b3a3-a492ceae4ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0dd309f7-2324-42a5-9b8e-a02d68ccd97c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_0dd309f7-2324-42a5-9b8e-a02d68ccd97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_495f4a06-2d86-40c7-b6d7-159e85e8590a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_495f4a06-2d86-40c7-b6d7-159e85e8590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_70b5c387-6e7b-4584-ab18-3159169256cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_ec1b6283-d5e9-4769-b892-289f02ffa6d7" xlink:to="loc_us-gaap_AssetsCurrent_70b5c387-6e7b-4584-ab18-3159169256cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9e532855-3a85-4c67-96a4-db249b11d06a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9e532855-3a85-4c67-96a4-db249b11d06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_77e3a7a3-20fc-403b-baf7-b39e99cd98f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_77e3a7a3-20fc-403b-baf7-b39e99cd98f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_60d1772a-6df9-4cd1-a616-d78e119aa604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0e18569d-5f04-42d5-9793-c708e3cd888a" xlink:to="loc_us-gaap_Assets_60d1772a-6df9-4cd1-a616-d78e119aa604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3a2a5776-0154-4f72-9071-e0a5e50ce8e9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_99b77da3-3267-422e-afa5-d0ed66cf8b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:to="loc_us-gaap_AccountsPayableCurrent_99b77da3-3267-422e-afa5-d0ed66cf8b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_34545aa8-59d6-44e2-a1ce-e1dbd95a1c24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_34545aa8-59d6-44e2-a1ce-e1dbd95a1c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f077bc9-6e4b-466f-ad9b-f3c70b2e5b0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_8f077bc9-6e4b-466f-ad9b-f3c70b2e5b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a50b07c-9a8b-441a-8712-158ec78fcb46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3a50b07c-9a8b-441a-8712-158ec78fcb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d983caba-957d-420c-937c-958fa810633e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_00b56897-de12-41bf-9e8d-b1c83ae9ab22" xlink:to="loc_us-gaap_LiabilitiesCurrent_d983caba-957d-420c-937c-958fa810633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4fc9538c-7a47-49a2-9e6f-38225c8d1629" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_4fc9538c-7a47-49a2-9e6f-38225c8d1629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d639ddb3-fde0-4651-a8a9-ea81491a7006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d639ddb3-fde0-4651-a8a9-ea81491a7006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_13c83a79-da74-42d2-b231-47dae84891dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_13c83a79-da74-42d2-b231-47dae84891dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3db81f89-3fe4-4ff8-b0c8-c14ba434f260" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_Liabilities_3db81f89-3fe4-4ff8-b0c8-c14ba434f260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_f4d21df2-491a-48cb-b877-8dda33845f93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:to="loc_us-gaap_CommonStockValue_f4d21df2-491a-48cb-b877-8dda33845f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ff7bb808-22f3-4b50-bfd1-f4dfec646c71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_ff7bb808-22f3-4b50-bfd1-f4dfec646c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_12af4e87-2e25-4413-aaf9-aa9da403375d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_12af4e87-2e25-4413-aaf9-aa9da403375d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99026399-4380-4f02-9651-2420ac407b8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_99026399-4380-4f02-9651-2420ac407b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9d6149d2-2058-42ac-a32c-3d956fcb443f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a8ad465b-d65f-4af8-85b5-def679db3238" xlink:to="loc_us-gaap_StockholdersEquity_9d6149d2-2058-42ac-a32c-3d956fcb443f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e47e060a-90d3-4f0f-8230-704299a0d3c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_661bd820-53f8-498b-a99d-fcfada279f81" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e47e060a-90d3-4f0f-8230-704299a0d3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8a60a7bf-7a22-433b-8aad-710c599fde05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d0720d-bfba-4818-aed9-08168ad7913d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a60a7bf-7a22-433b-8aad-710c599fde05" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d0720d-bfba-4818-aed9-08168ad7913d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8e7bd503-f6e8-44d7-a12d-afc7cc4f8fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c3d0720d-bfba-4818-aed9-08168ad7913d" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8e7bd503-f6e8-44d7-a12d-afc7cc4f8fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c94cecc-6fe9-40c2-b15b-d7ae24cbcbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e7bd503-f6e8-44d7-a12d-afc7cc4f8fb7" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9c94cecc-6fe9-40c2-b15b-d7ae24cbcbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_609f4866-2e0c-434c-9e38-a38bbc09f7d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e7bd503-f6e8-44d7-a12d-afc7cc4f8fb7" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_609f4866-2e0c-434c-9e38-a38bbc09f7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_905d31a4-8434-4191-a8c2-166a4f922818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8e7bd503-f6e8-44d7-a12d-afc7cc4f8fb7" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_905d31a4-8434-4191-a8c2-166a4f922818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cb88061a-c006-4de7-ad7e-b09b3f0e8b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cb88061a-c006-4de7-ad7e-b09b3f0e8b0c" xlink:to="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:to="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f8d526a6-09f3-4744-a462-9f43a27bfd25" xlink:to="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c3f60f4f-62fc-49a3-9953-9b9ce0f9b0af" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromCollaborativeAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:to="loc_mgnx_RevenueFromCollaborativeAgreementsMember_c3f60f4f-62fc-49a3-9953-9b9ce0f9b0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueFromGovernmentAgreementsMember_b9960263-eec2-4019-9dae-047fa36c1098" xlink:href="mgnx-20200930.xsd#mgnx_RevenueFromGovernmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_845168f1-3c4c-45b0-a6fe-6aea78e04e2e" xlink:to="loc_mgnx_RevenueFromGovernmentAgreementsMember_b9960263-eec2-4019-9dae-047fa36c1098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_3e411ae6-6c19-4ea4-b59a-874378bf7c8b" xlink:to="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_87b5f366-0a4a-4b25-85f4-19c5d29f4d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_50ca4d96-7231-4f2a-933d-9ce1e93c4331" xlink:to="loc_us-gaap_Revenues_87b5f366-0a4a-4b25-85f4-19c5d29f4d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_c7e4a444-21d8-4315-ac79-5edb8df14f8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_c7e4a444-21d8-4315-ac79-5edb8df14f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_bc1f1bbe-650b-4c73-a28e-4c0c83ac064b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_bc1f1bbe-650b-4c73-a28e-4c0c83ac064b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_27d08f76-8ebe-47c5-93a6-f83798ee61c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_CostsAndExpenses_27d08f76-8ebe-47c5-93a6-f83798ee61c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ce84c500-53fb-4422-80b5-135075c15b0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_OperatingIncomeLoss_ce84c500-53fb-4422-80b5-135075c15b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_894013c7-5d06-4526-988a-c25cfea44409" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_894013c7-5d06-4526-988a-c25cfea44409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a94355fd-09fc-4fd6-84ca-ac71175e982e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_286bedd3-0ab7-4c7f-ba19-a344d436782c" xlink:to="loc_us-gaap_NetIncomeLoss_a94355fd-09fc-4fd6-84ca-ac71175e982e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38d683a5-7a48-4cab-be19-e7815f09ee55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_076a73e0-4843-40af-97dc-d54603e9fccc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_38d683a5-7a48-4cab-be19-e7815f09ee55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_c992fbd1-e8b7-4ec1-a956-745f527f9f1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_c992fbd1-e8b7-4ec1-a956-745f527f9f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2b91dd80-56da-41ab-bf58-86fd67c1abe9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2b91dd80-56da-41ab-bf58-86fd67c1abe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_930913bc-573b-4520-8013-14b7ea9b4201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a51183ab-9ee8-4c19-badf-afdd9e3d625b" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_930913bc-573b-4520-8013-14b7ea9b4201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0e886548-3c0c-49b4-a44f-1d2546cf2bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0e886548-3c0c-49b4-a44f-1d2546cf2bab" xlink:to="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_c005fc81-59c5-4832-b2e7-4a506e06626a" xlink:to="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1a68cc97-6527-4c6b-9bb5-f7f0a96540e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_CommonStockMember_1a68cc97-6527-4c6b-9bb5-f7f0a96540e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_dafc219d-bd93-4565-898e-a3edf8829db0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_TreasuryStockMember_dafc219d-bd93-4565-898e-a3edf8829db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_9aaa0c1f-4d9f-4b36-b929-cb382698cccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_9aaa0c1f-4d9f-4b36-b929-cb382698cccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e8291510-c698-448f-b638-e11fe0ef5e94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_RetainedEarningsMember_e8291510-c698-448f-b638-e11fe0ef5e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d18d2821-047d-4e30-980a-92d1e508edf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a591114f-5f74-4af7-877d-2d0a57930335" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_d18d2821-047d-4e30-980a-92d1e508edf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ffc59b8-958f-435c-a777-686b7b9f7410" xlink:to="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_72f9713e-14ea-4e62-b5d5-18074fb3b4ae" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c2b1e056-0051-4504-af0e-2cdca3c363e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_SharesIssued_c2b1e056-0051-4504-af0e-2cdca3c363e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5505a87e-5ef9-485f-b44b-c265b931105f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5505a87e-5ef9-485f-b44b-c265b931105f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb716923-de80-492f-a728-734fdb156d5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_eb716923-de80-492f-a728-734fdb156d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b469788d-0ff9-4140-b5b6-0ac00c0cf101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b469788d-0ff9-4140-b5b6-0ac00c0cf101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_573e1cd2-0799-42c5-b23b-9caa0892744b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_573e1cd2-0799-42c5-b23b-9caa0892744b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_48fde7b9-fe5c-4ed5-a4d1-f6b29e26a725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_48fde7b9-fe5c-4ed5-a4d1-f6b29e26a725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_65f48337-8718-4fdf-bf90-697d19279632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation_65f48337-8718-4fdf-bf90-697d19279632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_05203c17-2578-4849-b898-1b08b3d51de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_05203c17-2578-4849-b898-1b08b3d51de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d08eaed-eed2-4974-a3ca-8c1503bf2f19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_1d08eaed-eed2-4974-a3ca-8c1503bf2f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_bd019d7c-134b-4c11-8c2e-9bcc36e23a04" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_bd019d7c-134b-4c11-8c2e-9bcc36e23a04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_501da499-c653-4c5e-86df-f9c24e256dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_NetIncomeLoss_501da499-c653-4c5e-86df-f9c24e256dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_62d6ac8a-4a4c-4bbd-810e-aa638aca3643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_SharesIssued_62d6ac8a-4a4c-4bbd-810e-aa638aca3643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a381bf76-e084-468a-be40-a76e6655a769" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ebbee71a-f76a-4fdd-9e27-88f43586919e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a381bf76-e084-468a-be40-a76e6655a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8693a5b6-e65f-4115-a30f-66df55eb2f73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8693a5b6-e65f-4115-a30f-66df55eb2f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_068f3b59-cd9c-47ea-89fc-945ab5cf1ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8693a5b6-e65f-4115-a30f-66df55eb2f73" xlink:to="loc_us-gaap_NetIncomeLoss_068f3b59-cd9c-47ea-89fc-945ab5cf1ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8693a5b6-e65f-4115-a30f-66df55eb2f73" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bc667a31-ff40-4c41-8a41-0e4a977065fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:to="loc_us-gaap_Depreciation_bc667a31-ff40-4c41-8a41-0e4a977065fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cb86de15-722d-45d6-a5e8-3be8feda2101" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_cb86de15-722d-45d6-a5e8-3be8feda2101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8f57e587-aa40-4d6f-8823-db0fa39cb0a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:to="loc_us-gaap_ShareBasedCompensation_8f57e587-aa40-4d6f-8823-db0fa39cb0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6ae6ce4e-c996-45d0-bb05-472776ce83f9" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d2e6ac20-3b59-4335-b9f2-423008e68842" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d2e6ac20-3b59-4335-b9f2-423008e68842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3e2a37b9-1376-40b7-b22c-4c1513751006" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_3e2a37b9-1376-40b7-b22c-4c1513751006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a1b23733-974d-46b4-9e45-1fb9186fe394" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_a1b23733-974d-46b4-9e45-1fb9186fe394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_414ab4cc-3049-4c90-bff7-ceddd7092077" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_414ab4cc-3049-4c90-bff7-ceddd7092077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f950302b-b858-431f-a0ff-6eee70b8f157" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f950302b-b858-431f-a0ff-6eee70b8f157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_4f9b81ce-81cb-45e4-a934-ed94c8adca31" xlink:href="mgnx-20200930.xsd#mgnx_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_mgnx_IncreaseDecreaseInLeaseLiabilities_4f9b81ce-81cb-45e4-a934-ed94c8adca31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_adc90514-1f77-4df8-826d-601ed710ccc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_adc90514-1f77-4df8-826d-601ed710ccc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_032f9292-1d26-4cbc-835d-08076881e8d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_32008906-4324-42fb-9f1a-6fe419df2b2e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_032f9292-1d26-4cbc-835d-08076881e8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9d0a0b0-5848-4c7f-b27c-5332f56fa3fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8693a5b6-e65f-4115-a30f-66df55eb2f73" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9d0a0b0-5848-4c7f-b27c-5332f56fa3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_858a8b1e-554b-4d4a-9828-86ab596dd43b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_858a8b1e-554b-4d4a-9828-86ab596dd43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_62dde27f-142a-4dc2-9c62-420dd194cb59" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_62dde27f-142a-4dc2-9c62-420dd194cb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79e5bc02-4de0-4b34-a0a8-b2abb5cf2506" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_79e5bc02-4de0-4b34-a0a8-b2abb5cf2506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b40f44c-d41c-43cd-b9e0-2cd6598bf547" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3a8c78bd-ff53-4cd5-ae83-71f1b9b63b9c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6b40f44c-d41c-43cd-b9e0-2cd6598bf547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38d15f9c-2b9d-41b0-946e-91f1387f9240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_38d15f9c-2b9d-41b0-946e-91f1387f9240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_9964680b-febe-47ea-84ef-af36dd911481" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_9964680b-febe-47ea-84ef-af36dd911481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RetirementOfTreasuryStock_044839b1-a733-4ccc-bc63-c6bf32ffd5a5" xlink:href="mgnx-20200930.xsd#mgnx_RetirementOfTreasuryStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:to="loc_mgnx_RetirementOfTreasuryStock_044839b1-a733-4ccc-bc63-c6bf32ffd5a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d7209e-5115-4c5a-97ef-b99569d616e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_48548049-8c85-4087-9d06-7691f6f920df" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_95d7209e-5115-4c5a-97ef-b99569d616e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a136454-33ef-4784-87c3-ca164560d613" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a136454-33ef-4784-87c3-ca164560d613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0263feb-8048-4329-8825-a8eafbf533bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c0263feb-8048-4329-8825-a8eafbf533bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c9ab3e8-566d-4510-8ae5-202effe98725" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3c9ab3e8-566d-4510-8ae5-202effe98725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_0bec04f7-ce1a-465e-9905-d44c85b08e1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_f9a31440-15cd-4d24-af81-320f7fdae325" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_0bec04f7-ce1a-465e-9905-d44c85b08e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3c82e635-0804-4a5e-9d45-dde1144c4a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_0bec04f7-ce1a-465e-9905-d44c85b08e1c" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3c82e635-0804-4a5e-9d45-dde1144c4a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="simple" xlink:href="mgnx-20200930.xsd#BasisofPresentationandRisksandUncertainties"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1252ab9-65de-45d0-bfe6-0b234bc68dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f00a4ff6-ada6-4cdc-9a2d-8d4582e73df5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b1252ab9-65de-45d0-bfe6-0b234bc68dda" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_f00a4ff6-ada6-4cdc-9a2d-8d4582e73df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_620cda54-c593-4b90-9690-96d3618737cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_faa4af87-950b-4fb0-a12a-72ebd869cd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_620cda54-c593-4b90-9690-96d3618737cf" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_faa4af87-950b-4fb0-a12a-72ebd869cd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2d7a2ed2-d02f-48ab-9bd8-2bd2dfea570d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c7216f10-4d18-4f9a-accd-d2d3f80d83b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d7a2ed2-d02f-48ab-9bd8-2bd2dfea570d" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c7216f10-4d18-4f9a-accd-d2d3f80d83b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_31f8dbde-ebbb-44d5-8804-c6641b1e7b4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2d7a2ed2-d02f-48ab-9bd8-2bd2dfea570d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_31f8dbde-ebbb-44d5-8804-c6641b1e7b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstruments"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_546d2010-4722-4c2f-a3b6-5c78c1cbbe84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_22e7c176-6aad-4de1-971f-4b98369ae83e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_546d2010-4722-4c2f-a3b6-5c78c1cbbe84" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_22e7c176-6aad-4de1-971f-4b98369ae83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2d879d01-c71d-4333-ac97-1b789867977f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7b423ab5-c6cf-4cee-9dcf-bcf9ccdf1273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2d879d01-c71d-4333-ac97-1b789867977f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7b423ab5-c6cf-4cee-9dcf-bcf9ccdf1273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#FairValueofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34871a87-de69-4750-b59c-2d64da61c248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34871a87-de69-4750-b59c-2d64da61c248" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_04044956-ced6-4aab-9c73-417dd090e83f" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_188f0288-dec0-4f31-bac1-e5d6da49e0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_30af20b5-db56-43cc-920e-6af031717646" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_188f0288-dec0-4f31-bac1-e5d6da49e0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_1d220c31-6d10-4049-933f-ed564297989c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_3847a81f-af12-45cd-871e-b561e4c9f130" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_MoneyMarketFundsMember_3847a81f-af12-45cd-871e-b561e4c9f130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_20b516f2-53df-43de-b3a8-43337e43e5e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_20b516f2-53df-43de-b3a8-43337e43e5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239036f0-d0df-4665-b72d-bd14e49b739f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_239036f0-d0df-4665-b72d-bd14e49b739f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_5d1baa55-0913-41f7-b84e-b6cec2b35e7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_12bac092-ed25-4b8c-95a0-093ce3c6df62" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_5d1baa55-0913-41f7-b84e-b6cec2b35e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_34da17a3-8684-4361-9784-4b78716c14f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21f35501-6085-4157-9086-6a6b955adb13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21f35501-6085-4157-9086-6a6b955adb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1e00270-8ccb-489e-98d1-d631d7293f40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1e00270-8ccb-489e-98d1-d631d7293f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f61b03e6-ccb0-4b69-a2de-46e9a4d5852e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6ea10c7b-ac64-4fc1-ba3b-96d63a75347d" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f61b03e6-ccb0-4b69-a2de-46e9a4d5852e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b59c2ab2-0778-4a4d-a27d-9fe13dd644af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2fe1a2ca-4aa3-41b2-b22e-497adc649e64" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bfff63c2-1e13-4e80-afa5-a31a16bc7351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_bfff63c2-1e13-4e80-afa5-a31a16bc7351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ec0fe75-7a8a-4d05-8304-35ab402d30d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_7ec0fe75-7a8a-4d05-8304-35ab402d30d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_3b6ab686-dec2-4a10-a70e-65ba9493a263" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_0aafc256-27b9-41e1-b466-b312785d0d66" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_3b6ab686-dec2-4a10-a70e-65ba9493a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24a3ce89-4364-482c-a214-b9df2eed8d3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_82d3fcad-6761-4325-9abf-819ecd866d38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_24a3ce89-4364-482c-a214-b9df2eed8d3c" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_82d3fcad-6761-4325-9abf-819ecd866d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2aa5b6a2-fb80-43d0-81a3-c7c3dd3552f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_ac856ecc-9361-4b7b-9c9d-4aca171602a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2aa5b6a2-fb80-43d0-81a3-c7c3dd3552f5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_ac856ecc-9361-4b7b-9c9d-4aca171602a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#MarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b4d9860-f5ee-4649-ab22-5b08d3db7009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b4d9860-f5ee-4649-ab22-5b08d3db7009" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c6fa5e8e-83d6-48e7-9eb7-18cf44a9eb8e" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_271ce433-f2a5-439f-880a-89ef29aca7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_271ce433-f2a5-439f-880a-89ef29aca7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b12933f4-0e17-4680-b0ac-ffef15be1b28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_b12933f4-0e17-4680-b0ac-ffef15be1b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_78c0df71-03ec-49ae-813b-c6e848b459fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f5cda3df-fc8d-4486-882f-de4e1e1d693f" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_78c0df71-03ec-49ae-813b-c6e848b459fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_c2b350c1-b88c-49c2-8b62-eea4a9db5d7e" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b630fd4-bc57-478a-b5f4-9841310e80d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5b630fd4-bc57-478a-b5f4-9841310e80d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1004b490-4b33-4949-8e31-4b98db87e4c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1004b490-4b33-4949-8e31-4b98db87e4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c361bb6a-4440-4c50-91db-80255129aec4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c361bb6a-4440-4c50-91db-80255129aec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d63cbd21-93c4-487b-9023-9f958cab92d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_94a42a0a-2430-4c53-ae2b-1cd0545aba0a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d63cbd21-93c4-487b-9023-9f958cab92d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a0db027a-0118-4e57-84ea-9b1d88e7ffbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b4d9860-f5ee-4649-ab22-5b08d3db7009" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a0db027a-0118-4e57-84ea-9b1d88e7ffbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_507c742f-0d3a-4aa5-ab04-e74ab471d74d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5b4d9860-f5ee-4649-ab22-5b08d3db7009" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_507c742f-0d3a-4aa5-ab04-e74ab471d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_fd35e347-a68b-41ee-b8af-f258ba6ebf17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c3ab1311-21e6-4076-8e06-7c3c79121236" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_fd35e347-a68b-41ee-b8af-f258ba6ebf17" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c3ab1311-21e6-4076-8e06-7c3c79121236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_5d3eac5c-be4e-45cf-ada7-9b7ed0b8ae0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_5d3eac5c-be4e-45cf-ada7-9b7ed0b8ae0c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ae737148-6172-4c65-b51e-ab221b169f9c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FollowOnEquityOfferingMember_16aa5a53-0b92-4157-b1b1-299d25ed7962" xlink:href="mgnx-20200930.xsd#mgnx_FollowOnEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_mgnx_FollowOnEquityOfferingMember_16aa5a53-0b92-4157-b1b1-299d25ed7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_739eb95f-fa86-472b-a361-090a9add5232" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_us-gaap_OverAllotmentOptionMember_739eb95f-fa86-472b-a361-090a9add5232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AtTheMarketOfferingMember_5cf40e35-abd8-42b8-ba49-d88be0864626" xlink:href="mgnx-20200930.xsd#mgnx_AtTheMarketOfferingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_468c2563-eab2-40ec-97cd-f311c9cb8eb9" xlink:to="loc_mgnx_AtTheMarketOfferingMember_5cf40e35-abd8-42b8-ba49-d88be0864626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_c8dad9e0-39a1-4cab-9289-d3bae7934df8" xlink:to="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6cf2f2d4-066a-4d19-b7e1-67a4ecb3b901" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6cf2f2d4-066a-4d19-b7e1-67a4ecb3b901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_4f9eccef-eb10-45af-980a-8039741cca9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_4f9eccef-eb10-45af-980a-8039741cca9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79e3048d-ff5b-41d1-b021-8e7c3def37c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79e3048d-ff5b-41d1-b021-8e7c3def37c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_fbd2007a-33e2-45d5-8ae7-64df3bd09422" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b1bd2638-656a-4b3d-a7ad-729d63cd7012" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_fbd2007a-33e2-45d5-8ae7-64df3bd09422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreements"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d5d3b72d-8811-4b88-a0aa-e4b69c02b3d2" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_42c90eec-da02-4802-8a8e-63fd9fd40ebc" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_d5d3b72d-8811-4b88-a0aa-e4b69c02b3d2" xlink:to="loc_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock_42c90eec-da02-4802-8a8e-63fd9fd40ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIncyteCorporationDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_abe7cd4f-6edc-4587-9c73-7cb78217e8ab" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_abe7cd4f-6edc-4587-9c73-7cb78217e8ab" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_31e52791-4ae1-4aa7-bf59-3c5ef25fec59" xlink:to="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_c3017abc-2a34-4453-b4e3-b3059b22c3f9" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_088fffbf-a8ae-4921-b700-6f1a44df746d" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_c3017abc-2a34-4453-b4e3-b3059b22c3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fbd47bf0-84d7-496c-817f-d3acdb7c9ad6" xlink:to="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_dd88244b-1c07-4458-8152-3889a6544c65" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:to="loc_srt_MaximumMember_dd88244b-1c07-4458-8152-3889a6544c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef7b7ed8-c5cf-4dc7-b72a-28248dccd4ef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_86988e21-623d-4a21-95c0-42273d1cdcb8" xlink:to="loc_srt_MinimumMember_ef7b7ed8-c5cf-4dc7-b72a-28248dccd4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_258176ae-3654-44ee-ac1f-54bf35e37108" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteCorporationMember_083080c1-97c2-4646-b3a7-b94821b61559" xlink:href="mgnx-20200930.xsd#mgnx_IncyteCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d3569e82-8f79-403f-9a9b-4b2617d76acd" xlink:to="loc_mgnx_IncyteCorporationMember_083080c1-97c2-4646-b3a7-b94821b61559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_35878135-fde0-463c-bcd9-7746d50de7a4" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ac8ee60e-8a79-4750-8afc-ce8a1fb70982" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5793423c-c00f-424f-b46e-039bf155d447" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementClinicalActivitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:to="loc_mgnx_IncyteMGA012AgreementClinicalActivitiesMember_5793423c-c00f-424f-b46e-039bf155d447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IncyteMGA012AgreementServicesMember_1e6c60f7-9c96-457e-a1e1-dbd12ef5d278" xlink:href="mgnx-20200930.xsd#mgnx_IncyteMGA012AgreementServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_0e8fd2a7-6177-4937-8d6b-2495fbe0e644" xlink:to="loc_mgnx_IncyteMGA012AgreementServicesMember_1e6c60f7-9c96-457e-a1e1-dbd12ef5d278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a6d6d3ef-f219-4e0f-b228-6c56c82902e5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_f6e8846e-d416-462e-9434-f505c031b2df" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_NonRefundableUpfrontFees_f6e8846e-d416-462e-9434-f505c031b2df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29a2afb4-2471-4975-be99-7abc43224c4a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_29a2afb4-2471-4975-be99-7abc43224c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_396e599e-535e-432d-9aa2-f0d72a1efe7a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_396e599e-535e-432d-9aa2-f0d72a1efe7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e3d54376-34db-4f9f-ba8e-47d961faf922" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_e3d54376-34db-4f9f-ba8e-47d961faf922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_3a935d93-e87b-414b-8d9f-bec557e9b624" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_3a935d93-e87b-414b-8d9f-bec557e9b624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_f1387007-3497-478d-9bcd-7f2d2851935d" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_NumberOfPerformanceObligations_f1387007-3497-478d-9bcd-7f2d2851935d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_ce704086-12ee-47fd-92b7-5be6eb09f77a" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_ce704086-12ee-47fd-92b7-5be6eb09f77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_077744cc-2e46-4974-b5a2-e24f6041a879" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_us-gaap_Revenues_077744cc-2e46-4974-b5a2-e24f6041a879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_afecbece-db79-494d-ad95-092669a28f45" xlink:href="mgnx-20200930.xsd#mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bdf00adc-03ed-4196-b851-dfee42017a18" xlink:to="loc_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_afecbece-db79-494d-ad95-092669a28f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsZaiLabDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c6f3d8d8-df6c-4755-95c3-a1bd599e67a1" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_c6f3d8d8-df6c-4755-95c3-a1bd599e67a1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_564fb295-c892-474d-afbb-1ff08a51d213" xlink:to="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_fffff82d-c1e0-476a-b2ad-95d1e743e480" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8be190b3-dc4d-46a0-8069-09d08b98a8d6" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_fffff82d-c1e0-476a-b2ad-95d1e743e480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_5709f337-94d1-4b74-aa90-1ecf9214dc64" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_1c1b9280-6dec-4565-8a6b-c0cf9c6d9f71" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabCollaborationAndLicenseAgreementMember_1c1b9280-6dec-4565-8a6b-c0cf9c6d9f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a040325c-5399-4811-a6bb-b0295f25da0c" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabClinicalSupplyAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabClinicalSupplyAgreementsMember_a040325c-5399-4811-a6bb-b0295f25da0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_ebf4fc15-9034-4d76-8e6f-513cb964df42" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember_ebf4fc15-9034-4d76-8e6f-513cb964df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_150afcca-1dc7-4e2f-9da4-a3a06f5fc418" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6d8e424-074d-4e2a-8585-28fa100c6151" xlink:to="loc_mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember_150afcca-1dc7-4e2f-9da4-a3a06f5fc418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_00379a6a-0126-432d-a04b-c8f0ac134f9b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ZaiLabMember_50aac22c-a354-41c8-a9fb-744b37ceb101" xlink:href="mgnx-20200930.xsd#mgnx_ZaiLabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b6e96e0-fa74-4217-acf4-1cb1a8ef4f18" xlink:to="loc_mgnx_ZaiLabMember_50aac22c-a354-41c8-a9fb-744b37ceb101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7da83125-87a7-431b-b531-590a93111bfb" xlink:to="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_fb5a9945-ed34-4d65-9faf-4d7d318775d1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4b36a9ac-223d-4e17-874d-219f884dfede" xlink:to="loc_srt_MaximumMember_fb5a9945-ed34-4d65-9faf-4d7d318775d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_78a0b1c5-5720-4f4e-a393-9e248a34cd3c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_393d9c37-9523-49a7-88f0-6f35b5c83104" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonRefundableUpfrontFees_393d9c37-9523-49a7-88f0-6f35b5c83104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_04cf5e93-3a71-4930-8e1e-86845be809b6" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding_04cf5e93-3a71-4930-8e1e-86845be809b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonrefundablePaymentTaxWithholding_d1e46157-53b3-4bfc-bd4b-2b826aa82e3c" xlink:href="mgnx-20200930.xsd#mgnx_NonrefundablePaymentTaxWithholding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_NonrefundablePaymentTaxWithholding_d1e46157-53b3-4bfc-bd4b-2b826aa82e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ffd7a11b-cabc-4605-9625-bcea21d5a672" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_ffd7a11b-cabc-4605-9625-bcea21d5a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b42c0376-edc5-4c95-b825-47c71832b0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_us-gaap_Revenues_b42c0376-edc5-4c95-b825-47c71832b0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesNetOfTaxWithholding_3ed99c37-743a-4a71-8745-1283e4597553" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesNetOfTaxWithholding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_RevenuesNetOfTaxWithholding_3ed99c37-743a-4a71-8745-1283e4597553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesTaxWithholding_6ef33076-fae0-4a92-a301-53269b196c71" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesTaxWithholding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_RevenuesTaxWithholding_6ef33076-fae0-4a92-a301-53269b196c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_17e1fab1-468c-4fec-8b93-d667263dff9d" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_17e1fab1-468c-4fec-8b93-d667263dff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f46a3fa2-8355-4322-bb69-5aca0a0873ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8eaa66fb-054c-4334-a982-4f821cd04982" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f46a3fa2-8355-4322-bb69-5aca0a0873ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsIMabBiopharmaDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_70d6d103-ec5a-4f72-b257-309af183931c" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_70d6d103-ec5a-4f72-b257-309af183931c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7e1b988a-4eef-4a5f-851a-91b5977d8c8e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaMember_15227145-4d43-4ed3-8262-78e906ede173" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c86be74a-8c40-474c-82f0-0eedb0a4ef35" xlink:to="loc_mgnx_IMabBiopharmaMember_15227145-4d43-4ed3-8262-78e906ede173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_02a49108-a661-4787-82cc-b21d0e227dc8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5b981b44-e583-485f-97cc-b88de0e4467b" xlink:href="mgnx-20200930.xsd#mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_03a35739-5f8b-46dd-821b-0abca017fe9c" xlink:to="loc_mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember_5b981b44-e583-485f-97cc-b88de0e4467b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f6ec4687-22d9-4b41-85f1-ec4efef3e313" xlink:to="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_322de2dc-53e8-4fd1-ab0a-35c624506eef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4576fb9c-a865-4728-9459-8273bf4194ae" xlink:to="loc_srt_MaximumMember_322de2dc-53e8-4fd1-ab0a-35c624506eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_73b93ae5-8a09-4bd0-a8b5-2d315cae843f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_12317d0c-946f-41cc-88ee-3624273c06b5" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_12317d0c-946f-41cc-88ee-3624273c06b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f661440d-bd55-4184-b38f-4319c77c2df9" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_f661440d-bd55-4184-b38f-4319c77c2df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_3b3d6783-23f3-4330-913a-ebd86976800b" xlink:href="mgnx-20200930.xsd#mgnx_ProceedsfromRoyaltiesPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_3b3d6783-23f3-4330-913a-ebd86976800b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_be945536-a493-4990-98f3-1a8780ffec12" xlink:href="mgnx-20200930.xsd#mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount_be945536-a493-4990-98f3-1a8780ffec12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b7af7f41-768f-4052-a72a-79defdf10df0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_Revenues_b7af7f41-768f-4052-a72a-79defdf10df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_0f1df097-4e44-4b3a-bbb7-8c2f454f5456" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_0f1df097-4e44-4b3a-bbb7-8c2f454f5456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9988c95c-0cd8-474a-9b2f-d68a54ee3474" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9988c95c-0cd8-474a-9b2f-d68a54ee3474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_98002763-b687-4ad9-a199-e78ab5cbf86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1eeffe5a-a3a1-48a4-a586-dae5704cb21a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_98002763-b687-4ad9-a199-e78ab5cbf86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsProventionBioIncDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dd957a57-6432-4ef0-a270-9a8477874fdc" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_dd957a57-6432-4ef0-a270-9a8477874fdc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_fb6cca9f-1cda-4134-a634-7c39b070fb08" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f731ecea-40cc-44d6-a202-cf4a6e8c46e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_af6e9199-1fc8-4731-b9e9-735a351b4db2" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f731ecea-40cc-44d6-a202-cf4a6e8c46e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a6ff5b1c-f965-417e-a63d-457544257a42" xlink:to="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromLicenseAgreementsMember_7246a072-47d9-41b9-a110-a3cbe0e96bb4" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d88bee1b-b0ab-42e8-884e-f66b72a68b60" xlink:to="loc_mgnx_RevenuesFromLicenseAgreementsMember_7246a072-47d9-41b9-a110-a3cbe0e96bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_083b2e31-ab83-4846-a70f-11f317c05f80" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionLicenseAgreementMember_f2940b9f-2366-4364-813e-f9ed452c2344" xlink:href="mgnx-20200930.xsd#mgnx_ProventionLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:to="loc_mgnx_ProventionLicenseAgreementMember_f2940b9f-2366-4364-813e-f9ed452c2344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AssetPurchaseAgreementMember_7aaf19b3-e6b5-4330-b6af-d2c48a384fae" xlink:href="mgnx-20200930.xsd#mgnx_AssetPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6b57ce18-69e6-42d5-a36d-eb5550411075" xlink:to="loc_mgnx_AssetPurchaseAgreementMember_7aaf19b3-e6b5-4330-b6af-d2c48a384fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e06e0544-530e-4f83-815d-a479c3e6640b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionBioInc.Member_aa14822e-e519-4e2a-a3a8-aefd63c86929" xlink:href="mgnx-20200930.xsd#mgnx_ProventionBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99452868-36e3-4980-9895-49c211e81634" xlink:to="loc_mgnx_ProventionBioInc.Member_aa14822e-e519-4e2a-a3a8-aefd63c86929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_071572a5-8843-487c-b2a2-fd04a9cd1d87" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV3279Member_deff683c-a43c-4667-b544-d9b50288d934" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV3279Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:to="loc_mgnx_ProventionPRV3279Member_deff683c-a43c-4667-b544-d9b50288d934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ProventionPRV031Member_6ff48fc6-5076-47ce-b13d-b2eb8de52c26" xlink:href="mgnx-20200930.xsd#mgnx_ProventionPRV031Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_f6f41653-0eb7-4c25-8825-20643423125c" xlink:to="loc_mgnx_ProventionPRV031Member_6ff48fc6-5076-47ce-b13d-b2eb8de52c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_8aa09cbb-34ff-428d-ab68-b6c9868be890" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_89bb700a-3042-4004-86de-b3352329d8a2" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare_89bb700a-3042-4004-86de-b3352329d8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_aa79bbe9-728d-4826-a4d2-b4ecdcd96d9a" xlink:href="mgnx-20200930.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_aa79bbe9-728d-4826-a4d2-b4ecdcd96d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4e9a3b3d-75bc-44ee-9a4d-520429c5a721" xlink:href="mgnx-20200930.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_4e9a3b3d-75bc-44ee-9a4d-520429c5a721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_2c538904-3f43-4513-8b70-478432653667" xlink:href="mgnx-20200930.xsd#mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement_2c538904-3f43-4513-8b70-478432653667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfPerformanceObligations_ae56049f-3fde-46d5-afd4-612575cd74a5" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfPerformanceObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_NumberOfPerformanceObligations_ae56049f-3fde-46d5-afd4-612575cd74a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementTransactionPrice_bed3fafd-096f-48bb-b655-6f2a845cae1e" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementTransactionPrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementTransactionPrice_bed3fafd-096f-48bb-b655-6f2a845cae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_f8c44f09-8f83-4c67-8b30-2cb9e7705af6" xlink:href="mgnx-20200930.xsd#mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares_f8c44f09-8f83-4c67-8b30-2cb9e7705af6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_60ac0227-e460-4dab-96db-9e89231b8a1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_us-gaap_Revenues_60ac0227-e460-4dab-96db-9e89231b8a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1574e8a-4e6f-4074-bcea-a0e3dde7380b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_22abc98f-b6d2-4d5c-8aff-9fe26a6aee2e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b1574e8a-4e6f-4074-bcea-a0e3dde7380b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsNIAIDContractDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f2ec606b-e117-4fdb-b4d1-8aaa3498b4c3" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_f2ec606b-e117-4fdb-b4d1-8aaa3498b4c3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_63ced5cb-0c62-4315-80d3-597e06558e7b" xlink:to="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_RevenuesFromGrantsMember_25d0d5ff-a0e9-40d5-9245-791ec39f2547" xlink:href="mgnx-20200930.xsd#mgnx_RevenuesFromGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3ef52737-4cc9-4fc9-b1fa-d88b6ce377de" xlink:to="loc_mgnx_RevenuesFromGrantsMember_25d0d5ff-a0e9-40d5-9245-791ec39f2547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0539a142-93ed-427e-9ac9-e77283ea9559" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0e6a5755-e614-45bb-8d8d-2c58cbd48053" xlink:href="mgnx-20200930.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a7d53ec4-76f2-4bbf-aee5-814911584c81" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_0e6a5755-e614-45bb-8d8d-2c58cbd48053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a49fa168-57f5-4ddf-befb-f1a0c44bca9e" xlink:to="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_522ced2e-f653-400e-9baa-57c827d7c781" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_da483aa8-19a6-4564-949e-9a55c9a40ec1" xlink:to="loc_srt_MaximumMember_522ced2e-f653-400e-9baa-57c827d7c781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21b3e374-d825-48c2-be81-6e245ea403a4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_3ef9dde5-fa75-4892-ad1d-3efebc3cb63a" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_3ef9dde5-fa75-4892-ad1d-3efebc3cb63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_FundedValueOfBasePeriod_9f11c93d-0ef6-439b-a7dd-053cbedc32fc" xlink:href="mgnx-20200930.xsd#mgnx_FundedValueOfBasePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_FundedValueOfBasePeriod_9f11c93d-0ef6-439b-a7dd-053cbedc32fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_35279502-df8b-4b5b-b5e8-a1f7d48deaad" xlink:href="mgnx-20200930.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_35279502-df8b-4b5b-b5e8-a1f7d48deaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_b430a93b-5072-4ad5-9302-9384746a4d0e" xlink:href="mgnx-20200930.xsd#mgnx_TotalPotentialValueUnderAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_b430a93b-5072-4ad5-9302-9384746a4d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_b872538f-8794-48cb-b409-661c4ba6331e" xlink:href="mgnx-20200930.xsd#mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement_b872538f-8794-48cb-b409-661c4ba6331e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_7ca0359a-1ad4-4e2e-b5e8-424c75d9345f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7e2fb6fa-0d0c-41e5-b520-de9656b164b0" xlink:to="loc_us-gaap_Revenues_7ca0359a-1ad4-4e2e-b5e8-424c75d9345f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2afa1e84-023a-443b-8300-b6b189db4adb" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_2afa1e84-023a-443b-8300-b6b189db4adb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_f1fd5a01-9394-46ba-9be2-fe07b58c492a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_392ed648-b338-4afe-af12-f34f393a1898" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_241f8773-7a80-4a39-9cce-51a2cd044b0b" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember_392ed648-b338-4afe-af12-f34f393a1898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:to="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_82f4e0f2-2451-4074-b9c5-97e1c312658d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_020e950a-eff7-4c20-8f94-d52c563af193" xlink:href="mgnx-20200930.xsd#mgnx_BoehringerIngelheimInternationalGmbHMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_77b5d89b-7160-4be6-b1c3-d1d658f1730e" xlink:to="loc_mgnx_BoehringerIngelheimInternationalGmbHMember_020e950a-eff7-4c20-8f94-d52c563af193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_90327c1b-d03b-4a7e-9d84-e5905ae6624e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementTerm_658ee993-1de4-48a5-b8e5-2de23f93435a" xlink:href="mgnx-20200930.xsd#mgnx_CollaborationAndLicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementTerm_658ee993-1de4-48a5-b8e5-2de23f93435a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NumberOfProductCandidates_66809b36-4367-420b-8eb5-cd118288549e" xlink:href="mgnx-20200930.xsd#mgnx_NumberOfProductCandidates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_NumberOfProductCandidates_66809b36-4367-420b-8eb5-cd118288549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_NonRefundableUpfrontFees_65abc63e-beea-4fc6-a7f6-5f5088c830d2" xlink:href="mgnx-20200930.xsd#mgnx_NonRefundableUpfrontFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_NonRefundableUpfrontFees_65abc63e-beea-4fc6-a7f6-5f5088c830d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentMilestonesAmount_06e21e42-734c-4aba-b885-d6b21f63c7e1" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentMilestonesAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_DevelopmentMilestonesAmount_06e21e42-734c-4aba-b885-d6b21f63c7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_acae437b-db44-473e-a08e-69bd424350dc" xlink:href="mgnx-20200930.xsd#mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_a980eb02-d465-4f38-ad4b-6c2eef456c8a" xlink:to="loc_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized_acae437b-db44-473e-a08e-69bd424350dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b907424-d198-4640-acd7-55b039d35225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_54754faf-ed85-4365-9aa4-0414c1ce296b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2b907424-d198-4640-acd7-55b039d35225" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_54754faf-ed85-4365-9aa4-0414c1ce296b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88ce580e-61da-4c71-86aa-bf62f9a299e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d02209e5-c097-45de-8aab-4be35d6b03dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88ce580e-61da-4c71-86aa-bf62f9a299e5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d02209e5-c097-45de-8aab-4be35d6b03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ce3b6990-73ec-4910-83bc-8ff748db49eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88ce580e-61da-4c71-86aa-bf62f9a299e5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ce3b6990-73ec-4910-83bc-8ff748db49eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_cf0cbf70-d5e6-4c5d-9074-ac663de80a81" xlink:href="mgnx-20200930.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88ce580e-61da-4c71-86aa-bf62f9a299e5" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_cf0cbf70-d5e6-4c5d-9074-ac663de80a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0ef81818-d62f-4dd5-b86c-f91f1bba1973" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_88ce580e-61da-4c71-86aa-bf62f9a299e5" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_0ef81818-d62f-4dd5-b86c-f91f1bba1973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e0cd126-769c-4c03-8cb2-96b59386f4f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e0cd126-769c-4c03-8cb2-96b59386f4f3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:to="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_39ed5c21-895c-49fd-82cb-6536345aa711" xlink:to="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_ac895017-5d91-48bf-a880-6f5b5ca585e6" xlink:href="mgnx-20200930.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_ac895017-5d91-48bf-a880-6f5b5ca585e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_A2003StockIncentivePlanMember_d5a26370-63d6-4ee6-bd60-26754797ed26" xlink:href="mgnx-20200930.xsd#mgnx_A2003StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_A2003StockIncentivePlanMember_d5a26370-63d6-4ee6-bd60-26754797ed26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_84934f28-ff4f-4ec7-8978-62602c03f9b2" xlink:href="mgnx-20200930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c3462f96-2e31-42a9-8a5a-7f0011603844" xlink:to="loc_mgnx_StockIncentivePlan2013Member_84934f28-ff4f-4ec7-8978-62602c03f9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_def62854-534c-4654-87bd-fcd869dde49a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8532d14c-c9b1-4716-a6b9-bd6e0d58268f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_8532d14c-c9b1-4716-a6b9-bd6e0d58268f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_187f825b-fe9a-491b-a6ba-63bdfa3b5def" xlink:href="mgnx-20200930.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_187f825b-fe9a-491b-a6ba-63bdfa3b5def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cc5466a3-fcdb-4ed2-a7c6-f3220009e582" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cc5466a3-fcdb-4ed2-a7c6-f3220009e582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_22ebdb4d-0aa2-47ae-b8b3-22bf1b3004fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_22ebdb4d-0aa2-47ae-b8b3-22bf1b3004fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_05bc974d-0a48-490d-a872-e82f53420c4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ProceedsFromStockPlans_05bc974d-0a48-490d-a872-e82f53420c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_a7958380-21dd-4f28-9be3-74eb26ac2320" xlink:href="mgnx-20200930.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_a7958380-21dd-4f28-9be3-74eb26ac2320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_bd27e2b1-acc8-4f75-b887-240652f74182" xlink:href="mgnx-20200930.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_bd27e2b1-acc8-4f75-b887-240652f74182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_961d3b17-290e-40b8-8e77-cdfee272feeb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_961d3b17-290e-40b8-8e77-cdfee272feeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_106e4975-1f56-4956-9d2c-03835100f338" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fabac6e0-9b28-4de3-9420-919402b1e937" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_106e4975-1f56-4956-9d2c-03835100f338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3e0cd126-769c-4c03-8cb2-96b59386f4f3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_75acc261-c6fc-435f-911c-7c86baec59a9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba43c289-8145-41df-8bd8-ccab93439e62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ba43c289-8145-41df-8bd8-ccab93439e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6cd1b5d-4413-4169-97f7-0e142aca07fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9c5f939e-adf4-4795-ab59-5c9676651869" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_c6cd1b5d-4413-4169-97f7-0e142aca07fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_29c9e8f2-f9d9-4d22-81b0-2f9014da1677" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_22fcbcf8-b644-4c39-90a7-268ad1e1372d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_43f9f683-897b-46e5-912a-d96328fb0a09" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_22fcbcf8-b644-4c39-90a7-268ad1e1372d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationOptionPricingAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bad2a151-cbc4-41dc-aa64-cce255f77e5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bad2a151-cbc4-41dc-aa64-cce255f77e5b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:to="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_66448558-d2b0-44e9-a059-043a060a14d0" xlink:to="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f44c0f47-6086-48b6-beab-2dd27e036ff0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:to="loc_srt_MinimumMember_f44c0f47-6086-48b6-beab-2dd27e036ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_658cdefa-57e0-4422-baa9-dcad2dcbfc11" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8d53f972-f5cb-4799-bb18-e655e1b3c475" xlink:to="loc_srt_MaximumMember_658cdefa-57e0-4422-baa9-dcad2dcbfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d66a8ee9-e420-407d-8a72-4e5ad31bbcab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90b82696-0012-4da8-bc4f-a5a57871fb52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_90b82696-0012-4da8-bc4f-a5a57871fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf381d80-e6c1-4638-ad29-8e5f1794f65e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_bf381d80-e6c1-4638-ad29-8e5f1794f65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_deff7401-9014-4d92-b741-9ae56f53f818" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_deff7401-9014-4d92-b741-9ae56f53f818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1409078e-f077-4b9f-b9e9-196b6c43f2ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ae77d8c6-deb0-4a58-86fa-5afa20ccb6e2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1409078e-f077-4b9f-b9e9-196b6c43f2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90b036fd-00eb-4c8f-b0e0-eda55346c1cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_90b036fd-00eb-4c8f-b0e0-eda55346c1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ad94bab2-a1cc-4aab-aaba-544f51390a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_ad94bab2-a1cc-4aab-aaba-544f51390a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8b97411-3dad-4964-b0f0-0f54a9c2e20d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8b97411-3dad-4964-b0f0-0f54a9c2e20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b0c7b862-f527-41f3-9b34-686054f28060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_b0c7b862-f527-41f3-9b34-686054f28060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49547559-f224-415c-97e1-74f548072385" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_49547559-f224-415c-97e1-74f548072385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8bb8c186-4e7e-4a0d-a80a-ea87c96f5b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8bb8c186-4e7e-4a0d-a80a-ea87c96f5b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c8abf49d-8d29-4b3e-898c-7a668c8c40ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1c965944-a62d-47b6-bb46-ec706d750d3f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c8abf49d-8d29-4b3e-898c-7a668c8c40ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1057fd7-f2cc-4c53-91d4-c59ffd913acc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e1057fd7-f2cc-4c53-91d4-c59ffd913acc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e33a99c3-4bda-4b30-9952-cff891f706e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e33a99c3-4bda-4b30-9952-cff891f706e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_23f830be-edae-440b-9fb1-643f1c48e107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_23f830be-edae-440b-9fb1-643f1c48e107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fd0becee-3016-42e5-92b2-0d8c733046e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_fd0becee-3016-42e5-92b2-0d8c733046e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fdea3134-3cde-46c1-a2e0-c044acdabbf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fdea3134-3cde-46c1-a2e0-c044acdabbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5823f47b-ca84-4bb7-bb81-b499c2b200dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_5823f47b-ca84-4bb7-bb81-b499c2b200dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5ad4a8f3-927f-4f88-b41b-a437cfbdffed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72220bae-bf31-4595-b14e-78eefdbac96f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_5ad4a8f3-927f-4f88-b41b-a437cfbdffed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dd7be208-717e-403f-84a8-be4c0baab4fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dd7be208-717e-403f-84a8-be4c0baab4fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f59b9c3a-5d9e-4f91-aad2-06b848491dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f59b9c3a-5d9e-4f91-aad2-06b848491dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d4a1027f-07f2-4623-9f7d-c1e54dc94b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_d4a1027f-07f2-4623-9f7d-c1e54dc94b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0ddc424-916a-49b7-b513-c269d1af2f75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d0ddc424-916a-49b7-b513-c269d1af2f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_043f0bc1-457e-45d7-b6df-070260011f29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_043f0bc1-457e-45d7-b6df-070260011f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_81d733b1-d4c5-44ed-ae42-86c6a85b691d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_3b7c864e-54c8-48fc-acf6-ee8498cde836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_81d733b1-d4c5-44ed-ae42-86c6a85b691d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e7d0a7a-fbf4-4779-8184-adaf00883a77" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3e7d0a7a-fbf4-4779-8184-adaf00883a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2cc3823-ff80-4297-bf80-8fd7de9db277" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f2cc3823-ff80-4297-bf80-8fd7de9db277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5a387b1a-061c-4632-be96-0c9d4b535ad5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5a387b1a-061c-4632-be96-0c9d4b535ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86b077ab-2722-4d1c-8511-ebb3cf490847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_86b077ab-2722-4d1c-8511-ebb3cf490847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33110d51-5eff-4678-8985-f2d64fae4427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_33110d51-5eff-4678-8985-f2d64fae4427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2c88960a-2b29-4ebe-99e0-beadd9c8c459" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8824ec64-f00e-4cee-b32c-9163e1ca6b49" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2c88960a-2b29-4ebe-99e0-beadd9c8c459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="simple" xlink:href="mgnx-20200930.xsd#StockbasedCompensationRestrictedStockUnitActivityDetails"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e0a7bb4-ba9f-4926-8819-1b84ee92f078" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e0a7bb4-ba9f-4926-8819-1b84ee92f078" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:to="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7372aa2d-5a05-4899-82b6-50aa8c42fbc0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cdb9bc42-2185-40e0-8f5d-33851f475d93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_77c3cecd-f43e-4311-bf31-f380fe8514ea" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cdb9bc42-2185-40e0-8f5d-33851f475d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:to="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2b6fc4c3-d6e0-4f2c-9957-5bcfd8ad631a" xlink:to="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mgnx_StockIncentivePlan2013Member_432276f0-98c8-4f56-bd2f-637873e20b16" xlink:href="mgnx-20200930.xsd#mgnx_StockIncentivePlan2013Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_33284262-2e18-4877-b435-3c3c999740e4" xlink:to="loc_mgnx_StockIncentivePlan2013Member_432276f0-98c8-4f56-bd2f-637873e20b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3a0e8321-fa5f-49b8-8fac-b53bc5824c11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4521ea14-1520-426d-8ee1-370aa27683b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4521ea14-1520-426d-8ee1-370aa27683b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3bd8f1b-9312-4b4d-add3-c2a39e3f6050" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f3bd8f1b-9312-4b4d-add3-c2a39e3f6050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_32037f3f-18b6-428e-a454-cb954226857d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_32037f3f-18b6-428e-a454-cb954226857d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07d38954-8102-488f-af3b-5f932df5aa11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_07d38954-8102-488f-af3b-5f932df5aa11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18c92f03-387b-49d8-9689-9417836a041f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_d65a5631-21b9-44a6-aa2e-bdf55c1ac347" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_18c92f03-387b-49d8-9689-9417836a041f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52cad51b-8dbd-4755-aeeb-69539fc6aa06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_52cad51b-8dbd-4755-aeeb-69539fc6aa06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fad09b4c-0efb-4d25-afb5-a121bb1b9a0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fad09b4c-0efb-4d25-afb5-a121bb1b9a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5851e5d-989f-4f28-a07e-8c2387756b05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5851e5d-989f-4f28-a07e-8c2387756b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ddce5d5-fc93-4847-8f09-e3b6ba0f2abe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_0ddce5d5-fc93-4847-8f09-e3b6ba0f2abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7aad1d4c-70f8-4d0a-88fa-276ad59dddb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7e75b70e-e650-472e-a50d-b7b6b3eb7219" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7aad1d4c-70f8-4d0a-88fa-276ad59dddb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14900b70-38c6-4630-bd15-ebec569e6f37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_14900b70-38c6-4630-bd15-ebec569e6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7c71050f-4bcd-4f71-bb23-ae2216c6f4dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_7c71050f-4bcd-4f71-bb23-ae2216c6f4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ec8883c-5f5c-4cde-b6f8-504cbbcca32a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_742fdbc6-6b3e-486d-b1b3-2cf8acdf1da7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2ec8883c-5f5c-4cde-b6f8-504cbbcca32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="mgnx-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bd3716b-3e35-4ff3-988a-3af2db8c59ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3080be8b-7fb0-43f9-83a8-430b435ee680" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0bd3716b-3e35-4ff3-988a-3af2db8c59ae" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3080be8b-7fb0-43f9-83a8-430b435ee680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>mgnx-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mgnx="http://macrogenics.com/20200930"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mgnx-20200930.xsd" xlink:type="simple"/>
    <context id="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i28ca4dfdd9aa48788b912cff0cd21aeb_I20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-10-30</instant>
        </period>
    </context>
    <context id="i656b1702d3e14be0be6085d06cdf2c30_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id03af012974e455383bba3223db02d75_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i11ab2ecbefa743f0831253b0bab43a2e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7cbc36cf427b4048bb3cd430116a3d18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib9aacc62ecec4769aef75e7e93eee7cb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f323311ba0f477e8a5eed6444e2f116_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromCollaborativeAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id0f0f42a48f649fb9adde86d8c8f3144_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice0dc1c1e98841ed97a1903b7430e16a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0f191c2ca22041aba70b10b4dc29f16c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieef210ab30594a5c96c8265ceede1a54_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenueFromGovernmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i93bb0acbca4c41b1918f1063893322c3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i251ea0d889734a40a60b2db0510e4d30_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c7c0500c96d4870a7cda546e1d57804_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8fbc608a7ebc4a189668ce0d769f101d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i5fcac574cbe44ff598b04d63a009d245_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ide541262618d4b8ca172e4936bda305e_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iecd98e62333946d2bde73cd3927ee687_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i678618f17ae24eca9cb47796aaaaadc4_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i5643da10e9664d89a666a86f3de255bf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i44b26809617d43939a5329f6885680fd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b6082892bd94f66800a06bc094d50ff_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="icc8d7e7284994e3a8718cbc86dddc39c_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="id2918b1588e24443b4687bb092493234_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i118dbb19ee294bef9dff06aee00e80a6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i31c17d69a6f44a56a03595fa8f30ca05_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i248e16c8b2404924963b17b9a022deea_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="if4a65ca63de24c97ba1095455858cfb6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="id28db8212ed74e888a6a05d24557a148_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i79a04baa748a409cac40497b1ac71047_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0034cf911ef4d0987f18fbcf9c12c54_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i89a9947c99a4486786e7e887b223f9bb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5da47fec875b45ca8dc4ef858f3b3373_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfbdee7a4f194e1f886e309d5f57e49c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1f2fcd1d3d2f4c02a9ca03c84aba1084_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i168d44892dc64bcfa877caa22d4d2f47_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i99d089ec986c490e9d7a9fe9003fab25_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i772e75c235df4ee2ba9c5db15a74d268_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="if99c4563ef8346599f6f5d683f3ab131_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i28c7c5e832994f4984a2b72a7c12a323_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i85172e0b52c945fcb48567a2d8cd5d66_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i923dde2fa85e430882f4c005512f9879_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i2a099bff17804023b9870c32927d44b0_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i083e553805e84a4ab30278ee0b21eea1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i86bc84252e164a12a5ef77a9c53239ab_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i1a85c5a33a1940e686e68c93aa8752a8_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="iad99730485234a69afe678ff8b091949_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i4dde4cd27157467b873b883bcb26a3e4_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i8dc1dbdce58a458eb5f7eb8d375ea1df_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i242d9a69e198416fb1411637de6c71d0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ifc1b1f56ad824f4d9f74ac2f6154dc3b_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="ic22ad87081f44452b54967d211ab676d_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i5862997f33c54ac6981fb6685d18aa17_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="idabb0d4b38a24297a10a88b8c412b614_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="iabea7eedc8ed4974a97afbe70ef669e3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i52d6b5ad2eb1439ca7b9d6e530b4acd3_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i89997c7fe90c43be8e6eac61d5f7f7ce_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i508ac6b80ba5482fb20c800a957c919f_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8a5362c6893440ed81f5656a8c74e7d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5d97bb4ee6084712b486bea7a21d603e_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i11cb9793489f45eeb9391db0da058532_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i0fdf9d4e0da94e1194a5a8b2baceb2c0_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ia192c40bd1d344abbf5835f4a19906fd_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2f1781eeabb7431089fcd817959eee47_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i2f3d327578eb4a8fad5a02f88b706a81_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i61390568815449f1b203b09838077cfd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifef9401807084084b4cfcd1497fbd03b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i18bc51ed445347d490417a0086d4ec6c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id1f44ee2b6604e6faceef147adab156b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib02652ca68b840fdb8345db6c3943506_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i95c791bd80414458bf798e3a5c8371ca_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i53df1531613345a4a20cd107a152c452_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i50a90c0416934ef191dae9248e6bd343_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3cd3e5b6f3bb423cb9c8241c4629352a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i853b145d4b5d4ff887fe3c813723757a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia965ddea0c0d4929bcaaf10ab3dce00d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i429a8d866ab94f0887344d549058d4a7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i367e0e3322684eb693f6e0db308b49be_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0dd66a09550047b488eecee849d1ab89_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i351eacc89eba4a779a3a805096b50266_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0e1427f09d0a4d849022fa592d4e2510_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifd24cb204af040a1896e0e2e134b823c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7eee048bc9214fcebfa85d929a62359a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib5637258cb9f467daa8468f96fe90010_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i76651544b7ed4a3aaf1e1ad08d30d686_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i96cf5c6e27734accb1a3e05be19371c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i631c1559593f4350a22a93d85ffed1de_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i661301857c8140fcace77bc9000a2645_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4617b92aae94471a82ddc03195cb0603_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifff3a59bcb8f40719209839b68d4b087_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i14cdb49cd71144059cc61727bd2504b3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i07e730e5685e4559a024b11728b95988_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8ac12fb37dda4afa812ff75ecbb55b47_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i930b7f72b4454a8986e9888ac10ffc56_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8dc5e6a1bc8c48528ef4028801eaf60f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92b7234ef3f94f8f922de6a29f863ef0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iac0308dd5c1146fd864acc4473bd9d02_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id98a1eb125924f9ebae87f7340768587_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4064a77523204a5c97651a32d316bd67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i57bf751d79c94691b038938d560d3571_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3c7c8218ffeb4024b44e5ecc01780199_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="iec648d78c60f46bdb12dc3ce89f30a15_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:FollowOnEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i97dd199628d2445cb4a47064a0b74d6a_D20190201-20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-28</endDate>
        </period>
    </context>
    <context id="i44e22609aae84c4ba9ad609e47840e0d_I20190228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="i6514c468c9e740d6b1d05c92467a1618_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia2d7928761a04561a98b1772b844011e_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2f6e1c1422a241b7865adbaac8d439a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2a91773145ff4dc6bed1e4e7d3de5929_D20171001-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i0d800a4cc7cd4980bee11f68119d53b4_I20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="ic13ad679ef8a4def92ebbc15dce2b871_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9e29c2c5bc4b44648d0a8b577e42de39_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="if59acebf30ba44029fdad1f534a68269_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="ia791781a92464af29c8f02db3c401ab8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i88964468ab69431eaebd92a52277944f_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="i4e228120dad34e57a7e7cdf18d7fa48d_D20171001-20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="iea44bd2966be41888177853b425961ff_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8bc7d94081d340628b9b2a71457956e1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementClinicalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8aff2b8c451a486ca958bc76fd5a67bb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4a340d54cb3d485989696d575daa8669_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie54ccd6d1f4249b7b4f1ac381f526911_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61e7d81a9da347bb85af6348231a2bab_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if3132c81f87a4d99ba4f564ef87782a6_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="i2b16f811de98474199d531dece74437d_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="ifd4f369c54f94171ad9af39bc0da5bbe_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2a7aa88cb654aa884f7e855835ec390_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8f6d41510162452d9a466e6c347714d1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61ca4c82e803497f86944bb5582a02f0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5e461a0cdef74333a6a3069cedba5031_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i107f7d71e8f24667bb86b994ab1d73a1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i314a584979b14a389f3c5d964af2863f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36d284e79f3044a3ac9625ecf4e891e2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib1ac8ba9b2e14e9493c732eb3111af36_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ZaiLabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ZaiLabClinicalSupplyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i3ea3b158fb7c41879720382aa02de77b_I20190709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-09</instant>
        </period>
    </context>
    <context id="i5f9cc003f349478ca3ed4fe7c6abc14e_D20190701-20190731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="i695b50b168414938849dea296be40228_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie164583eab6942249da5bef115ef55e3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i68ecfdcfeec84c4ea913ab203c146751_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia8369f5a9bc24605bd6959601bb26575_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8fb7e409d6b245e5b347e1f893c44d97_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i339805cc81504f138bc5f596b75adf4a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:IMabBiopharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IMabBiopharmaCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib280116fa7124f13b35c12a7dd273e86_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i57e35a0253554ab4b773d0e5048648bb_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV3279Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ProventionLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i398326bccf184051bda69d4a3c8a1a33_D20180531-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i280712410840475fadcbe6d4b410e8e6_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:ProventionPRV031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:AssetPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i456c33b61451427ebca4b6600c9eeb6f_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i709d5a4375bc46bfa8eb06e60b804476_D20180701-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:ProventionBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-15</startDate>
            <endDate>2015-09-15</endDate>
        </period>
    </context>
    <context id="i17e4e3bc99de4302af0c36215cc08f6f_D20170101-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i084bc672cb2542ee93482822566c90cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8ec7e2284b474d4997d8410cdd14f1b7_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied5a5d5f59e0443393b8732129f9e130_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8e1a76d57ce94e01be30cf3cfa42cd5e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">mgnx:RevenuesFromGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8e5332870f4e4706a838787952f9124b_D20101001-20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="ib37d01f8e8ec44a3b82be406e14e4895_I20151031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-10-31</instant>
        </period>
    </context>
    <context id="i5be796f261a24d47bb6a08dee44be3f7_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic8506fff30e343c0a108eac7ddb6eb91_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i682bc99e203a470fadd9467ce13ac26a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mgnx:BoehringerIngelheimInternationalGmbHMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i651dacb02b694c7cab3fc1042896bf4d_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4659cc916dd3432aa5e78628aca3effd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:A2003StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i301496abba464d8a8e453d6ff8bba901_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i35072c1e740040a296f33ad007daa74c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d3cb74cabac4267807f2a0c571ab8f3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib3c10bc20e144f36b196b86ec9fb610e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9ba2e860df1846c29d00f140ae5dfa0e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i267ca7ed35444cc1a4d6d12768b9c471_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb3041645d5148e2885536c8ef463ce0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie09d12dbaa6c4616ae1d1ef7740fb483_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic4b36cc5e5fa4780a5d86d9a4a7471c5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i328732a3cf7940cca770d218ab8234b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ied85acb778bf4e98a18112866d8afde5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id3f7b7f171b04570abfa521633907fa0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="performance_obligation">
        <measure>mgnx:performance_obligation</measure>
    </unit>
    <unit id="molecule">
        <measure>mgnx:Molecule</measure>
    </unit>
    <unit id="numberofproductcandidates">
        <measure>mgnx:numberOfProductCandidates</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV8yLTEtMS0xLTA_b2d39294-305e-428a-9204-19dbb1d5a870">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV80LTEtMS0xLTA_caff1e4a-08c3-41b4-83a0-89c0b2a20f4c">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGFibGU6ZWI3NGJmYjZmOGYzNGM4ZjgwMjZmOWU1MWVjOGMzYjEvdGFibGVyYW5nZTplYjc0YmZiNmY4ZjM0YzhmODAyNmY5ZTUxZWM4YzNiMV81LTEtMS0xLTA_44797ab3-ceba-4fb2-8340-637d8f674f7d">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGV4dHJlZ2lvbjozY2I2OGE4MWE2ZWQ0ZDI5OWRiN2MwYWQ1MDU4MzBiY18xMzA_5945b044-0026-4ca0-8b01-6bc008d37ad5">0001125345</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80L2ZyYWc6M2NiNjhhODFhNmVkNGQyOTlkYjdjMGFkNTA1ODMwYmMvdGV4dHJlZ2lvbjozY2I2OGE4MWE2ZWQ0ZDI5OWRiN2MwYWQ1MDU4MzBiY18xMzI_a480d401-29b5-4fdd-9b2f-4c5089dfd7e5">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl84Mg_5d0292ff-89ab-4f5a-9c91-57ce12494a74">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6NmNhZGQ4MjcxNzRkNGU4MjhlNjNiYTQ3NTViOTJlMDUvdGFibGVyYW5nZTo2Y2FkZDgyNzE3NGQ0ZTgyOGU2M2JhNDc1NWI5MmUwNV8wLTAtMS0xLTA_cf750e88-2af4-4dc9-89f1-6b400762f8f5">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xMTg_c88415c4-a363-405c-a649-525ff2b8d18b">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6M2I1ZTdiZGVmMDI4NDY4ZmIxYTc2YTlmNGQ2ZDVjYmMvdGFibGVyYW5nZTozYjVlN2JkZWYwMjg0NjhmYjFhNzZhOWY0ZDZkNWNiY18wLTAtMS0xLTA_ffe1124a-0d32-46e7-96ba-bea629b81af8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yMTA_7dd83aa5-aee0-41f2-aae1-1b946565b3ec">001-36112</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yMTM_1c5e5626-d4af-4c45-aa4a-047e76c4fd12">MACROGENICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18wLTAtMS0xLTA_c2a17b06-257e-4400-94ed-6cc7a2c1b4b0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18wLTEtMS0xLTA_d4f4528e-63bb-41d7-824a-fa433a0225d7">06-1591613</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl81_7783a045-bfed-48d2-87a9-53652f06177d">9704 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl84_9e52f0a5-74c9-43a1-b1ab-f960f011fa79">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTAtMS0xLTAvdGV4dHJlZ2lvbjowNzIxNDMzMGE3M2Y0NmZlYTMwNzRjNjdiNjdiNGNlYl8xMg_eccc5d40-fecc-495a-81e6-14b6b3d8fa0d">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6ODI0OGYyYzMxMTlkNGQ4ZGExOTc5ZjJlNWFmZmNjMjcvdGFibGVyYW5nZTo4MjQ4ZjJjMzExOWQ0ZDhkYTE5NzlmMmU1YWZmY2MyN18zLTEtMS0xLTA_812c5d7a-5926-4c17-8b95-b0e74440a711">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yNzM_6c158ede-0962-4c45-9210-fec3762bc9b8">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8yNzY_542e7ab2-126b-426b-8498-589b3b154378">251-5172</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTAtMS0xLTA_78fd29cf-ec67-417a-a09f-85913d038c5f">Common Stock, par value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTEtMS0xLTA_798b71b3-83bd-4feb-b905-1bf7720425cc">MGNX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MTExNTk3M2FmODMwNGNkNGE3ODRmNTk4ZTdhZTcwZjUvdGFibGVyYW5nZToxMTE1OTczYWY4MzA0Y2Q0YTc4NGY1OThlN2FlNzBmNV8xLTItMS0xLTA_991b9b47-fa8f-4d54-af08-b434ce0aa5dd">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQw_169f964a-22a2-4abe-a955-e2403dab4573">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQx_116c1737-a9c6-4937-89d8-c71a8f431a20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM18wLTAtMS0xLTA_a1ba471d-2b32-4b34-bcca-8e4f86a1ad19">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM18yLTMtMS0xLTA_a021688e-1ef0-484e-a6c3-52b0eacc665c">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGFibGU6MmQ2MGNiM2Q3MmY2NDk1MmFlODk1MDYwNmRiM2U4ZjMvdGFibGVyYW5nZToyZDYwY2IzZDcyZjY0OTUyYWU4OTUwNjA2ZGIzZThmM180LTEtMS0xLTA_f6180d6b-1b0c-4f84-9100-f6629a8c11fb">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTQy_9e19c908-aafb-448d-afeb-50e77a3d8666">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i28ca4dfdd9aa48788b912cff0cd21aeb_I20201030"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xL2ZyYWc6NjZiODFjYWI4N2I1NGUzN2ExMjQwZDQyMGUwOGU2M2IvdGV4dHJlZ2lvbjo2NmI4MWNhYjg3YjU0ZTM3YTEyNDBkNDIwZTA4ZTYzYl8xOTMx_01a6bc81-9d13-4400-8d15-ae68ee1f5cde"
      unitRef="shares">56204015</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNC0xLTEtMS0w_ce2f6018-eaa7-49c1-aea9-b8fb62bec2b6"
      unitRef="usd">201637000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNC0zLTEtMS0w_6a1b15aa-f4cc-47ec-9e42-3e49a31ee231"
      unitRef="usd">126472000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:Investments
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNS0xLTEtMS0w_25f44194-1f3e-4a64-96c5-ac65f7b0dfe0"
      unitRef="usd">79022000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNS0zLTEtMS0w_177beb0f-3846-45de-a762-d51d230b811c"
      unitRef="usd">89284000</us-gaap:Investments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNi0xLTEtMS0w_b564927f-151f-4cdb-880c-41d2fd8c1802"
      unitRef="usd">18777000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNi0zLTEtMS0w_7ae836da-c9d6-4afe-b65b-61a3be23273f"
      unitRef="usd">12744000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNy0xLTEtMS0w_d0e7bd42-7c2c-4951-bf28-6ff146977bc3"
      unitRef="usd">10632000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfNy0zLTEtMS0w_f3c76a89-f53d-4729-8df6-e736f3c1b104"
      unitRef="usd">11285000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfOS0xLTEtMS0w_ddbc06e6-d08c-4dd2-b33f-5ea23e5d672c"
      unitRef="usd">310068000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfOS0zLTEtMS0w_4d3d476f-2db8-405d-82d5-64a945ffd750"
      unitRef="usd">239785000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTAtMS0xLTEtMA_192536db-67fc-46e1-be2d-e3d3fc9ed204"
      unitRef="usd">41423000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTAtMy0xLTEtMA_864cae33-6b1d-4d6a-8337-9ca16a0cebe6"
      unitRef="usd">48211000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTItMS0xLTEtMA_3bda5151-bb78-46a7-b567-ae2f0dfe39c2"
      unitRef="usd">22889000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTItMy0xLTEtMA_d286f33a-bd18-4ba5-a353-2da69cfbea6b"
      unitRef="usd">24505000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTMtMS0xLTEtMA_8ab2560e-f456-4756-8280-eaf0773f5924"
      unitRef="usd">374380000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTMtMy0xLTEtMA_0e94c197-6a07-4630-9313-7521acfe326e"
      unitRef="usd">312501000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTctMS0xLTEtMA_ad6e8623-7793-4758-b4a7-089982686816"
      unitRef="usd">4380000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTctMy0xLTEtMA_e230e990-5a23-47ae-9540-13acfd6575ba"
      unitRef="usd">4308000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTgtMS0xLTEtMA_c0fa8f5e-6689-43f4-abfc-4820ca51649e"
      unitRef="usd">32674000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTgtMy0xLTEtMA_dea699e1-5ee3-4748-a062-71443af2dfce"
      unitRef="usd">27139000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTktMS0xLTEtMA_ea89592b-f098-4191-b6c8-8e7c26fbeb2b"
      unitRef="usd">9259000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMTktMy0xLTEtMA_8ab3f06a-fab4-4bfe-9547-7358a37ea9f8"
      unitRef="usd">10700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjAtMS0xLTEtMA_cf5ddf22-f8d8-4edc-9028-6455a84e7201"
      unitRef="usd">3808000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjAtMy0xLTEtMA_6cbb154e-fe35-4b89-8ea3-826eae3cb3d1"
      unitRef="usd">3020000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjItMS0xLTEtMA_79810b02-ebff-4201-b5f3-0290364dc3f3"
      unitRef="usd">50121000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjItMy0xLTEtMA_0153e471-aa0c-4398-b492-12791600c1a9"
      unitRef="usd">45167000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjMtMS0xLTEtMA_c6e8396a-6581-416c-a828-fa3113277b4e"
      unitRef="usd">5778000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjMtMy0xLTEtMA_8d0e1ccf-23a9-4c97-8b42-2a22ab4efcea"
      unitRef="usd">9153000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjQtMS0xLTEtMA_63fdbac3-f670-44ab-87bf-a5e717ee25db"
      unitRef="usd">24651000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjQtMy0xLTEtMA_9d26bc4c-c348-4f52-bebb-73e22a6ef776"
      unitRef="usd">27553000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjUtMS0xLTEtMA_0e219cae-e9ab-4317-8b28-2e13a4eebd06"
      unitRef="usd">2245000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjUtMy0xLTEtMA_21785c9f-c648-4ad7-987c-13bd480f7ce0"
      unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjYtMS0xLTEtMA_699490bd-61c9-4741-881a-2b839cde40a4"
      unitRef="usd">82795000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjYtMy0xLTEtMA_9a10c588-be9a-47a4-a557-67367709ebd0"
      unitRef="usd">81873000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzE4_617d96f3-c901-46d4-900a-e238545d43a6"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzE4_7653f4f9-2e13-4dc5-8641-82c9da1d1988"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzM0_1e3e0079-35e3-4416-9c5c-81f3dbccbb88"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzM0_c13354c6-1877-45b3-bb7b-c145dea9197b"
      unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzU2_9e1144c8-15bc-478c-a29d-8451557e1228"
      unitRef="shares">56174932</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMC0xLTEtMC90ZXh0cmVnaW9uOjNhMjVmOWRhMmZmZjQxODQ4OGU1NGM1NmYxMjQxNjM0XzYz_3e88063b-0e58-4fe2-8bb9-c1cd075dcacc"
      unitRef="shares">48958763</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMS0xLTEtMA_03674ce6-4129-4d64-87e8-5959801ee4eb"
      unitRef="usd">562000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjgtMy0xLTEtMA_333b89fa-eae6-4156-b399-81158a8110e9"
      unitRef="usd">490000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjktMS0xLTEtMA_50803bf0-fe5e-4108-b405-d8df0a8094be"
      unitRef="usd">1060755000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMjktMy0xLTEtMA_1927450c-c146-4f3c-a16b-f2f96b1e0820"
      unitRef="usd">872204000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzAtMS0xLTEtMA_10b57935-131c-4c04-ac53-21d27bcf31f6"
      unitRef="usd">2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzAtMy0xLTEtMA_72774324-6ef9-4cb3-a2ee-657fc3a05dce"
      unitRef="usd">16000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzEtMS0xLTEtMA_ddd49956-421b-4c84-8e79-17e96b418a90"
      unitRef="usd">-769734000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzEtMy0xLTEtMA_2a35b6fb-fd1c-44a2-82b4-85fb90e743b1"
      unitRef="usd">-642082000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzItMS0xLTEtMA_e008e6be-e0c9-4b85-af2e-67990dde9fab"
      unitRef="usd">291585000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzItMy0xLTEtMA_9aac9447-d8a9-40a9-906c-b10ac4c182b8"
      unitRef="usd">230628000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzMtMS0xLTEtMA_84b0eee5-c8c4-4592-8619-b27761829abe"
      unitRef="usd">374380000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8xOS9mcmFnOmVkYzJhZTdhNjdjOTRhYzU5MGQwYTBmOWZkZTEzODg2L3RhYmxlOjgzMTJmMjE4NWZhZTQ3ZjQ4MjQ3Yjc1YzE0MjBlMjM1L3RhYmxlcmFuZ2U6ODMxMmYyMTg1ZmFlNDdmNDgyNDdiNzVjMTQyMGUyMzVfMzMtMy0xLTEtMA_25807df8-3a59-4a21-8e49-f216b24d9762"
      unitRef="usd">312501000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="i11ab2ecbefa743f0831253b0bab43a2e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy0xLTEtMS0w_3c5d3ec2-85ee-45d6-9e8a-523109002120"
      unitRef="usd">17415000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cbc36cf427b4048bb3cd430116a3d18_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy0zLTEtMS0w_9b81b59d-4f84-42cd-9ca9-1e204a537863"
      unitRef="usd">17984000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9aacc62ecec4769aef75e7e93eee7cb_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy01LTEtMS0w_766aeb24-021d-4589-ae8b-43ff5c177577"
      unitRef="usd">46018000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5f323311ba0f477e8a5eed6444e2f116_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMy03LTEtMS0w_efb1db48-c4f4-414e-a150-490af31ff1c0"
      unitRef="usd">37468000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id0f0f42a48f649fb9adde86d8c8f3144_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC0xLTEtMS0w_c76d18ef-dcc7-403e-bea2-3571eaa63baf"
      unitRef="usd">838000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ice0dc1c1e98841ed97a1903b7430e16a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC0zLTEtMS0w_2b09ec63-c9db-4eb7-9c6d-d65b01441702"
      unitRef="usd">757000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f191c2ca22041aba70b10b4dc29f16c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC01LTEtMS0w_39e32326-ba76-4a51-aad1-d6a94a4df8f7"
      unitRef="usd">6174000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieef210ab30594a5c96c8265ceede1a54_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNC03LTEtMS0w_b752d7e4-0259-4f69-b006-ef3659942704"
      unitRef="usd">1528000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS0xLTEtMS0w_6e3eef16-6c84-455a-9048-83a57d44c758"
      unitRef="usd">18253000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS0zLTEtMS0w_30a49870-2bd5-4313-aacf-034af325267e"
      unitRef="usd">18741000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS01LTEtMS0w_0f02984c-a502-4dc5-b74b-4fd34b393c83"
      unitRef="usd">52192000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNS03LTEtMS0w_a16d45f4-c7fc-4c27-a7f8-9ca6dd2f6ae3"
      unitRef="usd">38996000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy0xLTEtMS0w_e98eab5c-be7b-40f8-bcf6-552df5732d83"
      unitRef="usd">44656000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy0zLTEtMS0w_d675960a-d4da-48d2-bf6f-5687c4fbb477"
      unitRef="usd">44852000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy01LTEtMS0w_e417c632-3669-4a5b-ba53-53c5b4849aa4"
      unitRef="usd">150901000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfNy03LTEtMS0w_59fc0f1f-93e1-4bc5-99c7-c41e38a563bb"
      unitRef="usd">143352000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC0xLTEtMS0w_b96a4d2d-ab13-4ef4-9cfb-66c63c421a2d"
      unitRef="usd">9732000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC0zLTEtMS0w_a258e614-7827-4a72-b42f-956e0d67e936"
      unitRef="usd">11833000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC01LTEtMS0w_25b14f98-2270-49bc-9d75-7bdefa4f8624"
      unitRef="usd">30181000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOC03LTEtMS0w_641aab83-c6e5-4e30-948e-0689f2e139b5"
      unitRef="usd">34174000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS0xLTEtMS0w_d9868b33-be00-47db-a796-49c7699cb107"
      unitRef="usd">54388000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS0zLTEtMS0w_376bcd5d-f953-4f0f-a5b1-485875f95648"
      unitRef="usd">56685000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS01LTEtMS0w_082d352f-e4f9-43e1-b840-f61e93cf39f3"
      unitRef="usd">181082000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfOS03LTEtMS0w_531b73bd-42fd-42bf-a013-d33c7b37ae13"
      unitRef="usd">177526000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtMS0xLTEtMA_efaa841a-3ec9-40b5-a864-1c4ea0b7e191"
      unitRef="usd">-36135000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtMy0xLTEtMA_a310b54b-58fa-4da0-b242-2efa7ea50d58"
      unitRef="usd">-37944000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtNS0xLTEtMA_acdbb600-3c98-4db5-b7ea-d7788cfd6c92"
      unitRef="usd">-128890000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTAtNy0xLTEtMA_b357b0c9-7e49-41f7-b7e8-dd576225161d"
      unitRef="usd">-138530000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtMS0xLTEtMA_a757f8b3-9b6f-4d14-8fb8-2a19c41ecfa8"
      unitRef="usd">92000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtMy0xLTEtMA_4d6ca3e7-514d-4d88-b094-5f0f24cc335b"
      unitRef="usd">-6687000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtNS0xLTEtMA_7e81beb3-f0a8-428e-9283-eafdad60dc39"
      unitRef="usd">1238000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTEtNy0xLTEtMA_3e6cf254-2db0-4588-ba9c-37459e61795f"
      unitRef="usd">17115000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItMS0xLTEtMA_7684835d-c002-4957-8ad3-571312df3d62"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItMy0xLTEtMA_15e31ae0-e9ae-42c1-b31c-f3a637a6de65"
      unitRef="usd">-44631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItNS0xLTEtMA_2b0868a0-d4bd-4e72-ae0c-998033f4ba3d"
      unitRef="usd">-127652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTItNy0xLTEtMA_8c17f6c3-36b8-40d5-84e4-e23666300d4b"
      unitRef="usd">-121415000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtMS0xLTEtMA_6146e3bb-b647-44f2-96cc-d80a6ea1bfb3"
      unitRef="usd">-15000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtMy0xLTEtMA_98075aae-7021-4e00-bab8-cb313788e581"
      unitRef="usd">-11000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtNS0xLTEtMA_f0e8a25d-4b88-4600-9bd9-64e3510efa20"
      unitRef="usd">-14000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTQtNy0xLTEtMA_6c5151d6-598d-4fa2-81ba-05dd58976d80"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtMS0xLTEtMA_873a2484-c8ca-492d-a17d-b5b03a72ffd5"
      unitRef="usd">-36058000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtMy0xLTEtMA_8fb9af9f-f486-4621-868a-52621add0202"
      unitRef="usd">-44642000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtNS0xLTEtMA_8a87e23b-35f9-4241-a452-cf3a73655397"
      unitRef="usd">-127666000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTUtNy0xLTEtMA_aa7e2de3-3001-4396-aca2-b4172f2c268a"
      unitRef="usd">-121389000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctMS0xLTEtMA_b5254df2-6092-4405-9cff-807adc9440a6"
      unitRef="usdPerShare">-0.66</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctMy0xLTEtMA_dd34df70-d054-469e-9ca7-51c1e386c4df"
      unitRef="usdPerShare">-0.91</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctNS0xLTEtMA_33c6727f-bd88-4ba1-8058-3e8d0ce5016e"
      unitRef="usdPerShare">-2.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTctNy0xLTEtMA_689ba82f-1123-4239-962a-84f608ae8d20"
      unitRef="usdPerShare">-2.54</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtMS0xLTEtMA_7a8058a0-5c0e-477b-a45c-4ae2e5a55a86"
      unitRef="shares">54463412</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtMy0xLTEtMA_e362e7a4-e149-4de6-84b9-bca56bed6f18"
      unitRef="shares">48902766</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtNS0xLTEtMA_038d39c2-1c95-437c-a26b-b8cce3c1b8bb"
      unitRef="shares">51176884</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yMi9mcmFnOjMzNDhiMTVkMDUwYjQ0ZWViZTVjYTIyZWVjOWNiZmE0L3RhYmxlOjBlZGM5ODU5YzU0OTQwOWI5Zjk1NGFhMGQ0Mjc1MDMxL3RhYmxlcmFuZ2U6MGVkYzk4NTljNTQ5NDA5YjlmOTU0YWEwZDQyNzUwMzFfMTgtNy0xLTEtMA_70e264b1-1f6d-4d30-90b5-a9fa9504ff9d"
      unitRef="shares">47796957</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesIssued
      contextRef="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xLTEtMS0w_f00a51c6-11ea-433c-834f-a033c9ba16bd"
      unitRef="shares">48958763</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1c27c41d216b4582ab1b5cf2e436fb31_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0zLTEtMS0w_21cd56ec-fcd2-4f13-ac5c-40424811833f"
      unitRef="usd">490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy01LTEtMS0w_9b567c52-d40c-4c7d-9c48-8c4f7483ef0b"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy03LTEtMS0w_5f6f7ce8-d402-4a4c-85b0-c2a8c9235f12"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i251ea0d889734a40a60b2db0510e4d30_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy05LTEtMS0w_33e0ad7a-8ebf-4111-b144-9c56a0f27bc9"
      unitRef="usd">872204000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2c7c0500c96d4870a7cda546e1d57804_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xMS0xLTEtMA_f50f0866-19de-4a7f-949b-776e99c515a8"
      unitRef="usd">-642082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8fbc608a7ebc4a189668ce0d769f101d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xMy0xLTEtMA_b9665053-8b78-4d46-bd33-42ef9f116e7c"
      unitRef="usd">16000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMy0xNS0xLTEtMA_6ea9271e-b16d-462e-80bc-bf5c17d40699"
      unitRef="usd">230628000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNC05LTEtMS0w_b1b52361-3fcd-4925-a92f-fc017ecf088f"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNC0xNS0xLTEtMA_0eca097a-e769-4e78-a9b3-5d0709da2333"
      unitRef="usd">4451000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0xLTEtMS0w_fe0f5225-3e51-4ad0-a9bb-bd4d512f8f1e"
      unitRef="shares">172387</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="if1b581bf1bc641ef957c18ef78c4ab87_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0zLTEtMS0w_8dce5678-0293-4ec2-9f1e-660bf579f89f"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i17e0ecd1abe34c71921eea330795a6d7_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi05LTEtMS0w_ba8529d8-8e81-4cc2-a1d4-8eb2f900c0b3"
      unitRef="usd">160000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNi0xNS0xLTEtMA_00a2614b-03e5-491b-af0a-7971941b87ba"
      unitRef="usd">162000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i5fcac574cbe44ff598b04d63a009d245_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNy0xMy0xLTEtMA_00131269-fb6a-4a40-9700-9b06cf146e2d"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfNy0xNS0xLTEtMA_a43788f9-3d00-418d-a5c1-5f08ca9c1212"
      unitRef="usd">56000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ide541262618d4b8ca172e4936bda305e_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOC0xMS0xLTEtMA_4f51d3b7-271c-4630-8580-30e1c9d229ce"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i49545357e7ce46d4b8f301a8873a49a2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOC0xNS0xLTEtMA_a0650c9f-6b69-4b1c-a116-85fa9156bd15"
      unitRef="usd">-44724000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="iecd98e62333946d2bde73cd3927ee687_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xLTEtMS0w_3d807e6a-93ed-4517-bf8e-b1300ab6e7dc"
      unitRef="shares">49131150</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iecd98e62333946d2bde73cd3927ee687_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0zLTEtMS0w_a8d17daa-b66d-4aa1-95e9-b4496c572d55"
      unitRef="usd">492000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS01LTEtMS0w_43fcb16d-2e7c-4771-8b41-d604cb87d4e8"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS03LTEtMS0w_471c7d27-81c5-4078-bdf7-e14fa710b8e4"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i678618f17ae24eca9cb47796aaaaadc4_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS05LTEtMS0w_3a24ea49-f28a-4a7a-8f8b-5007bbe4cab9"
      unitRef="usd">876815000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5643da10e9664d89a666a86f3de255bf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xMS0xLTEtMA_d57781e1-43f8-42ed-a867-9880007ad024"
      unitRef="usd">-686806000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44b26809617d43939a5329f6885680fd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xMy0xLTEtMA_6f2c8003-caba-4255-8fe9-863c879d5af0"
      unitRef="usd">72000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b6082892bd94f66800a06bc094d50ff_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfOS0xNS0xLTEtMA_64dfd98d-863f-4711-b8b6-9ee8226aad39"
      unitRef="usd">190573000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMS0xLTEtMA_72038cc9-bdcc-4e7d-bc30-e206cbcc4be4"
      unitRef="shares">4060482</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMy0xLTEtMA_5a2d75f5-0a4f-431c-9b12-c4354d163746"
      unitRef="usd">40000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtOS0xLTEtMA_f820a520-54a7-4ef9-8ecc-0ea7672ed964"
      unitRef="usd">96472000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTAtMTUtMS0xLTA_278bc417-f86b-4f8a-a633-3f2e013c4e53"
      unitRef="usd">96512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTEtOS0xLTEtMA_cb2ee657-d8d5-4098-8824-6643b5b4254a"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTEtMTUtMS0xLTA_f519f7c2-9d71-4c91-8c3b-274f42b74f42"
      unitRef="usd">5136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMS0xLTEtMA_ea090d33-8d88-47e8-9ca8-b049641b1604"
      unitRef="shares">173371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i00c44856d98142bf8ceb75a71ea4e836_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMy0xLTEtMA_db847d53-d9ce-43fb-b597-eb459178677c"
      unitRef="usd">2000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i1f3efcae3bac44cfb796f2c71cc7ff83_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItOS0xLTEtMA_b8e00f95-e1af-43f7-be7d-7e089296fefb"
      unitRef="usd">2501000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTItMTUtMS0xLTA_d28cf94c-d383-4ce0-89cd-594e5a1a8373"
      unitRef="usd">2503000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="icc8d7e7284994e3a8718cbc86dddc39c_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTMtMTMtMS0xLTA_41e88a55-776b-40ab-9a95-1308d5fc5408"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTMtMTUtMS0xLTA_cf19b4a8-c8b7-4588-b021-e00529ae5c31"
      unitRef="usd">-55000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="id2918b1588e24443b4687bb092493234_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTQtMTEtMS0xLTA_80d87122-9cb0-4db3-bcec-9663d533c89b"
      unitRef="usd">-46885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9815b310fe4345e6824beaca417eb44e_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTQtMTUtMS0xLTA_d3eb5d0f-d37f-4d2c-beb6-7ef8e228f898"
      unitRef="usd">-46885000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMS0xLTEtMA_159c5e57-b129-4f9b-8934-e0ff3008a0c9"
      unitRef="shares">53365003</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb640ed48fdc4fba99667b0f1f0212c6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMy0xLTEtMA_e7a8293e-f13f-45ef-9dc2-841da3adb3bc"
      unitRef="usd">534000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtNS0xLTEtMA_c6df2a6d-a705-4cd7-8da0-82b7f41dfafb"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtNy0xLTEtMA_08170150-cd87-495f-a8e4-b7854f3aae11"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i118dbb19ee294bef9dff06aee00e80a6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtOS0xLTEtMA_5bea8bca-e09f-4763-beb7-577758ea7855"
      unitRef="usd">980924000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31c17d69a6f44a56a03595fa8f30ca05_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTEtMS0xLTA_5e0b5da4-b8c7-4237-877a-b9fa34f0d6d0"
      unitRef="usd">-733691000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i248e16c8b2404924963b17b9a022deea_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTMtMS0xLTA_6831a198-ea81-4b6c-9529-5554ef083554"
      unitRef="usd">17000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4a65ca63de24c97ba1095455858cfb6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTUtMTUtMS0xLTA_e778c972-a71e-4846-a056-4d8dd3fe5fa2"
      unitRef="usd">247784000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMS0xLTEtNDc2_66502aec-0dd7-47f5-b09a-ba0f10fd9ee6"
      unitRef="shares">2552333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMy0xLTEtNDc2_6b753eed-589e-4b9d-b490-c5ee7802a8fd"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtOS0xLTEtNDc2_1793bc52-79fb-4b6b-a5d5-cc27138a7d8a"
      unitRef="usd">73956000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMTUtMS0xLTUwMg_fa6689f6-88f8-4ed1-a937-0df9be0256a1"
      unitRef="usd">73981000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtOS0xLTEtMA_2e6272e5-2a32-4c0d-894f-2a6333b977d8"
      unitRef="usd">5796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTYtMTUtMS0xLTA_39133654-ab78-4964-b518-ff41f50fe033"
      unitRef="usd">5796000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMS0xLTEtMA_18b795a8-5680-4906-9010-cf095d8dab80"
      unitRef="shares">257596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="id28db8212ed74e888a6a05d24557a148_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMy0xLTEtMA_b8acea12-8f29-4612-a731-b93fb7a72005"
      unitRef="usd">3000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctNS0xLTEtMA_e67806ee-d2d9-4bf6-8f18-2b20254c3051"
      unitRef="shares">74632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctNy0xLTEtMA_de283212-e77c-4adf-901a-be4029300dfa"
      unitRef="usd">-2012000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctOS0xLTEtMA_2704bffa-0195-4e44-abc7-eb777164c1ea"
      unitRef="usd">2091000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTctMTUtMS0xLTA_dc2f35cf-0d26-4ec6-a936-6c0ea5e5a70d"
      unitRef="usd">82000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktNS0xLTEtNDg2_05a7696b-3cd5-4efd-b510-fe73aa7c1c79"
      unitRef="shares">74632</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i79a04baa748a409cac40497b1ac71047_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktNy0xLTEtNDg2_e57a80e4-0e47-470b-83de-35da1e63e29b"
      unitRef="usd">-2012000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ie0e05b9d0cd64611a3c14b470082f4f2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktOS0xLTEtNDg2_315f31cd-fa83-4b07-a9f8-e7166403a766"
      unitRef="usd">2012000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTUtMS0xLTQ5Mw_4fa6c29b-9295-4696-9da4-e76c1be07e35"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ib0034cf911ef4d0987f18fbcf9c12c54_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTgtMTMtMS0xLTA_d9348b4e-9cb7-4711-9011-2adeb93688a7"
      unitRef="usd">-15000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTgtMTUtMS0xLTA_46691ed2-b2a7-418b-b57f-645230d40e6e"
      unitRef="usd">-15000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i89a9947c99a4486786e7e887b223f9bb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTEtMS0xLTA_b55d265f-6452-4533-89a0-b92f8e5d43e7"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMTktMTUtMS0xLTA_851cce80-83fa-4588-8e03-33138ec0f1cc"
      unitRef="usd">-36043000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5da47fec875b45ca8dc4ef858f3b3373_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMS0xLTEtMA_f89ed634-8435-4854-9310-1a01ae2dcfa7"
      unitRef="shares">56174932</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5da47fec875b45ca8dc4ef858f3b3373_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMy0xLTEtMA_09f21b03-88fb-47a7-98e4-3b25a52e3c1c"
      unitRef="usd">562000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtNS0xLTEtMA_532ebafb-3308-4bb3-bbfd-a31cc3178b39"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i93bb0acbca4c41b1918f1063893322c3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtNy0xLTEtMA_271223b0-04aa-4601-9610-e7b130b5ce54"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idfbdee7a4f194e1f886e309d5f57e49c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtOS0xLTEtMA_394fc4b4-5e0f-40ab-97e4-bd4d87cfa8dd"
      unitRef="usd">1060755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f2fcd1d3d2f4c02a9ca03c84aba1084_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTEtMS0xLTA_5f23c13b-4d5e-4f32-9657-347289a370c5"
      unitRef="usd">-769734000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i168d44892dc64bcfa877caa22d4d2f47_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTMtMS0xLTA_0d154991-16b9-4d99-a109-4799a06e5490"
      unitRef="usd">2000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmNiYjAwYmU1YjIwNTRlN2JhNzdjMzViNGY2ZDZiZDkyL3RhYmxlcmFuZ2U6Y2JiMDBiZTViMjA1NGU3YmE3N2MzNWI0ZjZkNmJkOTJfMjAtMTUtMS0xLTA_890908fd-05ed-49ec-abf1-0e6e51a2c29c"
      unitRef="usd">291585000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i99d089ec986c490e9d7a9fe9003fab25_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xLTEtMS0w_a1c80958-5d38-4f49-b3fb-bcc5f7be4340"
      unitRef="shares">42353301</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i99d089ec986c490e9d7a9fe9003fab25_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0zLTEtMS0w_013f241f-3601-422a-8b32-94a1b2521e04"
      unitRef="usd">424000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i772e75c235df4ee2ba9c5db15a74d268_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi05LTEtMS0w_31643560-0236-425b-9f91-21c0b14208e0"
      unitRef="usd">732727000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if99c4563ef8346599f6f5d683f3ab131_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xMS0xLTEtMA_627bae7a-fbd1-4ac3-b3e0-df7a1570a85c"
      unitRef="usd">-490271000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28c7c5e832994f4984a2b72a7c12a323_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xMy0xLTEtMA_56a8bf18-a672-48d9-8c5d-deccdafe8a99"
      unitRef="usd">-3000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85172e0b52c945fcb48567a2d8cd5d66_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMi0xNS0xLTEtMA_d2990a7e-bbf1-4046-9213-ed6f966788b4"
      unitRef="usd">242877000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMy05LTEtMS0w_48141a9c-e3a4-4da4-a429-8bafe47db6b0"
      unitRef="usd">3750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMy0xNS0xLTEtMA_ba94e736-a280-4000-9815-eb9d980bf861"
      unitRef="usd">3750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0xLTEtMS0w_1a394016-e3b7-4193-b8a6-84b94796f6e4"
      unitRef="shares">6325000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0zLTEtMS0w_ddaf502f-8d4f-4007-89d1-ee78505a32ad"
      unitRef="usd">63000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC05LTEtMS0w_ed725939-95b1-4b91-abf8-b162d15ce8ff"
      unitRef="usd">118594000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNC0xNS0xLTEtMA_f1463d2f-db08-4734-9554-36644f18b739"
      unitRef="usd">118657000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0xLTEtMS0w_69f09e1e-1b5e-44fc-b3f6-ab744c08a2f5"
      unitRef="shares">126707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i2a099bff17804023b9870c32927d44b0_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0zLTEtMS0w_1e3a3923-1a7b-4a00-b172-3f09b32b002d"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ie06081cb2c25448c91c08097ce2fcb58_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS05LTEtMS0w_73cbd9d1-9d15-4b61-aa14-719d17e55e6b"
      unitRef="usd">346000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNS0xNS0xLTEtMA_0d4a79e5-fdb5-4757-a537-c843a022f632"
      unitRef="usd">347000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i083e553805e84a4ab30278ee0b21eea1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNi0xMy0xLTEtMA_d80fea2f-10b2-4f2b-9269-605694441ddd"
      unitRef="usd">3000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNi0xNS0xLTEtMA_71704bde-94bc-4c4b-ba42-bf0851ee33e1"
      unitRef="usd">3000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i86bc84252e164a12a5ef77a9c53239ab_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNy0xMS0xLTEtMA_c8548321-b7b2-49dd-8476-43f055214c62"
      unitRef="usd">-45017000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i923dde2fa85e430882f4c005512f9879_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfNy0xNS0xLTEtMA_e088db8b-c5c3-4796-980a-52009aedc90b"
      unitRef="usd">-45017000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i1a85c5a33a1940e686e68c93aa8752a8_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xLTEtMS0w_a209fde7-1b8d-4003-9cc1-1201ae405e61"
      unitRef="shares">48805008</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1a85c5a33a1940e686e68c93aa8752a8_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0zLTEtMS0w_2d059e3b-72cf-481f-a21e-285f368af2d5"
      unitRef="usd">488000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iad99730485234a69afe678ff8b091949_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC05LTEtMS0w_d01d460b-2053-4e74-ade7-c47b0dc9de3f"
      unitRef="usd">855417000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4dde4cd27157467b873b883bcb26a3e4_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xMS0xLTEtMA_395005c8-9f9f-4604-8e7a-c40e567439c1"
      unitRef="usd">-535288000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8dc1dbdce58a458eb5f7eb8d375ea1df_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xMy0xLTEtMA_f79d1ff2-f09c-4d1c-a90f-62601efd452a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i242d9a69e198416fb1411637de6c71d0_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOC0xNS0xLTEtMA_c8b8ec45-55f2-41dc-add7-a0171842fe9c"
      unitRef="usd">320617000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOS05LTEtMS0w_5dc681c3-8998-4709-baf3-fe57b5794fdb"
      unitRef="usd">4933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfOS0xNS0xLTEtMA_56aeebb3-64d6-48c7-b261-53ac55a2cf21"
      unitRef="usd">4933000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMS0xLTEtMA_17bb3d00-ea7a-4d32-a212-d099756a3bb4"
      unitRef="shares">88443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ic90a453edd7244298ec36a8c9f819670_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMy0xLTEtMA_66d20526-8a68-4984-8f71-5159f988421a"
      unitRef="usd">1000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ie841a2119b6b4a188771e2fd3af75e30_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtOS0xLTEtMA_b34a8245-75ce-43d3-8e83-075be8077cae"
      unitRef="usd">633000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTEtMTUtMS0xLTA_13f308da-ba39-4db7-b73c-6b00c62ff7b7"
      unitRef="usd">634000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ifc1b1f56ad824f4d9f74ac2f6154dc3b_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTItMTMtMS0xLTA_748c5577-31d4-44c3-9f7f-154ec41216b3"
      unitRef="usd">34000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTItMTUtMS0xLTA_e783c57e-95fc-4577-8e81-e27bf1092b1c"
      unitRef="usd">34000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="ic22ad87081f44452b54967d211ab676d_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTMtMTEtMS0xLTA_ad4e5444-d26f-4202-b449-b431ac3bd441"
      unitRef="usd">-31767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia50ac5d0e5434c098fcf1ff2b0e915b2_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTMtMTUtMS0xLTA_c550c22e-b565-4df8-9c40-a5c03564d52e"
      unitRef="usd">-31767000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMS0xLTEtMA_f0d13fc1-c141-45f5-abec-3be113837197"
      unitRef="shares">48893451</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4887f435b96c4ff4a1d7ffe55dd2e353_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMy0xLTEtMA_e6886dc2-415f-460f-9242-f1ed15b751a2"
      unitRef="usd">489000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5862997f33c54ac6981fb6685d18aa17_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtOS0xLTEtMA_b1778dad-52f4-453c-9843-e3187ca7b3cb"
      unitRef="usd">860983000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idabb0d4b38a24297a10a88b8c412b614_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTEtMS0xLTA_1856ae7d-5611-4a21-b83f-17b2d3659c36"
      unitRef="usd">-567055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabea7eedc8ed4974a97afbe70ef669e3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTMtMS0xLTA_b8002a8e-859e-4f4f-ad78-6d0772fac2b3"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i52d6b5ad2eb1439ca7b9d6e530b4acd3_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTQtMTUtMS0xLTA_2841c2d3-94c4-492e-9d77-55a9de5b7a35"
      unitRef="usd">294451000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTUtOS0xLTEtMA_0fbcc624-59c5-47e6-b406-6288e5de2e45"
      unitRef="usd">5352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTUtMTUtMS0xLTA_636795f7-4524-4fed-ac96-aef5234c3287"
      unitRef="usd">5352000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i89997c7fe90c43be8e6eac61d5f7f7ce_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtMS0xLTEtMA_6f62aac3-99e5-49d4-a2aa-49bb49e0ac6e"
      unitRef="shares">20833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i0a938ec3caac4332bc3bebec10278f2f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtOS0xLTEtMA_124e03bb-beb1-493d-8dfa-7b7da09f69a0"
      unitRef="usd">37000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTYtMTUtMS0xLTA_a72063ff-2672-43d1-bba4-6ab01a121412"
      unitRef="usd">37000</us-gaap:StockGrantedDuringPeriodValueSharebasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i508ac6b80ba5482fb20c800a957c919f_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTctMTMtMS0xLTA_ba21f8c2-39be-4f5e-8957-622e172a8954"
      unitRef="usd">-11000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTctMTUtMS0xLTA_0a119fd6-537e-4e2d-b5d1-f72163602682"
      unitRef="usd">-11000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="i8a5362c6893440ed81f5656a8c74e7d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTgtMTEtMS0xLTA_bf50c6b8-6f58-4385-b060-89016ca68879"
      unitRef="usd">-44631000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTgtMTUtMS0xLTA_f29e6b08-fbf9-4dc1-be81-5dd166e19d14"
      unitRef="usd">-44631000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5d97bb4ee6084712b486bea7a21d603e_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMS0xLTEtMA_334ff5a7-ac08-493a-9445-3c0ce2a4f7e7"
      unitRef="shares">48914284</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5d97bb4ee6084712b486bea7a21d603e_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMy0xLTEtMA_867930ba-11a3-4221-ad87-8940fba39dee"
      unitRef="usd">489000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11cb9793489f45eeb9391db0da058532_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktOS0xLTEtMA_1db5a425-d508-4b8a-bc00-629ad78f49fb"
      unitRef="usd">866372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0fdf9d4e0da94e1194a5a8b2baceb2c0_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTEtMS0xLTA_397362a8-1fe2-438c-8d6c-1c7789a94c01"
      unitRef="usd">-611686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia192c40bd1d344abbf5835f4a19906fd_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTMtMS0xLTA_9a97e6e9-9793-499c-bb29-40ed0b0a784c"
      unitRef="usd">23000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f1781eeabb7431089fcd817959eee47_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yNS9mcmFnOmQyNzA2ZTZiYmZjZDRlOTZiYzUwYjc3OWQxMWViYTZkL3RhYmxlOmI3YTAxMGFmMGY3NjQ0ZjM4YTZlZTcyZTdlMzRlNTE1L3RhYmxlcmFuZ2U6YjdhMDEwYWYwZjc2NDRmMzhhNmVlNzJlN2UzNGU1MTVfMTktMTUtMS0xLTA_cb901ddc-e14d-4623-b938-ad7791e7aa78"
      unitRef="usd">255198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMy0xLTEtMS0w_1b39f1f7-d2e7-4eac-9cee-26057e3246f9"
      unitRef="usd">-127652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMy0zLTEtMS0w_535c0e1c-e082-4f80-a679-c8b11297f909"
      unitRef="usd">-121415000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNS0xLTEtMS0w_cfc7827e-db8d-4adb-afe8-a51601317951"
      unitRef="usd">9067000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNS0zLTEtMS0w_27d0eb37-151f-445d-95bf-b2647b3f4f25"
      unitRef="usd">9238000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNi0xLTEtMS0w_ce24182b-b0f1-4cec-a5e9-9f30045f5299"
      unitRef="usd">387000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNi0zLTEtMS0w_9ac25814-57e5-44c5-ae79-7c632e5cd5c4"
      unitRef="usd">1119000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNy0xLTEtMS0w_c9eed6ea-7473-4ad2-83e1-826b5b86201a"
      unitRef="usd">15419000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfNy0zLTEtMS0w_72a31af9-52fa-4616-ba78-12bb7b4db3d2"
      unitRef="usd">14081000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfOS0xLTEtMS0w_94cd0a85-ac36-4aa0-8e2f-039953f8b353"
      unitRef="usd">6033000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfOS0zLTEtMS0w_ec3fc70e-3d60-44d4-b9cd-64d4150fe0a4"
      unitRef="usd">-20080000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTAtMS0xLTEtMA_74ed6a08-0ac6-4257-b5b4-e08bed9d8529"
      unitRef="usd">-654000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTAtMy0xLTEtMA_90ea6401-66c5-41d9-a6b6-c7ec09a2a503"
      unitRef="usd">5612000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTEtMS0xLTEtMA_0a4987ac-4d46-44e7-9efa-cd9016b1847f"
      unitRef="usd">-1615000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTEtMy0xLTEtMA_1d53c372-80d1-4c00-b41c-bf535ece141e"
      unitRef="usd">2621000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTItMS0xLTEtMA_3132e7ff-3b18-4ce1-b110-42f29ad8b458"
      unitRef="usd">137000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTItMy0xLTEtMA_6bb232b3-1ce1-4372-b68e-c11acd5f5510"
      unitRef="usd">-913000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTMtMS0xLTEtMA_16dcf26a-91ea-4417-b938-60a56348c37d"
      unitRef="usd">5499000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTMtMy0xLTEtMA_7912d293-5dda-4510-9751-25f4f907343b"
      unitRef="usd">-4678000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTQtMS0xLTEtMA_bc0314cb-c083-4082-bf64-8ed18d30e3d3"
      unitRef="usd">-2113000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <mgnx:IncreaseDecreaseInLeaseLiabilities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTQtMy0xLTEtMA_7bd7b841-8c19-40b2-9b2a-3ed07bd7588e"
      unitRef="usd">3847000</mgnx:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTUtMS0xLTEtMA_6ba8e841-c7d5-48ad-84c9-bdd37ecf3686"
      unitRef="usd">-4816000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTUtMy0xLTEtMA_e1617f57-faba-4393-b460-f0180e962f34"
      unitRef="usd">-7114000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTYtMS0xLTEtMA_58c61fe1-b7e3-45e5-8f83-97b2001d4f32"
      unitRef="usd">2245000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTYtMy0xLTEtMA_7dc5a36a-c723-46b2-aa55-fefe0374a6ba"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTctMS0xLTEtMA_e653a6db-5550-4cec-9d3a-a58e5e75e7ba"
      unitRef="usd">-106365000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTctMy0xLTEtMA_567a0973-84bd-4705-9da5-70032130e58f"
      unitRef="usd">-96226000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTktMS0xLTEtMA_f33e2f93-cbb2-482d-97f7-a09df75afac8"
      unitRef="usd">151230000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMTktMy0xLTEtMA_ff1cd014-fbb2-4c48-a24b-2943c2b6a36d"
      unitRef="usd">214178000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjAtMS0xLTEtMA_79f14aba-baf4-49d2-a545-976df7829cd7"
      unitRef="usd">161866000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjAtMy0xLTEtMA_9d017467-c1d4-4e89-8ef0-0b41558f282d"
      unitRef="usd">130236000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjEtMS0xLTEtMA_380d1bb2-5268-4764-9ede-55a895f3e9ac"
      unitRef="usd">2346000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjEtMy0xLTEtMA_0a78e0b1-cd9d-4e35-a441-ec072f55e412"
      unitRef="usd">3042000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjItMS0xLTEtMA_fbe06c56-18ae-4045-9880-a197d58f0f64"
      unitRef="usd">8290000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjItMy0xLTEtMA_fd0735c2-c80e-4e50-9282-9ab130421717"
      unitRef="usd">-86984000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjQtMS0xLTEtMA_843dd71b-edf0-4875-a217-95962cee9a88"
      unitRef="usd">170494000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjQtMy0xLTEtMA_2518b2b7-d813-4b9c-806e-72612c2edd17"
      unitRef="usd">118657000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjUtMS0xLTEtMA_635d4080-04b8-4c54-8cfd-a9c1e276f810"
      unitRef="usd">4757000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjUtMy0xLTEtMA_f364283f-fc27-4a21-8cb2-d075d8db421b"
      unitRef="usd">1018000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
    <mgnx:RetirementOfTreasuryStock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMS0xLTEtODE0_334805bf-dfb4-4532-933a-dfab0c02e14c"
      unitRef="usd">2011000</mgnx:RetirementOfTreasuryStock>
    <mgnx:RetirementOfTreasuryStock
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMy0xLTEtODE0_1080eb17-3f56-4d91-9a98-e96439130b89"
      unitRef="usd">0</mgnx:RetirementOfTreasuryStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMS0xLTEtMA_f66266bd-00b5-4ee0-a8bf-2d9d81087951"
      unitRef="usd">173240000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjYtMy0xLTEtMA_f74d0017-6949-4d01-992f-5d891bc9dbae"
      unitRef="usd">119675000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjctMS0xLTEtMA_c0d68bac-5745-4dc2-a1f3-b6c879c78045"
      unitRef="usd">75165000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjctMy0xLTEtMA_300a1d62-f36c-4ccb-b4b7-bd502f902917"
      unitRef="usd">-63535000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjgtMS0xLTEtMA_03784b8c-0c8c-4032-89b3-e16030808bb4"
      unitRef="usd">126472000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i85172e0b52c945fcb48567a2d8cd5d66_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjgtMy0xLTEtMA_a6bbfb69-dcca-4866-a94b-29caf3a23dd9"
      unitRef="usd">220128000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjktMS0xLTEtMA_a75aeaa7-2ee0-4843-b661-ad8b9a947551"
      unitRef="usd">201637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2f1781eeabb7431089fcd817959eee47_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMjktMy0xLTEtMA_b5d8681e-caee-43f3-822d-4bff400ef90b"
      unitRef="usd">156593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMzItMS0xLTEtMA_4565438e-c593-4763-988e-11e83590742e"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8yOC9mcmFnOmQwNjE3M2M5OTNlODRlOTNiYmNmNWI4ZTliNDkyYmVlL3RhYmxlOjBhYmE5NTQ1ODYzMjQxYzY4ODExMzFkZjJkZjM4YWY1L3RhYmxlcmFuZ2U6MGFiYTk1NDU4NjMyNDFjNjg4MTEzMWRmMmRmMzhhZjVfMzItMy0xLTEtMA_81b9cb73-8cff-4c0c-ac53-2cad755bbca1"
      unitRef="usd">6408000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNC9mcmFnOjdhODgyOTE5MTc3MTRkNTM5YWRjMmVhZjhiODAzMjY2L3RleHRyZWdpb246N2E4ODI5MTkxNzcxNGQ1MzlhZGMyZWFmOGI4MDMyNjZfMzAxMw_e0f3a4a4-4cc3-43a1-a7d4-3491ca48ea01">Basis of Presentation and Risks and Uncertainties&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. To date, although there has been some negative impact on the Company's business and operations, including, for example, slowed clinical trial enrollment, the Company has been able to mitigate against more severe impacts of COVID-19 on its business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on the Company's business in the future depending on the depth of the effects and the duration of the crisis. The COVID-19 pandemic is an evolving situation and the Company continues to monitor its business very closely to try and mitigate any potential impacts. Significant delays in the timing of the Company's clinical trials and in regulatory reviews could adversely affect its ability to commercialize the product candidates in the Company's pipeline. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notwithstanding the foregoing, the Company cannot precisely predict the impact that COVID-19 will have in the future due to numerous uncertainties, including the severity of the disease, the duration of the outbreak, actions that may be taken by governmental authorities, and the impact to the business of the Company's supply chain. Given these uncertainties, COVID-19 could disrupt the business of certain of the Company's collaborators and impact the Company's business operations and its ability to execute on the Company's associated business strategies and initiatives, and adversely impact the Company's consolidated results of operations and/or the Company's financial condition in the future. The Company will continue to closely monitor and evaluate the nature and extent of the impact of COVID-19 to its business, consolidated results of operations, and financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNC9mcmFnOjdhODgyOTE5MTc3MTRkNTM5YWRjMmVhZjhiODAzMjY2L3RleHRyZWdpb246N2E4ODI5MTkxNzcxNGQ1MzlhZGMyZWFmOGI4MDMyNjZfMzAxMA_c55df289-40f0-4818-bf10-fea4da0dd2a8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNy9mcmFnOmExNzk1Nzg2ODcyMzRlMWY5MjBjYTA5MTZmYmY1M2FlL3RleHRyZWdpb246YTE3OTU3ODY4NzIzNGUxZjkyMGNhMDkxNmZiZjUzYWVfNDAyNA_ce1def6c-8e6a-4ea6-ba63-f2603a30766a">Summary of Significant Accounting Policies&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2016-13) during the nine months ended September 30, 2020, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 4, Marketable Securities, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2020 on a prospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2018-18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2020 on a retrospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV8zNy9mcmFnOmExNzk1Nzg2ODcyMzRlMWY5MjBjYTA5MTZmYmY1M2FlL3RleHRyZWdpb246YTE3OTU3ODY4NzIzNGUxZjkyMGNhMDkxNmZiZjUzYWVfNDAyNQ_d59bc1fd-f8c1-4558-bfea-00132ba8f076">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (FASB) issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13,&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 4, Marketable Securities, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles - Goodwill and Other - Internal-Use Software&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Internal-Use Software&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2020 on a prospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808)&#x2014;Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted ASU 2018-18 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on January 1, 2020 on a retrospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements&lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMzEzNA_fb8795f6-7154-480d-b1cf-2bd49714bf4e">Fair Value of Financial Instruments&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at September&#160;30, 2020 includes approximately $64.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between levels during the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMzEzNg_6abea33a-e684-47f6-b079-9cbc338be5e8">&lt;div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active Markets for Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(b)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(a) Total assets measured at fair value at September&#160;30, 2020 includes approximately $64.5 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2f3d327578eb4a8fad5a02f88b706a81_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC0xLTEtMS0w_0bcf9e8d-64d4-4545-a2aa-977fe2af7d5a"
      unitRef="usd">45708000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i61390568815449f1b203b09838077cfd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC0zLTEtMS0w_2bfed584-4730-4be2-8241-efb72e39a042"
      unitRef="usd">45708000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ifef9401807084084b4cfcd1497fbd03b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC01LTEtMS0w_53970d09-e5c4-4831-8c45-395994272ed0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i18bc51ed445347d490417a0086d4ec6c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNC03LTEtMS0w_14f6a226-8fd2-4a7e-80af-f29994c593bd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1f44ee2b6604e6faceef147adab156b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS0xLTEtMS0w_cf31e817-c614-4b66-97dc-3311b49f26c6"
      unitRef="usd">60005000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib02652ca68b840fdb8345db6c3943506_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS0zLTEtMS0w_567df5c3-f665-4c58-abcc-c34ebfb1739a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95c791bd80414458bf798e3a5c8371ca_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS01LTEtMS0w_266a4158-7355-4d59-bbf5-2b3a1f716e16"
      unitRef="usd">60005000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i53df1531613345a4a20cd107a152c452_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNS03LTEtMS0w_a7d600e7-6175-4fc2-bf2e-575ba40645be"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i50a90c0416934ef191dae9248e6bd343_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi0xLTEtMS0w_de293367-0f0c-42bf-b5e1-b2ee35575f04"
      unitRef="usd">14007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3cd3e5b6f3bb423cb9c8241c4629352a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi0zLTEtMS0w_4a5855cc-4104-4806-a11b-bb6ec64b29c6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i853b145d4b5d4ff887fe3c813723757a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi01LTEtMS0w_370d3450-9fea-4e27-890e-62a74c61e7c3"
      unitRef="usd">14007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia965ddea0c0d4929bcaaf10ab3dce00d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNi03LTEtMS0w_0e390615-cf6c-4e88-ab87-b2bc2bffb393"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i429a8d866ab94f0887344d549058d4a7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy0xLTEtMS0w_4e56a813-ec58-4f73-88b1-8603f1f487e9"
      unitRef="usd">23759000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i367e0e3322684eb693f6e0db308b49be_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy0zLTEtMS0w_7edb4668-c366-4fc8-b129-1e31e1996fc6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0dd66a09550047b488eecee849d1ab89_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy01LTEtMS0w_da325c16-bae6-40cf-8296-3763fc3faaba"
      unitRef="usd">23759000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i351eacc89eba4a779a3a805096b50266_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfNy03LTEtMS0w_7ed813c8-2eae-4c3e-b656-aa93739f81b3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0e1427f09d0a4d849022fa592d4e2510_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS0xLTEtMS0w_a2eba3ce-5806-4072-a34f-f19cd2169217"
      unitRef="usd">143479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd24cb204af040a1896e0e2e134b823c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS0zLTEtMS0w_4b3bece0-9c2a-4539-a26c-73328f566c59"
      unitRef="usd">45708000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7eee048bc9214fcebfa85d929a62359a_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS01LTEtMS0w_efa9a05e-1e18-4f13-b55d-1845a72aab94"
      unitRef="usd">97771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5637258cb9f467daa8468f96fe90010_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQzZTQ3N2RkMWQ3ZjQ2ZmQ4NmM2YTcwOTEwMzZkOGFhL3RhYmxlcmFuZ2U6NDNlNDc3ZGQxZDdmNDZmZDg2YzZhNzA5MTAzNmQ4YWFfOS03LTEtMS0w_6aa913bf-8984-455b-8b6e-f5a8528543f1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i76651544b7ed4a3aaf1e1ad08d30d686_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC0xLTEtMS0w_4886a80c-cf32-4832-90d2-084a4cc6e514"
      unitRef="usd">46149000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i96cf5c6e27734accb1a3e05be19371c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC0zLTEtMS0w_66d86f52-43a0-462c-864e-0e996129d3da"
      unitRef="usd">46149000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i631c1559593f4350a22a93d85ffed1de_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC01LTEtMS0w_f95f5aa9-8b6c-4e16-8318-c8170c42f458"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i661301857c8140fcace77bc9000a2645_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNC03LTEtMS0w_0d01522c-6eb2-483b-9d39-31f6a77f9583"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4617b92aae94471a82ddc03195cb0603_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS0xLTEtMS0w_c86a0fd9-0b3b-4fc1-b38b-bdc139869266"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifff3a59bcb8f40719209839b68d4b087_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS0zLTEtMS0w_644192b1-8ead-4337-9719-d6c400a96054"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14cdb49cd71144059cc61727bd2504b3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS01LTEtMS0w_192032ae-74ae-45e8-b3ba-02ba98c93eae"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07e730e5685e4559a024b11728b95988_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNS03LTEtMS0w_2a3b3a67-7062-4f3c-b154-79a3665a9c90"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8ac12fb37dda4afa812ff75ecbb55b47_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi0xLTEtMS0w_c8b6edbd-5096-4ae0-bcef-2db73549904f"
      unitRef="usd">103135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i930b7f72b4454a8986e9888ac10ffc56_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi0zLTEtMS0w_fcd0529a-677c-4678-be7c-dbd0f9c3e16e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8dc5e6a1bc8c48528ef4028801eaf60f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi01LTEtMS0w_48df6d5c-9dcf-496f-bfb8-e30d26cab997"
      unitRef="usd">103135000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i92b7234ef3f94f8f922de6a29f863ef0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNi03LTEtMS0w_8019cbbe-fb7f-46af-9725-0d002e70e107"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy0xLTEtMS0w_c402f025-19fe-41fc-a37f-5d7ce02144a6"
      unitRef="usd">162506000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iac0308dd5c1146fd864acc4473bd9d02_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy0zLTEtMS0w_2a8616e7-e06c-44fe-98da-c27a91358386"
      unitRef="usd">46149000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id98a1eb125924f9ebae87f7340768587_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy01LTEtMS0w_e9fc825c-45e4-4c87-88ce-4f9c8a0591fe"
      unitRef="usd">116357000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4064a77523204a5c97651a32d316bd67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RhYmxlOjQ3NjdmMDlkZmRjNzRmMTVhYzQ1ZDVkYWYzNjE0YTM0L3RhYmxlcmFuZ2U6NDc2N2YwOWRmZGM3NGYxNWFjNDVkNWRhZjM2MTRhMzRfNy03LTEtMS0w_5f85afad-8654-4538-b422-4deaa301374d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0e1427f09d0a4d849022fa592d4e2510_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMjUzNg_a0164729-7e5d-4d5f-9d2a-b929f9143ece"
      unitRef="usd">64500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib6e9b0870b6b4dd2b74dfc92276c16db_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80MC9mcmFnOmRjOTY4ZWU3YjcwZTQ3N2ViNjY4YzU0OWJjOTYzOTUwL3RleHRyZWdpb246ZGM5NjhlZTdiNzBlNDc3ZWI2NjhjNTQ5YmM5NjM5NTBfMjY4MQ_078c632b-bf48-4cfb-9d38-2ef5a13960fa"
      unitRef="usd">73200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfMTE3Ng_4c8d4dcc-b602-46f8-b760-baf29a754297">Marketable Securities&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt and equity securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;All available-for-sale marketable debt securities held as of September&#160;30, 2020 and December&#160;31, 2019 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the nine months ended September 30, 2020. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. No losses related to other-than-temporary impairments of our available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended December&#160;31, 2019</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AvailableForSaleSecuritiesTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfMTE3Nw_cd1564a2-d939-4416-a4b5-1d5e4910f74b">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the Company's marketable debt and equity securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.877%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.247%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:0.297%"/&gt;&lt;td style="width:0.0%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.855%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.244%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.798%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.801%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi0xLTEtMS0w_cd7ddf8e-32e7-4e9c-b222-1c6d90fd2149"
      unitRef="usd">60003000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi0zLTEtMS0w_2e46a61b-baf6-4494-b629-562b6f032594"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi01LTEtMS0w_9add6272-7fb5-44a4-9857-03608984e3c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic0ffe118db724b5ea85a3f2b9dbf15cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMi03LTEtMS0w_a8a90f8d-7be0-42dc-8ad4-6e8cd68e1166"
      unitRef="usd">60005000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i57bf751d79c94691b038938d560d3571_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy0xLTEtMS0w_1be289fb-bcd3-416d-abd1-cc322bcf2f48"
      unitRef="usd">14006000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i57bf751d79c94691b038938d560d3571_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy0zLTEtMS0w_29a673e3-8811-49ce-9c51-bf842253b2c0"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i57bf751d79c94691b038938d560d3571_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy01LTEtMS0w_e7218f50-8e51-4653-97e2-0a1863d8a0ba"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57bf751d79c94691b038938d560d3571_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfMy03LTEtMS0w_519a4e15-cfb4-4729-9da0-168a42479360"
      unitRef="usd">14007000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC0xLTEtMS0w_5b7b7c73-24dd-4e54-9c0d-ff9c5300b296"
      unitRef="usd">5010000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC0zLTEtMS0w_15ae06bf-44ca-4658-a271-bc7addba0f0b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC01LTEtMS0w_443643b9-908f-467c-8975-b0bf32c3b937"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f31f74c1a5c4b5eb4a05adf5855dd85_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNC03LTEtMS0w_b0c352fa-0edf-4951-a20d-9c706171ff0f"
      unitRef="usd">5010000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS0xLTEtMS0w_bad3a63c-6247-463b-baa0-828134561c78"
      unitRef="usd">79019000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS0zLTEtMS0w_a9b0b75c-dd82-464d-a077-8e5fed5de066"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS01LTEtMS0w_166d5476-e896-40f5-b4d0-e00c1354ba91"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOjI3N2QyMWIwZGRiYzRhN2FhYzZlOTA3MDI4M2Y3ZWFiL3RhYmxlcmFuZ2U6Mjc3ZDIxYjBkZGJjNGE3YWFjNmU5MDcwMjgzZjdlYWJfNS03LTEtMS0w_e11dddaf-0e19-4b4d-ac3d-7a21641f1ee4"
      unitRef="usd">79022000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi0xLTEtMS0w_6912cbd3-65ff-44d9-bf03-a35051dc5d45"
      unitRef="usd">13216000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi0zLTEtMS0w_efefe1cb-96ed-4054-809b-eab9c28c1fc1"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi01LTEtMS0w_f437d520-4ca6-482b-aa91-ecf929c8a3aa"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3c7c8218ffeb4024b44e5ecc01780199_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMi03LTEtMS0w_d649b639-fb99-47d9-ae38-c42060c6cbc1"
      unitRef="usd">13222000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy0xLTEtMS0w_bb4e403d-e937-4c68-b7b9-523d5d57a3ab"
      unitRef="usd">76052000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy0zLTEtMS0w_91d076db-ba6f-43af-8f6c-f8672dd8e9d5"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy01LTEtMS0w_44604e36-a5ef-44e7-83c9-2fbaa3e5bc84"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i35a3cd8f7d1f4fada8159926a4db0c5d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfMy03LTEtMS0w_51828cfe-d662-4960-9532-f78697bd576f"
      unitRef="usd">76062000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC0xLTEtMS0w_2bd91a92-8f8c-4a90-bf80-b099b5511ba7"
      unitRef="usd">89268000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC0zLTEtMS0w_e6e4415b-b42b-49a9-b4a6-ffb561bee910"
      unitRef="usd">26000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC01LTEtMS0w_1fe808ac-8880-4302-8293-468a3847fe49"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RhYmxlOmZiYmUxYmI3ODlmZDQ5ZDNiNmM2N2Y0ZmYxMGE0MjQ5L3RhYmxlcmFuZ2U6ZmJiZTFiYjc4OWZkNDlkM2I2YzY3ZjRmZjEwYTQyNDlfNC03LTEtMS0w_a8659ffb-0bd3-4b84-abb5-7d4384495346"
      unitRef="usd">89284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfNjgy_4e16a7b9-5193-4df1-939c-90a6f90dd0f1"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80My9mcmFnOmYyOTUwNTQ3YWQ2MTRkNDg5ZWQwMmYzZTA0NWE0ZjM1L3RleHRyZWdpb246ZjI5NTA1NDdhZDYxNGQ0ODllZDAyZjNlMDQ1YTRmMzVfOTk4_3afeda88-0f1f-46c1-8153-5bd77ca6a166"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTUzMg_0c27e777-1473-47fb-8585-539de16f89a9">Stockholders' Equity&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company completed a &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;firm-commitment underwritten public&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#x2019;s common stock at a price of $20.00 per share. The Company received net proceeds of approximately $118.7 million from this offering, net of underwriting discounts and commissions and other offering expenses.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0 million through an &#x201c;at the market offering&#x201d; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0 million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on December 23, 2019. During the nine months ended &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2020&lt;/span&gt;, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5 million, pursuant to the ATM Offering.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTQ0_024f218e-3d00-482e-9137-bbab5cc417ea"
      unitRef="shares">5500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="iec648d78c60f46bdb12dc3ce89f30a15_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTg4_3fcd6491-9f86-485f-9836-96ddcaaaf05d"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i97dd199628d2445cb4a47064a0b74d6a_D20190201-20190228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMzQ1_a1f62f33-a586-4819-90f6-3f441278d2f2"
      unitRef="shares">825000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i44e22609aae84c4ba9ad609e47840e0d_I20190228"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMzk5_32cf95ce-e6bc-4bb5-97d2-321578691d8c"
      unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfNDY0_703aa4ef-23e3-4bc8-90e5-ae1e1765f34a"
      unitRef="usd">118700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="i6514c468c9e740d6b1d05c92467a1618_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfNzEy_078d2e58-a6c4-4d94-acf9-dd9466990341"
      unitRef="usd">50000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <mgnx:CommonStockMaximumAmountAvailableForIssuance
      contextRef="ia2d7928761a04561a98b1772b844011e_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfOTI2_4e96a68d-8d83-4463-9b4c-b215b88dbedb"
      unitRef="usd">175000000.0</mgnx:CommonStockMaximumAmountAvailableForIssuance>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTE4OA_4fa0b3e2-4344-4635-93c0-c0a8d6c32dc4"
      unitRef="shares">6612815</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i2f6e1c1422a241b7865adbaac8d439a6_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTI1NQ_ac71a723-b7b5-43cd-a7b1-d1f496259e9d"
      unitRef="usdPerShare">26.46</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i1c8ce594f7d741d3bcd3d98559397e32_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80Ni9mcmFnOmQ5M2MxZmZlY2U1OTRmNDk4MGU5ZWU2N2ZjOTFmNzFiL3RleHRyZWdpb246ZDkzYzFmZmVjZTU5NGY0OTgwZTllZTY3ZmM5MWY3MWJfMTMwMg_656f4897-b851-4adb-8cdc-f48a69b82cb5"
      unitRef="usd">170500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjQ2Mzk_d7e5949e-302f-4130-8fdc-00a72d29c8d0">Collaboration and Other Agreements &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Incyte Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From its inception through &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September&#160;30, 2020&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company has recognized $30.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Incyte License Agreement under the provisions of ASU No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling $15.0 million related to retifanlimab meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three months ended September 30, 2020, it became probable that a significant reversal of cumulative revenue would not occur for a $15.0 million development milestone related to the initiation of a Phase 3 clinical trial of retifanlimab.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  The Company recorded a receivable as of September 30, 2020 and the milestone payment was received in October 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized over a period spanning 2017 and 2018.  The Company recognized $15.0 million in development milestone revenue during the three and nine months ended September 30, 2020.  No revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2019.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#x2019;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $0.7 million and $4.9 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $8.1 million and $13.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to September 30, 2020, the Company entered into a commercial supply agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#x2019;s obligation to pay royalties under the Incyte License Agreement.  The Incyte Commercial Supply Agreement also includes customary provisions relating to, among others, production forecasting, delivery, inspection procedures, warranties, confidentiality and indemnification.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Zai Lab&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#x2019;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly MGD013), a bispecific DART&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#x2019;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#x2019;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#x2019;s territory, which may be subject to adjustment in specified circumstances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#x2019;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  The Company recognized no revenue during the three months ended September 30, 2020 and recognized revenue of  $4.0 million during the three months ended September 30, 2019 under the Zai Lab Agreement.  The Company recognized revenue of $3.6 million and $12.1 million during the nine months ended September&#160;30, 2020 and 2019, respectively, under the Zai Lab Agreement.  Revenue recognized during the nine months ended September 30, 2020 reflected milestone revenue, whereas revenue during the nine months ended September 30, 2019 was the recognition of the deferred upfront payment.  At September&#160;30, 2020 and December&#160;31, 2019, $5.0 million of revenue was deferred under this agreement, all of which was current.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#x2019;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2020, the Company recognized revenue of $0.5 million and $1.9 million, respectively, related to the Zai Lab Clinical Supply Agreements.  No such revenue was recognized during the three and nine months ended September 30, 2019.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I-Mab Biopharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#x2019;s territory, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#x2019;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $1.0 million and $0.6 million, respectively, under the I-Mab Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $3.5 million and $0.6 million, respectively, under the I-Mab Agreement. At September&#160;30, 2020, $10.0 million of revenue was deferred under this agreement, $4.3 million of which was current and $5.7 million of which was non-current.   At December&#160;31, 2019, $13.5 million of revenue was deferred under this agreement, $4.4 million of which was current and $9.1 million of which was non-current.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Provention Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of $2.50 per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#x2019;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#x2019;s common stock at an exercise price of  $2.50 per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  As of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale in July 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NIAID Contract&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The NIAID Contract includes a base period of up to $7.5 million to support development of MGD014 through Investigational New Drug application submission with the U.S. Food and Drug Administration, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024.  In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  The Company recognized revenue  under the NIAID Contract of $0.8 million during each of the three month periods ended September&#160;30, 2020 and 2019.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue under the NIAID Contract of $6.2 million and $1.5 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Boehringer Ingelheim International GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to the adoption of ASC Topic 606 on January 1, 2018. The remaining obligations under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   In June 2020, BII agreed to a payment of $12.0 million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0 million during the nine months ended September 30, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;</mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i2a91773145ff4dc6bed1e4e7d3de5929_D20171001-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk3_b38063a4-9e36-425e-bfe3-cac97175fef1"
      unitRef="usd">150000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfOTM5_396def02-00a5-486c-8f77-d711949953e2"
      unitRef="usd">420000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfOTkz_24daf51a-8070-4f9c-90e2-df531e40b847"
      unitRef="usd">330000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic13ad679ef8a4def92ebbc15dce2b871_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA2Mw_5c16007d-4bb0-4bd0-9b5f-0a5eed39a4a5"
      unitRef="usd">30000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i9e29c2c5bc4b44648d0a8b577e42de39_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI0Mg_5c2377da-cd92-434d-9daa-268997f9317d"
      unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="if59acebf30ba44029fdad1f534a68269_D20171001-20171031"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI0OA_3c0c2478-ac65-4842-9b59-c042b60ca012"
      unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i0d800a4cc7cd4980bee11f68119d53b4_I20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjg3NQ_7b24288c-888b-4b1f-b83b-e2f135c0f7e9"
      unitRef="usd">154000000.0</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ia791781a92464af29c8f02db3c401ab8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDQ3OQ_a60358fc-4cab-44b5-a828-e44213d747e1"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA3OA_24130a8f-a2a4-40c2-bd76-0928899df77b"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ2OTA3OA_f0636448-7266-4f47-a14f-e9855b3500ee"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="i88964468ab69431eaebd92a52277944f_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDgwMw_04323558-e59a-49b5-8792-ea9970565e01"
      unitRef="usd">150000000.0</us-gaap:Revenues>
    <mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
      contextRef="i4e228120dad34e57a7e7cdf18d7fa48d_D20171001-20171031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNDkyOA_dd70c239-ae21-47af-8417-6d8ebae729ed"
      unitRef="usd">4000000.0</mgnx:RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="iccf9ad15d778492ca10ae383c74e813b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MTYxOA_24130a8f-a2a4-40c2-bd76-0928899df77b"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ib617b7609d60412291d9bfee2d3cfa8c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MTYxOA_f0636448-7266-4f47-a14f-e9855b3500ee"
      unitRef="usd">15000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:Revenues
      contextRef="iea44bd2966be41888177853b425961ff_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTAyMg_8fd253d6-134d-41ec-ad13-cd928b469c2a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8bc7d94081d340628b9b2a71457956e1_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTAyMg_e6a8d026-8449-4fa5-aea3-2aadb2e90ca6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8aff2b8c451a486ca958bc76fd5a67bb_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTk2NQ_b7d67b0c-ba4e-4028-8d29-3701190cd24c"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a340d54cb3d485989696d575daa8669_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNTk3Mg_ace10586-ffe3-499f-a4d8-c9d283576b4b"
      unitRef="usd">4900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie54ccd6d1f4249b7b4f1ac381f526911_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjExNA_517f7e12-a1dc-4f2b-9484-ab5b860d241d"
      unitRef="usd">8100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61e7d81a9da347bb85af6348231a2bab_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjEyMQ_38acd4ae-7c3c-45c4-b01a-d5fb2decc70f"
      unitRef="usd">13100000</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk4Ng_d13cf34c-d7f0-487f-9fa6-1d27794d8a27"
      unitRef="usd">25000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNjk5MA_5b419c1c-3fc5-47e5-9407-125d4f5f38a2"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:NonrefundablePaymentTaxWithholding
      contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzAzOQ_36073dc1-a9ff-42e0-9efc-9558a291406e"
      unitRef="usd">2500000</mgnx:NonrefundablePaymentTaxWithholding>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzE4MA_33e84f4b-ab9a-4965-86ce-38b7b4e2f1f5"
      unitRef="usd">140000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <us-gaap:Revenues
      contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzIyNQ_588ba1f9-7ed0-4168-9c8e-c64d702f7d2e"
      unitRef="usd">4000000.0</us-gaap:Revenues>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzIzOA_37905c2b-efe4-4c1b-bbfa-e56fb32f4fc0"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesTaxWithholding
      contextRef="idf737413de474782a8fc7cf9729fbd92_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzI4Nw_61a89bae-86e1-4bdf-9292-33cb7ab7f4a4"
      unitRef="usd">400000</mgnx:RevenuesTaxWithholding>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="if3132c81f87a4d99ba4f564ef87782a6_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzQxMw_6c05ab87-58a1-42e1-b9b2-385d123b2bb6"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i2b16f811de98474199d531dece74437d_D20181101-20181130"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzUzMQ_d0c2bb17-f6d6-4eb9-8aea-f7170cf04e6d"
      unitRef="number">0.10</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding
      contextRef="ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfODgyMQ_5b419c1c-3fc5-47e5-9407-125d4f5f38a2"
      unitRef="usd">22500000</mgnx:NonrefundableUpfrontFeesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="ifd4f369c54f94171ad9af39bc0da5bbe_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA4MDg_351fc606-6871-4d60-b248-b5edf114a657"
      unitRef="usd">0</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="id2a7aa88cb654aa884f7e855835ec390_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA4NjA_3a011e0c-454d-462f-b7c9-59d4dca7b135"
      unitRef="usd">4000000.0</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i8f6d41510162452d9a466e6c347714d1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA5NDE_6fe6efd9-affb-48d1-80c5-019f49a55450"
      unitRef="usd">3600000</mgnx:RevenuesNetOfTaxWithholding>
    <mgnx:RevenuesNetOfTaxWithholding
      contextRef="i61ca4c82e803497f86944bb5582a02f0_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTA5NDg_d4ca4e19-32ed-47e0-8b6a-cfc5c7628f61"
      unitRef="usd">12100000</mgnx:RevenuesNetOfTaxWithholding>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5e461a0cdef74333a6a3069cedba5031_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTExOTM_454da658-f5ff-457c-b3ef-a939c3b72b17"
      unitRef="usd">5000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i4dc7cde86ba24a4eaa1971e4016a35b7_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTExOTM_9577764b-e9c9-4970-8b95-63d38510cf76"
      unitRef="usd">5000000.0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:Revenues
      contextRef="i107f7d71e8f24667bb86b994ab1d73a1_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIxNTA_e5b01eb1-b2af-438e-b033-e5cda6f4bde5"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i314a584979b14a389f3c5d964af2863f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIxNTc_92f38317-cbc9-468f-8e01-42f6f75bf949"
      unitRef="usd">1900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i36d284e79f3044a3ac9625ecf4e891e2_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIyMjc_64776b78-7dce-429a-8cf5-c9cd7d4595a7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1ac8ba9b2e14e9493c732eb3111af36_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTIyMjc_8e4b07c7-2f51-4a41-9b72-7a2630954655"
      unitRef="usd">0</us-gaap:Revenues>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTI5NTU_d92bdd92-b6de-4de5-acfe-9ba1c49b42f2"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i3ea3b158fb7c41879720382aa02de77b_I20190709"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTMwNjQ_ed175b0b-b4e6-4da1-9608-b85a76990391"
      unitRef="usd">135000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:ProceedsfromRoyaltiesPercent
      contextRef="i5f9cc003f349478ca3ed4fe7c6abc14e_D20190701-20190731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTMxOTM_8cf07965-3159-4b8b-b086-f06e148d66d0"
      unitRef="number">0.20</mgnx:ProceedsfromRoyaltiesPercent>
    <mgnx:NonRefundableUpfrontFees
      contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTM5OTQ_d92bdd92-b6de-4de5-acfe-9ba1c49b42f2"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount
      contextRef="ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTQ0MDk_6feee8db-7d45-4cb6-99ab-3c1caf7a7872"
      unitRef="usd">1000000.0</mgnx:RevenueInformationUsedToAssessVariableConsiderationAmount>
    <us-gaap:Revenues
      contextRef="i695b50b168414938849dea296be40228_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU4MzI_44c0fbba-01f7-4392-b059-c5036437799b"
      unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie164583eab6942249da5bef115ef55e3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MjgzMQ_30544851-904d-4c22-93b7-50f4d899f23d"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68ecfdcfeec84c4ea913ab203c146751_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MzAxNg_d2254e3a-5d76-44e5-ae7e-3d0f218fbaa2"
      unitRef="usd">3500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia8369f5a9bc24605bd6959601bb26575_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY0OTI2NzQ3MzAyMQ_2de57425-9283-4860-97f7-bf2268cfb145"
      unitRef="usd">600000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU5NDg_1309d1bd-1e2a-4f09-8624-39c83ad89036"
      unitRef="usd">10000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTU5OTc_6ca39ac5-2596-46fd-b94a-6b046f5cb980"
      unitRef="usd">4300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i8fb7e409d6b245e5b347e1f893c44d97_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYwMjU_07b2ca5d-783e-4bd9-b0ef-2634028eac12"
      unitRef="usd">5700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYwNjM_3b51a75b-5024-4adf-b5c9-ac084e0c94ee"
      unitRef="usd">13500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYxMTI_0fa267da-e726-4f7c-b0c5-34afc1cb26ef"
      unitRef="usd">4400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i339805cc81504f138bc5f596b75adf4a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTYxNDA_41e0c435-68a3-4cdb-a7bc-3077b8825e78"
      unitRef="usd">9100000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="ib280116fa7124f13b35c12a7dd273e86_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY3MzY_9b75d7ab-1c51-4f77-adfa-8de11747909c"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i57e35a0253554ab4b773d0e5048648bb_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY4OTY_e3eb9186-9f51-461d-bfd8-b9adfa4570bb"
      unitRef="usd">65000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i57e35a0253554ab4b773d0e5048648bb_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTY5NTA_d122b48a-0ef5-4108-87f1-5ed07c143108"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare
      contextRef="i398326bccf184051bda69d4a3c8a1a33_D20180531-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTc5Nzk_8fe48a58-9903-45a1-9457-afdaec4320fd"
      unitRef="usdPerShare">2.50</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare>
    <mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement
      contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTgxMzg_5b9ac2d6-7547-4fd9-b130-2cea6c55de11"
      unitRef="usd">170000000.0</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
    <mgnx:PotentialCommercialMilestonePaymentsUnderAgreement
      contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTgxNzY_60b599d0-f344-4fd5-88d4-1e8bf3412268"
      unitRef="usd">225000000.0</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
    <mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement
      contextRef="i280712410840475fadcbe6d4b410e8e6_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTg2MzM_54803e41-c199-4a0f-904f-9e28547fc8a8"
      unitRef="usd">1300000</mgnx:PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement>
    <mgnx:NumberOfPerformanceObligations
      contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTkyMzU_e6a7977d-d196-4699-8823-469cb85d837d"
      unitRef="performance_obligation">2</mgnx:NumberOfPerformanceObligations>
    <mgnx:CollaborativeAgreementTransactionPrice
      contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTk0Mjg_d5c4db7f-e416-40a3-b6af-49ee9e4db3be"
      unitRef="usd">6100000</mgnx:CollaborativeAgreementTransactionPrice>
    <mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares
      contextRef="i456c33b61451427ebca4b6600c9eeb6f_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMTk0OTc_97be503d-04df-4177-b031-ab84581135d7"
      unitRef="shares">2432688</mgnx:CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares>
    <us-gaap:Revenues
      contextRef="i709d5a4375bc46bfa8eb06e60b804476_D20180701-20180930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjA0MzU_0fd786a1-98c6-44f9-aa2f-3bd26befc7ae"
      unitRef="usd">6100000</us-gaap:Revenues>
    <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement
      contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjEzNDg_70f1794d-b07d-4a05-bdd7-2ee6117fdc95"
      unitRef="molecule">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
    <mgnx:FundedValueOfBasePeriod
      contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjE5MTQ_6e4485d9-dc1b-4b13-8f74-37e828895823"
      unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
    <mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIwNjc_435647ab-d601-4611-8b0c-ed6d447ec443"
      unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
    <mgnx:TotalPotentialValueUnderAgreement
      contextRef="ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIyMTU_c9513d20-f0b3-4278-8b40-fab435f3f672"
      unitRef="usd">24500000</mgnx:TotalPotentialValueUnderAgreement>
    <mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement
      contextRef="i17e4e3bc99de4302af0c36215cc08f6f_D20170101-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjIzNjY_9d18b83f-7d45-408d-a98f-9d3623c98075"
      unitRef="usd">10800000</mgnx:ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement>
    <us-gaap:Revenues
      contextRef="i084bc672cb2542ee93482822566c90cd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI1NTE_b93c7368-2897-4fa6-84ad-c71f2183e2e0"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ec7e2284b474d4997d8410cdd14f1b7_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI1NTE_fac37b82-fa54-427d-86dc-9fdae6dbdb92"
      unitRef="usd">800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied5a5d5f59e0443393b8732129f9e130_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI2NTk_f835e8d7-276b-4c70-b18e-45f2e6639206"
      unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8e1a76d57ce94e01be30cf3cfa42cd5e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjI2NjY_1755c02a-3135-4b77-87b4-560dbd4cf2a6"
      unitRef="usd">1500000</us-gaap:Revenues>
    <mgnx:CollaborationAndLicenseAgreementTerm
      contextRef="i8e5332870f4e4706a838787952f9124b_D20101001-20151031"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfNzE0NjgyNTYxMzQ4MQ_548736bb-4990-4846-9b83-39619acf921f">P5Y</mgnx:CollaborationAndLicenseAgreementTerm>
    <mgnx:NumberOfProductCandidates
      contextRef="ib37d01f8e8ec44a3b82be406e14e4895_I20151031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjMyNjc_24d5438c-41fa-41a4-a571-bef9fb6a1912"
      unitRef="numberofproductcandidates">2</mgnx:NumberOfProductCandidates>
    <mgnx:NonRefundableUpfrontFees
      contextRef="i8e5332870f4e4706a838787952f9124b_D20101001-20151031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM0MDE_fbed070d-edb6-47e1-975d-c8156a20b482"
      unitRef="usd">15000000.0</mgnx:NonRefundableUpfrontFees>
    <mgnx:DevelopmentMilestonesAmount
      contextRef="i5be796f261a24d47bb6a08dee44be3f7_D20200601-20200630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM3MTg_b1370e0a-a9ba-4d55-8286-dc5d60126845"
      unitRef="usd">12000000.0</mgnx:DevelopmentMilestonesAmount>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="ic8506fff30e343c0a108eac7ddb6eb91_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM4NDE_9765df0e-5a90-47ce-8fac-44f4dee1e069"
      unitRef="usd">12000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized
      contextRef="i682bc99e203a470fadd9467ce13ac26a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV80OS9mcmFnOjA2NzYyNWFjZDk4NzRlZjhiMjczZGE5ZWU3NWE5NmU1L3RleHRyZWdpb246MDY3NjI1YWNkOTg3NGVmOGIyNzNkYTllZTc1YTk2ZTVfMjM4NDE_acf9b8b3-d0d1-48a8-832e-d789afe17191"
      unitRef="usd">12000000.0</mgnx:DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzMg_76b6253f-7c93-4ca4-bf75-b774603456cf">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company&#x2019;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#x2019;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2020, 18,304 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.3&#160;million.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2020, under the 2003 Plan, there were options to purchase an aggregate of 259,904 shares of common stock outstanding at a weighted average exercise price of $2.73 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 11,896,613.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2020, there were options to purchase an aggregate of 7,079,313 shares of common stock outstanding at a weighted average exercise price of $22.10 per share under the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.7% - 76.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  &lt;/span&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#x2019;s common stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(735,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,339,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $10.50 and $14.33, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $3.9 million and $2.8 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $4.5 million and $0.7 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2020 and 2019 was approximately $12.4 million and $12.8 million, respectively. As of September&#160;30, 2020, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $31.7 million, which the Company expects to recognize over a weighted-average period of approximately 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, there was $2.8 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of one year.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i651dacb02b694c7cab3fc1042896bf4d_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDI3_8d90901b-c5b3-4289-8ec7-671d6d485efe"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNjI2_a6b7510a-da76-483e-80a8-8341034a5f7d"
      unitRef="number">0.10</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ie7c537115e304d87a177a55fcb518a9a_D20170501-20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfODcz_80c3b7a7-0555-49a7-92c0-cc36fdcf5ebc"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTAwMw_3e7c6e7c-5875-414c-9383-29cc8e595566"
      unitRef="shares">18304</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ProceedsFromStockPlans
      contextRef="id7fb24f30d204876a84e6b3a8220d36f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTExMw_492abd2d-0d2b-4be8-9517-5de72fe3230e"
      unitRef="usd">300000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i4659cc916dd3432aa5e78628aca3effd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTk3Nw_d5b36a01-ded1-4da9-88bf-6f1fa2cf6883"
      unitRef="shares">259904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i4659cc916dd3432aa5e78628aca3effd_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjA1NQ_588131ad-b865-4981-b5c5-418b9c97fa52"
      unitRef="usdPerShare">2.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance
      contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjQ2Nw_f3630760-ab81-4abe-be7b-f6deac8fa8a5"
      unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
    <mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan
      contextRef="i35072c1e740040a296f33ad007daa74c_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjQ4Mg_91973734-ff0e-48b6-a14d-20b019649244"
      unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMjgzNA_ea128ab6-b9ba-485f-9eb8-3ec53f9b9515"
      unitRef="shares">11896613</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMzQxMA_60e9db47-52b1-410f-9b95-4f05cb7bcbf2"
      unitRef="shares">7079313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i301496abba464d8a8e453d6ff8bba901_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMzQ4OA_5675c424-5b36-485c-8350-0fc70d6bd31a"
      unitRef="usdPerShare">22.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkyOA_013e3f37-5846-4260-b262-c1523194f6c4">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following stock-based compensation expense was recognized for the periods indicated (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.121%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.437%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.731%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7d3cb74cabac4267807f2a0c571ab8f3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi0xLTEtMS0w_7d9ba0eb-c930-4753-acff-c93804b1d736"
      unitRef="usd">3059000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib3c10bc20e144f36b196b86ec9fb610e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi0zLTEtMS0w_11f8b06d-2a01-4d92-808d-a23cba4bae5c"
      unitRef="usd">2765000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9ba2e860df1846c29d00f140ae5dfa0e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi03LTEtMS0w_0f6367b8-96ef-4c26-bc88-f8cefc79a361"
      unitRef="usd">8082000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i267ca7ed35444cc1a4d6d12768b9c471_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMi05LTEtMS0w_b5a7a5b9-26c6-47bf-9c3a-b7072e6a5301"
      unitRef="usd">7032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icb3041645d5148e2885536c8ef463ce0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy0xLTEtMS0w_6e09f41e-eef0-4c1e-a749-71b976cd4308"
      unitRef="usd">2773000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie09d12dbaa6c4616ae1d1ef7740fb483_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy0zLTEtMS0w_3d4b34a1-c014-4ffe-9376-cdeabfae4cbc"
      unitRef="usd">2633000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic4b36cc5e5fa4780a5d86d9a4a7471c5_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy03LTEtMS0w_d36ee2d5-8895-4eb0-ab12-8f64e72da926"
      unitRef="usd">7337000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i328732a3cf7940cca770d218ab8234b5_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfMy05LTEtMS0w_7fefd8e9-c534-4ca0-9c56-3cda18ebcd3a"
      unitRef="usd">7049000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC0xLTEtMS0w_d523a1da-ad5e-4b45-9c6e-aff0f954138b"
      unitRef="usd">5832000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i92d4b77d2ca844548424ca7accfb84cf_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC0zLTEtMS0w_45c9d45d-9b50-4903-b201-b9b8bb2e6150"
      unitRef="usd">5398000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC03LTEtMS0w_663095ef-9483-4609-8def-00bc157ca0e4"
      unitRef="usd">15419000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjM4YTA0ZWU4M2I0ZDQyZTY5NmUyMGEzZDhjM2Q2YzZiL3RhYmxlcmFuZ2U6MzhhMDRlZTgzYjRkNDJlNjk2ZTIwYTNkOGMzZDZjNmJfNC05LTEtMS0w_c305ac69-df20-43fa-b86c-4953748896c9"
      unitRef="usd">14081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNA_b2e116db-e905-4df0-9a61-dc78f153d602">&lt;div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.391%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.667%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67.3% - 109%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.7% - 76.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4% - 1.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4% - 2.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.25 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMi0xLTEtMS0w_9745c0c1-3596-4357-87ac-1c72c5db5b2b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMi0zLTEtMS0w_292208cd-c1f9-4c3b-8e9b-eb580d0a1fb3"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0xLTEtMS0wL3RleHRyZWdpb246NjdjYzlmNTJmODY4NDVjZmI5OGI0NzYwYjlhNDkwNjZfNA_61d1355e-fe40-4140-b828-fbc9381c6284"
      unitRef="number">0.673</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0xLTEtMS0wL3RleHRyZWdpb246NjdjYzlmNTJmODY4NDVjZmI5OGI0NzYwYjlhNDkwNjZfOQ_4e4e890f-d679-4221-94c2-e6eefefacab8"
      unitRef="number">1.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0zLTEtMS0wL3RleHRyZWdpb246NDQ0YjkyYjlkMDUzNDFjN2I0N2Y1NGZhYWYwMzVkMjZfNA_53421dff-00b3-4c47-86a1-63a4ee9c9c09"
      unitRef="number">0.737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfMy0zLTEtMS0wL3RleHRyZWdpb246NDQ0YjkyYjlkMDUzNDFjN2I0N2Y1NGZhYWYwMzVkMjZfOQ_946ecaa8-34d7-4314-84f1-32da891d37ba"
      unitRef="number">0.766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i354e55f2af3b4e2e8f359b4ee7c09756_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0xLTEtMS0wL3RleHRyZWdpb246NDBhYzI4MzU4MjQwNDU1Njg4MjIwYjVjMmM0ZmIzMTFfNA_28d0290f-526d-4abb-b724-e290f0403666"
      unitRef="number">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iaa40a9460c034aae97f88571e02ed238_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0xLTEtMS0wL3RleHRyZWdpb246NDBhYzI4MzU4MjQwNDU1Njg4MjIwYjVjMmM0ZmIzMTFfOQ_a40af749-db8b-427c-a6fa-3e3c90ca2067"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1b2405936d854f6293bdc9c39eb11210_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0zLTEtMS0wL3RleHRyZWdpb246YzUzOTg2ZjY3MjgyNDBjN2FiMzFiZGYzZTQ3MzlmNDNfNA_166883c7-fd5d-4544-a441-0f151d90c203"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ide2a7547a55c41699b6e2fbe9af24359_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNC0zLTEtMS0wL3RleHRyZWdpb246YzUzOTg2ZjY3MjgyNDBjN2FiMzFiZGYzZTQ3MzlmNDNfOQ_352c2ce9-4c93-4f07-90fb-b6d87893ffeb"
      unitRef="number">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNS0xLTEtMS0w_0b613e4b-2541-41da-96e1-e3ba02b88b35">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOmI4OWRmY2ZiOTM5ZDRlMjBiNTI5ZjFhZTQ5Njg5Y2Q1L3RhYmxlcmFuZ2U6Yjg5ZGZjZmI5MzlkNGUyMGI1MjlmMWFlNDk2ODljZDVfNS0zLTEtMS0w_fe1b829e-53ae-4090-8fa7-83f9cdca870e">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNQ_b56ccca3-d1bb-4c92-9688-8b4276fd94bf">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity during the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:27.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Term&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt; (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,706,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,816,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(448,732)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(735,322)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,339,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;As of September 30, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,407,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,027,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS0xLTEtMS0w_257cf022-b2f8-4806-a86e-944b768a1d75"
      unitRef="shares">6706994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id03af012974e455383bba3223db02d75_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS0zLTEtMS0w_f75807d0-924d-418d-b995-5113631295e1"
      unitRef="usdPerShare">22.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4cbec8f71f2e4f048a9703c07efe16f0_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMS01LTEtMS0w_61aa6698-7684-4914-be8c-827e6ea14fe6">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMi0xLTEtMS0w_af45b475-4987-4300-9b06-9733f1a482eb"
      unitRef="shares">1816277</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMi0zLTEtMS0w_3b259571-ea8c-45be-b7c1-06d6bdde3314"
      unitRef="usdPerShare">14.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMy0xLTEtMS0w_60a35602-c0ac-4579-817e-53555d42825b"
      unitRef="shares">448732</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfMy0zLTEtMS0w_97a6a12f-e940-4983-9e9d-d9a6f36805a2"
      unitRef="usdPerShare">9.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNC0xLTEtMS0w_8da24896-ab65-4cb9-9981-2c45f0f26cae"
      unitRef="shares">735322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNC0zLTEtMS0w_6c263d7d-13ab-4261-966a-141d9a7f0e6e"
      unitRef="usdPerShare">20.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS0xLTEtMS0w_2e830dad-9e86-46ef-ba0f-d33e9f003f22"
      unitRef="shares">7339217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS0zLTEtMS0w_80dbedc5-ed31-4071-a162-552de44d3f12"
      unitRef="usdPerShare">21.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS01LTEtMS0w_54a500fb-ca27-4d56-8f30-1ed37a88bb86">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNS03LTEtMS0w_e3ab26a0-8321-4bc0-92d2-fcd71a9adeaf"
      unitRef="usd">39014000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy0xLTEtMS0w_7da8ceae-d97d-4517-b759-5e74a4ce1fec"
      unitRef="shares">4407713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy0zLTEtMS0w_ca540fdc-4b59-49f9-8881-2172ddc5e5f1"
      unitRef="usdPerShare">23.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy01LTEtMS0w_27ec35fc-adf5-4897-9a97-454a77e48269">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfNy03LTEtMS0w_57bdb772-04f1-411a-8ff2-d2c68a42d7b4"
      unitRef="usd">18806000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC0xLTEtMS0w_af8a58f3-026b-410a-ae01-db64b06e926b"
      unitRef="shares">7027237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC0zLTEtMS0w_9a88fe6f-0669-41db-b49d-49fcf4c09533"
      unitRef="usdPerShare">21.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC01LTEtMS0w_1a18f6a2-9625-4da9-a472-7d0367539a6b">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjA3MjViNTMzMDdjMTQ0NGZhZTA1NjdlZTIyMDM0MGI5L3RhYmxlcmFuZ2U6MDcyNWI1MzMwN2MxNDQ0ZmFlMDU2N2VlMjIwMzQwYjlfOC03LTEtMS0w_7af57eca-27af-404a-ba0b-a1fb811194fb"
      unitRef="usd">36973000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDU3Mg_3dfae3f0-13e4-4658-970c-58f339b8d873"
      unitRef="usdPerShare">10.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDU3OQ_0d242eeb-f7d7-48f8-a843-ecfdbc2ee964"
      unitRef="usdPerShare">14.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDcxNA_257cc411-69d1-4d1e-8fef-aa3f25d92a7a"
      unitRef="usd">3900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfMTA5OTUxMTYzMzgzNg_4586cd7c-c1d5-4381-b167-40bcaa35b44c"
      unitRef="usd">2800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDgyMA_1ebf86ad-58b2-438f-b2fb-eda945842e5f"
      unitRef="usd">4500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDgyNw_61e812bc-5b6c-4460-bee9-3766d7265baf"
      unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDkzNQ_fdfddc5e-630f-4483-8d90-1e1b812dc7c8"
      unitRef="usd">12400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNDk0Mg_e62b3545-11a6-4279-a3ab-51eeaf23402a"
      unitRef="usd">12800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i656b1702d3e14be0be6085d06cdf2c30_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTEwNA_d0a8e77c-5d62-47fb-baec-d93848323da6"
      unitRef="usd">31700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTE5NQ_30740122-a96c-4041-b8a7-afd96268495e">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTkzNg_920d18de-4013-4a9c-acc0-40a92306c35e">&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes RSU activity during the nine months ended September&#160;30, 2020:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.178%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(210,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ied85acb778bf4e98a18112866d8afde5_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMS0xLTEtMS0w_d39d846d-ea2a-4dea-adff-e349df15c3d9"
      unitRef="shares">452500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ied85acb778bf4e98a18112866d8afde5_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMS0zLTEtMS0w_2f90164c-e14c-45e5-b9c1-f483b570e2e3"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMi0xLTEtMS0w_11835122-ea34-4a14-af65-771c4a8a0b36"
      unitRef="shares">15000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMi0zLTEtMS0w_f5417f51-1fdb-41bb-9e9a-9a7e1f26f177"
      unitRef="usdPerShare">23.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMy0xLTEtMS0w_0d4067f3-5ebc-4ca4-bf7d-2052c26df18e"
      unitRef="shares">210950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfMy0zLTEtMS0w_45bb7b18-6ac5-4930-b9c2-43c625b75d32"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNC0xLTEtMS0w_783eaa4c-212d-4fd9-8067-40c8e6eabd91"
      unitRef="shares">40950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNC0zLTEtMS0w_e478d2dc-5095-4472-8200-e8481e48b43b"
      unitRef="usdPerShare">15.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNS0xLTEtMS0w_e4f2191f-3d42-4b2c-b218-7834296564f3"
      unitRef="shares">215600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RhYmxlOjU1NjcwNGMzYmUzNzQ5M2FiZWY3ZmY5NjUxNWM5NjY1L3RhYmxlcmFuZ2U6NTU2NzA0YzNiZTM3NDkzYWJlZjdmZjk2NTE1Yzk2NjVfNS0zLTEtMS0w_86888352-3925-450c-a286-57b920932dbf"
      unitRef="usdPerShare">15.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="id3f7b7f171b04570abfa521633907fa0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNTc2OA_e22334cb-ed0a-430f-a680-d8a1d79bcda3"
      unitRef="usd">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idf5bb52011cc454e83c5730e50f17f5e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81Mi9mcmFnOjExMDFhZmI4ZGFmNDQzY2NhZGFjODZiNWEzYjQyMmVlL3RleHRyZWdpb246MTEwMWFmYjhkYWY0NDNjY2FkYWM4NmI1YTNiNDIyZWVfNzE0NjgyNTU4Njc2NA_dd094552-319e-4b17-abad-faaf1642cd24">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOjgzN2Q5NzVjMDY4ZjQxYWE5OTdjOTdjNDBkOGJiY2Q1L3NlYzo4MzdkOTc1YzA2OGY0MWFhOTk3Yzk3YzQwZDhiYmNkNV81NS9mcmFnOjg5NGFlNWZhMjdkNjQ5YzM4YjhjMjQzZWM2ODM4MWJlL3RleHRyZWdpb246ODk0YWU1ZmEyN2Q2NDljMzhiOGMyNDNlYzY4MzgxYmVfOTY1_bf346bcb-5bed-4fb3-ae82-6d96cd1df0ba">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#x2019;s SOPHIA trial.   On August 17, 2020, the Employees&#x2019; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760913584664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Oct. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1591613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9704 Medical Center Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">251-5172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MGNX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,204,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760913619800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 201,637<span></span>
</td>
<td class="nump">$ 126,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Marketable securities</a></td>
<td class="nump">79,022<span></span>
</td>
<td class="nump">89,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">18,777<span></span>
</td>
<td class="nump">12,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">10,632<span></span>
</td>
<td class="nump">11,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">310,068<span></span>
</td>
<td class="nump">239,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">41,423<span></span>
</td>
<td class="nump">48,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">22,889<span></span>
</td>
<td class="nump">24,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">374,380<span></span>
</td>
<td class="nump">312,501<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,380<span></span>
</td>
<td class="nump">4,308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">32,674<span></span>
</td>
<td class="nump">27,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">9,259<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">3,808<span></span>
</td>
<td class="nump">3,020<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">50,121<span></span>
</td>
<td class="nump">45,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">5,778<span></span>
</td>
<td class="nump">9,153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">24,651<span></span>
</td>
<td class="nump">27,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">82,795<span></span>
</td>
<td class="nump">81,873<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,174,932 and 48,958,763 shares outstanding at September&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,060,755<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(769,734)<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">291,585<span></span>
</td>
<td class="nump">230,628<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 374,380<span></span>
</td>
<td class="nump">$ 312,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760907579352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">56,174,932<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760913554632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,656<span></span>
</td>
<td class="nump">44,852<span></span>
</td>
<td class="nump">150,901<span></span>
</td>
<td class="nump">143,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,732<span></span>
</td>
<td class="nump">11,833<span></span>
</td>
<td class="nump">30,181<span></span>
</td>
<td class="nump">34,174<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">54,388<span></span>
</td>
<td class="nump">56,685<span></span>
</td>
<td class="nump">181,082<span></span>
</td>
<td class="nump">177,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(36,135)<span></span>
</td>
<td class="num">(37,944)<span></span>
</td>
<td class="num">(128,890)<span></span>
</td>
<td class="num">(138,530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="nump">92<span></span>
</td>
<td class="num">(6,687)<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">17,115<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,043)<span></span>
</td>
<td class="num">(44,631)<span></span>
</td>
<td class="num">(127,652)<span></span>
</td>
<td class="num">(121,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (36,058)<span></span>
</td>
<td class="num">$ (44,642)<span></span>
</td>
<td class="num">$ (127,666)<span></span>
</td>
<td class="num">$ (121,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per common share (in usd per share)</a></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (2.49)<span></span>
</td>
<td class="num">$ (2.54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">54,463,412<span></span>
</td>
<td class="nump">48,902,766<span></span>
</td>
<td class="nump">51,176,884<span></span>
</td>
<td class="nump">47,796,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember', window );">Revenue From Collaborative Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 17,415<span></span>
</td>
<td class="nump">$ 17,984<span></span>
</td>
<td class="nump">$ 46,018<span></span>
</td>
<td class="nump">$ 37,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember', window );">Revenue From Government Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 757<span></span>
</td>
<td class="nump">$ 6,174<span></span>
</td>
<td class="nump">$ 1,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromCollaborativeAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenueFromGovernmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906195336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 732,727<span></span>
</td>
<td class="num">$ (490,271)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">118,657<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,805,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2019</a></td>
<td class="nump">320,617<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,417<span></span>
</td>
<td class="num">(535,288)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,353,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">242,877<span></span>
</td>
<td class="nump">$ 424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">732,727<span></span>
</td>
<td class="num">(490,271)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(121,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,914,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">255,198<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,372<span></span>
</td>
<td class="num">(611,686)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,805,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2019</a></td>
<td class="nump">320,617<span></span>
</td>
<td class="nump">$ 488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,417<span></span>
</td>
<td class="num">(535,288)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">634<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,893,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2019</a></td>
<td class="nump">294,451<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">860,983<span></span>
</td>
<td class="num">(567,055)<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,914,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2019</a></td>
<td class="nump">255,198<span></span>
</td>
<td class="nump">$ 489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,372<span></span>
</td>
<td class="num">(611,686)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,724)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,958,763<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 230,628<span></span>
</td>
<td class="nump">$ 490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">872,204<span></span>
</td>
<td class="num">(642,082)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="nump">1,816,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (127,652)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,174,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">291,585<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060,755<span></span>
</td>
<td class="num">(769,734)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,131,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">190,573<span></span>
</td>
<td class="nump">$ 492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">876,815<span></span>
</td>
<td class="num">(686,806)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,060,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">96,512<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">2,503<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,365,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">247,784<span></span>
</td>
<td class="nump">$ 534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980,924<span></span>
</td>
<td class="num">(733,691)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,552,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">73,981<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,596<span></span>
</td>
<td class="nump">74,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation', window );">Stock plan related activity</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (2,012)<span></span>
</td>
<td class="nump">2,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,012<span></span>
</td>
<td class="num">(2,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,043)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,174,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 291,585<span></span>
</td>
<td class="nump">$ 562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,060,755<span></span>
</td>
<td class="num">$ (769,734)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 30<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121321822&amp;loc=d3e3913-113898<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121323062&amp;loc=d3e15009-113911<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760905855784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (127,652)<span></span>
</td>
<td class="num">$ (121,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">9,067<span></span>
</td>
<td class="nump">9,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="num">(387)<span></span>
</td>
<td class="num">(1,119)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">15,419<span></span>
</td>
<td class="nump">14,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(6,033)<span></span>
</td>
<td class="nump">20,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">654<span></span>
</td>
<td class="num">(5,612)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="num">(2,621)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable</a></td>
<td class="nump">137<span></span>
</td>
<td class="num">(913)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">5,499<span></span>
</td>
<td class="num">(4,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(2,113)<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(4,816)<span></span>
</td>
<td class="num">(7,114)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(106,365)<span></span>
</td>
<td class="num">(96,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(151,230)<span></span>
</td>
<td class="num">(214,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sale and maturities of marketable securities</a></td>
<td class="nump">161,866<span></span>
</td>
<td class="nump">130,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,346)<span></span>
</td>
<td class="num">(3,042)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">8,290<span></span>
</td>
<td class="num">(86,984)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">170,494<span></span>
</td>
<td class="nump">118,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">4,757<span></span>
</td>
<td class="nump">1,018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RetirementOfTreasuryStock', window );">Retirement Of Treasury Stock</a></td>
<td class="num">(2,011)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">173,240<span></span>
</td>
<td class="nump">119,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">75,165<span></span>
</td>
<td class="num">(63,535)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">126,472<span></span>
</td>
<td class="nump">220,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">201,637<span></span>
</td>
<td class="nump">156,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets modified in exchange for operating lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,408<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RetirementOfTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Retirement Of Treasury Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RetirementOfTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760905047240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Risks and Uncertainties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Risks and Uncertainties</a></td>
<td class="text">Basis of Presentation and Risks and Uncertainties<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to additional risks and uncertainties due to the COVID-19 pandemic. To date, although there has been some negative impact on the Company's business and operations, including, for example, slowed clinical trial enrollment, the Company has been able to mitigate against more severe impacts of COVID-19 on its business and operations.  However, the COVID-19 pandemic could have a more significant negative impact on the Company's business in the future depending on the depth of the effects and the duration of the crisis. The COVID-19 pandemic is an evolving situation and the Company continues to monitor its business very closely to try and mitigate any potential impacts. Significant delays in the timing of the Company's clinical trials and in regulatory reviews could adversely affect its ability to commercialize the product candidates in the Company's pipeline. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, the Company cannot precisely predict the impact that COVID-19 will have in the future due to numerous uncertainties, including the severity of the disease, the duration of the outbreak, actions that may be taken by governmental authorities, and the impact to the business of the Company's supply chain. Given these uncertainties, COVID-19 could disrupt the business of certain of the Company's collaborators and impact the Company's business operations and its ability to execute on the Company's associated business strategies and initiatives, and adversely impact the Company's consolidated results of operations and/or the Company's financial condition in the future. The Company will continue to closely monitor and evaluate the nature and extent of the impact of COVID-19 to its business, consolidated results of operations, and financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903468456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the exception of the adoption of Accounting Standards Update (ASU) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2016-13) during the nine months ended September 30, 2020, discussed below, there have been no material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature </span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 4, Marketable Securities, for additional information.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a prospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a retrospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:12pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903350488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text">Fair Value of Financial Instruments<div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for recurring and non-recurring fair value measurements in accordance with Financial Accounting Standards Board Accounting Standards Codification (ASC) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity - e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</span></div><div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:30.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2020 includes approximately $64.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 securities is determined from market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between levels during the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903531080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text">Marketable Securities<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.247%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,003&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:53.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table>All available-for-sale marketable debt securities held as of September&#160;30, 2020 and December&#160;31, 2019 had contractual maturities of less than one year.  All of the Company's available-for-sale marketable debt securities in an unrealized loss position as of September&#160;30, 2020 and December&#160;31, 2019 were in a loss position for less than 12 months.&#160; Unrealized losses on available-for-sale debt securities as of September&#160;30, 2020 were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities.  Accordingly, no allowance for credit losses related to the Company's available-for-sale debt securities was recorded for the nine months ended September 30, 2020. We do not intend to sell these investments and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. No losses related to other-than-temporary impairments of our available-for-sale debt securities were recorded in Accumulated other comprehensive income during the year ended December&#160;31, 2019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903350488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company completed a </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">firm-commitment underwritten public</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offering, in which the Company sold 5,500,000 shares of its common stock at a price of $20.00 per share. Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional 825,000 shares of the Company&#8217;s common stock at a price of $20.00 per share. The Company received net proceeds of approximately $118.7 million from this offering, net of underwriting discounts and commissions and other offering expenses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock in amounts of up to $50.0 million through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended. This agreement was amended in June 2020 to increase the  maximum amount of the offering to $175.0 million. The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on December 23, 2019. During the nine months ended </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020</span>, the Company sold 6,612,815 shares of common stock at a weighted average price per share of $26.46, resulting in net proceeds of approximately $170.5 million, pursuant to the ATM Offering.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903468456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text">Collaboration and Other Agreements <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incyte Corporation</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for retifanlimab  (formerly known as MGA012 and INCMGA0012), an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1) (Incyte License Agreement). Incyte has obtained exclusive worldwide rights for the development and commercialization of retifanlimab in all indications, while the Company retains the right to develop its pipeline assets in combination with retifanlimab.  Under the terms of the Incyte License Agreement, Incyte paid the Company an upfront payment of $150.0 million in 2017.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Incyte License Agreement, Incyte will lead global development of retifanlimab.  Assuming successful development and commercialization of retifanlimab by Incyte, the Company could receive up to approximately $420.0 million in development and regulatory milestones and up to $330.0 million in commercial milestones. From its inception through </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2020</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has recognized $30.0 million in development milestones under the Incyte License Agreement.  If retifanlimab is commercialized, the Company would be eligible to receive tiered royalties of 15% to 24% on any global net sales. The Company retains the right to develop its pipeline assets in combination with retifanlimab, with Incyte commercializing retifanlimab and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global commercial supply needs of retifanlimab, subject to the separate commercial supply agreement. Finally, Incyte funded the Company's activities related to the ongoing monotherapy clinical study and will continue to fund certain related clinical activities.  </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Incyte License Agreement under the provisions of ASU No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and all related amendments (collectively, ASC 606) and identified the following two performance obligations under the agreement: (i) the license of retifanlimab and (ii) the performance of certain clinical activities through a brief technology transfer period.  The Company determined that the license and clinical activities are separate performance obligations because they are capable of being distinct, and are distinct in the context of the contract. The license has standalone functionality as it is sublicensable, Incyte has significant capabilities in performing clinical trials, and Incyte is capable of performing these activities without the Company's involvement; the Company is performing the activities during the transfer period as a matter of convenience.  The Company determined that the transaction price of the Incyte License Agreement at inception was $154.0 million, consisting of the consideration to which the Company was entitled in exchange for the license and an estimate of the consideration for clinical activities to be performed.  The transaction price was allocated to each performance obligation based on their relative standalone selling price.  The standalone selling price of the license was determined using the adjusted market assessment approach considering similar collaboration and license agreements.  The standalone selling price for the agreed-upon clinical activities to be performed was determined using the expected cost approach based on similar arrangements the Company has with other parties.  The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, as they were determined to relate predominantly to the license granted to Incyte and, therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. During the year ended December 31, 2018, it became probable that a significant reversal of cumulative revenue would not occur for three development milestones totaling $15.0 million related to retifanlimab meeting certain clinical proof-of-concept criteria.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  During the three months ended September 30, 2020, it became probable that a significant reversal of cumulative revenue would not occur for a $15.0 million development milestone related to the initiation of a Phase 3 clinical trial of retifanlimab.  Therefore the associated consideration was added to the estimated transaction price and was recognized as revenue.  The Company recorded a receivable as of September 30, 2020 and the milestone payment was received in October 2020.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized the $150.0 million allocated to the license when it satisfied its performance obligation and transferred the license to Incyte in 2017.  The $4.0 million allocated to the clinical activities was recognized over a period spanning 2017 and 2018.  The Company recognized $15.0 million in development milestone revenue during the three and nine months ended September 30, 2020.  No revenue was recognized under the Incyte License Agreement during the three and nine months ended September 30, 2019.   </span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also has an agreement with Incyte, which was entered into in 2018, under which the Company is to perform development and manufacturing services for Incyte&#8217;s clinical needs of retifanlimab (Incyte Clinical Supply Agreement).  The Company evaluated the agreement under ASC 606 and identified one performance obligation under the agreement: to perform services related to the development and manufacturing of the clinical supply of retifanlimab.  The transaction price is based on the costs incurred to develop and manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $0.7 million and $4.9 million, respectively, for services performed under the Incyte Clinical Supply Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $8.1 million and $13.1 million, respectively, for services performed under the Incyte Clinical Supply Agreement.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to September 30, 2020, the Company entered into a commercial supply agreement with Incyte pursuant to which the Company is entitled to manufacture a portion of the global commercial supply needs for retifanlimab (Incyte Commercial Supply Agreement). Unless terminated earlier, the term of the Incyte Commercial Supply Agreement will expire upon the expiration of Incyte&#8217;s obligation to pay royalties under the Incyte License Agreement.  The Incyte Commercial Supply Agreement also includes customary provisions relating to, among others, production forecasting, delivery, inspection procedures, warranties, confidentiality and indemnification.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zai Lab</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the Company entered into a collaboration and license agreement with Zai Lab (Zai Lab Agreement) under which Zai Lab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (Zai Lab&#8217;s territory) for (i) margetuximab, an immune-optimized anti-HER2 monoclonal antibody, (ii) tebotelimab (formerly MGD013), a bispecific DART</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> molecule designed to provide coordinate blockade of PD-1 and LAG-3 for the potential treatment of a range of solid tumors and hematological malignancies, and (iii) an undisclosed multi-specific TRIDENT molecule in preclinical development. Zai Lab will lead clinical development of these molecules in its territory. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Zai Lab Agreement, Zai Lab paid the Company an upfront payment of $25.0 million ($22.5 million after netting value-added tax withholdings of $2.5 million). Assuming successful development and commercialization of margetuximab, tebotelimab and the TRIDENT molecule, the Company could receive up to $140.0 million in development and regulatory milestones, $4.0 million of which ($3.6 million after netting value-added tax withholdings of $0.4 million) was earned during the three months ended March 31, 2020. In addition, Zai Lab would pay the Company tiered royalties at percentage rates of mid-teens to 20% for net sales of margetuximab in Zai Lab&#8217;s territory, mid-teens for net sales of tebotelimab in Zai Lab&#8217;s territory and 10% for net sales of the TRIDENT molecule in Zai Lab&#8217;s territory, which may be subject to adjustment in specified circumstances. </span></div><div style="margin-bottom:9pt;margin-top:5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Zai Lab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement for each of the two product candidates, margetuximab and tebotelimab:  (i)  an exclusive license to develop and commercialize the product candidate in Zai Lab&#8217;s territory and (ii) certain research and development activities. The Company determined that each license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that these promises should be combined into a single performance obligation for each product candidate. Activities related to margetuximab and tebotelimab are separate performance obligations from each other because they are capable of being distinct, and are distinct in the context of the contract. The Company evaluated the promises related to the TRIDENT molecule and determined they were immaterial in context of the contract, therefore there is no performance obligation related to that molecule. The Company determined that the net $22.5 million upfront payment from Zai Lab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, and the transaction price was allocated to the two performance obligations based on their relative standalone selling price. The standalone selling price of the performance obligations was determined using the adjusted market assessment approach considering similar collaboration and license agreements. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to Zai Lab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Due to the relatively short-term nature of the recognition period, the revenue associated with the tebotelimab performance obligation was recognized on a straight-line basis as the Company performed research and development activities under the agreement. The fixed consideration related to the margetuximab performance obligation is also being recognized on a straight-line basis as the Company performs research and development activities under the agreement. Straight-line recognition is materially consistent with the pattern of performance of the research and development activities of each product candidate. The variable consideration related to the margetuximab performance obligation will be recognized upon certain regulatory achievements.  The Company recognized no revenue during the three months ended September 30, 2020 and recognized revenue of  $4.0 million during the three months ended September 30, 2019 under the Zai Lab Agreement.  The Company recognized revenue of $3.6 million and $12.1 million during the nine months ended September&#160;30, 2020 and 2019, respectively, under the Zai Lab Agreement.  Revenue recognized during the nine months ended September 30, 2020 reflected milestone revenue, whereas revenue during the nine months ended September 30, 2019 was the recognition of the deferred upfront payment.  At September&#160;30, 2020 and December&#160;31, 2019, $5.0 million of revenue was deferred under this agreement, all of which was current.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company entered into two agreements under which the Company is to perform manufacturing services for Zai Lab&#8217;s clinical needs of margetuximab and tebotelimab (Zai Lab Clinical Supply Agreements).  The Company evaluated the agreements under ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: to perform services related to manufacturing the clinical supply of each of margetuximab and tebotelimab.  The transaction price is based on the costs incurred to manufacture drug product and drug substance, and is recognized over time as the services are provided, as the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date.  During the three and nine months ended September 30, 2020, the Company recognized revenue of $0.5 million and $1.9 million, respectively, related to the Zai Lab Clinical Supply Agreements.  No such revenue was recognized during the three and nine months ended September 30, 2019.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I-Mab Biopharma</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a collaboration and license agreement with I-Mab Biopharma (I-Mab) to develop and commercialize enoblituzumab, an immune-optimized, anti-B7-H3 monoclonal antibody that incorporates the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's proprietary Fc Optimization technology platform (I-Mab Agreement).  I-Mab obtained regional development and commercialization rights in mainland China, Hong Kong, Macau and Taiwan (I-Mab's territory), will lead clinical development of enoblituzumab in its territories, and will participate in global studies conducted by the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the I-Mab Agreement, I-Mab paid the Company an upfront payment of $15.0 million.  Assuming successful development and commercialization of enoblituzumab, the Company could receive up to $135.0 million in development and regulatory milestones. In addition, I-Mab would pay the Company tiered royalties ranging from mid-teens to 20% on annual net sales in I-Mab's territory.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the I-Mab Agreement under the provisions of ASC 606 and identified the following material promises under the arrangement:  (i)  an exclusive license to develop and commercialize enoblituzumab in I-Mab&#8217;s territory, (ii) perform certain research and development activities and (iii) conduct a chronic toxicology study. The Company determined that the license and the related research and development activities were not distinct from one another, as the license has limited value without the performance of the research and development activities. As such, the Company determined that the license and related research and development activities should be combined into a single performance obligation. The Company determined that the $15.0 million upfront payment from I-Mab constituted the entirety of the consideration to be included in the transaction price as of the outset of the arrangement for the license and related research and development activities. The Company has also determined that the chronic toxicology study is distinct from the other promises and has estimated the variable consideration of that performance obligation to be approximately $1.0 million. I-Mab will pay the Company for the cost of this study as the costs are incurred and I-Mab will be entitled to a one-time credit of eighty percent of the total amount of such costs against a future milestone, at which point the Company will reassess the transaction price for that milestone. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to royalties will be recognized if and when the related sales occur, as they were determined to relate predominantly to the license granted to I-Mab and, therefore, have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;Revenue under the I-Mab Agreement is being recognized using a cost-based input method according to costs incurred to date compared to estimated total costs. The transfer of control occurs over this time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligations.  During the three months ended September 30, 2020 and 2019, the Company recognized revenue of $1.0 million and $0.6 million, respectively, under the I-Mab Agreement.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue of $3.5 million and $0.6 million, respectively, under the I-Mab Agreement. At September&#160;30, 2020, $10.0 million of revenue was deferred under this agreement, $4.3 million of which was current and $5.7 million of which was non-current.   At December&#160;31, 2019, $13.5 million of revenue was deferred under this agreement, $4.4 million of which was current and $9.1 million of which was non-current.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provention Bio, Inc.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the Company entered into a license agreement with Provention Bio, Inc. (Provention) pursuant to which the Company granted Provention exclusive global rights for the purpose of developing and commercializing MGD010 (renamed PRV-3279), a CD32B x CD79B DART molecule being developed for the treatment of autoimmune indications (Provention License Agreement). As partial consideration for the Provention License Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of $2.50 per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-3279, the Company will be eligible to receive up to $65.0 million in development and regulatory milestones and up to $225.0 million in commercial milestones.  As of September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-3279 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product. The license agreement may be terminated by either party upon a material breach or bankruptcy of the other party, by Provention without cause upon prior notice to the Company, and by the Company in the event that Provention challenges the validity of any licensed patent under the agreement, but only with respect to the challenged patent.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in May 2018, the Company entered into an asset purchase agreement with Provention pursuant to which Provention acquired the Company&#8217;s interest in teplizumab (renamed PRV-031), a monoclonal antibody being developed for the treatment of type 1 diabetes (Asset Purchase Agreement). As partial consideration for the Asset Purchase Agreement, Provention granted the Company a warrant to purchase shares of Provention&#8217;s common stock at an exercise price of  $2.50 per share.  If Provention successfully develops, obtains regulatory approval for, and commercializes PRV-031, the Company will be eligible to receive up to $170.0 million in regulatory milestones and up to $225.0 million in commercial milestones.  As of </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2020, the Company has not recognized any milestone revenue under this agreement. If PRV-031 is commercialized, the Company would be eligible to receive single-digit royalties on net sales of the product.  Provention has also agreed to pay third-party obligations, including low single-digit royalties, a portion of which is creditable against royalties payable to the Company, aggregate milestone payments of up to approximately $1.3 million and other consideration, for certain third-party intellectual property under agreements Provention is assuming pursuant to the Provention Asset Purchase Agreement. Further, Provention is required to pay the Company a low double-digit percentage of certain consideration to the extent it is received in connection with a future grant of rights to PRV-031 by Provention to a third party. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluated the Provention License Agreement and Provention Asset Purchase Agreement under the provisions of ASC 606 and determined that they should be accounted for as a single contract and identified two performance obligations within that contract: (i) the license of MGD010 and (ii) the title to teplizumab.  The Company determined that the transaction price of the Provention agreements was $6.1 million, based on the Black-Scholes valuation of the warrants to purchase 2,432,688 shares of Provention's common stock.  The transaction price was allocated to each performance obligation based on the number of shares of common stock the Company is entitled to purchase under each warrant. The potential development and regulatory milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. Any consideration related to sales-based milestones and royalties will be recognized when the related sales occur, therefore they have also been excluded from the transaction price. The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized revenue of $6.1 million when it satisfied its performance obligations under the agreements and transferred the MGD010 license and teplizumab assets to Provention in 2018.  The warrants were revalued at each reporting period based on the current Black-Scholes parameters until the warrants were exercised in July 2019. The resulting increase or decrease in the value of the warrants is reflected in Other income (expense) on the 2019 consolidated statement of operations and comprehensive loss.  In July 2019, the Company exercised the warrants on a cashless basis, and subsequently sold all the shares of Provention common stock acquired through the exercise. No shares of Provention stock were held subsequent to the sale in July 2019. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NIAID Contract</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of September 15, 2015,&#160;to perform product development and to advance up to two DART molecules, including MGD014 (NIAID Contract). Under the NIAID Contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. NIAID does not receive goods or services from the Company under this contract, therefore the Company does not consider NIAID to be a customer and concluded this contract is outside the scope of Topic 606.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NIAID Contract includes a base period of up to $7.5 million to support development of MGD014 through Investigational New Drug application submission with the U.S. Food and Drug Administration, as well as up to $17.0 million in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to $24.5 million. The total potential period of performance under the award is from September&#160;15, 2015 through December&#160;31, 2024.  In 2017, NIAID exercised the first option in the amount of up to $10.8 million to fund the commencement of the MGD014 clinical trial and development of the second DART molecule.  The Company recognized revenue  under the NIAID Contract of $0.8 million during each of the three month periods ended September&#160;30, 2020 and 2019.  During the nine months ended September 30, 2020 and 2019, the Company recognized revenue under the NIAID Contract of $6.2 million and $1.5 million, respectively.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Boehringer Ingelheim International GmbH</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2010, the Company entered into a collaboration and license agreement with Boehringer Ingelheim International GmbH (BII) to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in 2015 (Boehringer Agreement). Under the terms of the agreement, the Company granted BII an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.  During the evaluation period, BII selected two product candidates to develop (BII DARTs). Under the terms of the Boehringer Agreement, BII paid the Company an upfront payment of $15.0&#160;million which was fully recognized prior to the adoption of ASC Topic 606 on January 1, 2018. The remaining obligations under this agreement included potential future development and sales milestones and royalties on net sales in the event that the BII DARTs are commercialized.   In June 2020, BII agreed to a payment of $12.0 million in order to retain rights to develop the BII DARTs under the Boehringer Agreement.  As a result, the Company received and recognized as revenue $12.0 million during the nine months ended September 30, 2020. The remaining potential development milestone payments are fully constrained until the Company concludes that achievement of the milestone is probable, and that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price.  Any consideration related to royalties will be recognized when the related sales occur and therefore, have also been excluded from the transaction price.  The Company re-assesses the transaction price in each reporting period and when events whose outcomes are resolved or other changes in circumstances occur.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903359256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended (IRC), and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved 800,000 shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 10% of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at 85% of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the nine months ended September&#160;30, 2020, 18,304 shares of common stock were purchased under the 2016 ESPP for net proceeds to the Company of approximately $0.3&#160;million.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the IRC, or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of September&#160;30, 2020, under the 2003 Plan, there were options to purchase an aggregate of 259,904 shares of common stock outstanding at a weighted average exercise price of $2.73 per share.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2013, the Company implemented the 2013 Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards.&#160;&#160;The number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) 1,960,168 shares, (b) 4.0% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Company's Board of Directors. During the nine months ended September&#160;30, 2020, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to 11,896,613.&#160;&#160; If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards.  As of September&#160;30, 2020, there were options to purchase an aggregate of 7,079,313 shares of common stock outstanding at a weighted average exercise price of $22.10 per share under the 2013 Plan.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:33.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.002%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:64.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7% - 76.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods through December 31, 2019, the computation of expected volatility is based on the historical volatility of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">several public entities of similar size, complexity and stage of development, as the Company did not have sufficient history of its own volatility.  </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2019, the Company had sufficient company-specific historical and implied volatility information.  As such, beginning the first quarter of 2020, the computation of expected volatility is based only on the historical volatility of the Company&#8217;s common stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735,322)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,339,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,973&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of options granted during the nine months ended September&#160;30, 2020 and 2019 was $10.50 and $14.33, respectively. The total intrinsic value of options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $3.9 million and $2.8 million, respectively.  The total cash received for options exercised during the nine months ended September&#160;30, 2020 and 2019 was approximately $4.5 million and $0.7 million, respectively.  The total fair value of shares vested in the nine months ended September&#160;30, 2020 and 2019 was approximately $12.4 million and $12.8 million, respectively. As of September&#160;30, 2020, the total unrecognized compensation expense related to unvested stock options, net of related forfeiture estimates, was approximately $31.7 million, which the Company expects to recognize over a weighted-average period of approximately 2.5 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2019, the Company awarded restricted stock units (RSUs) under the 2013 Plan to all employees with at least six months of service as of the date of grant except executive officers. Each RSU entitles the holder to receive one share of the Company's common stock when the RSU vests. The RSUs vest in two equal installments on the first and second anniversary of the grant date. Compensation expense is recognized on a straight-line basis. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,950)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, there was $2.8 million of total unrecognized compensation cost related to unvested RSUs, which the Company expects to recognize over a remaining weighted-average period of one year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760904761672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and ContingenciesOn September 13, 2019, a securities class action complaint was filed in the U.S. District Court for the District of Maryland by Todd Hill naming the Company, its Chief Executive Officer, Dr. Koenig, and its Chief Financial Officer, Mr. Karrels, as defendants for allegedly making false and materially misleading statements regarding the Company&#8217;s SOPHIA trial.   On August 17, 2020, the Employees&#8217; Retirement System of the City of Baton Rouge and Parish of East Baton Rouge was appointed as Lead Plaintiff, and on October 16, 2020, the Lead Plaintiff filed an amended complaint.  The amended complaint asserts a putative class period stemming from February 6, 2019 to June 4, 2019. The Company intends to vigorously defend against this action.  However, the outcome of this legal proceeding is uncertain at this time and the Company cannot reasonably estimate a range of loss, if any. Accordingly, the Company has not accrued any liability associated with this action.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760905560296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements of MacroGenics, Inc. (the Company) have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments) that the management of the Company believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiaries, MacroGenics UK Limited and MacroGenics Limited. All intercompany accounts and transactions have been eliminated in consolidation. These consolidated financial statements and related notes should be read in conjunction with the financial statements and notes thereto included in the Company's 2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 25, 2020.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13,</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which modifies the measurement of expected credit losses on certain financial instruments. In addition, for available-for-sale debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses rather than reductions in the amortized cost of the securities. The Company adopted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2016-13 and all related ASU amendments on January 1, 2020, using a modified retrospective transition method, which requires a cumulative-effect adjustment, if any, to the opening balance of retained earnings to be recognized on the date of adoption with prior periods not restated. The Company evaluated its available-for-sale debt securities at January 1, 2020 and determined that no cumulative-effect adjustment was required.  Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new guidance, at each reporting date, entities must evaluate their individual available-for-sale debt securities that are in an unrealized loss position and determine whether the decline in fair value below the amortized cost basis results from a credit loss or other factors. The Company evaluates various quantitative factors including, but not limited to, the nature </span></div><div><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, and the severity of the impairment.  The amount of the decline related to credit losses is recorded as a credit loss expense in earnings with a corresponding allowance for credit losses and the amount of the decline not related to credit losses is recorded through other comprehensive income.  See Note 4, Marketable Securities, for additional information.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles - Goodwill and Other - Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-15). This new standard requires a customer in a cloud computing arrangement that is a service contract to follow the internal-use software guidance in ASC 350-40, </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Internal-Use Software</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to determine which implementation costs to capitalize as assets and amortize over the term of the hosting arrangement or expense as incurred. The Company adopted ASU 2018-15 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a prospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808)&#8212;Clarifying the interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2018-18). The amendments provide guidance on whether certain transactions between collaborative arrangement participants should be accounted for as revenue under ASC 606. It also specifically (i) addresses when the participant should be considered a customer in the context of a unit of account, (ii) adds unit-of-account guidance in ASC 808 to align with guidance in ASC 606, and (iii) precludes presenting revenue from a collaborative arrangement together with revenue recognized under ASC 606 if the collaborative arrangement participant is not a customer. </span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted ASU 2018-18 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on January 1, 2020 on a retrospective basis. Adoption of the new standard did not have a material impact on the Company's consolidated financial statements</span><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div>The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these ASUs will not have a material impact on the Company's consolidated financial statements<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903521736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:12pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:29.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.692%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,759&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,708&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:30.223%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements at December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active Markets for Identical Assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable Inputs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable Inputs</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,149&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Total assets measured at fair value at September&#160;30, 2020 includes approximately $64.5 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Total assets measured at fair value at December&#160;31, 2019 includes approximately $73.2 million reported in cash and cash equivalents on the consolidated balance sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760903350488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-for-sale Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the Company's marketable debt and equity securities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.247%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:0.0%"/><td style="width:0.297%"/><td style="width:0.0%"/><td style="width:1.0%"/><td style="width:3.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.855%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,003&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,005&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,019&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,022&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:53.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.651%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.798%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.801%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government-sponsored enterprises</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,216&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,222&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,268&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,284&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760904751096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following stock-based compensation expense was recognized for the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:33.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:2.002%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.441%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,059&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,773&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,049&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,419&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Using the Black-Scholes Option-Pricing Model</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table for options issued during the period indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:64.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.3% - 109%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.7% - 76.6%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4% - 1.8%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4% - 2.6%</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.25 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.110%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Term<br/>(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/> (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,706,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816,277&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.97&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(448,732)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.93&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(735,322)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,339,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,014&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">As of September 30, 2020:</span></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,407,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,027,237&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,973&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of RSU Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes RSU activity during the nine months ended September&#160;30, 2020:</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:95.467%"><tr><td style="width:1.0%"/><td style="width:52.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.330%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.178%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452,500&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.68&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210,950)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,950)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760910307752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 79,022<span></span>
</td>
<td class="nump">$ 89,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">64,500<span></span>
</td>
<td class="nump">73,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">143,479<span></span>
</td>
<td class="nump">162,506<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">97,771<span></span>
</td>
<td class="nump">116,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">45,708<span></span>
</td>
<td class="nump">46,149<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Money market funds | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">60,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">60,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | U.S. Treasury securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">14,007<span></span>
</td>
<td class="nump">13,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">14,007<span></span>
</td>
<td class="nump">13,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Government-sponsored enterprises | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">23,759<span></span>
</td>
<td class="nump">103,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Quoted Prices in Active Markets for Identical Assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">23,759<span></span>
</td>
<td class="nump">103,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring Basis | Corporate debt securities | Significant Unobservable Inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906534152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 89,268,000<span></span>
</td>
<td class="nump">$ 79,019,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">89,284,000<span></span>
</td>
<td class="nump">79,022,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss related to available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Losses related to other-than-temporary impairments of available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,003,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,005,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13,216,000<span></span>
</td>
<td class="nump">14,006,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">13,222,000<span></span>
</td>
<td class="nump">14,007,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">76,052,000<span></span>
</td>
<td class="nump">5,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(10,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 76,062,000<span></span>
</td>
<td class="nump">$ 5,010,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906699704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 28, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember', window );">Follow-On Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Over-allotment option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At the Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,612,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_FollowOnEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760934988968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Incyte Corporation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,253,000<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,192,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">330,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">154,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Variable consideration recognized</a></td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development and regulatory milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Clinical activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Incyte Corporation | Incyte MGA012 Agreement - Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementClinicalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760905968952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Zai Lab (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="nump">$ 52,192,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember', window );">Zai Lab Agreement | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding', window );">Non-refundable upfront payment, net of tax withholding</a></td>
<td class="nump">22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonrefundablePaymentTaxWithholding', window );">Nonrefundable payment tax withholding</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesNetOfTaxWithholding', window );">Revenues, Net Of Tax Withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="nump">12,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenuesTaxWithholding', window );">Revenues, Tax Withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember', window );">Zai Lab Clinical Supply Agreements | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember', window );">Zai Lab Agreement, Margetuximab | Zai Labs | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember', window );">Zai Lab Agreement, TRIDENT molecule | Zai Labs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundablePaymentTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Payment Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundablePaymentTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable Upfront Fees, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesNetOfTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Net Of Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesNetOfTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenuesTaxWithholding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues, Tax Withholding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenuesTaxWithholding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ZaiLabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ZaiLabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabClinicalSupplyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906603944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jul. 09, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,253<span></span>
</td>
<td class="nump">$ 18,741<span></span>
</td>
<td class="nump">$ 52,192<span></span>
</td>
<td class="nump">$ 38,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount', window );">Estimated variable consideration</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember', window );">I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties (percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Information Used To Assess Variable Consideration, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_IMabBiopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760905995544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Provention Bio, Inc. (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>performance_obligation </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,253,000<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,192,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,022,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,284,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member', window );">Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPerformanceObligations', window );">Number of performance obligations | performance_obligation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementTransactionPrice', window );">Collaborative agreement transaction price</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares', window );">Number of shares available under warrants (in shares) | shares</a></td>
<td class="nump">2,432,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember', window );">License Agreement | Provention | Provention PRV-3279</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 65,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember', window );">Asset Purchase Agreement | Provention | Provention PRV-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare', window );">Warrant to purchase shares of common stock, exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments under agreement</a></td>
<td class="nump">$ 170,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments under agreement</a></td>
<td class="nump">225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement', window );">Potential milestone payments to third parties</a></td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember', window );">Revenues From License Agreements | Provention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborativeAgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_ProventionBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ProventionLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV3279Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_ProventionPRV031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906401704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - NIAID Contract (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,253,000<span></span>
</td>
<td class="nump">$ 18,741,000<span></span>
</td>
<td class="nump">$ 52,192,000<span></span>
</td>
<td class="nump">$ 38,996,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options under agreement</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember', window );">Revenues From Grants | NIAID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=mgnx_RevenuesFromGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906946248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details) - Boehringer Collaboration and License Agreement - Boehringer Ingelheim International GmbH<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">61 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2015 </div>
<div>USD ($) </div>
<div>numberOfProductCandidates</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration And Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementTerm', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfProductCandidates', window );">Number of product candidates to develop | numberOfProductCandidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentMilestonesAmount', window );">Development milestones</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized', window );">Development milestones recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration And License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development And Regulatory Milestone Payments Under Agreement, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DevelopmentMilestonesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Milestones, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DevelopmentMilestonesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mgnx_BoehringerIngelheimInternationalGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906017288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,339,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,339,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,706,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,832<span></span>
</td>
<td class="nump">$ 5,398<span></span>
</td>
<td class="nump">$ 15,419<span></span>
</td>
<td class="nump">$ 14,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Payroll deduction discount</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock percent of the fair market value</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from stock plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember', window );">2003 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,896,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,896,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Potential annual increase in shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Potential annual increase in shares reserved for future issuance as percentage of outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,079,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,079,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price of stock options outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,059<span></span>
</td>
<td class="nump">2,765<span></span>
</td>
<td class="nump">$ 8,082<span></span>
</td>
<td class="nump">7,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">$ 2,633<span></span>
</td>
<td class="nump">$ 7,337<span></span>
</td>
<td class="nump">$ 7,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_A2003StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760910275256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.30%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">109.00%<span></span>
</td>
<td class="nump">76.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906431752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning Balance (in shares)</a></td>
<td class="nump">6,706,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Shares, Granted (in shares)</a></td>
<td class="nump">1,816,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised (in shares)</a></td>
<td class="num">(448,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited or expired (in shares)</a></td>
<td class="num">(735,322)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending Balance (in shares)</a></td>
<td class="nump">7,339,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,706,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable (in shares)</a></td>
<td class="nump">4,407,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Shares, Vested and expected to vest (in shares)</a></td>
<td class="nump">7,027,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)</a></td>
<td class="nump">$ 22.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted (in dollars per share)</a></td>
<td class="nump">14.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised (in dollars per share)</a></td>
<td class="nump">9.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)</a></td>
<td class="num">(20.78)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)</a></td>
<td class="nump">21.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable (in dollars per share)</a></td>
<td class="nump">23.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted- Average Remaining Contractual Term, Vested and expected to vest</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending Balance</a></td>
<td class="nump">$ 39,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">18,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="nump">$ 36,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 10.50<span></span>
</td>
<td class="nump">$ 14.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received for options exercised</a></td>
<td class="nump">4,500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates</a></td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139760906354648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Restricted Stock Unit Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning Balance (in shares)</a></td>
<td class="nump">452,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(210,950)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(40,950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending Balance (in shares)</a></td>
<td class="nump">215,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">23.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">15.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited or expired (in dollars per share) | $ / shares</a></td>
<td class="nump">15.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending Balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awards granted in period (in shares)</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized compensation cost | $</a></td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>43
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )B 9%$'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "8@&119OPG%^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>.FG'#E'7"]-.("$Q"<0M2KPMHFFBQ*C=VY.6K1."!^ 8^\_G
MSY(;':3V$9^C#QC)8KH;7=<GJ<.&G8B"!$CZA$ZE,B?ZW#SXZ!3E9SQ"4/I#
M'1$JSM?@D)11I& "%F$ALK8Q6NJ(BGR\X(U>\.$S=C/,:, .'?:40)0"6#M-
M#.>Q:^ &F&"$T:7O IJ%.%?_Q,X=8)?DF.R2&H:A'.HYEW<0\/;T^#*O6]@^
MD>HUYE_)2CH'W+#KY-?Z8;O?L;;B%2^$*/AJ+]:2KV1]_SZY_O"["3MO[,'^
M8^.K8-O K[MHOP!02P,$%     @ F(!D49E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MMS_1,LDWQA92:QGEAVO!?:', W!_*:4^GI@7%'NK@_\ 4$L#!!0    ( )B
M9%%7J40J7@4  ',4   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULE9AM
M<YLX$,>_BL;7N8<9)Y;$@Z#G>"9UTFEG>FVF3N]>*UB.F0"BDHB3^_2W8 <<
M)(CO11LPNZN?%FG_6N8[J1[T5@B#GO*LT!>3K3'E^]E,)UN1<WTN2U' DXU4
M.3=PJ^YGNE2"KQNG/)M1C,-9SM-BLI@WO]VHQ5Q6)DL+<:.0KO*<J^</(I.[
MBPF9O/SP/;W?FOJ'V6)>\GNQ$N9'>:/@;M9&6:>Y*'0J"Z3$YF)R2=XO*:L=
M&HN_4['31]>HGLJ=E _US>?UQ0371"(3B:E#</CS*)8BR^I(P/'S$'32CED[
M'E^_1/_83!XF<\>U6,KLGW1MMA>3:(+68L.KS'R7NT_B,*&@CI?(3#?_H]W!
M%D]04FDC\X,S$.1IL?_+GPZ).'(@_H #/3C04QV\@X/73'1/UDSKBAN^F"NY
M0ZJVAFCU19.;QAMFDQ;U:UP9!4]3\#.+Y;>OJV]?/E]=WEY?H0^77RZ_+J_1
MZM/U]>T*G:$?JROT^[L_T#N4%NAV*RO-B[6>SPR,7/O/DL,H'_:CT(%15J(\
M1QZ>(HHI=K@OQ]VO1 +NI'8G\6OW&<RWG31M)TV;>-[0I"NE1&$0UUH8_7XD
MHM=&])J(_E!$KK<(<H.2^D+\K-)'GL$0SESM0X5-J'J;/2Y@7J''YK/'XYS8
M9H2&/J.MV2M2OR7U1TG_XNI!&'Z7":1%4JG4I,))N0\3' W/8DQI#]*VBF(:
M^6[&H&4,1ADODT16D#RH$XF 3 *LBS"PQB818_TT.JPH\P<(PY8P'"6\4:+D
MZ1J))ZBG6NCFW4NS%0HV[?'B<G&'-A$.O7YF'5:$1H&;F[7<;)3[5AJ>G8#(
MK,$] L(0]1AM,^K%; @R:B&C-Y(+*J7,\[392&7>H$)^M=R8'5=BB@IA7-21
MA>,3GWH]:(=51 EQ,\<M<SS*_*UY]\,)C>U,T2B*>V@.*S_  ^DDN*OQ^(2W
M/@QW<'_UNIGO1;B'Y[(C-, #N2-'(D1.*LA9RN_2K"E)8U69=(6>T-,J2<F?
MA\K((<2K!>&8N\L*1P,S[W2#C L' *I*C!:2HZ0X\3W[I="0^7U^VXPRXL4#
M$^CDA(SKR978".!<0ZU^%$7ESK"M$C$-^HO?844PPWB L!,3,JXF7P0<\][,
MHBT3L ;Z]<YEU9QHG(2=F)!Q-7E=E=\BM84!=B E?53;S ](R 98.P$AXPK2
M?]]-,49RT^*74M4'=">ZK1<!8U:2;:N8!-X >"<J9%Q5K&7PO\AMT:!^&%A)
M=YBQ8)"]$Q=RBKH4LC@[=9&X],8/^KBVU<!:IIW6T%.TY@T\:@M)1%G<YW.9
MP1%O()VTDQLZ+C<K(Y.'K<S60NG?FD.&>1[3&WK46(SKS5+F.32GNAY@BM[A
M<TQ >A2";J 2Z.P,@5Q.,<;U/Z2W<)B!BE^9K53IOV(]14$X)<R?QAYMA,"/
MIG$035GHO1A#)ZX-/$J+>\0-@L;*B/Q.J%]_(2'^\Z7%:IRA:SI^=&B?IK!Q
M=2F:[CE[=KX<6^F"L'\Z=1CY\=#BZ=20OJ&&ZW5:;T%80?7Q^@RZSH27*:PH
M)Z@M:7"0QK#A^K"V8<0HQ0-- .W$CXZ+'ZAWE5<9-Z(5;9F72FSK[QR/ KIF
MN'=*(K7%SDJQ0P_# >).#.F;K55+O!:;-$F=)VEJ"]T9"V/F]8\5+L/0IS@:
M:%-I)XKT%%'4CJWJ!+;ECH)J1-92<-AY.*0#!SG:Z2(]I;,ZJGO[EN54?&8U
M^\X3N,O.=0*?'7T1JC_'0==_GQ8:96(#COB<00+4_@O7_L;(LOE(=">-D7ES
MN14<L&L#>+Z1TKS<U-^=VN^,B_\ 4$L#!!0    ( )B 9%$;>1_.:0(  /L%
M   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE53;3N,P$/T5*UII06+K
M7!I*41JIM%V!Q$)%V=UGDTP;"\<.MM/"?OW:3HA*H5SZT'CL.6?.F<23;(2\
M5P6 1H\EXVKD%5I7IQBKK("2J)ZH@)N3I9 ET2:4*ZPJ"21WH)+AT/>/<4DH
M]]+$[<UEFHA:,\IA+I&JRY+(IS-@8C/R N]YXX:N"FTW<)I49 4+T+^KN301
M[EAR6@)75' D83GRQL'I)+;Y+N$/A8W:6B/KY$Z(>QM<Y"//MX* 0:8M S&/
M-4R ,4MD9#RTG%Y7T@*WU\_L/YUWX^6.*)@(]I?FNAAY)Q[*84EJIF_$YAQ:
M/TY@)IAR_VC3Y,8##V6UTJ)LP49!27GS)(]M'[8 07\/(&P!X6<!40N(G-%&
MF;,U)9JDB10;)&VV8;,+UQN'-FXHMV]QH:4YI0:GT\GUU>+Z\F(ZOIU-T=GX
M<GPUF:'%^6QVNT '<R*!ZP(TS0@[1#_0-X21*LRN2K VU2T'SMI*9TVE<$^E
M!50]%/E'*/1#_PWXY'WX%#(##RP\&+Z$8^.Y,QYVQD/'%^V3HT5V7PB6@U3?
M$3S45#^=OL,;=;R1X^WO:Z@H2_-Y*DM_A"HBT9JP&M !Y2@7C!&I4 6R:>/A
M6VUL^ >.WU["=>KW_"#!Z^UF?9#T0GJ_D][_@O3F/2-2ZT)(^@]R9Z'9?5-W
M0QYO20K"V'>_'?&?R7SA(.X<Q%]W8&:7TH3GE*\^LA"_$A8?!X/^, IW'+Q.
M[)\,XY/!<;1C &]=33L6?Q&YHEPA!DL#]7L#PR&;4=,$6E3NMMX);>Z^6Q9F
M.H.T">9\*81^#NP Z.9]^A]02P,$%     @ F(!D48EM:U=4!0  >A0  !@
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MA'C ]: %U%F"%BL,8S>&>U-/+SRP"5LW/+!B+G8S%TP]O?S )F5!?K1V;GX
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M$)R%A(0]T!L^P6\02JOJX\66J>.K/M(0"1DFDOM2)NO8Y&8H%8XN"(B#5W"
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MF30"\'TIA-Z]F WV_U@X_Q]02P,$%     @ F(!D4<9/FR%[!@  :Q   !@
M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6RU6-MRVS80_16,7FK/J)(L.VV3
ML3UC.]=)TWBL.'WH] $B5R1B$F!PL>Q\?<\")$7%<IK.I"^Q"&)WS^Z>/0!S
MO#;VQI5$7MS5E78GH]+[YMETZK*2:NDFIB&--RMC:^GQ:(NI:RS)/!K5U70^
MF_TRK:72H]/CN'9I3X]-\)72=&F%"W4M[?TY569],CH8=0M7JB@]+TQ/CQM9
MT(+\=7-I\33MO>2J)NV4T<+2ZF1T=O#L_(CWQPT?%:W=X+?@3);&W/##F_QD
M-&- 5%'FV8/$GUNZH*IB1X#QN?4YZD.RX?!WY_UES!VY+*6C"U/]J7)?GHQ^
M&XF<5C)4_LJL7U.;SQ/VEYG*Q7_%NMT[&XDL.&_JUA@(:J737WG7UN%[#.:M
MP3SB3H$BRN?2R]-C:];"\FYXXQ\QU6@-<$IS4Q;>XJV"G3\]ETXY85;BTI(C
M[66JE<[%E7(W+OZZUAE9CP9[1>YXZA&6C:=9&^(\A9@_$N*I>&>T+YUXH7/*
MM^VG@-MCGG>8S^??=+B@9B(.9V,QG\UGW_!WV-?@,/H[?,3?>UM(K;[$U,?B
MPFAG*I5O*K%5&I3JI=)29TI68H%% D6]$W^=+9VW(-G?WT!TU",ZBHB._L^N
M_. 08K?%AY(P6IFI&ZGOE2Y$T#+DRE,N8$=6U2+K*XK%55\\MRD>G+Z3F36O
M2*O,C<4;G4W$GH?KB^1X7Y3REL222 N(3R-M]!\CVQP."7/C2W$]64Q$09JL
MK*I[?DT-1^5] 6D 7V,5XC<5,MI[=79VN2\@;3W6#3RED^0AR4G,<B=R^*I"
MCA)4E9#Y)PQL6M_CI)6+$8T&%*2HV5\%*<N"M?QB8+ O?"F]X)1KJ2&'O,I&
M@R(@_4K1+8 C?:$I(^<@I!&_%"NI+-=FBZILW2 QD[ON'>4Q'4<[<L8.J%GK
MW_@^AD("2N<JDZRA[+C;27<-])7["A <;150B95R&=S=D[0"ZQ$@\+NP=/0Y
M<&9=[ 1N\F-HU#7#M\["H]QB=BN\7)>&>6+6&CX9GLH5TB7L&QB)Z[?B=U5'
M-&PY?-6N3\19526H;1(;!&P":=!.QI/(#;B,AD+494ISD&%'.G3IW]-F_Y:J
MN %= S]<:4*5(X3@@[IU_2GH=!+&2?&/,9J])2_88LF;KJS1SX"./SD(\,%3
M<:9U@(LK:HP%9;7@XU(<S'Y^BP 5S/IX"V:^BF+"45[<9:741718*Q?/^;W%
MBXO]Z(26-C"[YT^2T$\>%:8/@Q&!0J&-G\!) >0R!X7@EJG=&X<MXSP0[XQY
MO?_XYOG/R B><JH5>/+!""[\&//M4=.B3$5!!UUJH#,UCV*1!D,!1!9KL%VG
M97"07Y?BXT)E8X=!LE1:\'T<AX3N9 UE&@N'RQ(JET&U%4^2M]PETA9TY3:-
MMW2A1R.75<P&E%2 A"DHD*?SHC8 [: =M@,9!Z//&(AY'![!.1&O 0?&X]UU
M KN8;I'6LHVE"JU6P*[]?RA/2[!5\ $^<L+5,T\*&M>Q ":ULD:K%67==/'+
M8+=D+T/'E4O*\A"Q8D-!MZ:ZY0!.^; Y 8>UQ>! Q ./ ^IJM/)\6@QKA;I@
M6V5PU;R/5,(C>]DT 6X:3!0<\;F2RC\1BT&)<HSO?9^_9U$HOE)_U&F;#BEU
MQ7?C(F#Z#>):NN5[:]L0F0-;A"5CL2)NN525\A$IE*J&7L&7^I)4L[$F#]@(
M4'F4'/=PZ!O5$-\F)N(/XWFV(1ZI3;%WZ'YA(J.WRB@U'R@X@S(5$>$7SI-T
MXK6\B"=@WZJU@J!&2GW%BC2P.@"Z"6Y[G <3%6TBY3G;MI8Y@N,./][)&'RS
M+*&7-V/1"75$5$L^>867-YBPY;TH#'QJGD)T0@;H0M*T<<^=+I\D*SU1'O33
MA:9!*:"""G+_"B,2,X7H?Y547Y345V1A0^,?>&]M=A 'LB&7QC))6MIT)=\Y
MAYO1[T_* 6WH#CH.7C^88^F< 9OX'.I=\:784]%I/@B,*6 U:.NUX>A.2%NG
M7W?I0'[;"*?MY6-CMSG:X"$= ML\FFP=&Y%LW:C'T6CGN9MXADJWL@H\T.P%
MAS:S,:[?^<%EK1.Y@;KR&3I0C/%W9)6*LR.+R:[/B^G@ Q!C4<3/W*@"VJ=O
MP7ZU_Y(^2Q^0F^WI,_R=M 6.#%'1"J:SR:]/1C@[XZ=M>O"FB9^32^/Q<1I_
MEKADD.4->+\RD+KV@0/T_[]P^@]02P,$%     @ F(!D4;/\;I;H!P  9!0
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M)_DS#<M)Z57@\=>-!?!B9^KU&H2[D#(S;5T9P+>S7\#UPCEP0B/7 @R![!A
M-&+R$M:4YQNOY7.4K8A;7QOVY!3M?"E!:? !GD07"XT<1). ME"L@;NPBP"E
M,%M59QMB/F%'"@"EBIHD"Z<!TU B?_R8_L5FOEB&Y)7(:YY^A^P'ZH$[I QM
M&;#K[/U/R1L]0AP\'8Z?#I)W('Y(T!Q5^ 60A]Z'8;EZ0:Z@+!D3T$(X,@5,
MDK&Y/T3S+,G/11Z>O7^1/!H_.J)7P#C!>N?*4CN')_4U\JJZULE:EN3? V2
M><NM;0TUV^_1-\FA.J*/G.5OHR3.=JCL0]'(<\_C#MYZF!+)K%02S(!,EX7.
M]0+,>2D*,P=28#BELW@;,HF6@RPRF?V0-L+UCKE08[Q$]JU^)E-1&S*\&WHC
M%6N!6(3:(9%WF0)'I$BK >\*/.(^0;Q 0E#*Y$WES%IJ=Y57X*A$W#45#"'
MC2&A3]FW4=4&G2%5(5Z"0O$+2,,@]$B, L2>PQI!VHA&E?,R@0B[.*36,Z(J
M0?L,$VV'03QN5A>\!%0C'QO6H3A"=-?227#*='Y%$O)M!#HP<#Q:.%96E^[3
MUA;CL@6 4P5[2X*CP>L#(((]NGWW:2S!8=^Z5"QZ.W64O$5G+Z]A;G!73AOC
M-\#Y#6WM(MA* TIEG5L $?#2 *(C*P8#H=95.?G4Z# N1;&0WCT,Q13=;9@
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MNU$I*S^=L;K;\9PO/DL>K?8N*[UG2OUV]L=MC)U)6A;_/RQ%VWE"Y@Z\BWE
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M8B\&."^=BR\+";#_GV+^)U!+ P04    " "8@&11-*2@?\@(  #I%@  &0
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M@2_P8H1S!5XMV6)ND]:]"H'8RM#"1<S<VM[$UV)@[S(SUTQWB9,1%$G-A@H
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M%X$G_RQPNU:>-F!]Y=#MF@=2T'W=OOT54$L#!!0    ( )B 9%'. V;SN@,
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M-M-X4@VA?^'5**>SO9 *609S2HW:I[V F6H\5H;5A1]),VUIP/GEDKXH8%P
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MLP"MSY6R^PD[Z/^23/X!4$L#!!0    ( )B 9%$RJ!HQN04  $$D   9
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M@3?@YOH2O'SQ"KP (@/?UC+7+%OJV=C87%S$\:*\[OO]==&)ZU[S[1G T6N
M(A2UN%^$W2_YPKI#YPZGA^YC6X&J#*@J RKBX1/QWFG-C7X;B(2K2+B(1$X.
M;)$K801O+<K>-RY\W0S;S9-IA-!LO*N/O6DUF:()J:P.$B-58B286$WISYSI
M7/%"W=?@J\M8B>P.O&=:Z$ -:'4IVK.:<14I#B9]P?0:V#L,+-P!_YF+'4M=
MVFW%W8>BM;+%A$;147&;5@E&-:N#/),JSR28YS=I[*1AQ;C!9E_>)6 &K%S5
M=Z[J;1DGC5P@P229'J7<8A8C&L7M.4^JG">#W!#@/_!/+HT=SY42"Z[=S']7
MT!=\9NJ'&[%=3L#'I?46"UN&O?S@Y2>^XRF KP+WP;3*==KSCH*1)U[T'%J5
M4>LJ$)I$DR.MVLQB2*;M6L$:I^%0:EV+NTRLK!29 5_,FBOPY59SM6.W*;=@
MW^9>'!02!WIZPK[XA)Z?, S0I\J#&W6?)DD"C^5IFD$88YJ<T,?3%0Z#UR-]
M;C)Y2AL<U,:S&/:%,?0TAF$</U6;)G./J1PT.<S6,QF&H?P(23[+C/^V^RJ'
M,[#*&UN:PPP\8>&D;^T] >%TN*6PC-4)JQ:ST[!"'K$HC-A>E7_.]09YWB+8
M4SI4VURBX:0K8W5)UV86D,[C%X7QVU>ZH18?Y,F+2%^E/"P1'5 IVHFUH,EA
MCA["* SA(15ZZO*#/(11TE<=CU,4WK$^3IU)MSHAD\,</:91&-./4.?F[/H,
M?%.%U6^@3S2.AUVH1S".^G:TGH4XO/?LZ&EAL^^*HHBV5Q)[:N(P-0>HY',N
M);CV1 #WE<+##H>WF1U2D(?>T-@C$8>1.(P,0RT+V&,2QWVK[B&&PSO)CJHW
M^_/0!/"XPX,UZ ^L_%-QCSW^<-]&G7B$D? N,EQUTFRT3]SKQ(..#-9D_R5W
M7&7NZS=Z*S,M72=DS[C:*J&#$"<>@:1O7TT\A4B?!Y.DI2\F490<K9AM9AC5
M'F >)E=[-CE8]]Q5^.=D/O'4)'V[;N))1L(;O@[ENIOKH,EA4AZ)9+#F^@&*
M#;4\$ ]7TK<U)QYZ)+SGZQ"HV62W3JT6L]-3BWJ*TL%Z\4<*]=35A'H>T[Y-
M./4LI>'M9%@DVFRGCV=1T.0P*0]E.EBW?2'55BIF.%CR6_.P=H%Z -.^332M
M_?H3WC%V5+K9$B.<T./?/%K,8(0A/K&KHIZF=+#V^63)GW.-H1[!M&]K33T.
M:7BOV:%9=R\=-#E,RG.5#M9+AZ0::G&)/7/COLUW[!D8]VF^XV;SW3:;6LQ"
MLRGV5(T':](?*M%3EY784S?NVY#''IQQGX:\=(X#$R=HLD]J7'N_P[U<8QES
M)S(-4KZR/M%98G55^_=5]B=&;HM7/FZE,7)3'*XY6W+E#.SW*VGA59ZXMTBJ
MMX;F_P-02P,$%     @ F(!D41ZL!-(S!   Y1$  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C N>&ULO5AM;]LV$/XKA+ /+5!;(FW+=F$;2)2U*] "0;UT
M'X9]8*2S+402-9*VN_WZ'25%+]5+W"7(%UN4[KE[>"<^1VIU%O)!'0 T^1Y'
MB5I;!ZW3][:M_ /$7(U%"@D^V0D9<XU#N;=5*H$'&2B.;.8XKAWS,+$VJ^S>
MK=RLQ%%'80*WDJAC''/YSS5$XKRVJ/5XXVNX/VASP]ZL4KZ'+>B[]%;BR"Z]
M!&$,B0I%0B3LUM85?>^QN0%D%M]".*O:-3%3N1?BP0P^!6O+,8P@ E\;%QS_
M3N!!%!E/R./OPJE5QC3 ^O6C]P_9Y'$R]UR!)Z(_PD ?UM;"(@'L^#'27\7Y
M-R@F-#/^?!&I[)><"UO'(OY1:1$78&00ATG^S[\7B:@!J-L#8 6 _0B8]@ F
M!6"2331GEDWKAFN^64EQ)M)8HS=SD>4F0^-LPL24<:LE/@T1IS=?N'P S>\C
M(%OPCS+4(2CRY@;OA9%Z2T;D;GM#WOSR=F5K#&= ME^XOLY=LQ[7E)$O(M$'
M17Y- @B:#FSD69)ECV2OV:#'&_#'9$+?$>;090<A;QB^A13ACH$S9X#.I,S=
M)/,WZ:5SKVM9>T>N3I@TD\L1KJ^1XIC4/S\CB'S2$*N_!D).RY#3+.2T)^15
M+*0._X6 >$+IKIKD>#?#FS5\VBR6S%TX#L[X5,]5VW"^Q+36#1L49R7%V2#%
MCU(H1>X2%)4H8_H1Q41U4<W]S&H,F-OFV;::]')T2X[NSW'\C&/H).FVPH^H
MTV;9-NNA."\IS@<I?N"A)-]X=(0N5O-6.*SR8MKFU3;$*C/6F\%%26\Q_")&
MV !XX@/!5YWX$H)0D\AD54+$-:94"\+;ZR$P:T:5:Z9K$2\N3>6RY+H<Y)H7
MMTY,Z /(D3[P9(0K,Q42.Q@)XQ1SCBU**R)V_X_\]?)2\M2I%-H9I'\WWH[)
M[_BJJB.R[ O?=%Z3?_I:&D99%90]3\6\PD$]CT8:^E<^K42;3EY&G[S"44.@
M^@E4$DZ'-?QR\?$*3Y>\3I4\TV%]'A06C[;EUB1^UC_O2G/I$Z(K3B 3L[Y&
M*A6)$B@:!$<@4QFV$M ,4JDFG;_:^UQI(7U"#)_LRK0M:G3":$>[Z[)$77?[
M"U#)(!W6P<L[,VW+6!?5MA7MI<DJO6/#>O<3S;GPU+T^BBWAD$F3826:C#ZC
M-Q?@'VK=[+D%MPY+K/6\/XF5Q+)AB?6$-&U-/]&TFMXK#66OMO-EE6ZRY^Y]
M65LNYZXSZ\I\VW+F-/=U39:5O+*7VOZRCOUOQ\ZRPZR/9"7%[,7VO^S"#7"'
M71_-2LS9<_; !=AM5MOMJG;;LKO:=NT@'8/<9]\7%/'%,='YF;J\6W[#N,I.
M[G9EGG\ P8/U'@M/(M@AU!G/,3,R_Z:0#[1(LV/YO=!XR,\N#\ #D,8 G^^$
MT(\#$Z#\LK/Y#U!+ P04    " "8@&11N-].<KH#  #B#   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6R]5]%NXS80_!5".* )<+%$V;*<P#:0V#[T
MBJ8)SDC[4/2!EM<6$4G4D91]]_==4K*LY"0U*)KF(28ISNQPN1JOIT<AGU4,
MH,FW-,G4S(FUSF]<5T4QI$P-1 X9/MD)F3*-4[EW52Z!;2TH35S?\\9NRGCF
MS*=V[5'.IZ+0"<_@41)5I"F3W^\@$<>90YW3PA>^C[59<.?3G.UA#?HI?Y0X
M<VN6+4\A4UQD1,)NYMS2FQ4-#<#N^)W#437&Q!QE(\2SF7S>SAS/*(($(FTH
M&'X<8 %)8IA0Q]>*U*EC&F!S?&+_9 ^/A]DP!0N1_,&W.IXY$X=L8<>*1'\1
MQY^A.E!@^"*1*/N?',N]X=@A4:&T2"LP*DAY5GZR;U4B&@#D:0?X%<!_#1AU
M (858/A6P*@"C-XJ*:@ ]NAN>7:;N"73;#Z5XDBDV8UL9F"S;]&8+YZ90EEK
MB4\YXO1\K47T'(MD"U+]1%9?"ZZ_DXLE:,83=4FNR--Z22X^7)(/Q"4J9A(4
MX1EYRKA6'W$1Q_<\2?#.U=35*,C0NE$5_*X,[G<$I^1>9#I69)5M8=N"7_7C
MKWOP+B:BSH9_RL:=WTOX2Y$-R-#[2'S/]UKT+/KA2X@03@V<7K? E_WP3[ 9
M$'_2"5_UP]>0=XE_D8QA71I#RS?JDB,2M)&KA^Q4%@^['4B>[7NX1S7WR'(/
M.[@7"5.*B!VQ]4?^_!6?D\\:4O57#WM0LP>]RG\KT@U(0W^J6*4*V!*!#HFE
M3BZP:LLGEVVW5)('EMP8[6$>!)[YF[J'%E7C6M6X5]6:)6 UV2/GA8QB=#B2
M2QZ!E;3%A#.I2([:K;Q6=660<4.=WR$LK(6%O<(6^/)R- "F2_>/ +T;LY41
M+5FFF+7T-BDE[:0AA=+)(&Q7,ZG53'K5/!Q 7C$L/8W?1YJ(_,?H+WBO:][K
M=R@YZIV-U'O/HJO8FU4W\8/.HJ,-@Z?_1]E54=Y2=]0_:_-[M=UJHF,@]TP^
M8T_T!G^A9_.BP_>X[K.!T=$[7O>J8F]>]WA,_0D-.G)Z]C[:;W[_S7VOJBAA
M\[['@]&X0][9!&F_"_Y;LUE5O"_<)O0&7?DZFQ_])_=+4XQ>I@L[*YX6*6&I
M*-!\V ';(+;!A&)+;F^891&T-CKA#Z\'#<_:RNZA95/P^AUR&[U<"G)OFVA%
M(J.G;&3JU;I1O[7MZ:OU.WJS+-OM,TW9_>/KMN>9(@GLD-(;A'C5LFRHRXD6
MN>T8-T)C_VF',?X( 6DVX/.=$/HT,0'JGS7SOP%02P,$%     @ F(!D44EK
MP-+1!   91<  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&ULO5C;;N,V
M$/T5PFB!+-"-1$KR)7 ,)/8Z";#I!@EV^U#T@9%I6UA)5$G:3A;]^(XN%A6+
M9MQ-ZCS$NLR9.>0,SU <;KCX+I>,*?24Q*D\[RR5RLX<1X9+EE!YRC.6PILY
M%PE5<"L6CLP$H[,"E,0.<=VND] H[8R&Q;,[,1KRE8JCE-T))%=)0L7S)8OY
MYKR#.]L']]%BJ?('SFB8T05[8.IK=B?@SJF]S**$I3+B*1)L?MZYP&?7GIL#
M"HMO$=O(QC7*A_+(^??\YF9VWG%S1BQFH<I=4/A9LS&+X]P3\/B[<MJI8^;
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M \.RGPG@^R7'H)6#S$#U96;T'U!+ P04    " "8@&11R*G].GH$  #=$@
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M+A)1 [C^&0 I .0? (+/ )P"X'0%# K H"O +0!N5\"P  R[ KP"X'4%^ 7
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M!CB_E-@4U<!>J^J_ N/?4$L#!!0    ( )B 9%%S*+EW'0,  *H)   9
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*U66T_;,!3^*U;$ TB#M.F%#K65
M*&6#"0:"L3U,>W"3T\;"E\QV6ICVXW?LA-"--'337A+;\7<YQW:.ARNE[TT*
M8,F#X-*,@M3:["@,39R"H.9 92#QRUQI02UV]2(TF0::>)#@8=1J]4-!F0S&
M0S]VK<=#E5O.)%QK8G(AJ'Z< %>K4= .G@9NV"*U;B <#S.Z@%NP=]FUQEY8
ML21,@#1,2:)A/@J.VT>G S??3_C,8&76VL1%,E/JWG7.DU'0<H: 0VP= \77
M$DZ <T>$-KZ7G$$EZ8#K[2?V=SYVC&5&#9PH_H4E-AT%@X D,*<YMS=J=09E
M/#W'%RMN_).LRKFM@,2YL4J48'0@F"S>]*',PQH@:F\ 1"4@VA;0*0&=;0'=
M$M#] ]#M;P#T2H //2QB]XF;4DO'0ZU61+O9R.8:/OL>C?EBTNV36ZOQ*T.<
M'6.".9TI38MEDPFYLBEH<KS0 +@?K"'[9*(@U4PN</P<GSP%)K!E04N/HYR\
M%[,SLCL%2QDW>[]C7FI<L!BW&CRK_(7(#F&27#+.<<P,0XM)<*&$<1GPI @X
MVA!PFUPJ:5-#3F4"20W^I!G?>0T_;<:_?0U_VHSO-P40XNI76R!ZV@*3J)'Q
M0RX/2*?UAD2MJ'5W.R6[.WMU>6EFN85L&Y;I?V$Y;6:YBBVRM!U+NU>RR%S,
M0%_-K[5*\MB>X#9D";5@&C+8J0Y1Q^MUMCI$QW6'Z.L%8LBY!6&^-2AV*\6N
M5^QN4/P$6A U)[0Z0+MX*AZ!:E.;KV:V7H%L\-6K?/4:F3[Z+#MG69%G$E>)
M)E;A+WR)I2DC/\F6ZU'8+T1[7M15ON4X&H;+&I_]RF>_V:>2^UB1<IG0&0>2
M9W.-AXID]-$EL\Y"P==?L]#NU7LXK#P<-GJ8%KGPJR<8!_S7R]KP)X<OM3?$
M/ZBT!_^@C84_5@O)?M3_& =--HK3W3BE<!JN%2L!>N%O"8;$*I>VJ%O5:'41
M.?;U-WR>7MQB+JE>,&D(ASE"6P>'N$-T<3,H.E9EOO3-E,5"ZILI7J9 NPGX
M?:Z4?>HX@>IZ-OX%4$L#!!0    ( )B 9%$6*G>AZ 4  %L:   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;,U9;6_;-A#^*X31 2W0V")E2U:0&$CB
M)"NP8D:RKA^&?6 DVA8BB1Y)V<E^_8Z2K#?+E-%N70JDEJB[XW,OO(>4+G9<
M/,LU8PJ]Q%$B+P=KI3;GHY'TURRF<L@W+($G2RYBJN!6K$9R(Q@-,J4X&A'+
M<D8Q#9/!["(;6XC9!4]5%"9L(9!,XYB*UVL6\=WE  _V P_A:JWTP&AVL:$K
M]LC4E\U"P-VHM!*$,4MDR!,DV/)R<(7/[^U,(9/X/60[6;M&VI4GSI_US:?@
M<F!I1"QBOM(F*/QLV0V+(FT)</Q5&!V4<VK%^O7>^EWF/#CS1"6[X='7,%#K
MR\%T@ *VI&FD'OCN9U8X--'V?![)['^T*V2M ?)3J7A<* .".$SR7_I2!**F
M ':Z%4BA0$Y5L L%NZTP/J(P+A3&I\XP*10FI\[@% K.J0INH>!FR<JCFZ5F
M3A6=70B^0T)+@S5]D>4WTX:,A(DNQ4<EX&D(>FKVJ+C_?'8-R0S0#8^APB7-
M:N0,'7UT^Z*O&7H_9XJ&D?P PE\>Y^C]NP_H'1HAN::"210FZ$L2*OD1!N'Z
MMS5/)4T">3%2 %Q//_(+D-<Y2'($)$:?>:+6$MTF 0LZ]&_,^G:?_JU9WS/H
MCR#@9=3)/NK7Q&CP,WU%-OZ(B(7=+G?,VH]L,T2VI=6)U:$^/UD=>UW!^+[9
M[[YO]GNS^ISYPWWH/$,F[++^[<R>?0R.KM6SI\,BOQ*")BL&75>AIU=4EUO0
MUVSX:D=%@/[X!4RB3XK%\D\#H'$):)P!&A\!].M&3R\1T(94L%S"9(7>P_+)
M%]6'KFK)#4XR@YIZMC/7MCVB2VM;S^N)<O>'<HYK.9XW+N4:GDU*SR9&S[YF
MM,"",[IE F@.L1<F_! :R4:$/D-\B:1N.8@?"4' HX@*B39,Y.'HC$8.PJVA
M)W@X)JU8G"1UWR%%AK;='0>GC(-C++G;>!/Q5\;0(Q-;[?BQ&OR(KJ*(^WD]
M0G0>F,]72?BW+D$F0JZEI9*G5J!;XG.-><K[?@['KR\)EO?]KJ#G%IU:H"93
MNQ7->8>0[4U;B3D4PI.Q7NIUJ;L.J;$UQ=V)F9:.3XV.0TMQ4)6=K!87J?#7
M$ JTB&AB"*Y7SN&]C7Z#K6H'8)GS79O*;Y1?DL9/L-;TPLPIG:9JS456@>:>
M=%W,66\B4TO_ZTX1KNU7L!$M!$- 'X#M9I#FN]D@E#Y/$]4)PVP,6T/+^LD4
M15+A(F9<^T(IFQG$,@9X>4^#GN7K',*X6C.TI*& ;9QXAL/&ED9IUZ*Z[IEQ
M.ND#7Y$@MHVF;AI0"T_Z<GQ;&*WG&$]MZPA-X(H!L9D"%X+[C 42+06/]Z .
MEE^!87S0">RC158Q%393%1SD[*(!?$ITWN"XU-<!<-7_L9D ?EP/J%H^-O?\
M;]AU%!;KV2<3SZNEO\A0KUP3<]6ML;E=_Z#]1(&BL0D8NG;;RQZIIH\56V"O
MGXM;-:BWOK;I$%)U?F*]C4(D57LGYH[\7Y#133%GHU'AJ><XN)W&4R2;GE4$
M07H(@BN=1!HAFB0I_(2)+YAFC!(\@C_8$X)#2R[0,E6I@*=2IA0*H-=)<@C=
M<V!+T]YAG2#8=+&B$6*FD>]VD<H]4>KU#*FN+]G,0.=YU8QJW$.3I"(F\J^?
MS4C'H<MR/?NP\OH%FZ@K,B-OXMQ%.@]+N.UFCU33QXI2B6/T\0&JBL*V!0HO
M0'.V91'?Z#9E2GM%CL1]DP<V4E$A,5/AMQS9"I/-G=.D==":%U(-]G:=23NK
MA[:FUK1U_KOKL.5:M5-BT_F*(XF9(^]9 G4=9:F_"N(P":425-.EZ?U019*V
MF23_K^S;%6?:/9SY#=DO3#J-O+9W-?,N*<=NMZX.*=>V6V^5[KJDK+'7ROZH
M]BH[9F*5?:60*#O@Y6_URM'R2\A5]OZ_-7Z#S^>X8_P6G]_EWSDJ\_EGE\]4
MK$)H?Q%;PE36T(5"%?F7C/Q&\4WV(OV)*\7C['+-:,"$%H#G2P[\5]SH"<KO
M2;-_ %!+ P04    " "8@&11""C+_P #   ="P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6S-5EUOVC 4_2M6I$F;-/))"52 !+33*JT:*MKV,.W!
M)!>PB.W,-@7^_1P' JS!,*T/?4GL&Y_C<ZYODMM=<[&4"P"%-C1CLN<LE,IO
M/4\F"Z!8NCP'II_,N*!8Z:F8>S(7@%,#HID7^G[+HY@PI]\UL;'H=_E*983!
M6""YHA2+[1 RONXY@;,//)'Y0A4!K]_-\1PFH+[E8Z%G7L62$@I,$LZ0@%G/
M&02WHR J &;%=P)K>31&A94IY\MB\I#V'+]0!!DDJJ# ^O8,(\BR@DGK^+TC
M=:H]"^#Q>,_^R9C79J98PHAG/TBJ%CVG[: 49GB5J2>^_@P[0S<%7\(S::YH
M7:Z-.PY*5E)QN@-K!92P\HXWNT0< 8+X#"#< <)K =$.8#+GE<J,K3NL<+\K
M^!J)8K5F*P8F-P:MW1!6'.-$"?V4:)SJ3Q1/EHVA3D2*1ISJZI#8Y+>!ON9F
M,!8D(6R.!E(?M0E)]/X.%":9_-#UE!914'G);L-AN6%X9L,.>N1,+22Z9RFD
MIWA/BZ\<A'L'P]!*.('<19'_$85^Z-?H&5T-#SH6.5&5T,CP1>?X%EA 8_HR
MH0,A,)N#?@44FF[1\;HQWIKP8(U%BGY^T93H00&5ORR"FI6@IA'4/"/H?I/K
M5T;ODI)GD@)+T99 EM:=G)W(=WW_75V"_QEVXN.F\G%SG0\%@M:IM\-;: M8
M2!0A:NJOSLC_,)QX:E6>6E;*1\((75$+4UPQQ6^C[-J5H/9UQ_7,,ZTD(VI;
M=VAVDE;L1O4U9\?%D1M;BZY3N>A8B9Z(7#9F @ 1INL.I$("*ZAS8B?RW6:]
M$3LL> D[\1'XA^^\;R\UO+E0:L'1/R-X&\46A =)X6N4VP66P.^<^\A=0,8M
MMV4_J<,/)(A>J^8N, 5N^XP9.RX\Y\4[:C0HB+GIOR1*^(JI\H]=1:L>;V Z
MF[_BPZ+W,PW,@:9L'!^QF!/=8F0PTY2^&^N/LBA[L7*B>&[:F2E7NCDRPX7N
M7T$4"_3S&>=J/RDVJ#KB_A]02P,$%     @ F(!D4:3"S*C"!0  E!@  !D
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M<#U!?=\R)B\O6D'QCXC%/U!+ P04    " "8@&11@R2&%:<#  !S#0  &0
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MI-U@WJ^%T,>)!:B^L^9_ %!+ P04    " "8@&111.@^LC<"  !\"@  #0
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M%     @ F(!D49>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M;',O=V]R:V)O;VLN>&UL+G)E;'/-V,V.@C 4AN%;(;T RSE5U(FXFHW;B3=
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ F(!D46;\)Q?O    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MF(!D49E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " "8@&11-MUYZSD%  !G%0  &
M    @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MF(!D45>I1"I>!0  <Q0  !@              ("!?0T  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( )B 9%$;>1_.:0(  /L%   8
M          " @1$3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " "8@&11B6UK5U0%  !Z%   &               @(&P%0  >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ F(!D46<K'3/O"0  0#X
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M965T.2YX;6Q02P$"% ,4    " "8@&111\!Y^NT"  "I!@  &0
M    @(%00@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M )B 9%&S;4:,$00   X)   9              " @71%  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ F(!D41TKT-<K&@  @FX  !D
M             ("!O$D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " "8@&11  JWWLP+  #[(   &0              @($>9   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( )B 9%&7-GJ:Z0,
M %\(   9              " @2%P  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ F(!D432DH'_("   Z18  !D              ("!
M070  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " "8@&11
MS@-F\[H#   ,"@  &0              @(% ?0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( )B 9%']^P^) 0,  *\&   9
M      " @3&!  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ F(!D48C'3UL2!0  G@P  !D              ("!:80  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "8@&11,J@:,;D%  !!)
M&0              @(&RB0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( )B 9%$>K 32,P0  .41   9              " @:*/  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ F(!D4;C?3G*Z
M P  X@P  !D              ("!#)0  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " "8@&1126O TM$$  !E%P  &0
M@(']EP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )B
M9%&@ZRSDLP0  '04   9              " @06=  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ F(!D4> (HM5D!   I1$  !D
M         ("![Z$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " "8@&11R*G].GH$  #=$@  &0              @(&*I@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )B 9%%2.0-!5P,  !8,
M   9              " @3NK  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ F(!D47,HN7<= P  J@D  !D              ("!R:X
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " "8@&11%BIW
MH>@%  !;&@  &0              @($=L@  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( )B 9%$(*,O_  ,  !T+   9
M  " @3RX  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MF(!D4:3"S*C"!0  E!@  !D              ("!<[L  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " "8@&11@R2&%:<#  !S#0  &0
M            @(%LP0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( )B 9%%$Z#ZR-P(  'P*   -              "  4K%  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ F(!D49>*NQS     $P(   L
M     ( !K,<  %]R96QS+RYR96QS4$L! A0#%     @ F(!D4392PILO P
MA14   \              ( !E<@  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( )B 9%&/>K1A70$  "03   :              "  ?'+  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )B 9%'O6\H)A@$  -43
M   3              "  8;-  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   G "< B H  #W/      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>262</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>50</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Basis of Presentation and Risks and Uncertainties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties</Role>
      <ShortName>Basis of Presentation and Risks and Uncertainties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2107104 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2110105 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2119107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstruments</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2320303 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2406401 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/FairValueofFinancialInstrumentsTables</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements - Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2414405 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails</Role>
      <ShortName>Collaboration and Other Agreements - Zai Lab (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails</Role>
      <ShortName>Collaboration and Other Agreements - I-Mab Biopharma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Collaboration and Other Agreements - Provention Bio, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails</Role>
      <ShortName>Collaboration and Other Agreements - Provention Bio, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2417408 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails</Role>
      <ShortName>Collaboration and Other Agreements - NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2418409 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails</Role>
      <ShortName>Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2424413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-based Compensation - Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mgnx-20200930.htm">mgnx-20200930.htm</File>
    <File>exhibit31-1q32020.htm</File>
    <File>exhibit31-2q32020.htm</File>
    <File>exhibit32-1q32020.htm</File>
    <File>exhibit32-2q32020.htm</File>
    <File>mgnx-20200930.xsd</File>
    <File>mgnx-20200930_cal.xml</File>
    <File>mgnx-20200930_def.xml</File>
    <File>mgnx-20200930_lab.xml</File>
    <File>mgnx-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>48
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mgnx-20200930.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 210,
   "dts": {
    "calculationLink": {
     "local": [
      "mgnx-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mgnx-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "mgnx-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mgnx-20200930_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mgnx-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "mgnx-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 319,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 5
   },
   "keyCustom": 33,
   "keyStandard": 229,
   "memberCustom": 28,
   "memberStandard": 19,
   "nsprefix": "mgnx",
   "nsuri": "http://macrogenics.com/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://macrogenics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107104 - Disclosure - Marketable Securities",
     "role": "http://macrogenics.com/role/MarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110105 - Disclosure - Stockholders' Equity",
     "role": "http://macrogenics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - Collaboration and Other Agreements",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreements",
     "shortName": "Collaboration and Other Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndOtherAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119107 - Disclosure - Stock-Based Compensation",
     "role": "http://macrogenics.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i3a50a689c4e3497fb529200c81c55de8_D20190101-20190930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Commitments and Contingencies",
     "role": "http://macrogenics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2203201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Marketable Securities (Tables)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320303 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://macrogenics.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:AvailableForSaleSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406401 - Disclosure - Fair Value of Financial Instruments (Details)",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i0e1427f09d0a4d849022fa592d4e2510_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "id03af012974e455383bba3223db02d75_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Marketable Securities (Details)",
     "role": "http://macrogenics.com/role/MarketableSecuritiesDetails",
     "shortName": "Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "id03af012974e455383bba3223db02d75_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Stockholders' Equity (Details)",
     "role": "http://macrogenics.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ibce29c226a60423e8c9b83fe1234fc51_D20190201-20190228",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Collaboration and Other Agreements - Incyte Corporation (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
     "shortName": "Collaboration and Other Agreements - Incyte Corporation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i2a91773145ff4dc6bed1e4e7d3de5929_D20171001-20171231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414405 - Disclosure - Collaboration and Other Agreements - Zai Lab (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
     "shortName": "Collaboration and Other Agreements - Zai Lab (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ib3e02e14b91b40519cf07a885f7d06ee_D20181101-20181130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
     "shortName": "Collaboration and Other Agreements - I-Mab Biopharma (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ib65b57f10b78435fa49b1262fb501f35_D20190701-20190731",
      "decimals": "-5",
      "lang": "en-US",
      "name": "mgnx:NonRefundableUpfrontFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Collaboration and Other Agreements - Provention Bio, Inc. (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
     "shortName": "Collaboration and Other Agreements - Provention Bio, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i456c33b61451427ebca4b6600c9eeb6f_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfPerformanceObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "performance_obligation",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417408 - Disclosure - Collaboration and Other Agreements - NIAID Contract (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
     "shortName": "Collaboration and Other Agreements - NIAID Contract (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ic0f76b1400bd48b2ada2b193defe1d6b_D20150915-20150915",
      "decimals": "INF",
      "lang": "en-US",
      "name": "mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "molecule",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i8e5332870f4e4706a838787952f9124b_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418409 - Disclosure - Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "role": "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
     "shortName": "Collaboration and Other Agreements - Boehringer Ingelheim International GmbH (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i8e5332870f4e4706a838787952f9124b_D20101001-20151031",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "mgnx:CollaborationAndLicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Option Pricing Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i656b1702d3e14be0be6085d06cdf2c30_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "id03af012974e455383bba3223db02d75_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423412 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424413 - Disclosure - Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "role": "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails",
     "shortName": "Stock-based Compensation - Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "ied85acb778bf4e98a18112866d8afde5_I20191231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i55fa02bbb93e4ed2a83aa5a30c075ed2_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i99d089ec986c490e9d7a9fe9003fab25_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i2a099bff17804023b9870c32927d44b0_D20190101-20190331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Basis of Presentation and Risks and Uncertainties",
     "role": "http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties",
     "shortName": "Basis of Presentation and Risks and Uncertainties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - Fair Value of Financial Instruments",
     "role": "http://macrogenics.com/role/FairValueofFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mgnx-20200930.htm",
      "contextRef": "i03e1b1b5d97b4b39832498d8f3e6eea0_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 50,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "mgnx_A2003StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "A2003StockIncentivePlanMember",
        "terseLabel": "2003 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2003StockIncentivePlanMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "AdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Additional development funding options under agreement"
       }
      }
     },
     "localname": "AdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_AssetPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AssetPurchaseAgreementMember",
        "terseLabel": "Asset Purchase Agreement"
       }
      }
     },
     "localname": "AssetPurchaseAgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AtTheMarketOfferingMember",
        "terseLabel": "At the Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH Collaboration And License Agreement",
        "label": "Boehringer Ingelheim International GmbH Collaboration And License Agreement [Member]",
        "terseLabel": "Boehringer Collaboration and License Agreement"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_BoehringerIngelheimInternationalGmbHMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boehringer Ingelheim International GmbH",
        "label": "Boehringer Ingelheim International GmbH [Member]",
        "terseLabel": "Boehringer Ingelheim International GmbH"
       }
      }
     },
     "localname": "BoehringerIngelheimInternationalGmbHMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration And License Agreement, Term",
        "label": "Collaboration And License Agreement, Term",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementTerm",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mgnx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://macrogenics.com/20200930",
     "xbrltype": "stringItemType"
    },
    "mgnx_CollaborationAndOtherAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Collaboration And Other Agreements Disclosure [Text Block]",
        "terseLabel": "Collaboration and Other Agreements"
       }
      }
     },
     "localname": "CollaborationAndOtherAgreementsDisclosureTextBlock",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
        "terseLabel": "Warrant to purchase shares of common stock, exercise price (in dollars per share)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantExercisePricePerShare",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "mgnx_CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
        "terseLabel": "Number of shares available under warrants (in shares)"
       }
      }
     },
     "localname": "CollaborativeAgreementConsiderationReceivedCommonStockWarrantsNumberOfShares",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CollaborativeAgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CollaborativeAgreementTransactionPrice",
        "terseLabel": "Collaborative agreement transaction price"
       }
      }
     },
     "localname": "CollaborativeAgreementTransactionPrice",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
        "terseLabel": "Potential annual increase in shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "mgnx_CommonStockMaximumAmountAvailableForIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "CommonStockMaximumAmountAvailableForIssuance",
        "terseLabel": "Common stock maximum amount available for issuance"
       }
      }
     },
     "localname": "CommonStockMaximumAmountAvailableForIssuance",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "label": "Development And Regulatory Milestone Payments Under Agreement, Recognized",
        "terseLabel": "Development and regulatory milestones recognized",
        "verboseLabel": "Development milestones recognized"
       }
      }
     },
     "localname": "DevelopmentAndRegulatoryMilestonePaymentsUnderAgreementRecognized",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_DevelopmentMilestonesAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Development Milestones, Amount",
        "label": "Development Milestones, Amount",
        "terseLabel": "Development milestones"
       }
      }
     },
     "localname": "DevelopmentMilestonesAmount",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Payroll deduction discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
        "terseLabel": "Proceeds from additional development funding options under agreement"
       }
      }
     },
     "localname": "ExercisedAdditionalDevelopmentFundingOptionsUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_FollowOnEquityOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Follow-On Equity Offering",
        "label": "Follow-On Equity Offering [Member]",
        "terseLabel": "Follow-On Equity Offering"
       }
      }
     },
     "localname": "FollowOnEquityOfferingMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_FundedValueOfBasePeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "FundedValueOfBasePeriod",
        "terseLabel": "Base period"
       }
      }
     },
     "localname": "FundedValueOfBasePeriod",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IMabBiopharmaCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "I-Mab Biopharma Collaboration And License Agreement",
        "label": "I-Mab Biopharma Collaboration And License Agreement [Member]",
        "terseLabel": "I-Mab Biopharma Collaboration and License Agreement"
       }
      }
     },
     "localname": "IMabBiopharmaCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IMabBiopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "I-Mab Biopharma",
        "label": "I-Mab Biopharma [Member]",
        "terseLabel": "I-Mab"
       }
      }
     },
     "localname": "IMabBiopharmaMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in lease liabilities",
        "label": "Increase (decrease) in lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_IncyteCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteCorporationMember",
        "terseLabel": "Incyte Corporation"
       }
      }
     },
     "localname": "IncyteCorporationMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementClinicalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementClinicalActivitiesMember",
        "terseLabel": "Incyte MGA012 Agreement - Clinical activities"
       }
      }
     },
     "localname": "IncyteMGA012AgreementClinicalActivitiesMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementMember",
        "terseLabel": "Incyte MGA012 Agreement"
       }
      }
     },
     "localname": "IncyteMGA012AgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_IncyteMGA012AgreementServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "IncyteMGA012AgreementServicesMember",
        "terseLabel": "Incyte MGA012 Agreement - Services"
       }
      }
     },
     "localname": "IncyteMGA012AgreementServicesMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
        "terseLabel": "NIAID"
       }
      }
     },
     "localname": "NationalInstituteOfAllergyAndInfectiousDiseasesMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_NonRefundableUpfrontFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "NonRefundableUpfrontFees",
        "terseLabel": "Non-refundable upfront payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontFees",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundablePaymentTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonrefundable Payment Tax Withholding",
        "label": "Nonrefundable Payment Tax Withholding",
        "terseLabel": "Nonrefundable payment tax withholding"
       }
      }
     },
     "localname": "NonrefundablePaymentTaxWithholding",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NonrefundableUpfrontFeesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "label": "Nonrefundable Upfront Fees, Net Of Tax Withholding",
        "terseLabel": "Non-refundable upfront payment, net of tax withholding"
       }
      }
     },
     "localname": "NonrefundableUpfrontFeesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
        "terseLabel": "Commercialization of molecules"
       }
      }
     },
     "localname": "NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfPerformanceObligations": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NumberOfPerformanceObligations",
        "terseLabel": "Number of performance obligations"
       }
      }
     },
     "localname": "NumberOfPerformanceObligations",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates to develop"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
        "terseLabel": "Potential annual increase in shares reserved for future issuance as percentage of outstanding share"
       }
      }
     },
     "localname": "PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_PotentialCommercialMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialCommercialMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential commercial milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialCommercialMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
        "terseLabel": "Potential development and regulatory milestone payments under agreement"
       }
      }
     },
     "localname": "PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
        "terseLabel": "Potential milestone payments to third parties"
       }
      }
     },
     "localname": "PotentialMilestonePaymentToThirdPartiesForIntellectualPropertyUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProceedsfromRoyaltiesPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromRoyaltiesPercent",
        "terseLabel": "Potential proceeds from royalties (percent)"
       }
      }
     },
     "localname": "ProceedsfromRoyaltiesPercent",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "label": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
        "verboseLabel": "Proceeds from stock option exercises and ESPP purchases"
       }
      }
     },
     "localname": "ProceedsfromStockOptionsExercisedAndESPPPurchases",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ProventionBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionBioInc.Member",
        "terseLabel": "Provention"
       }
      }
     },
     "localname": "ProventionBioInc.Member",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionLicenseAgreementMember",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "ProventionLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV031Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV031Member",
        "terseLabel": "Provention PRV-031"
       }
      }
     },
     "localname": "ProventionPRV031Member",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ProventionPRV3279Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ProventionPRV3279Member",
        "terseLabel": "Provention PRV-3279"
       }
      }
     },
     "localname": "ProventionPRV3279Member",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RetirementOfTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retirement Of Treasury Stock",
        "label": "Retirement Of Treasury Stock",
        "negatedLabel": "Retirement Of Treasury Stock"
       }
      }
     },
     "localname": "RetirementOfTreasuryStock",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueFromCollaborativeAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromCollaborativeAgreementsMember",
        "terseLabel": "Revenue From Collaborative Agreements"
       }
      }
     },
     "localname": "RevenueFromCollaborativeAgreementsMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueFromGovernmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenueFromGovernmentAgreementsMember",
        "terseLabel": "Revenue From Government Agreements"
       }
      }
     },
     "localname": "RevenueFromGovernmentAgreementsMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenueInformationUsedToAssessVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "label": "Revenue, Information Used To Assess Variable Consideration, Amount",
        "terseLabel": "Estimated variable consideration"
       }
      }
     },
     "localname": "RevenueInformationUsedToAssessVariableConsiderationAmount",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "label": "Revenue, Multiple-Deliverable Arrangements, Determination Of Selling Price, Amount",
        "terseLabel": "Variable consideration recognized"
       }
      }
     },
     "localname": "RevenueMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesFromGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromGrantsMember",
        "terseLabel": "Revenues From Grants"
       }
      }
     },
     "localname": "RevenuesFromGrantsMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesFromLicenseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "RevenuesFromLicenseAgreementsMember",
        "terseLabel": "Revenues From License Agreements"
       }
      }
     },
     "localname": "RevenuesFromLicenseAgreementsMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_RevenuesNetOfTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues, Net Of Tax Withholding",
        "label": "Revenues, Net Of Tax Withholding",
        "terseLabel": "Revenues, Net Of Tax Withholding"
       }
      }
     },
     "localname": "RevenuesNetOfTaxWithholding",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_RevenuesTaxWithholding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenues, Tax Withholding",
        "label": "Revenues, Tax Withholding",
        "terseLabel": "Revenues, Tax Withholding"
       }
      }
     },
     "localname": "RevenuesTaxWithholding",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivity [Table Text Block]",
        "terseLabel": "Stock Option and Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "mgnx_StockIncentivePlan2013Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "StockIncentivePlan2013Member",
        "terseLabel": "Stock Incentive Plan 2013"
       }
      }
     },
     "localname": "StockIncentivePlan2013Member",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_TotalPotentialValueUnderAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "label": "TotalPotentialValueUnderAgreement",
        "terseLabel": "Total potential value"
       }
      }
     },
     "localname": "TotalPotentialValueUnderAgreement",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
        "terseLabel": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandSixteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabClinicalSupplyAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab Clinical Supply Agreements",
        "label": "Zai Lab Clinical Supply Agreements [Member]",
        "terseLabel": "Zai Lab Clinical Supply Agreements"
       }
      }
     },
     "localname": "ZaiLabClinicalSupplyAgreementsMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab Collaboration And License Agreement",
        "label": "Zai Lab Collaboration And License Agreement [Member]",
        "terseLabel": "Zai Lab Agreement"
       }
      }
     },
     "localname": "ZaiLabCollaborationAndLicenseAgreementMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Lab",
        "label": "Zai Lab [Member]",
        "terseLabel": "Zai Labs"
       }
      }
     },
     "localname": "ZaiLabMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, Margetuximab",
        "label": "Zai Labs Collaboration And License Agreement, Margetuximab [Member]",
        "terseLabel": "Zai Lab Agreement, Margetuximab"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementMargetuximabMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mgnx_ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zai Labs Collaboration And License Agreement, TRIDENT molecule",
        "label": "Zai Labs Collaboration And License Agreement, TRIDENT molecule [Member]",
        "terseLabel": "Zai Lab Agreement, TRIDENT molecule"
       }
      }
     },
     "localname": "ZaiLabsCollaborationAndLicenseAgreementTRIDENTMoleculeMember",
     "nsuri": "http://macrogenics.com/20200930",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r29",
      "r64"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r275",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r165",
      "r166",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r275",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r97",
      "r153",
      "r155",
      "r276",
      "r293",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r97",
      "r153",
      "r155",
      "r276",
      "r293",
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r275",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r156",
      "r165",
      "r166",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r275",
      "r294",
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails",
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r12",
      "r100",
      "r101"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r199",
      "r200",
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r168",
      "r170",
      "r205",
      "r206"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r170",
      "r195",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r32",
      "r35",
      "r36",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r63",
      "r86",
      "r89",
      "r95",
      "r114",
      "r217",
      "r220",
      "r234",
      "r278",
      "r286"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r7",
      "r28",
      "r63",
      "r114",
      "r217",
      "r220",
      "r234"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r224"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r109"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r106",
      "r121"
     ],
     "calculation": {
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r103",
      "r107",
      "r121",
      "r280"
     ],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://macrogenics.com/role/MarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "verboseLabel": "Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Available-for-sale Securities [Table Text Block]",
        "terseLabel": "Available-for-sale Marketable Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r171",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r18",
      "r59"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r54",
      "r59",
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r54",
      "r235"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaboration And Other Agreements [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r133",
      "r134",
      "r135",
      "r136"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r66",
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r11",
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value -- 125,000,000 shares authorized, 56,174,932 and 48,958,763 shares outstanding at September\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r38",
      "r40",
      "r41",
      "r44",
      "r282",
      "r292"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r151",
      "r152",
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r151",
      "r152",
      "r154"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue, current",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r151",
      "r152",
      "r154"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r157",
      "r164",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r108",
      "r121",
      "r124",
      "r125"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss related to available-for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r57",
      "r130"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per common share (in usd per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to non-vested stock-options, net of related forfeiture estimates"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r196"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r80",
      "r115",
      "r140",
      "r147",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r231",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r224",
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r225",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r227",
      "r228",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r157",
      "r158",
      "r163",
      "r164",
      "r225",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r157",
      "r158",
      "r163",
      "r164",
      "r225",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r225",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r248",
      "r249",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r230",
      "r233"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Measurements, Recurring Basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r111",
      "r112",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r122",
      "r123",
      "r126",
      "r127",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.",
        "label": "Increase (Decrease) in Accounts Payable and Other Operating Liabilities",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r290"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r277",
      "r285",
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r21",
      "r63",
      "r90",
      "r114",
      "r218",
      "r220",
      "r221",
      "r234"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r17",
      "r63",
      "r114",
      "r234",
      "r279",
      "r288"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r63",
      "r114",
      "r218",
      "r220",
      "r221",
      "r234"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r54",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r37",
      "r39",
      "r43",
      "r58",
      "r63",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r76",
      "r77",
      "r78",
      "r86",
      "r88",
      "r91",
      "r94",
      "r96",
      "r114",
      "r234",
      "r281",
      "r291"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r86",
      "r88",
      "r91",
      "r94",
      "r96"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r65",
      "r83",
      "r223"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Risks and Uncertainties"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/BasisofPresentationandRisksandUncertainties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r30",
      "r31",
      "r33"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Losses related to other-than-temporary impairments of available-for-sale debt securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-allotment option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r49",
      "r51",
      "r104"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r171",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r128",
      "r129"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r49",
      "r50",
      "r104"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r53",
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received for options exercised"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from stock plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r9",
      "r131",
      "r289"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r209",
      "r304"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r14",
      "r147",
      "r202",
      "r287",
      "r300",
      "r301"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r115",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r297",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r42",
      "r63",
      "r84",
      "r85",
      "r87",
      "r92",
      "r93",
      "r97",
      "r98",
      "r99",
      "r114",
      "r234",
      "r283"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r243",
      "r244"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets modified in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued or sold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock purchase price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "License And Collaboration Agreements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsBoehringerIngelheimInternationalGmbHDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIMabBiopharmaDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsIncyteCorporationDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsNIAIDContractDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails",
      "http://macrogenics.com/role/CollaborationandOtherAgreementsZaiLabDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r170",
      "r194",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r170",
      "r194",
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r171",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Valuation Assumptions Using the Black-Scholes Option-Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r25",
      "r61",
      "r81",
      "r82",
      "r137",
      "r138",
      "r139",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security with change in fair value recognized in net income (FV-NI).",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]",
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI [Table]"
       }
      }
     },
     "localname": "ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Awards granted in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Ending Balance (in dollars per share)",
        "periodStartLabel": "Beginning Balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Share-based compensation, number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Shares, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Shares, Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Shares, Granted (in shares)",
        "verboseLabel": "Stock plan related activity (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding, Ending Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r176",
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Shares, Outstanding, Ending Balance (in shares)",
        "periodStartLabel": "Shares, Outstanding, Beginning Balance (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted- Average Exercise Price, Outstanding, Ending Balance (in dollars per share)",
        "periodStartLabel": "Weighted- Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)",
        "terseLabel": "Weighted-average exercise price of stock options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Shares, Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Common stock purchased (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r169",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockbasedCompensationRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "negatedTerseLabel": "Weighted- Average Exercise Price, Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted- Average Exercise Price, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r190",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted- Average Remaining Contractual Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock percent of the fair market value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r77",
      "r80",
      "r115",
      "r140",
      "r147",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r297",
      "r298",
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r80",
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": {
     "auth_ref": [
      "r167",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock plan related activity"
       }
      }
     },
     "localname": "StockGrantedDuringPeriodValueSharebasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r140",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Issuance of common stock, net of offering costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r10",
      "r11",
      "r140",
      "r147",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Shares, Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r10",
      "r11",
      "r140",
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r11",
      "r15",
      "r16",
      "r63",
      "r102",
      "r114",
      "r234"
     ],
     "calculation": {
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://macrogenics.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r63",
      "r66",
      "r67",
      "r68",
      "r70",
      "r75",
      "r114",
      "r115",
      "r147",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r215",
      "r216",
      "r222",
      "r234",
      "r236",
      "r237",
      "r241",
      "r298",
      "r299"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r147",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r111",
      "r112",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r26",
      "r149"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r11",
      "r140",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of treasury stock"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r11",
      "r140",
      "r147"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedTerseLabel": "Retirement of treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CollaborationandOtherAgreementsProventionBioIncDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r157",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "Government-sponsored enterprises"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r157",
      "r164",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/FairValueofFinancialInstrumentsDetails",
      "http://macrogenics.com/role/MarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Basic and diluted weighted average common shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://macrogenics.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121321822&loc=d3e3913-113898"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121323062&loc=d3e15009-113911"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r305": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r306": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r307": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r308": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r309": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r310": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>49
<FILENAME>0001125345-20-000152-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-20-000152-xbrl.zip
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M41'D:J-0377M_K[OVZ00OK0FK\+S#^^F6+K0]V%%4IP#^!/0YSNXKP@4.X/
M):W&"&\CQ>_S&Q$82MX#XAUHU L G66U\4A8R[8;[97:.CS)_"XLAT]HXH]X
MUL3VMHQSP!BD]IY=XR;V710.)/Q9154O?7D</2FX7<H13X<!]B1"G@BC;SA\
MSI2\)M6<3KQGGWS$A'PTR'=]*S?<.9#?=2L7#C[%8F4D*[[R]+F.U!5U><3=
M091L25XXQ2%XG39VJ0#" S16EM(YHAL30JJA+GR)D/ I5-\#DL&_UO,[_GO!
MO5AR]$<MX7)89'65A<.*Q__OTCYMSG^AH.$P5Q*0\[MEO^_.) $C3?9>[I9F
MQ*]].HZ:+B3DH$;#X>KBM.E.R&LV-O&LX@:FXP(5+2V)[@:4-NH5Q@ <1&82
MU8"%%+!U";A@?L(PFD1RXXG<O<_TN[>!>H&$GAMP2@(04"! P"B<C#=X2V*&
ME-54JRGY-%GQ<7/ ;QK.I'*B])Q0.BMT)$J^@6:@[R,50^=?O,3\YW>#F^MP
M./A,J(C@%'[5A$4P"EM*;]4Z>?C@X.F1#=>-UZ.[/J;6R>;+W%>=LT["+@O\
MVWW7+[&!D9XJ E^=%I)R=OZ.LMKO@]@/41/L_C#V+N/^'8MHR_O'._+6_\QO
M<H/28*^Q\%?O@P^:U\%_.\WKWVI,=/Q2913/#J>T]?7&HE:3-WJK*CRU6M5N
MN\H'/OAHKO';D_ 5S,E?4$L#!!0    ( )B 9%%[[;Q7.@<  &(C   5
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M HFC2'L>N0Q,NZ4AS8P"(!,B$XXD.H\]]0!:'2(&L ZB3C&37#3%EH9,TPZ
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M6L6S^^@V$LGQX$9WH-6ZQC=IBA)%5QY$_ENG_CI*X,E-W+KWO=#OC_YY!0/
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M3D3JI#!*9Y%3GS%)=*9\%%F05, Q;#%B(+EXE2@^1Y*[1$ED]PO=09'VHDX
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MQ!!B0)"C"R:M[0)@F2-A7OJ@R!<+01,%&[_$<O7L%HAJS?2#FNG-39@A:/3
MNC2+0J*,,6,S)6W,# \2RQ (]U6U(L'GJ1ACG7:R>#BCEN.)R_$UPM">".N8
MRQQE*F.1D\P&:S-) T ,$:*4HDQEY3\/,>8OYV1^(495HQ0F.ZMWQ,P9K$B4
MN1%PK?70#^JAMS?Q! H$:V="%C1 "49Q\G2(RDC U+ 0+- 0]- J8?-4_+ .
M6\PEG/@<>H4W_9-:=)].=*\A!,%2<:=CYD2"$,;+3"OI,DRM9PI%Z0): 2%5
M!),_YDAXESY,4>5NU#D;"P J;BBE6A4]2A4=WHI*:,TTLCX3V.FT,0]G2F&3
M$:NH=CXP9-C*FB*K4D^J'V:=K+%4LC[=9(U:UA\KZS<B%P8CQY7*++@,J<8'
MRPSG,A.2"BF13BX#R#I>57)2D8LZ2^-G)7'_GJJ+=:&^B2!,GW\:WWAT?99.
M?B'*\<RD*&/1Z13=JM+F:N-_OJ6%7X?>_HGIA8EH8_+E2G4:2,E[KTUOM[<_
M,(/@WYGV,%P_>*2)4:V)'Z")CP?-C9$FWM#HZ-\GR'7>=<U[/=P];9TT3]_!
M^/9.FIVC3IJ?W<TW;'?[+6YM-W&K<W@!X[EHG3;1OS]OL0\"2Z]%I)G3"&=,
M>)9IA$P6"%6<<<^H$=\VX5]AGA^#[37S+!+S2,%I9%&7<<*,><<S)1+J)TY[
M@SW62JVLH6?W5+S^XH?&F>DU/B6Z-K*L\56&ZR>*]R?":SNMEX_*M[EBQ)+K
M^NO#P4G1 X7L:P:<"0,VT0<<:$!(ZHSR5 J&89%IQUVF< 0CY9RUB0$?QTP_
M9O5J9EIX9G*84LZ<R+"2,F/<TM3(S68.@QT,1F,M[<H:)GP5@%OZ\P"E5G%8
MPUR1=W415-ON<- ?F&Y"L34[SH0=WY(/.F#,F%,9YM:!AZU<9HCVF6(<@Z<=
M,"&@V[A8Q9*M:DJ^9+Y4UW$!=%_-;;/FML//'VA0"@EJ,Q1XRD0))%/6:E!^
MSB/)O3/N_['WI4UM'=O:?T5%W:I[3I7:Z6'UY-RBBAC'E_,&2 Q.ROF2ZF&U
M+0<D7TG8P;_^[98 "0,V0D)L27TJ!V1-[-VKGV<-O88P&N]KI6EK=3.F<TEU
MO8DT6V[8.L*/0SSUV!_'? 1MMPIAC?;F+H;IEUAYB=EV*W_-1\S?^@E/)D,A
MLH-=,\ 6>3IR)RI'SE6-C<Z*Q*EL"J$T!%0$,I.64=E C$9#I)764(8(Z MS
MWZ3LFIJY-L!\^%%&!>9B@3DYM!!">&.3(^A&Z)2*>&%M=A>9-"[_I%A*2^T:
M]O=J[J'$3K[.LL;NI/71=2+I=%O!?>P,W4E-M'S*UN-78ODU2V6O^V(LDRDZ
MJDPT$Q-=:QLJJ:'")TH22LQ,1$N1.Y4DFIBH,]1FJ6YMLS95M*UE3;I<8RPO
MHPUYQ?+"L3RQ*ICE&B0-)5"8K8HD G%,>9)XLIFFD1I>4B$T;W/:I($":Y^!
MN1/"V>G923DPO)QOTCO]V,?WV!UT/F&KT\W_KNW)'SVV,"6'40[XBVDI[(V$
M\$MO,-CYY#HG9033S[W^42:C(PQG_5&BUD[\<#88GF)W>(##PW3L_JE\-0M?
M?;G68)11+[45DC#! H% @;@@!>$L<NU#$BR58H\&^4 U.-$8FZ,BNW'(GE@B
MFFL-@@-1F$K#"B^(XXA$29V"<%3&,AF%J09!>_W#&U-&2,34"9WAAL4U_K44
MDV.0[S,_FL$K>HU#ER\VOG3];E[2P92D=L>"JEPT$Q>]G+8R8HQ@K<P.$6<^
M<Y&!,A/%$J8Q>T7 C+/9*]+*MK6XZ17]NX8VU@'.#[<S*IR; .>I,E,GI%?)
MDQ2+TP".$\-]QK1,WE+,9H=G6]L*>)N:FZ[#D\!Y[>,;XPK3P2U%';74M*G'
M*M,E."]'LJJL-!,K76L/CI0:5!X)TE)QZHTD+O'L\&AK:8QHDRM]L"QK2U-+
M3BOFG^;XI6)^?LQ/5YZZ8 $TB:9TY:3YA\T,33RC+D!@V2PQ&?."MA5?U'SY
M6GJZ\&X8HPS0^]@NWUN""]F,U_.YR *(O3-_@E?RF8_<;EO&)^6V_WK"!5H;
MUE]N4Y&=;JPZ8$X=<*W-N@%/$5&28 (0D#9[HXI9XKG6*FL ZTKZC-#0%F91
M$[86!Z,GCD]50JV$NHIF="7411/J5'A/&JIC,D0XF8UJQQDQ")8DSI3G$*U6
M/!,JXVUY2S'WJA+JR.K^85A.IB\KC$8_QO?A^S]L7R\_NGKQ$8 X^L;G)2VO
M$[X-33YJY8+8<J'D,[GN>:FUZO:&.'AVXWHOK_3BPR#SW_O8&XS2 9_W\<25
M,JL?/W?B\/TEZ*<^=2$;.OF(\UD,9\.[/S(E@8"9(/K+YZ[1 K&O*L>F?I:K
M'1&$$3KO;!FH,@F8<];JD/\#&HWW(<J_.-^Z_-#[_J2_RSLDOH_N;^)2OL'G
M[N2S.Q]L_7!M'4X[73*]Z%^OUSUVV6TOWA#L\M=;W[K>^SLO7A^^>GFP]^*H
MW=H[>''W5FS*%;\X/#@Z_&5O=^?XY6[KZ#C_VG]Y<'S4.ORY=?CKR]<[QWOY
M#:V=@]W6B\/]7U^__-^7!T=[O[]L_7)X=-3XF_O76=>=Q<X0X[^;?ZV=;FOX
MOG>6OR,.VBW\)V"A^U)/.HH2?,3^Q;^B&[K9[^<.D%TAU?7?9;!><-VX8=-(
M)TQ8<*2'\G*<N(\#?'[YX,?+F;2=[NBF1A^Z)>1R@7UKGQDI"OPO CT77W_!
M#,]&S/"5\AR_)N 9%?;.E^DS=N=KW_I:!L^ />QKO_V:%'Q5+I8]8TRORL4^
MWLIR<:^O_4Z8\KM'$?;&6V]Q$,?8?2)'Z 9#C:.7[_O9WMK/[WL_:+WL1HR3
MPO:6H.U[]-!;V[4YR,_<=VGFW3]348\9?(.&+R ?38'_?A/&^]SQIJT<LXN
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MP)#-%^HE<48!85D9.>HU,LNVMH5J,W'3;?GWK&'4QA@N"SPPV60&6$"HHC+
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MWOWJM[[UVZ\)919^K?#,<KXBUVJ>::/JM3["M5JZ*OO5/N.P.M?Z4'9YBCT
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MN,Q>/8W&6"WRKJ9.4<^CIV6D7:D5N!]K?3L,4ZGK":A+7E&7$$A=U(X8](D
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MK#FHW81\R ,<CB)#&Y;\6,\7JIBJF*J8JIBJF*J8JI@>V5N)W#+C6;9WD0.
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M9N<Z)&:)IQ!9%)$G")0[&QP5P8#SCE$#=_/L \>%5,)=>E!Q*GU')BX"$YY
ME$@@"9[-6JF) ,V-=4+3(+>VM;)M+6#^TH-*M95JUYIJ9V%:92* L3P&!;X8
M-UH'YSC/QD[F7EV/9AK.HI.*2QJ9!&L98<K;3*76DJPL\R-MK:,*\XME=FJU
M5RN)5A)=*(DJJ3S3E$>!##Q2CXH:&:D*,?$@: T+K"Z_3J4^6FJI29%0B9&
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MRH??XT-N@@X2C>#6EI"6 <>]YDX'QIW@XAY\6$FO":0WZ1@BE3,^,4.<TIR
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M SU#:M R(]'$FZ I5T%:SSCK5(TUA:A>RP'@ ]6,R1+AB!WBU$9D12#(TA!
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M=Y4[U.Q0\V9%&SSESE+,3<0<&Z*T##C00!BWBK(;WHWN4/-GH&8K6<DR&US
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M3BR8D,)X:PR0,&?:R-7)*9VQ?CU-O"*[KS\:5Q)34I9J.@D@#.>1*2U!J:2
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M^!4.AHUTL./,PX<MGIVG.B5-\.*5\40P"5\G_2HG/7RMZES-@J-M/$K19GA
MBDVL?D0N1+0*(8?)%U%S4VA@\"*MYP1YP'?7J+W!)+M@)<KE*CZ^R$[+=#NU
M43W;>)2NDZ3]R*/73[WLXV9%S8)/\PV &8=.QS,4\)] GL);]46"9,R,QQ4O
M)C,E3;G9EAPYZL$1F=%-XO+CZ^;8G$K^A4?3D^$E(FEQPR]?3+KPY"9-8:39
M_&=[VTS>C$:)+"IQO>P,S4I&=9,*!%-M2J1US"VZFX0MFD!T)>32%>2SO)%
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M)JYK),\NJ85W00YMS-[Z >4@+0N8!L*M)I9C0;2+N#1*B5AZ+$.HK@20V94
M\JU!]JX<Y,5RD'SW\*,GS$7&'?)E3#U#RXAT-!(1G[/[O#*T?/247IGI_WA=
M3WRTZL1WPV0O[INO[T']2LV=03/_G8E [&Q]%);#.1"'6'0"\3((I#DN$:$
MC%%$!E0 1$"O*-U>9(1/I66R390"7P'5V;[F:]9UZ\T>KS-&S"FF3KKI"*4B
ME/.M\[W7'YG$)?..(*-C1)P&C'2(#FDA@$0TX7 >0"A7T,F3S6^OCKIH;;2M
MAB8VMZPL7E\Y]591$Y]NO <EK:'<\& ,T64JJ4BD8<*6J_N-=+52?P)U/N<
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MYG&>2)UG CL9KH&,->,!OUJ^K8?#RV,;I<(E0!U4 )DHD\61="87+LV8B[8
MKC=-)Q<PYF$L0'?524H2:QQ01Z9(:G))3&9L8H7,I%K/*M%,F52K3&/VBP,J
MXR;AD=.<,:9R'F_QE&_E'%,G-$U,0J)<PBU7@I$,;$J2J"CF-),BEG)%)%X?
MZE\"Q_LS6+N;$'Y>$UAGC[2!Q?U>],Z.%9#D@P38^>\(N/(5QM,:X#HS6])X
M[E]X<7D.J^NB03$<_1@M [5I!E2;WQ/R)U\$:Q/,#]#N>_VS7JC2P-5L 44N
M 11A#QE0Y$J D!E $6.L,4+2#&,)BBJ=4F7S&%[3F8Y== 6@R#V=T:3[.=B3
M8->Z(2*BO3&-M^%BE)F"DS[V9T"OWN@.]VX:)SN\=(=P5OZ!_Z[#6#57P F:
MX@:S*$%C(",_CN]B;(JS,N6]!. ;#$<64SF  M">AZ5.&]QK%4%L"*=> ATS
M<\K-\H7;@(V)I99)SBAH@X++7 FPUZ(XRK6D+.=R5G%+KEM N86-F=?AY/[!
MIT.;1=K"'T3'%G1QL,2),KD#14XQ Z<!MEMT18=8#"E=%PIB1DC?),H#=XIK
M)M-<)T:P-,F2B/(T4HI&UB6)#C$HH*ULB_)PQZ37/M\_>7_H+$NDIIIHX6(@
M/07F0TQ3@F#"29QEE&<8#.:78A:M"O,P4[ ;.-J*Y;J8\H[$[5-P?Z)(5^:9
M,93RG(M,)*E1W%F1N\3$2ALP7*_@=MMJRI5HR\?'4BQ]0> 0SF1&A$Z!RBAB
MMM/8,9':.+9T296N-T5 +>S4BBJ!RN;4CC52FS=%WB^/_,R(_#NI<;Q^>>*<
M,N>GOZBNU5<D5C&C-2H3:["6I<*']NHQJ V%@;E]+TQ0C5$KO+BZDNM)53%.
MK7:=E5ZSY/'J[=^JI ^$=\/<W]^$2KJX9"XPN7LKF!M'2Z]Y/Z;IW(=GL:AB
M$<$OXU08;9YF(W[&OI!GS*P]XB_"HDS:>B^O4?#+#'@FB^H1PO;YVKGO?K#.
MQ6;>QM*IO]<-'X=I?1HX>]#;\;54?Y>+?U5?^Q-O(]P^>$_;NU\QE]>YU&J"
MH1LBC(Y)EBE-N&%&Y8E*T@2OZZ4&9*F.!^_+M#9>71I,M0C4!C0<B+F4>B$)
M _,CQHD82,*U,;6;ZK>@4'@2GV5AX--%<!"AGG11X?*,81=Z0W0(^Y/VT-@C
M7P'J'W@$NL0 ]8*R?'%L;#01X">D 9WUBNYP:CU^0ICU.? -&!8RD[!F5>M0
MNBT>W1:/UHI' VUO2T<WM'2TRANO=3*9L:\PD6RV&#*4H2O/7DA(,RNZ9Z"T
MGSI0WJW/L$.<?^Q4LJ@[(Q(0)E^I\H6:_/9<S'^E-<ELRV%N<$=]>EVO$S9]
M4&:@(9/U#')ROLW@J>^JH,V,K:V3D3T*;N(BD(V&!\.<U:"LC@4V >M&9M<[
M5WT+5Q/NUB"_J(*Z2W( -ZF=8IR!&D(UBU/!1,;35&36J2C#_LTTBM)MVMB-
M*A:?8'Y[AT(8FFNM"&AZ"1$<+0(J,V(DY;'@29)E^G+%8NVT,<=B(5/NE(XS
M$45PRDIJES,F72ZEX]M^BK?5]1W6ABW.J!0BE8QD%(L/3121C.N$2)H+FV99
M'G&+F8++Z\*6%_C,L. -ZID8I\[D%DQ<9["3A5,9XTI'%#1H$2=RVS/QUJCN
MQ\YW[)T015(XKHBT24R$0(>#2QSAEN812W.M$*.'WV1^JDIYG.529=K _*G4
M%D1,%E.F=13+1&[[)][>D2,L4V2=3$0D21:EG(@TIB1+0,KH/(KBU.2:"7EC
MC&9YP=UZ5748R@1]([,Q[(!T4G.1.):G&3="V.S6BZ^>, %]\N6KC,/F,VT)
M<Y$B(J<92>-($)Z9E"L04*"8($CG%5#D:U19/23RV-;F?8*YF\/8*)XI(TD$
M')V(.+=$9T*16%/X11J=I101%/@*>/6UPKJU9<Q]T\-^KVN>/$E\/F^??#JD
MB8Z,DI8D8%P@4GD&IHS+211S[!/OE&$1EFM>TAI^BB3@$V12;XD"YB:JMCD'
MRI3&I$Q2D3.>:B-SH&&=2&5SH6Z[:OM)D\G^2?N0:XE-[#38.R!5!&PZT=)D
M1!F:"D=-)ISS'9XOT41O3[[<-WELY<OG[^V#O4.:JRA.K"(NB4"^Y%C4C^ I
M7*C<, ,&A,M1OBQO>W S\N6^Z6$K7SQ)[._N' I$;!)<DCA58,X8JXE*M"&<
M)HE.TTBZ)'WV,KL,5F6I?%F26G__A3+O^CT,-N#D?R]Z36P'OFRR2XH$-CYA
M:Z_;:*N+J]M4+ZF;6;1#C>>35U]<T:>^BCC5QIED:I5Y\646_[@2?-0_\Z&?
MO(I1^J#&3 H7ON;[0M/&<R RA4"5[S[\37B49+Y3]*M='OW>^ Y_)]GOOEGT
M!+V[1! /HY=X R%<56]G/!KV0KT/-ELO^ZP/ZHN?;ROO>]J%]'\?+JD' JN'
M7/;]9OW=<;2NGC!?-8;W-?2COCE6\/W!L>H'C,C)UR<0$+!K/:2[GOF*866?
M+(?;Z+'B2ZSC2[GV.]?_B$^8S:R(4LI8G*N$1<B]-9>@A*K$VBCA+BT[QE#)
M U@X_C!7,UG+GW@UJ>7ZYL8[,I4O\2&D<MM7?DD?<47_A.UX7:[H'2YH,M^2
MJ=.GQ]1Y^\?GPPP$J4V4)LQ@>66>) 3DJB*I=8PE(LEH9GR3Q@7>AC/0]3Q=
M885.G;!J&?J=B^H2#9IE <]@"B 4LW:^P4T VF_.9V$.QC=VFC6-,RXZQ5&!
M"4,^O'W=+'Z9."X5C2274B@M=))P2QUH'&DL4AVR^!=3YS:-_[;)5+P]^'SH
MN-,92V.2^2K@F%FB<YL2G2&U"IE0K9^]C&\DB]^_L\E$]&I\0[9DLY1L)(*"
M6!9%6J2*4)=+(AA-29KDC$AG:6*8X/ *-D:XBFXF/&FJV@,E.4C&JQ!ECM6@
M3#\:!_'PY3FLOH7F<\NSUI()8O;#%'^T,VRQRFU>Q!=#?C.Q\,ZPEF@$*YQK
M[%3B"84\CGF]KVSA%'*+5%FFZ(J0X0F:S47 @U:3)'VLPT5(I'Y#J^[7_NAL
M:,:YL+W)]YHX4$V.5!GEH=.+'Q3T$6Q%U1NB6E(F+Y7+#_)C!J*H3*;U*4,A
M?:PV/NA&G8[S^4$A_;13V")DZ>)WRY5C]<YPNF"AYMW0,+]>MW,1M.$R7E/-
M;/R :HP'6-"Q@\E>Q6I&0H7_--8[EQL+\U9![4UE_C<J^M.:[5A=+?PC!Z&+
MCSN#>^!+-*:4?,J9U_$75=ROI-L/+\Y<@S5LH;3#HOSG.WYA[ZJ%K:70+_ON
MO2GSU]+F>9;R*-;&Y"S%UC_:JCBS0G&3*J8XWVKS]R?O#*SEZV&:.Y!V,B58
MV$B$Q&I'4(Z(RJUR1O"(YO;>M7F*@8/;4^;!Y$1K$R2[H"*1N;)&N]@*#2^Y
MU,6+];!M2>X=$.G1]_:/HT,)2KN);$P2*1(P.3%.Q3@ED7$J-E*BY?GL)4NN
MZKQ^D\K[G1'-5G=?A4S@.8<QU3+++"4Y%P+)1)(TM8(PEVIXB6$.S<_K[EN<
MG4MP=J*'C+-S)6[.#,Z.8GGB+(\DLTHD4::P 7%D,DTC$=E<;B;.SMW8GB"R
M[]STK&L@XSI$/S5;HL/B;/N6!(NSEM3?+$LI4<OO],Z7/!VM U]@4H]+X2)]
MM9:O0JRJKR8SAJ>J<FW3AN<13.P(BR,65$;!Z$$B7;]$\<[DTZQ4.N@=X":_
M0_/&#=[T^GLPJPYV&QBI#IP0:(W#BZWDJB17U/[1/I0BI=P)1@S+,@*\)\=4
M<_C#12FH/#F82RG6%%R2FX5:3%F_5+>'FMZBK" &ZN1?U([%0VXY[X;QE[J&
MN%V[4[X!6HFH4[?%9P)0RTS75N/-J!^  :8'[;O*=._-U5DJ?Q]M;Z3'][&L
MA00AXNN$RJ7-U4=['\YW[X4IAB6>M3<-RQZZ76?&'J-)M:0WJ7VV2@@@PD 5
M.YMV-/D I]_/X(AZB$!;RX$W+HLG>E);X;Q70NNX<?CVI2RR5L]U.&']LXTD
M9&PXUS$3DHDH<=HHH>.84I,YI^-\-9?\93WB]CT$S]O\W60Z;R>"Z G[([Y>
MM']\.G2Q2K(DL<0RGZ4*[#!-(XX_&9U*F_+$/GLY/%_0)VX]T'[$>*F7L0)=
MEJ'_<<MX[^'#\FS/3L9NPYE>!8N #N9+5$M=I>ZPG/!8S&U91[9?CTI7E^V+
M_6P'DT5Y']H3EMI?:?ODZ-!*(ZQ.<@*2&VB5*DYTC%#R< J9@[>X=L]>QI>D
M-S6G^S;\WE'F*_EHCGNHW@:&/$:S<)5C=S#EV5U*-L'E>RO\;6W26=%%.ZB8
MX\=R[D^7&5),V<\2[23EEE!A@:Q8DF"' D; ,A4R98Q+FSQ[&34%CYIQFB[
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MD\/#X3'K9;W97N4TN57_R$8SH*U_9)8!_7C_O;US&%.762T2(B,-*B3#%G[
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M<!T8$A?1J]9_ZA1ZUO-1I^'RW!G/;_SN>5$ ?R'S^C<PTU,WA$];OPE=;..
M;/&T!ZS,GQ?8[GW<E,8 K4X#,QXT ]<\U< .:UP3/U\_9+!F\1GK ,]NSMU
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M[L0[4_*JN6G/[%[-@?35N;&-.VE:,E"Y:U:<M>ZG",Z+8)4&/11N79D[B$,
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M/#EH/MF\YC,\GRH9J.LP=3"(8E W0RXQ.V9OQKSU,76W/=NLZQ,58UEJC@R
M%2V7BC>JHM^8GKRL^'+3E7?1\D6?>Z0-)_)[5>%P1Q6KBPFYL922U]#A9Q8$
M-C"^\&*Z+&=:!7"+LIQFM.>K\IHJAZ\I2R%0QDR7$C;>F,;;,%Q8Q()RL7*V
MTP:Z?^4.C0W_P'_7C8SF5;KM;*+8K+([5LC].%@85&6?8'9NF6U<YKY-<E=\
M_3RHR9X[XQ]7:Y]ALZYT)K=HR/P?5S1<6VN<H9RE"B&??>;*6N&,=A96>+EN
MA@;3&/%H3B/S]\>G+TSTH?GSNH%*T)\,@B<;'03'!!6\!CL3S(9W8)Z:*LY9
MSX;Z[\@>3? '7I>X3:N&SIF<W>+[R[/S@=AJZ76XBO'2T:GI(^'CEX+&45:S
M^0M[BL"D]2#VR=0&5<!6X_RQ4#XZOG-S>2>+H![@3L-E/CU%SEM]Y[*)%QBE
M<P/7'2Y(% HW-VE6(]T(. 2F-??K*=?=WM2F!(".096P<OFV3VU;+>#013?Z
M%?&&59/ALANZV0G=Y)O]89(!]':< ;061-5FJ* ?0M'VP\O/F<8"@JL?KN4@
MQ!JPCGPPX0-E:?H$<\('V'Q:[W+*GRZ ])_&&[E&UL@M 9%E28O'Z75PR#@Z
MXU=##%MG6-G*Y/7@S2Y_(I/7_>9VKG<_5R[C&Q^5M3*ZI=?M7&^%7N/E[UX#
M.W%YUQJV"BAA<+7>36.:="5@P@,O)-M!-KZ>UPK7 &%\='NSCVK#\JV9[ZKV
MLT14:Y^TK&O39>WH-F\'+^T[M\YJG]*6U6 ?MENVRI:]\M;Q=M/6VK1_W01G
M?W2[LF586X:U95@;N6G_6J1JS>1-\.".N7UFML(@V^=MG_<TG_=4;>GG%EV]
M_1!F#Z'=P8NG;$!?O2%WU)3];C9A<>??#U58 B/PM=R5;ZY6!#O)S?J9=JT+
M>R%OVG[\\E,KO*<NSZLMC24M<7]-=V^H$?>6X!X0P:55*M&6X#;G5!XQP3VG
MK7A.I7E M#91J=;3,1;2W>:=#K_KL[F'1:[BN-SRH$?,@T2\%7I;@KO#I?&D
M);<$MR6X.UM:^@CH[7%K6A&_EP.Z=W5K;7]=[O]YL/ZZ6CN?Y2ZZE4A]P48\
M#%*GK71-6E]\YK?*C&8>>2UF](!/*-F>T(:?$-N>T$:?$%O7I+R9 [IW@;XE
MCA6V+&Y%V^N[T2?$UK:8MB=TQUZ[K9*RX2?$Z?V<T+W+P">0A'+0PW8:_9DZ
MX!6=%F7Z5UGRRN&$;6^$%:\^!6RU]-+'Z5*\D9W9Z)O"TK5UGQO<FPWWF6\O
MQI.^&.N*R^W%V%Z,QW\QGM.67#L-Y1'<B<<=\-JF%FUYY997WO26R&BK76\O
MQO9BS/NBLNOF^&TOQO9B/.*+P?@3EAB/6\7F]U,[=N]ZMG>__\?#(;Y<'55S
M&>[HPJ^Q:+,P+:TS?>R4'9J=AWRST(ICTOID&L;RJCYQ 0XS]-Q9\5O8!5PA
MU&T!FP7K+'M_KPI]&=]TJZP;W>6[0=U?&V-?38X>^QG--#QL)?5&,15AE.T#
MZ^W/K,M='T\[[_2&KD):KV#PC_J(&9R[,H?Q+UC27V6_X:(/OWS$3@XN],[>
MZPZ&Q7"$77L;'YPY=GWX?_*1Y[!9'6>P6KEST:Q>?E&UB2]___>@T>T!<W'E
M_(H^8O5C!Z?0#! AVD/OIRF,]@9PKS!VX[^J.T)X9B8#/?^V)<)[(\+H$B+$
MYF&3EJM7]12LR*1ZG)V&N<>C+X87OZW:_6I[V#=_V'1=CC/;16%"#7,-T1K7
M:'<Z"*U :Q,X@[WHV?(K16@+LF4/=T8QO[!6>A6-K'W,5Q%5$%QO6HT_>WD.
MB^R2OQ0L%T13XZ^A]8)K_AW@1JW&<__SBU4):=76%O%&Z8^#B08Y:)QCYP#8
MC($;8IN4F;NK9AH3UQGPN+%(V.Z2F_MN8Q-%LL"QU&2X=\=(&'S2_&78QVX+
ML]VE?WY?KU#PGUZGM&QZ+QY>I[3-ND38H6FA$88NECDK;)7F&7-&V-5?ND\;
M+)+X[\]MLA]QTWJAK2WQ;IMGGA7??/X=]K6ZF&656UWF;D\VJIULI6_XL_R]
MYXY1CW'85?W(=6!P/&!@HJ'3.QS@'Z?ZS\;SW_?V7E0MQDLC%\\4I^);]&"S
MQ:F.R(/M&=^FOMJ=L/)%)DZ\LCV[7YUSY17Q ^YT.JY_=%&Z2[S'HC<:-':+
M05# GN_O[>SMOL ^5,,^&+65U5M-RL[J2I7ABX/[?MK"CSW310\G-'#8 F^:
MF+;F\ATRC*F^R@'%L.S%=ZGAB\<Y0X>LE8T'JHF+)3U6RQ:L4]1Y=<_4W_#!
M6^JX+U83U8YX=;?)3)O/ZRF1VADU&LSZ5U&U=-^!:Y2-[/X[@FFN:_9.;T0Z
M0R3W2"/!$*[.HS2$?4-1U>E<3$SB7R]I)+R]$[?K8 1MB]VFAW'-]H9;_^*F
M$XQ8GUY6B8%5\:QMW.JQ$@Z_-S=U\#ZOREFV*MH]$HF\--YU&\'--7IG8^>*
M6V@DRBAMT>#97;N3:-:*Y&K]\]89EO$63Z[7\/'R]W@JMI-]6)/-;J([8W4A
MNF"87YYR>%>??' 3?BB?W&[L0]S8[:D]Q%-[RI_<;NQV8Q_6)]=)HV?R-LW&
M-9,"/KB!4WUS[*,FNS4;ZO7W,_3EK&Y!;5)V20[66N\<_0U]=]:')7:'@X;Z
M_]M[UNZTD2S_2IULSJYS%BL\C7%F^AQB.QE/)W'&=G?O[I<]A52 .D*B];##
M_OJ]]U;IA<&6, 8!=68ZG;:1J+KO]U71?3N0<2POPB1RYOI9%U+(Z\\U N"G
MG@AURA:2--X)G\:P0]&"DM=S0WM=X^1D-2^T931.U[\;_L1HMCJOX"IUVJ<[
M<]96[[#/VC':IR=K/VO3Z/;6[RZ?&*>MU=ZZ#1K09WTE>BU(68>Z@_..E.17
MJ1LO'P?V#WD=YS<T&Y:#ACU:?OY2(MJ['=1Z/?P*(-/KX4N"3*^'?_%Z>"VP
MM,#2 DL+K H#;>$,ZO@,ZI,M&8YY?6%6X"7Z^_3W'>;W':HO?61AJ-</5.,#
M5DT%CZ: :H <V"J!K]P?B3#"HKK!BU9P[N4$NAV:)-=8=8!YA2;":8+;*8+;
MSM9437"'27!U8SL3%==);ZG-M(\C+P]TXJ6610<GBUK=TFN4JR>,-,'M$,'U
M2J_$U 2G">X%&V+ G]STCAAM:17&3OO@]O>4CL4M7F=:6)PDH_$V?.M/F?[W
M5^G&[1C- @=9,(41 ^S'30.O,0\T'@A\ 1 F?Y>O32[%CSN[;+=K]/0ZY$IC
MJ%DZ>J QM%D,=?32]XICJ-G<CI3;NNVAJ:-(0J!7.@.E&7BS*.II)5AQ##7J
MI;-J&D6;3GR6W66X)UIPT]4PV_+ ;S+CO%_@S.YL<*FC$ZT5QU!;8ZCB&&JL
MNO!68VA3SNQVJI>VKL4U<10ACKIQHOFWTBAJ=/>@X'6_4=0LG171&-HP$VU'
MRFU="6XZF;R%"]\)^';A+.KKV._X3,=HZ A:I3%TJF.<%<?04<MH%J\PTMC9
M-'9ZFT;.UC6V)HPBYMRI3L%6'45=K?RJCB*=):\XALKVWNR)#CR$<02?S^N-
MTY4<UIT-PC1UK+GR&-+9O&IC2.=KJHZAUG98:.M*6Q-'H<+4W9\ELM\8.M4"
MMN(8JNM\>,4QM)V1$5O7@ >0;+UTO8%CSW7M'D8LIFDT=;2LTAAJZZ1 Q3%T
MU#0Z.MU:6>QT6CK=J@ECX0A,G2FJ.(K*!]<UBC8L7ANZUJC*V*D?G/([B#SK
MQ5.+<?8R_**S>-7'D YA5AM#1W4]%K+"V&F>'-Q<2$T8A7IBM&"M.H:T<5)M
M#.G\:M4QU#C0!10'D&!%?[6^FK^ZLZ&7\C6-.CBVZ4X1G5FM-H:.&D9#!Y<K
MBYV3C:>]MZZL-6$4"@3J6>#5QI">UEYU#!VUC(VG[C1VBA<5'9[J.Y"\:KU[
M6'G5\B/+=6!LTWYJV1IMC:&-YU5+S/31V-DP=KHEE/6>!)4U8;Q* %"S[J:;
M7W1>M=H8.FH:)?HK-'8V[:>>'ISJ.X!\ZG4X%CZ;VE/:V\JFOC?R^20XK 3K
MB=[:6GD,Z>;B:F.H?%64QM"&?93MC$/?NA;7Q%$DT=K2>;SJHV@[\TXUBDI$
M;S<^(D!CIW@-F,ZT[E^F]<X+N<-\$0CNFV/&78M9XEXXWG0BW)")GU/A!J)L
MZ&+@^9;PC^7%SEJ >LN+!HY@\7W4!T)O>H:$$7B.;26_?)8WJ@;$MUN$3Z79
MJ5U^:-+:(;3EN*9F%<TJ!5EEQ35_FE4TJQP4JX"?4&+4S;YQR7XGRO[]WTZ;
MC>:'P^Q U')4R]%-AK0[=6US:%[1O%*$5]JMTE,J-:]H7CE$7NF63H;M&Z?L
MMXV^(G9WW3JG;,#[D -!PK\M^_Z7O\$?\9$FW!_9;DR[C29\@?H14FN/R&.M
M5VC4G[M#DYQE_HXQ]LGS63@6\(\O!$7Y72Q8F\#CXX )UQ(6NQ734$P&PF>M
M>HTUZXU>+8[_!XS[@@5C[\%EK@B9-V2^L">#R \$Y@D"-O2]"9*]PX%'>>CY
M1@*[>4BIX[4[</ZI%]BA[0'NA<-#^UY\>+"M<*S@GWU* ;:>/L('P/]1N/R1
M#&F9<$CA;PD%S7H>%MD_QWY\FBD?B>.!+_B/8SZ$PYYQYX'/@C?O\V0&!)4%
MX/S=Y0U_^=O A^?F,;#\E\^0<^\1-4N^M8%PW/"L=;(U\KZ._&>S5VR8H_XG
MB;Y9AS>8@(4 ?CF8L;=UH\G@W Y0'-#W9 J,8+'0*_J^1H]-?1M@!U=G5@3/
M>&=+.>-9H"L1>HRFT%FG/8>&X\9I&3R< VL,?'L9_!N%X(_QFN9)H@LV3P)Y
MF#2:1J>%0$B1F"4(TPM 5I&L45@4 &SA ((&"CLLM(''1BCBX&31D)MAY.,/
MX"_V/4@>$7Q@%<'@6CFI:IAL&YT\(DUX  T#%OHV_/D(EQZ( I'=( 3'CRS"
M%P@&C;(*HDSV>9/<EJ/)& ]0L@9I+3T;\WO!!D*XS+(#$PYDNY&PEIL7Y317
M0QYY*^B[HXO&T K8@P C"Q1,"+ ";>$-AP'86H-9513&(="N[<:T.W1 ,\22
MY+$24=HB_?P<K0O7!VN8'D#R]L4H<M NGLGG:_13-"+ ;D!E@S\%"YN3KGFP
MPS&8$OZ]+?P/&OM;P'X6X8BIO"WP2)#Y(K2'W"UI2)!A>N6:,W!BM([:$J:+
MF!5?/Y_7&Z?L^QB>8 VR*V:K:Z W3SII<V_997_K^1@#N%LI)M#=ZAJ=I>Y6
MD9!%>6]+L]#AJ$J-Z_U4C#H^4C8^LI09YV7Z0GWHN2,/,98-GZQ).5;-/8L!
M52WWK-G!_[WL\O3&,SL$,C=SX.CN!"4_%VQ 0O[XI0\&@0"D\5!:%$C,*%P0
M$:"R?B+I:MN[(BC;3GSH]9!3DL,^"U?XBG+[%NA(.PA]RHJQR[D^G.>)M"+^
M0O9./'^G)+>83[@TC4;B >!3;]M&/?G!<(4\)O@8BQ,WQ=.@X/%,!5HGPIG5
MR(Q)W0QX97H!^!C:J"Y<+A2^B\:MNF4--8D36=)*<H/( 4(=[2*9RJ$G8)UY
MDQTD2-#JS!QS=R1DSMJCVZR0*01?$ZTA>MPF8)3,,\9>34P]\);%KRM$XJMY
MRW;PR&'.4+/MWHL@)#-0'2D^LR_NN1-)I<I#]L\(OBMY*1CV^)D'[OO<)8%N
M"F =BT5P#'FE[[YW#Z_%Q[_8)H&^/P*@)6Y%/T#CZGODFV16)K\T&)-V6?)V
M,LO$3^&;-IPY=1:Y^5=D(SS04P3Z":)!(/Z*X!UPU<!S+&1D\CLDCR/D!8 <
M(.?!A\UQ[I(V7F/H@! @N.01I=Y37C M8'_;^OL;^[35M7K=CED_.1VV&YSW
M>ET3_M^N6Z>#@6EU_K?;>K-ZX.GU6&ZQP/AB R8L.YP17,[Y%$4-NQ$!N!*F
M" K*D)/JR! ,@DU0@$\=,D2LR 1'"2YG6V"Y!,R,?%_2F:3XK#_U )H,2(EH
MDP7VR+6'8 $AU8.EA*3V9#ON$ @T1!.(ATJ?"%(U;H :%4S=Q*)2N4]Z16IF
M 3L#I=;FXRQ\"K< 8D=A@$+'0VDR09:"GT6!*./.501'?;AZ<G%0<1P$_L &
M;]4<NW"$T4P*3!?T^8.01F0J"8<1,2RYNE,AG8= AIH 4*80EJIX0I8/.% !
MR#S\-(+-P[MZY@\4$XCGD'Q%@2(B0%,"!%\4*Y\L(:754R158XFGXE]HV?K<
M#"5&1U+VT4N^7?6O+HS7,?*;A1B<;<_#>//+5^X";HD])$7[@$" LBT> @(P
MO^>V@U5[S$D$45QNE@0T))9!B \B"QQ# C(J Y,'(7X(L&J'2A\'T1!XUA:N
M.8OQ_N#Y/\BRD\)-H@Q0!!^;2I$@'1-2$Z!B??[ HBFB.3F<DH84X%0B,D1%
M-)T"R].7Q)(F%X)+8F8&*D:0*2!,P!U")<:#( (ZP9>2P' !X N^A202/)$>
M!;XW"IB,P"LI ##5!7U)05]C#PKZM@0[;II@!DDR$_X$_:(AFI! 8@;K.X&'
MO(,2.(S\.9D(GR7G48QL$S]O2]J646C_AY"JS4(/TQY$)$6!8QVR+RF^C!;C
M2!6L3O@L4<- [$#R(Y0'T118!$PZ>)"CHL:3TV]YPGXH!5(M D=W1$ <!E8B
MRN0(GIN"HG$Q4,C0A!0&NQJBFL$JVLB->8Q(&+0$_!59,W<\J85!*H$0FB@S
M0ID5^#L%GE1)X ^]0<A!YV0,B40<P7<3FX-(P,.2JE+L[\=VF +D#&6!@HPE
M_0&'SU!QP>V%%( FR$L0(37\5@S_VBY@!00&P6V"-K22BS',EEHT21@''IRW
M74B*OH=?6-Z#BS0F1;4_XJ[]?T01X WTG7#L1:,QP!Z-=,M&V0PJE< '9[9-
M*3Q1I2,1J)LIS8HX2:2TE)(2-L&X1G^2!@<<$HQ32I,26P!&9+Z"DT1-#'Q9
M(!];^364HP/@!$N:$ A"]K;1R<0U$A>)-+K,?&0\%KS,TI?G58U%_YW27]ZJ
MF/*9NGD 4',LH$&ZBN0 A-&\T4/D"5_4JI$^D9D;B5F).&F<9-D4*/ >61.A
MDIK"J '%9$JQ/<#;[EF4MT#G8%W$_K7T 'T[^,$PA>7Y ;(KR""%+P32( +!
M PQ'WB4[O_[]ZN(8'>0H)+T Z(?7 W</^3T ;P!0LL$F513+![:#M@J*)HJB
M$4D@#Z4,KJC:8)^!>ESZE@@@[Z,@@$=M^2,?6-U"%&#< Q$HB9A0)P OW@0$
M*OQ;OC9?()L]-P#=$O#95)[$\5829]);EB("! ()*/P&]$_"."H07U#^5P()
ME-49@$G["\2*2RY(;"(8)<BF,O&R<Q0CGQSOH:BG6R&:QVC9$)C;>R#+E62%
M+Z8HSDD@ D%.X/")'4PB<XAW+1*]RDLRPCG&8DHDU  L2A;'1B4UB)$\F@;B
M+/[+![ *0/3,SFR7+DD/S;<:A=Y4F5^]GM$Y:: %IJ9_J=<KX\P@XVRN[TG^
M[J1M]+J]I;^N&XVEOWOJM: LVKW62J]]^G>=5OMU#EOLM<],6'NVOZ[WZ*,+
M&NBDK["9QK+G0V)DV7]#IO@JF>+R<7"PS!2Z9V&4Z6,LT3Y9<0"BP"@R.Z/(
MC0\-<HW>(OJ:\^9;4KANA.0*O.=5O_)0I="1A>K11R,_]D2"=V5D3[4G8#YO
MXTA9+$)IMV ,W+9D&OHHD@FP=V=%I,S*_>';?,>:]G-0'_=)Q7%\G<1WTX#I
M2Z;9;GE 1<%;%Y]0L>B*6VK-+WBWHT;]Q&CO\KAH36\[16^]DS)3!]=(;FO2
MP3LAIZ^HXN1I.;VKPU4*@N!4[P&N.HJ.3KMEEL*O$3^'9+-]DN'?E\N""JY<
M* B"1K>E5W=5'DF-WC:W=QV,BRZ+=FU7.NN4=IQ+T&YNWMQ>&^=KADZUN;?;
M*2UAUPN?O1WJJ7ED7WCDZ*1E=#8X<7]]>K'@N,;ME LL*2Y/0I7]QV;O+A0.
M-#K9H+J*HV<J;#-MWJJE BN])AX6%E%-33B6I=+4Q3$!R@H#^1KL)X]DH4B^
M<U#6BV3+W[-UL5@8B\7=+E9(43V[+'^%TRT[V%#5_\'O;,_")AFJ>, *+IXO
ME<)QF(Z')3[<^C,*\"/XL.NYQ_(;0C&)SU"HD6<@7#&TP[@6#('PMM',U(JI
M&B[YZX]75W&EA8V3.4+558,3.I/:Q?#!8Q?]FSOX;@!WY(C,3(5";4(+#]5L
M9F9U1%/X!=;S90_W/]QF7_@@^:Y\S=O"1ZZ.O_)!M;OB%A-\&KG:4;9M+LV%
MV0N"<MF>IV)C7A9TFDVP2$R^CH9!+*BLK"WJN&=3U1>V_#G@N$<BZ.7W6-(Q
M]_QQ%E^CP/UWC!6:^<#-WK'"<$%,JN2XHP7T$Y)^RO85H6;IWWUEUZIQ".F#
MFK1P8$$HX-&WC6X](W^E_LN^0O8@>5-2!W%_9(XOUGBQ)8RQ^&)#VY\<8VN)
M+7M+J;K] >@=E!?PT@"H+.F86G3QQJG1C2_^5"7Q$D):-G>K8.?E2:'.RRVU
M6@*]''_D#E5?WXX%8+J?Z2K8/2;\0X#3 ,94*#OTL#,$*.-XH*X8T!6SC1-8
MI<XLL%7<7+^QCT9/MNN1ZIQ5$?)MIHX?/G'Y4X6:SI%$@P#YY^CV\OR='FF>
M=D UEW= E>"E7L)+56N;*C.B[_7+D<']/NFN4H[<-4XZRW^[:H%O#QXL^-J"
MI775"@XMKI:[NKO\REI&@7JP7;K5OW[K?[N[NNO?7?U^R?K?+AC\X$O\WQ=7
MM^=?KF]_N[F\9?V/U[_=L:_]FU\O[]C-U>VO*R_'J)!^N:9.)ENV, S^E#->
MV,-8N#2D!:PC/VYXR@S#R)A(=J :S>  ]R)IJL.X@D_*9V%7E2$CSJ#=N!-X
M8.Z+'](? BL'^]SB 2"QQ91^M^Q"]Z(P[<;*#A' =B3U<ODG7C#N&\S<8.J!
MD353IY<_3R,D#C4.68+4DM2)F58WT(B1M!E1=_YFW!ILY %%N\GL#GIH).!E
MZ/A\3G]Y.X6[>]A6>(FZ"[XP$/*38#&*0<AP>/LH[O4T/7_J4=?3_.]D(Y[G
MBEG<R62[0>A'!*#<]?M/]^51Y[]5OMT/WOFV>5K/F*'S,(^)2OP$*&(G%*&7
MSDHM8W:NRTH:'(%T4@$RB Z\>?XR3W39KV,>W).,<I$:],'8\\-C;-Z=<V"3
M!J""/9,J*N1X#Q(F8.4/[726PA)'&MML)Q-AV4@9(,/8@ ?H>WBVFTT2YN'(
M'JC;,34D\>A"3A\%3P,;TF2KW)#;\3?+UMWR%S/8'VJ@! 4PTRZ^L>=8RV\&
MUFIH.S%(9S)"]R R<VF4)8RSBN# /'/9A MR=\:N976YW(@#^$CDR);A3+\6
M?AK,ZZPTL03V%Z\\I.:T^49;5-JB>L:B:N^;175^_>WNYOK++5E3WV^NSR\O
MT(!ZB;FTI6C"A1V8CE1?Y_!AWU.)EN\8TK'@QSL84:#93<G(F.Q4/MG5'F>)
MQ$^0S&0->CA1 $PY&6*+?Y\V)ZO?UT#F!TD3M!I83>(76[-IZH+4)%8*53,+
MU6D"U:?'"1CLNN!;4&<(%.C2RE#Q/H;3W3S9]Y^,B)&S#ZA!V\61$W)<0'8,
MQ$#$WZD2>@@N2H_9)O8$TV JU-^9*0>WE^?L2/:LXX0,4-/_BK@/2@I,S!LA
M!]NXN)QN IK\^%_O"(0TRY-B?@!M&?/SA8ERWZK)ZP4TZ$VV'@/J+178P?>I
M;U>-[R%03I+#PQ&.H-GDZ=7I_B/(A(;PWDEF#*!!!\^" \[/33.:1$XR: '#
MF!&F'#/3D5^)O%!!8R<VW0ICK'"=0/7KC[B?G6YA9<C#8!]IF)\T<,"ZR4RU
M6Q-%UEYZ.6DNP7?31#,K'<11D,H3/F.*B!>2N(-S1RJ14'EZ7D#J#%RY:HJH
M$K\%SWY:'7$K9U+1C$8WY^?08 DY@>T_ FFYTL0:>5&&3F.&3B1SRT0=DH9)
M/JWU>/+B<^D7>IRH+78 @).DE8PR!=/^?H9\9LRQ?P@YY37S@*2WVJJ76-VB
M[JS%HMX&57_'^H.K*U!>=_^XO&%7WSY=WWSMWUU=?RM]])<E<$Y/JYS N0*"
M90V#L2\@TQUI:0D4[<M-K8IP^I7D:0\5$:?=';@=%K5&.@5'C<"B^>LT9\IV
M[SWG7JKD>U#F7A2 F,:;>WYV0.4TA4.-F0ZWY<0H_"L.BS$?S:T!-A4C^"N.
M1*+0UQ %A9J5A1HD'N *]@66($4T_!)]9)P.2)4S-34$C-YS;WM.HC/3L7B9
M*%4M%Z6@<4AR_,UDZG@S:0VD7PS"!(0%R@S31LS):7_9$3@41I N/YB6W@,H
M+[\6._]DFDA 94!#08:Y\ :WX+E 9,(<^<%$J7A*!@!)V*L8P3 ;MF3_B,]A
M"9QT37:-.S_P)]WOP6FH&DUFGT8((B!+G'])X$[''@D:0N9$:D8_1FH>26<9
MA'DT 6WA.?.1C<?2MD!R:-/U<K<"%60HV&E-YAW#E%11^2/QJH"J"L-A?!HK
M)HGB4RP&(?Q [62.A[%E;-B%^?)B@K/7J'(XI]MHK1;.Z?::KQ'.J==/#RZ<
M0[JKOV_QG!N,37^2(]Y*!'&VKY9)L$@#/%V2X::&[+PYGIME9XG ].V!5,VT
M2*3^(48PRX*$?M?X$/N2?=>-:+KWO'?_:U).-!/<5Q;ZA3"S_F0C7KC ,?66
MUIKF3F;'7N) @'A?/BRL7/G/QFF+L/,QGG='OH,?36-#1NV'2$'P>'@@0#-0
M(PE5T=18<"<<,Q/S:H%2I";'>F>.*EB]/BY[R8[AG!O7F9EE+A=WD V1'T^8
MVBGE]&MU^$/Z)8M %X>LIFK@89 %=HR &,+/0 ?LXIC*8^(&)@30,QQF:[O2
M3KJW?3!]73Y!M[5_<WM\[OU^W&1' 9I;N,P S"=:0V+[TB(.9J[E8Y(8#%!P
M5>7SS7=DM&9^!#;WV(;+$!D$N0\#1>":!WHBIJX:U;<GH;38G@PB'[A/RH(_
M(I :8*2,P>0@ZAC3$]P<P^^38>9J.J88)?E:$POY?3N_">4R0IL[207^YE*-
M^6U(N4^JF7\T?!*C< *]AF20/<ZHQ60@'L1)QU;J:JVD6JNU._.JMP,AX%R'
MK.;$QXN]4>0Y;WZ!3UKP< Q/4D3\KXCC3'YD^AJ-@Y>DZ7/D=$S*^K:9%B](
M]LB+[8 /!3B?$V!*&=B4H<RAL'"#4DU:]O2TXV&+"X4S=UW\WDE/1B[M8L$4
MR(]V?*;JSE? &CG> &Z=$]2UQY):IF'&7&V"P3A#=D@MBC-R0V._.".SYWJ*
M:HOV:61]>$Y+H9*\3C*[ELP<GBC5<&S[UC'6_\^H"\"%[S70+**J%8Q,+QL/
MC#?!\U%$?VXDL%R:BO$-FYP][(N>/W]R\7A?XWS7%(8H,&Z.A#6WBPUD'-Y6
M%G+7R'83/SFR"4"8,"@PK92M;TDN@!/=W8RA@M%:.B&/DS F&PF<'ST=SVJJ
MJ,0>ABIJ(%%LRD!L/)P\]!ZX;\T-#9;V)&8(U*,T[QV<YSC^8)HTF]U+;P=Z
M#&$H6T0^13YB$IWD6@I*%9M2@]KAE9&+PX[5[@8%>'MQ'QI\>I"=\8Y+1L R
MH(S8'(3!V H]](T07@GLXAA63F0 $8 4B$\(3OV]7'CA^:GAF 4;%J/9)EWQ
M\Y.B*D/-N2]$$%!I6GY$/@[P]GQ9XA]$<MF9*H:C2?@YB! %P0F2JR4O=<6(
MRV5J<7"'T)J)WPQS7!/O/DG'R&>'P*OM%@](+;AR!]=J(.2YCT5]T1+>5K23
M_U()"06].%_JIT84V7O2.)<E<@XH2'Q5:ETGWA1N[G!F3UC6B60K*$?,9,BZ
MAP*D[\X20,92+ $U2@YJ%90$D]FPC"\%Y@F3_Y!I4NK\H&'=E+I+<X/S!)[U
M*M3]5>!R?O]F4B29!U]J+F<">QG!1L601)9RG<&B-45#%5O-+2K"PDFL8)*?
M$M8"F->2=:YS)5')+D)IT)8)H<Z-*E<!R45QMEW2RTHRUN8$[C!/8ND6X<1+
M)XKEC#)=J:^)!A$@#55=+B,.&$&I@!MU,!KO.#'A$V<\8'UH3ISB>P"T<8%=
M8K:A[1#RV3$/C\=R?0?RK:SA#4*Y=TO5)&070,3'^S."LUN)M'45P3[$\@&.
M3<_G5G3$I@>\"P.WB<TW=,1/FV*<Z!)1=0'2JYK*C^7 IJIPY;B]CK9RQ%F!
MV/9#J4X!$EJAG2S>0 @G_"83"T)D5E'EA^LG'A/<QL&$)[P5_HF+$;)Q_=TF
MUC]$JEO03\VNFI\-D'<I,3-3\+.RM:RIV8$<_Z?GRWU=2N+&%<@)TG)EE(AW
M62P=.[H2 ;(\>@%!8C0@/IDTWZE16Q*0,E;(8D4)+;*+'CQ: Q6Y:6,>W0S,
M8%R^XLCRS1#U,RV? 'GF>';([B,'-T<,E,FCK-<<\2AKAQ(%H--Q.X^MN&TZ
MMH-QK!D"C^2;P T20I;%JR_<!Q]$+:E $4.LG]JRA-%@?BT*:4XO$ N5L]R-
M(5-DJ"Y4KBH3<$MT(EIK8S@+[0J,182<;>1BL>] Q%MLXKHJD&E#3!FB+$U+
MJV@))<^*W)C[:[1<*%O&1"(:T0Z"S!_)NANP$>-""@HY*2[(NF$+"]KBU"MI
M8A(O^6>0D*DA0,(Q-^A!ICC51=6$!6>6;.U)-PW)#H3T5*CETPTWB2(.QE%(
MJX+F++)X^Q(9#;,8/F1@RK9LH7;[/0"KX@>!QG%=(!H%/JYY$_E72UF=?&WF
MFVKSQ@SF5*.YD&!L( +=NJHTRDO+U1PRRS/0</!CEC*>!OFZ%5PS.F]+8QE+
MUMY:9LW$NJ)(0EC6URW,"*^K^W;%FH^M/'9X <3V.MH]>VW=[EDHF]TTFIW5
MML\8K7:QM'.I;';#:'>*)<GW+9M]LF_)[,N?8WM@AT42V97B"3B]49?L7I8I
M<%S$Z6J[DYZL'.D9]49W?[EB\2BX5L-HO")+/)4 &@Y?[5[R?!9V&9!=<T:3
M(_!3<"8>GP7>;1[#!S$4>28D(WW8^@'9V!?#O[]1YVDUCAM_M:A-9!P"1&\B
M8,5&BQ\WVD?\'3M'N&-W7^PI?$^*\B^3HOUK693_M_=\7ETN7Q?4Z*QG7]!+
M]O/L"/\T-?]4FG^:J_'/I\1OTOSSBOS3U/JGTOS3S.N?6T$!(F"A3EUKGPIP
MC]8^U>:>YBK<HW7/1A8]U!O&U;?;G8T(++[5?WV\^<*N5"42N_!,&J-38$.H
M)IOB9'-[_H]]))M;<RPF7!/-ZQ#->?_+/A+-.7=,-8*3?;'='P,LQ]$D]"HD
M=''Y:1])Z ('O-J:@C9 05_Z'_>1@K[P 5;?:.IY7>KY?G.YC]3S799G:!WV
M^C347C_]A-YT2]<YIXDPW[&XB$;[<#FTZ(*'G!W) BT:+!7 K_%I1M0FN^>H
MN$JVX*DD+@,.4Q.WL,D72YC>%:"]WJ9)[R3=3E9TXU.EB?(_ 3L6C?P*,K.^
MTBX%ZL"<8$&Y&E[B<-<HD'#?E:JD7"1-3F&;91&VW5*ESEI*E;J5+55:2B5;
M0,&B&49/16-OKSY_Z]_EIF'NS.#([Y$?1%S6""_K(\ALDDBV2/1E07ZCUVK7
MU(,C&UN_W9!Z**S(F<E^&DN.2)3=UVKDHIK>B,,'0QR-..;.,)Z]38"-QSNB
M!HA<;(7&]_$H''LT&['<O+M7*6?K&=WZ2K-VVUWCM+O^RIV6T7F%F2_MCM%L
M==99#[14"9_LI"WWM7]^<_WY\MO5^6V-77T[7Z 2-VLGK]^D+O'Z7<#8Q_\^
MVS/O[7WPGMV:< +VJR=<>[2(!#=+;OMA$F=A6F-?C0NCQKZ/X5_;!_ N@1'C
M"C0.4,Y]&]MBN*@R0H.TQ.[B)VI,BGC+6@-I#;1N#?1/CB_\E?O@G2^HQ-<J
M:!7 5@RHNP2Z6U#;GL]^QZ$7BU30@O(B#=Z55- C2"Y40?MPZ0N<8G/&ON&H
M&AQ]UY8#V$M(\Q=IRI>OHJM*M+4R@=63Y8'5]P//FL&_QN'$^>7_ 5!+ P04
M    " "8@&11"R_4^C$-  !]?0  $0   &UG;G@M,C R,# Y,S N>'-D[5UM
M<^(X$OX^O\+'E]VK6H)Y22:D)K-%",Q01P('9&;OOFP)6X!J;(F5Y 3NUY\D
MVV!>+&P@:W:A*I6 K7ZDUJ-N=[=EY].O,]<Q7B%EB.#[7/'*S!D06\1&>'R?
M>QDT\[>Y7S]_^/#I'_G\;P^]MO%(+,^%F!MU"@&'MO&&^,3X;D/VPQA1XAK?
M"?V!7D$^_UD)U<ET3M%XPHV263+7S]*[81G"TJUMYZ_+)9BO5*N5_/"V>)._
MAC>5VVNK:IHWX)?Q71&:Y0HTS?S-Q[)H-JR6\V XO,U?VY8M3HT^#D=0@<[8
M';,FT 6&4 RSNQF[STTXG]X5"F]O;U=OY2M"QX62:18+OSVU^ZII+FCK(/QC
MI?5L2)VP?;D@3P\!@V%S=XQGB^8NL"@90XPL=F41MR"U-:ME,VPLH9 &'&'&
M ;86X)A@[+G;!6Q."WP^A071*"]:08JLA=QNH5  <$[1T..P2:C["$? <_A]
MSL-_>,!!(P1ML10<*,E>:1 YS0$=0_X,7,BFP(*[)^/S!\.0%"%W2B@W\(;D
M"+"A&BZC7(GES6*^7,P9/JEM8@&N5FK07JFW(52 #F?R6WX)<35C=JZ0?  >
MRX\!F*8?1%30'TAP)/U@(BNV6*U6"S.Y!&.'L;FH5/N\_)@OEM)U&[<ZD_<M
MON5#N6.,86E^Z<80RATXANU&EV0H4<EG7U".I2K'4KPY;"S[C6/?02@H!JVK
M,7DMV!#M- X6)R0_Q-H#P)APA2*/!,>F4X1'Q#\@#DE6[T)J>W 4NMD-'[[%
M?M2?.T"%DW)V&%MA2LD44HX@B_I_!3"A<'2?DU>!?.C@?K> <R5&$C;9Z&!U
M?<K3!2%B>8Y2M[W4)T20A-WGF*#$@?X,G;+Z-ARE55^(((S^%MH[8)A6>R$"
MG;^\XE,*TRHN1)B(+/99]E)^(,X;R+[/U8D(7KM@+,8GC[_T6K%1B.IWV3X$
M#6&7"_&S*<)#\6/DE^%NWE"2AA3]5%@76(/R&+0[^+/ZO*YH(!PTT0BN^87$
M<JL&M54L.!A.I&YZ.\_]3KOU6!LT'A]J[=ISO='_VF@,^DFG.U9>,_U%-?TE
M,>=],6\PG/\(E!%@&3[8A9!!OPNHT&H".1+C/)2=53 ]5=*FDU-E_+R"_<\S
MI:X_$+^?&L^#?J?9Z39ZM4%+G*T]/]8[3]U>XVOCN=_ZUFAW^OL86@IP/;5E
MTZSHJ%UV9'2:QK(K0_1EK'1FR-XN7#?[@T[]7U\[[<=&K]_X]TMK\)\#^=T"
MJ.>T8IK7R3F-PO]D^!U<:&S6:_VOS7;G^Z'6N<31DW9MFC?)29.HAH(](ZH>
M $.,C+H1)0"V>XC]8.+O"[9$/ L0EC%M0M+2(&KH*Q7-8M$/)A&S',(\"L47
MA6Z0D1'%-P2PH7I0GU;Z.",N^Y[K CHGHSX:8S02@0+F-<LBGI@(/.X2!UG)
M:4P(IF=0_JPS& !+#B/0QA+;",$OU*W-]KM0F(C*DEDN;1IC<BI%_!I\.J?0
MM0D0_08<#Y)1$PDO:"'@M##C5"7'26G<A:(WP4I1Y1DKO$E$0T%*ZA:@1@3U
MPE(X$P,P=!*;7#(L'6-E\[J\:6D)&#-^]M$O!K:8DD<HH@#G2-R%8#KR*N9-
M94_R OAS8N\)T!]":[%H^]#R*$H19&X5U3O"CT65E:\PLX0QECAGSD J?Z<!
MT#NYV_)F9+B5C7-T:]MF-9TOTR'H'5BUDIB8,W19?4ZL'Q/BV)"RQA\>XO.D
ML?BFH-9=B=17%9Q6X^T(R$^&#W/6DY_.*.+EM291+%8V0^AM5)RE1=2)XX A
MH6&AI\,GD-;&%,(T.<XN%+VMB*O[S3I!*XBJ+*0PC27HA:1P)EK8FG-8)W0:
M-$EG5_NBZZVN7-F,UW:3*AKY_1F1#B^&N<G*?P%J@^%1B5Z%U+-;J6Q>WA*Q
M*SHQ1"\72K<8VA,8/B RG0#J@N.:\#9D/<'7E7U\LC3?O.C,6/1V(7J3CBXE
MK^*O.">F2;B[HW(=!ZZG^Z9B?MR+[F5WDO-?I/>^NG"^2<MSJ]9ZK!/,*;#X
M40G?BJQG^V/%O-V+;=67$79VX7F3C0<")Q3A,:0M\<N90.2V,(<4^^V=+^[P
MZU'I3].A?E7<5LSJ7JMB.01C,09C91"&',59+A>5:#X (5TG[A1BIL:3)N/=
M%-9G4]7BIBM70'F%9$2ASIZ(5-52+82V7EHRRS$UB"VDG&/)=/O4;C_:F,F/
M<(_BT7X=:+UFJ5@IFHF9U9P*.KTXR<64=*;R=Y<B2UQ;:HQYKCJ0LI2^'[:>
M<UE43,&YWYD1]&9$NKNPO6J*_DS5+(Y>]RL/IX'5<URN%#?W/NVPZY#IL*?S
MI7>XSD,/,B[6/X>V.O\BNCN YGW@]717*L68"_1P&]W+_@+F98_GS;N8(1=Q
ME1.(/$'FB#(EP"DVO.D0M#%OZ;JX+:%=H*G$907O[\G+I\+J,Z/^]Y7G2N53
MI<'S[8HU^4C;[RM97@W;;63)6&21Y T@=7,&&#*5]M_G1L"1C\;)1V77$N)8
M88QD*_F$'*>>?*Q.OAG@;@HI(O9 /?9F>S3(C9@G>D+<D]^^4.)-[W-^<\2A
M@/*?DO./A$(M<4;"+!^GU2GY&AD=!<*JK3 :@$G4U(KO5M1_/)R'IX; D0^+
MBPF 0\13:>\2+/P,G2?0_MESAY!V1EU*;,_B=6$1R 9<VF:,PAJ)%#JFT 9A
M#F498[<R7<)ES1$XC_ 5.F0JS\I-ZG LK8W0^1,2^1,7L],%<^4!7K =*9K$
MZGPX\/[T6Q3:[\>_?U?MZ4O-+)86PWV"DN+H;/B#]B=#*W)T>_9?_7%G$Q>@
M).8LEJ4%H<WDZU=Z9 X<N:FE"ZFEY5<K='R=A$)3'SV!1I$U5TNQYGK0(F.,
M_B=?31*C]A&0T\S-G[JP>T(W[,&F8'2[BV;Z59Y</O,E'PR5/4/>&0W [#OB
M$[F'140UL=1K94Z=5"9968\GDO&I%\V<RHU-%4E<\9;FV2L2O;6\*Q3<H>0^
M4)E/@+]K@NT<KWIIE#=#+ACJI^$ P,PG(VI\7T1HG,985]MGKDJ-,<B['K4F
M(/$*ULMDKE(8T3^)I%'DI9 -R ,,8@-HUV3*[;HB7!'QK[SH)XR9#T1]I\0P
M>3*Q_:I?)Y@A,=*@NF1!<5)I$I04OP.JUFNH?5]X+4TR==Q.WB?_8@H]6>@=
M[/E(Y^!WRV5O(I*'D8=M.8J7J<@3,&]"798<*W"RP=6 <. L,EWU8%-"4T\@
M>;):1\RJ#J9(*.);TQ/"R/5<$6%1*+QV"_N'>Y!!*JRQ26C3XQZ%+<8\_V6
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MT:B97<\$OD7VZK(O,5ZV+O2AYHKX0@NBO2Z7RV1E_I'E_?M/_P=02P,$%
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M&6]@=H6FWDFA5$Z$NAS1%4JX4LGHB\7"F%'@+&]B)EZ3XH'@OKUF;\*LJRP
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MN\8/7+[U*YQ,</7XM'C?HB!5W/#G*\O,E4CPD#*E/L5R@9W0&'":!*L821E
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M\:M=O7;N2WY-@$=N\%3!I>(=X^T]O;L(53OL>,_-[&\+0MX=J$[=[+?1<N4
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M%GKN9W 9R'-U!ADP*A@*Y=0?'0V#D\<KFD@PH1P[!,/9?75H^^CA'JV4]^:
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M>))EE2^*?_M+^-?@+T 6?"'RXO;?_O+URSN(__(__OV?_NE?_P\(_^>K3[^
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MUT(W=GU;RGJMG 5Q$G.!&62A,E,^EI#2)(.IB!G/9* 4(O;>%>?^IT8,:PT
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M8CSA2,604QI!%,0A)!0%,$XDXH3&*5+(QL ^:'EJ!FXKG)T=>XA3-TM=I/W
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M22@"B%0B( L)A53$ LF04A53YZ3(E\LU-3+]<"3SV5RK]+<>Z8T]C)H=C[[
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MO[D1AX.,G 5Q1L?C?(=S7^R=\KS2F\V:65;O<K.9G'%)8)F1 +E)EHR4 HS
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MN]]UO.+4O37>*T3=_R[]C/]O7Y^*<JO1:C5=^RH3F2*HN 1AHA1 '(6 H52
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M0]7.H=,C".WH5K<.+SNGFT7@V-E+>^Z'?LKB?K'(U^;>519P79@G2R75QH<
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M>J(%.S0Z2>'"+<:C!#M=]@C!\I*1_1#:F*G,FB.SIPE7$C,*E38@T@00A!E
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M'6TSVJE6>U?:_<5^[NTO<DWG2RG>TV*IE^@F^SI,L$1QC$ :IA*@%!/3HD4
M(5,D,TP3G%H5\.H>9FHO=KL)Y3NIYGSNZ*(^@Z:=._IZC ;?V%4"!HV$ ^2B
M=X/@TYU\9J117<?=VAZZB2]\NV\WQ7::^?U/.E\8:_Y#7GREVJA?+/(_34"9
M_O?;0HKYVI2(G"&>Q8HF#*0$(TT/(@0D4P(D!">*9%F,J5.GZSY"3(X\&BD#
ME1<!+^4L"Y &A:PH99T'M%$-Z"^!E58N$*:^PVJKO&M#QQZS9T='0\_)T*;(
M?MF,N^#^"'K]V=Z<57H$'[N*QO9H*=D?1K^M)WO(,7*+ROY(';>RO.)>_8BT
M7>-(KE?W2]$TQ"K+=]#51H_T:*KX;8K"M*99FJBIHOGG&[J:E[WW'M;R63-L
M1)625 (>APP@'F.0L80 13 EB*LT(U:!3(-(-S7JW>4=WM7=FLH3\):&0:-B
MD"^#K9+EM]IJ!J6>P1]&TZ!4U;%2@-^'P(ZH;S:U S/X36;5F=\'0=\G\?L5
M<-0581!L#Y>*80;IF6PQ_[Z<ZWVGB?K@W#C*R_[J"[T3E:LG^=?ZC8;GGS,H
MTY!#$@*H& =($@(H91$0.*$TC:@0@CO58K :=FJL_W7S_$R+5Q->UE(@V&D0
M-"HX9D3838(=.?N'=F#6O0!E\(<1.BBE]IG:[P23UX0!NY''#?UW0N,HB-_M
MZGY,]4FNW]+5#Y.+.A=2O'G]MI+B8?E0)K ;EN3K^<^20F<T$E#04($HXC%
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MN+[,9F Y2^:+!2%%M<^!4!X=0F B&Y=2]G;+E7T/)]<#1(W3MF,X[/2F@ ;
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M:95/C?HNV8F)%QXC10*:Q2HH"4$XI+^Q6F.:F%&#^+T_H&M<\S0(K/K41 /
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M]"$K"7[$3/]%Z@_4NS!TSFCRL&2JA4Z$$@A*%>!9D+>7BHAAV(2DAZCKN;)
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MO*VNMNVO>!IQ.>'.%2:<H_,E,5!%<H@A<4"=31U4CRP.,@ND"W&-(*XO1'1
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M1L#6/Q+NP]R!:FD48>*"E<"1,6$9N%3G^SF/X%WF0 +BV0HORS ->A^@J9%
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M#,(,<I5S+T7C!D$# ZP7-?369KS?JJ[SM)"Z?6Y8BULD=ZOAVOHY?51L_9C
MGNJSS@>[792!Q<NQ@^L;V0K7Q84JR(3.UYMG"J.=2!1D< 6Q3H%'S"[+07)-
MNY-XJ.FYL=*K^<5:UYKX;E4Z_,_;8GY<AMJ2_WS+7.^4ZT)(5_NGI)#!6,-K
MBW,-/L0"CGM,V1F3Y2"%;D,Q-*Y?-Q!F[UK )M#0:%GL-ONT?P^!!SYM*&,Z
M8+> 7> 9@J;35$")%!0HF1F!@"+@9)/,66HMAFFA>CR3>K^?>KT?0G+:8"WR
MJ$^:*MI:8%1GZ(44N.6&B3#,%<N/:7L\AFX')'6/)?;3T2.R60?4[S_T<4-9
MK2$K]7< FXXJ>V<8%(WUN4-Y"%$(J"WCL\S1DI0>M]GZD#YC/IMA':&W.<UO
M'?1OUY]Q>>N8/[^&WZ22L?J\Y%P"Y2D\<M$(0 PJ^!QU'B99<"]J'XUIVP5M
MWS5P'5R/#5S8;>GIL<D72J8$C0[!R5JXZ]""QVB!NU04,8+1#?-LO)V>D6=B
M#(^$NP]K/:BE 7215.8K6KF*Z0,NOT[K_,:WVUMPT4>NMO_HXBF^Z)1#+7<H
MR9'SH)RIL[X*9%3(D6?CAVD/T2<3(S^\]8&J12,J;@#>#Q7H6)Y020E%!$T^
MM2^U_V@ Y[$(3XZOQ4&>UPXLL!H,>N/!9(>BJAUTU@3Z]BBPB5S4*EX%#+F%
M.@ <(@L)2L'"=40>Q2"WB8,550WV!M<08@?6<P-8?K@$Q[K$<K$<F,3J204Z
MJ;B,D PZY:+2O@PSK_7@0JK!'O":06=_FFL AM>._OWW6J^O,H^\"DH$.B"$
MDJQ.'Y<04$3@*3.M=(CTLV%#]@Y4CFM$CQ\Y#:?"!O!YEZ7;>^[D=+%<3_\3
M\[/%:KW)DIOH:"0K64%,VM:QW@&BIE/!.\4E9^A8'J3.?U="6XGO>\?,#Z[+
M>U5@ W/9?\!?2F>G9S,Z+/+?EHO5ZK<YN>*SRO#?Z!CZ!0MY-A_#'Q/.F(K*
MU[QX\L:55QX<2K[IF9ZCLTA"'P&UW:AOQ>".#.4!5-V^ ;Z7Z=?TKVNFDS0\
M1A/(U5(;L3/P/-<A]D)K<MP#ID'J'WJA?ER_MWU\[Z_JW?'MS_$]QT^5D.-F
M\&8C4\R"@Y>IIL?45UTF)/CBM4LA>I&/_/*^1P;O8/4YX^&T%X4U8&KO[+<[
M7)[,9HO?*9ZM_WY&Q$W7==]- LN1"1L(-W4(&9+/Y!0&\)%GY]"6$@>Y*=B'
MV'$=A2,]H@ZNQ0:0>A[&?@[SCWA:[T*6WUZ=?@G3915NY>=A&4PTL\DJ48!E
MN:EBTB1>I@"M"E%9GJT:!+.'D3VN&W D]!Y1LXTF/GU8+](_/B]FI,[5N8CW
MR7?:\BF]S&C] 7$]93>=?_05H$J6&J6R$(R+M3("(;I0H CM8C 8"Q_D3N4V
M&0=?=7XGNS>+-6Y+.4XR1"XY!\'1@&+64(C&#-@DD_5<<"$'<?0Z4SCNY=$!
MZ/CN[G(0G3P:RW) 0N7]'S:,G1DRF?(.H'26&)).$%%A;3I;(.1@R1FRF!EA
M"]D@I3,]FYNK>&@CS%^^;9KW75SWNQRR1P;2!T[13QT2(9R'+&- ZZ7*99 W
MZ0=H:LJD[(* ^Y]##I-[ V[VA[.XFN8I.6'5N;I@:)._1-1*RY4#PVV=WEF[
MAFJ.&S^/1VXHPAUDB]Q+42O/&0?J_"Z6>E% "TBZ)O]-.#U_G)RO:*N1@BZ>
MQ)5QM?I5 M;6*(IA F]3AD*';O(I.HR#I*G_F+21L=4/!NXBJU^%C BQZII,
M7B[JO<;;^;D=?UN(@AOS8PS%@4%+8-&+\^YUD>0#POLL-&;K[\ZO^-[=^>$J
M(X.D9W4NAI!M W;H[5=<UBNPS47&VR]5/)=Y,]*3 #2%#<&9.I0Z0JC%4\RS
MX$/.6LA!AIS<2]'(KYK# *I?/8QM=4[6'S_C>>77G6U!'B,)1-;;I^Q B>@@
M!D6'OG,1F3/*"-/)Y-R[Q,B/@@/:FWZDVH"QV3B!%U*Z?GDB\YB%D71JZ_I(
M&66&8$,&*WQ]+\J6\4$,S59J6DF=Z-=M/ESP#:#GYA8[J_"G?WPFL:Y>K59G
MF%_-;VRYB4E%%)$5,%-YR]P#A:H<C T*4Y31LT&*'W8A<EP/J0=,/.!"]ZJ@
MML#W;CE-^ Z7&]XFJGA,"0M@K#/*="C@-Q4;3'JK>$IAH,#_'H+&-6"#@FI_
MP;<%H&>+.06PN-QHY3TFG'ZMS29O[@[K43+ER#DHNE[A9PZ1"0X.:T,$+-*F
MH6/_'U,YKL<U*-1Z5M'8?OFSQ>GI8K[A[-?PQ_3T[/3D='$V7]]\+JY&NN9!
M3 I)D#$;0$JL(^:R!D<>!ACR,&3,S"O1[79@EU7'397J#TO#BKO1=[1GBQFQ
MM3C?+>&BJ.+DTQ+/.YOO\YKVHX_LXTUM)[(/?%F[P,6-!3<]AQ/.5WB]Y-5[
M2];DUM>I8\[QFHGL' 06 F!MTYZ8("QVW8,=ESS0OMQ>Y8XDMST?*Y$\0XJ!
M<V $>T=?7' (1I;L2Z:P-J:]./SQVN/XW0,BX([Q&507C],$O9JG;VN\+!2L
M=S+[/_3ON]013%8W-H]KRN@_M"FK @9SHO/-6?#)2K I6B>X11=B&Z;L^UN8
M&TM^Q9,E>7^?+I;:](-/]_SXAIMX<7D33#998LW!H4!7(2NU0SQY%DF;Y(1G
M @<I)^J?E4=A/'?!W/WI"J-H?\108;5<3]XM%_DLK=\NSRNZ\7QR&T<MK*=C
M*&#]$BS$HCW(I+$(73#I+M$H??X-Y-*_[J+V/@):R648!Q"+'K73!KJN.P;@
M9?T_<ZZ4$@L$"GY >0JD:UHTF,*#HDC(*M,E WT7B'U/Q3@XZT>QWZ/D0"F/
M?6?Q'K_B_ Q7+TE0WUGZB_>O)!FW(28002I02DN("NF+9-K3CDJR^$Z^18?%
M1@?'H?I<#"C<D>W*^VIJ-WNFQ*QL+ R<RI8D8A(X;@MD&5*.-OG0J22PDQVY
M6K651\/1SZ?]]- ">"XP[XQW#FD;&2%K=^!:JJ@3 R6$E9FGG&*7/.#N\!G;
MMNRIL;LZWT-\(VO]XF+V@O"<G1-*U7)79JNM<\2\%B"=\\%H57,)^]+[K95'
MUOP^>EOT(<2QM3^=WR <BZUY[ Y236Q7.9&C944 0>RXG"B2Q"YM/;MI_^;*
MXQP<O6E_;R&.K/UG]3$&ER2E];>:K;6Q?T*3N3/D1DF"*J$7$4+B!;2*I=93
M6<YZ,_W;"&BEJ<7H3L3!VAG;G\ O9\OT.=QPJ>^R=.&^9ZF-1R? %4L28K*
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M(I>9MB!&E[%>_W0;G+C]\\>]+6D)-ON)O(%CMM?L?"%")'>FD%>3!:BL$[A
M[HXO*$PP 5%TZ<G4?FN5P6K,&O,\1T/'V/;T-N/7\>J-ZN'WF)!^F)\M3D\7
M\P_K1?K'WS?7M>L7?^ R35?X;CE-2*;GPV?2_<3Y&"VK39:8(O894^!,)NL@
MI192^.Q"MS+Q_FE[0NU<=@+9HAV-CPWX@UN'A&")W9JH6"V,<J+6TY,*HL*4
M4_8F^]#-U?BS$<S!8#ZJ-IN!;MV7=1^&V8_84^A#;4X"5M>!K H1//$'6M!.
M]4D'*[I-#MQ][2?4-.9P> ZCL68 >9>ICXN/GZ?+_"XL:Y<<BD9>S=<XFV%:
MGX49Q1-?<+G^=H=QD;0D#TV!+/4"17,)CDZ5VO1:24&!"\6ENT&U!ZJ>4,.9
MPT%\;"V/#>\W9S70?5LN@NHP3_@VSJ:?-OI?30)JPY0OQ KY.LK4I(22%1B*
MI*U.V:K0L?G@@^L\H>XS>T.P1TV,#:KM[O<->6U<ZTG$+ LQ <S7WHJ.PMIH
MM 931'"J=@KEW9* NJWWA!K.]!P8':29-L'6,=9;7>ZZ39"WFA27E"K,@ZLI
M#2H92Z9;,A I>K26Z5"ZW;'V2=43:DHS3D1_B)8;N-:]:DIF6$A," NH#+D3
M.42@X(V^H/-"\NC"78,Y0I.XQ]%[9A\@'J2/!G!T\C5,9_4:F=S8#V&&'VHQ
MZ;3ZM<\QKJ__-8E<6X6;V7O5_#.K(-8BT\!0YHQ6NDY)E[O7$G0D\ F-O#X$
MAX/H\W$V07KSZN35\\LGPN$Z(&U=Y@CMCW[,WG%['Q6!R3 3 3FW=>0$^8<J
M<X)N"%)Y%U7J-GKR,?<^$CQ*E+27<GUB5BX)B.@X&!1*8U!,AD'Z&/Z3]C[:
M!7-'Z'VTB_;;J(V_70)N9$(Z;2*P9$3M":_!L2Q!>XN,8CV'=V?"C=!YX3%U
M,]H)$#_JO+"+=MI UY8:<HE%"RMK(D[RM&/I2^0E0*TM-XED97-O4[T>2^>%
MG13;J?/"+E(>^Z[F9G. OVTB\XM$*Z$SRYK\7G))B0GZ.WC:-F ]QR1]$5IU
M>QBY;X7187"HYN[KL;"W&%NL]F-:^L"5 "\Q@Q*V/@RFVJW5"B<Q>*U]7Q9C
M[VJ_Q]0.:-]#Z6#M/)IJOV"SEI@46%/((,=(FP?K[#*N/.?:J>1X7Y![K-5^
M.RE^KVJ_7;0P]B'VYCQ(G[V:K];3]=FZ=I28S7#YZ1OMSE?S@G4#GJV>3U=(
MG%^:9H8F:*LUH.$*E(X17'891-(NQ:P<";G;2^H^RS^&2L&=,+ XJD+&MF97
MTV*#\B5PXT#;0O8\YT+VO$0H/+"D5$S!]SLH]TDV%]KW5-Q/#RV Y[(*)B@G
M0W# ?3"$>:/ *U^MN=;)$^.8^COLVIJSO)/&[IFSO(OXFIJSK(6@L%/4]FU:
MUN1EHCF&0+)(3MALD^W/R6EPSO).>KMWSO(N0FS@M:_79RJ+HD1#L2FKLU 5
MIV,Y:E)]1F^TB=RH.$BSNS_G+/=\C(V.CM&]]XM4D%_I,Q/I8_5Q\0M>9-9C
M)NZOTYBG_XGY3FJGQ.)S)OY*L%7D7D#(/ -]'V.2*1K9K3#B(#*>4(G/3M#9
MEBXYO!['1NS+L_JPNVD%_K;\0A',.UQ.%WGB"^?)RPP,2VT&YR-0"$7_U+6-
M:DY2E&X#:.Y9X G5WNR-LCYD/S9^3G*>G@?(-PJ(*F/3^:>W7S:2NKL[M+!>
M,P&YN$B1N(XD+G00>+$4&&<,(7="ULY+/Z&"FKTQ-ZR^QD;CQ\4ZS*[*+38[
MZPXW44D6O(RUZ%[4D6T:"%3U\M$IJTQ0F75+"__A4D^H\F5OM/6KC['1=5F[
MFW??1-%9H:4KX*Q7U9NN^27,@S$\J1B,E!VK$?:GX0F5P>R-QR-IL($ _2J-
MV*; I/8!>,BJ=K3#<_.MA$I6U\XTNHR>UOTX"F/V@=U!^GB<Z;*_+/!SG2*$
MRU?T9?89IZ>UKG$YOWA)^=MI_+?ALFAW6?T(R;5["^.X.;<BE,#1*6!"!E"*
M#F0G66WG'+GS.=+!'#N=3X\YY]8S*6SB$3(C_E6H+]&99(+:,QW0&*$&J8#Y
M)\VYW05S1\BYW47[31SP?31=++QD'0B27E:OQL0Z9AT%%&0V:I>4%X/,(S]>
MZ]?'E.6[$P0':?VZ"QX>]R:XT=A/*%Z<M1)L<(S$+CWXE! T#R)EILBM&Z0B
M[<_6K_N@;I#6K[M 8.QKB"XNY8].X8M79^D%9J-<;31&(4@H"*%P$KQ417H9
MZ!QVG=R^_FAZM'C>%TV+\57;8K:V$T4A*P*$TORBK-0G#=XB3Y(+HUWN8)3_
MS-8^Q+GH13MCIZAUSA&U=-ADYR-87BON(QJ(Q UDGHF?PJV\^S;PSY>MO9/B
M]\K6WD4+C^$HOLP(%@R]9@&PE$WW: :ND+>3M4C:R#I(JUN*=O<U'T->]D[:
MWO6HW$/T#00UO=Y9!^\8QOIZJ^HPYD*^0,@J@DD"L2AMDALDP#]Z;MUC2A$_
M),X?#1UCV]H?^;T?<7DZ(9N!Z+T$GK&^T@4-T:$&D5'(XJ62NEL*79?5GE"F
MW$Y N*=U5C]:&1MF5YT2SRMKGX5YGN:PK@V9C&,^RLUH5#I&!(O@,&I(F7,G
MG-/J;GG,C]I5WEWB"27%[0VH?N0_.HIJQ[AR-L_5WO_VA80]7[_$RH0.,1F)
M$!%#+<NNXZ"+ 5TT<RXYR7*WWO[WK?"$DMSVQU ?TA\;0C?NGZ[Z!J].3JL;
M/6$&!4<EP$J5R(&(@0RJTY!-%+P8F2@:ZX2B!Q9Y0OEK>P.I+QTTA*63'9K[
MO\>T^#2O&>Z3D (J:<EEC8J.<$M[*#"'8'S,2M !SG*W?/"#27E">6Q]X/((
M^MP;O5]Q&1<#)B)MVK#6Q/E:C_&%_,[-!^Z35'3/)_61(-2%R .3?2[!^7RZ
M2K/%ZFRY"5:O%WN/!(^Z_FJ]VG2IC96<2XQ<)V1$SRPI'S+W#I11#$+*%K2.
M3/HLM1!W^K'W<U=P&-F'7K=T7OV7FZM_))7]0A_SCXE65JL2"F FZT^^J08?
M@@*FN$H\H?!FD-?C ^D>-W@](E+O7J <4]^-)G!N-TF;NZF]4C(?_+SA;.@V
M@MNPI!1+H*:S'0S/%&<DR\&90 YB,:+X(+S')VA)KV]*7Q!J%M\0+WJ276^G
MFT2=S#8?27][6ZX]D_,:N VEUWLN,R$8R0P2\Q3ZZXRU,V>M1D*IR>%F\J[W
MV7=F9L\</6KKNPNZ[T_<'!,C#;SR7 OBN\/FY/>PS!N3=U&*4@NGSL6Q6IV=
M?KE^2;CF/J&,QGM&T2A2-.HY R=C E>*58Z<?(^#>"']LC'N!6@3V^+H:!C[
M;F(;ZS>E?Y/U3;!+XIXFTL?F![_-IZ0""JR_3M??[DJAL!2+99 U&E*(SE#=
M1G(5C9$9'0MW&]/<<V<Q&(GC7M:.@/>&--[>&1#O"N(.Y[O)@F%QG/X7,JFC
M]J2JCVXF0?&\\!@#]U8>X43HE:EQ[Z3;.1_&0\JCBFBW?_?%'_6O>$ )X@&K
M#1<-[\YL&[&R1)8R%P:L\>2K)";!I2C FZB]=*:H,HB=:B56OB?PN?&T\,NW
M[4[A>3)11K(?3BO0FW<H0W]S-F8H*3M3^Q"IN^.TA_/\]^+@4<?"NZ"WB],_
M/ 8:\'O>S<+\*J-8^CJS0-!AZ'6-54H&)U*$.LI6*AV"Y5W:1^Z,WYM$M%))
M>%0<+'I22D. ND@J3E)5E\J 0,E!B>#!!1W %L8X-TPZ-<CPI-MDC NJ_=5Y
M#R[VD.W85PL??U]\_+PX6X5Y_C E9P?G5Y>.U5EZ=Y&C7CF\2!4/B23$N 6=
M/:^S:0L$YQB8HJ-.03N**SM=&>R\=!MHV4?)BZ-)?&P\G=1/W##R:IY(JM.O
M-SG).@@C+9$NLP&%M90A&P;"6*VLMYA%-^P\N,RX5Z1]X:0_28Z-B>^9$(S+
M"T:<\E(5X:"0'TB,)$L6V#HPPC!!OF+QL5NVYT.KC'N)V!<B>I-C ^[(#]VX
M^[RXUU>I827$D PR(,X<J(P2O"*GPW.OF(@<O;1#N#"'D]Y*X>R8OO21 ?"8
M(7][>OK)V?KS8KG)4'1:BLQ)],E'LB26&P@F^GH2(,O:">,&:5S7.R<C!Y='
MAF)?.Z$77(SM'-SO_)X/?SB9S\_";--38AK/-@]>[W!Y^5_17^MQ..'.%B=T
MA((^U-?<6#D.Y!W%7(*,FDQ5)R^B%W)&MN_CP'DD;;9BV+][;_I>X/&NP*\$
MM)RF\[O5TXM'BDM)I*25,4'6(S625Y<%!)L,%"F(DYK+X\1@%GX0ED:N5&[
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M[0W<_AOU#R2C_M>__!]02P$"% ,4    " "8@&11=@ND'#X'  !@(P  %0
M            @ $     97AH:6)I=#,Q+3%Q,S(P,C N:'1M4$L! A0#%
M  @ F(!D47OMO%<Z!P  8B,  !4              ( !<0<  &5X:&EB:70S
M,2TR<3,R,#(P+FAT;5!+ 0(4 Q0    ( )B 9%&];L>'[P,  )(/   5
M          "  =X.  !E>&AI8FET,S(M,7$S,C R,"YH=&U02P$"% ,4
M" "8@&11GG"T[> #  #M#@  %0              @ $ $P  97AH:6)I=#,R
M+3)Q,S(P,C N:'1M4$L! A0#%     @ F(!D40(^Q@D/9 $ !<L/ !$
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7;%!+!08     "@ * )8"  "IRP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
